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Abstract 
   
  This dissertation comprises three chapters, which focus on the development of new synthetic 
methodologies and the construction of a screening collection.  
 
  An Application of the Schmidt Reaction: Construction of an Azasteroid Library. Ring 
expansion chemistry is a powerful way of introducing a heteroatom substituent into carbocyclic 
frameworks. However, such reactions are limited by the tendency of a given substrate to afford 
only one of the two rearrangement products or fail to achieve selectivity at all. These limitations 
may prove critical when seeking to carry out late-stage functionalization of natural products as 
starting points in drug discovery. In this chapter, a stereoelectronically controlled ring expansion 
sequence towards selective and flexible access to complementary ring systems derived from 
commercial or readily synthesized steroidal substrates of the A- and D-rings is described. A 
requisite intermediate in the reaction was leveraged to afford over one hundred isomerically pure 
analogs with spatial and functional diversity. This regiodivergent rearrangement, and the concept 
of using chiral reagents to effect regiocontrol in chiral natural products, adds value to late-stage 
natural product diversification programs.  
 
  New Variations of the Schmidt Reaction. A strong hydrogen-bond-donating solvent, 
hexafluoro-2-propanol (HFIP), was found improve the intermolecular reaction of ketones with 
trimethylsilyl azide and hydroxyalkyl azides. This study prompted the hypothesis for interrupting 
the classic Schmidt reaction with an added nucleophile reagent in HFIP. An extensive acid screen 
identified aluminum tribromide as a promoter for intercepting the Schmidt reaction iminium ion 
 iv 
intermediate and combining it with subsequent reaction with 1,3,5-trimethoxybenzene to form 
substituted imines, enamides, and amines. This new variation of the Schmidt reaction provided 
access to unique heterocycles.  
 
  Enabling Chemistry Technologies: High-Temperature and High-Pressure Continuous 
Flow Chemistry. The synthetic applications of a high-temperature and high-pressure flow reactor 
were investigated. The Gould-Jacobs reaction, nucleophilic aromatic substitution reaction with 
amine nucleophiles, and tert-butyloxycarbonyl deprotection in flow were explored. The protocols 
developed were applied to the high-throughput preparation of small-molecule libraries, as well as 
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An Application of the Schmidt Reaction: Construction of an Azasteroid Library 
 
1.1 Introduction 
1.1.1 Strategies Towards Development of Screening Libraries 
Over the last two decades high-throughput screening (HTS) has become a staple in early 
stage drug and probe discovery.1-5 The HTS format is a proven scientific toolkit for the 
identification of starting points for medicinal chemistry campaigns, and indeed has led to the 
development of many approved U.S. Food and Drug Administration (FDA) drugs (>19 drugs) 
such as imatinib (Gleevec), sorafenib (Nexavar), and maraviroc (Selzentry).2-4 Although HTS is 
a highly effective strategy, the success of HTS in discovery is defined by a number of factors 
including the quality of targets, bioassays, detection techniques, compound screening collections, 
and others. In this section, I focus on the composition of compound screening collections as an 
essential aspect for the advancement of drug discovery and chemical biology programs.  
The composition of compound collections has evolved from the early 1990s, where 
simply collections of chemicals and crude natural products were screened.1, 3 Screening libraries 
continuously evolved because researchers have become more aware of the variable suitability of 
molecules for biological investigations. Modern efforts have focused on constructing chemical 
libraries that expand the traditional chemical space to consider physiochemical and diversity 
properties; e.g., to incorporate molecules with higher levels of sp3-content and three-
dimensionality (stereogenic centers) or filtered to comply with Lipinski’s Rule-of-Five and drug-
like properties. In this direction, numerous strategies have been devised to source molecules for 
HTS, which include among others, combinatorial chemistry, “diversity-oriented synthesis” 
2 
 
(Schreiber6), “biologically-oriented synthesis” (Waldmann7), and natural-product inspired 
libraries (Aubé8 and Hergenrother9). Mindfully, these strategies are under constant revision as 
scientists continue to seek out collections that yield the most probable results for their biological 
inquisition.  
 First and foremost, the advent of combinatorial chemistry demonstrated the feasibility of 
synthesizing large compound collections. In fact, Merrifield’s publication10 on solid-phase 
peptide synthesis and Ellman’s publication11 on the library synthesis of 1,4-benzodiazepines 
paved the groundwork for combinatorial chemistry. However, early combinatorial libraries were 
predominantly peptide-centric, resulting in collections with poor physiochemical and diversity 
properties.1 Moreover, in early combinatorial days, it became apparent that majority of biological 
targets could not be addressed through the use of common libraries comprising of structurally 
similar compounds. Thus, efforts were made to expand into new chemical space, which led to the 
renewed investments in natural products, development of new synthetic strategies, and 
contemporary late-stage functionalization (discussion in section 1.3).  
 Diversity-oriented synthesis (DOS), coined by Stuart Schreiber in the late 1990s, was 
developed to complement combinatorial chemistry namely by increasing complexity and 
diversity compositions within library collections.6 The DOS program adopted a divergent 
synthesis approach, particularly employing organic chemistry that would achieve efficient 
generation of chemical scaffolds in a way that maximized diversity and provided appendages for 
post-screening optimization. Amongst these efforts were the execution of short syntheses guided 
by a build-couple-pair algorithm, and assessment of libraries by chemoinformatics determined 
the coverage of new chemical space.12-14 Indeed, it has been shown that DOS collections aided in 
the discovery of antibiotics as well as molecules for challenging targets such as epigenetic 
3 
 
enzymes and protein-protein interactions.13 Another complementary approach to combinatorial 
chemistry for library construction is biology-oriented synthesis (BOS), which was conceived by 
Herbert Waldmann.7 The BOS program employed chemocentric analysis as a hypothesis-
generating tool to identify compound classes based on the structural conservation stemming from 
the coevolution of proteins and natural products/ligands (e.g., hierarchical classification of 
compounds annotated by Structural Classification of Natural Products–SCONP, bioactivity, or 
target information).7 Basically, BOS helped to identify scaffolds that are enriched in biological 
activity as starting points for medicinal chemistry research, and generally these scaffolds may be 
natural products or non-natural compound classes such as pharmaceutical agents. The conceptual 
framework of BOS is notable because the logic outlined a biological prevalidation of natural 
product structures as well as a guided basis of library design towards successful discovery of 
chemical tools for various biological targets.  
 In addition to Waldmann, other approaches were initiated in recent years that revisited 
natural products for library construction and synthetic tractability in medicinal chemistry. For 
example, Aubé and coworkers synthesized a compound collection resembling four families of 
biologically active alkaloids.8 Using enabling azide chemistry, the diverse set of natural product-
inspired compounds synthesized was comparable in structural complexity and sp3 content to their 
guiding natural products. On the other hand, Hergenrother and coworkers started from 
commercially available natural products; they developed a divergent synthesis approach to 
systematically distort ring systems forming new scaffolds that were significantly more complex 
and diverse than those in the standard screening collections.9, 15 Historically, natural products or 
their analogs were considered as end points in discovery research; however, Waldmann and other 
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researchers have shown how modern thinking can give rise to new and fruitful platforms for 
medicinal and chemical biology research.  
 In this chapter, the approaches discussed above are acknowledged in our library design 
and development of azasteroids—nitrogen-containing steroids. This library was designed to use 
readily available steroids as the starting point for systematic transformations to afford a diverse 
set of compounds in equal complexity. It is known that steroid-based analogs have continued to 
demonstrate biological importance, and the substructure is broadly considered as a successful 
drug and natural product chemotype. Despite this, there are only a few reports of steroid-based 
libraries for screening purposes.9, 16-18 Herein, a re-imagination of the steroid substructure was 
conceived with enabling azide chemistry precedent within our research group. As such, an 
approach to a steroid-like screening library may become useful in the pursuit of new biology.  
 
1.1.2 Steroids: Structure, Biosynthesis, and Implications in Drug Discovery  
Steroids and related triterpenoids belong to a broad class of secondary metabolites called 
terpenes (terpenoids or isoprenoids). In this classification, the defining carbon skeleton of the 
substructure originates from the same 5-carbon building block, isoprene. Although the terpene 
structural feature does not resemble the ‘typical’ therapeutics (heterocycles or planar aromatics), 
as secondary metabolites terpenes have been tailored to interact with various biological targets.  
Commonly, steroids have a tetracyclic molecular framework that consists of seventeen 
carbons arranged as four interconnected rings: three six-membered rings and a five-membered 
ring; formally denoted as A, B, C, and D ring respectively (Figure 1.1).19-20 Steroids may contain 
additional carbons, functional groups, and a variety of oxidation states. There are fundamental 
structural properties of steroids: (1) in two-dimensional representation, the steroid scaffolds 
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appear planar and substituents on the carbon skeleta may be located above or below the plane, 
designated as D- and E-substituents, respectively, (2) in three-dimensional representation, the 
steroid rings are actually not planar, but generally exist in the preferred chair orientation; as a 
result substituents can be located in axial or equatorial positions, (3) steroids are generally rigid 
because they have at least one trans-fused ring system, and (4) commonly, two possible ring 
fusions are observed between A and B, where the ring junction can assume trans- or cis- 
isomerism, that is, 5D and 5E stereoisomeric forms.19-20  
 
Figure 1.1. Introduction to steroids. (a) Representation of tetracyclic ABCD rings and 
numbering system. (b) Representation of trans- and cis-fused AB rings.  
  
While the biosynthetic pathway of steroids is not universal to all organisms, they are 
typically biosynthesized by consecutive condensation of isoprene units. For example, the 
biosynthesis of cholesterol from isoprene can be outlined into two major stages: (a) conversion 
of acetyl-coenzyme A substrates to a C30 hydrocarbon squalene, and (b) the conversion of 
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squalene to cholesterol.20 The rate-limiting step in cholesterol biosynthesis is the mevalonate 
pathway towards the synthesis of squalene epoxide. Specifically, the enzymatic step is 
irreversible (enzyme: hydroxyl-3-methylglutaryl-coenzyme A or HMG-CoA), and has become 
an important therapeutic target for the regulation of cholesterol biosynthesis. The second major 
stage is a well-known electrophilic cyclization the advances squalene to the preliminary steroid 
tetracycle. In general, cholesterol is an essential component of cell membranes, and a critical 
lipid-precursor to endogenous hormones, bile acids, and vitamin D.20  
Numerous therapeutic agents and chemical probes are based on steroid skeleta, with new 
examples continuing to appear in the clinic (Figure 1.2a). In this field, discovery efforts have 
generated over 100 FDA approved steroidal agents as therapeutics and are prescribed for various 
indications including inflammation, pain, hormone therapy, cancer, and more (Figure 1.2b).19-20 
Arguably, steroidal analogs are one of the most successful classes of natural product-inspired 
pharmaceuticals, and deserve to be described as a ‘privileged scaffold’ for biomedical research. 
Since the early days, steroid modifications were based on semisynthesis strategies, whereby 
available natural steroids were chemically altered to provide new steroid collections. Historical 
examples include Merck’s bile acid-to-cortisone process,21 Marker’s degradation from plant-
derived steroid diosgenin into sex hormones,22 and Djerassi’s semisynthetic pursuit of the first 
oral contraceptive23-24 (progestin, Figure 1.2b). While industrial access to important steroids via 
de novo syntheses remains an ongoing challenge, semisynthesis of steroids have continued to 
play a valuable role in both academic endeavors and commercialization of steroid-based 
medicines.25-26   
There have been a number of investigations on the incorporation of nitrogen-heteroatoms 
as part of the steroidal framework with or without alterations of ring size, as well as attached as 
7 
 
part of functional groups, side chains, or additional fused ring systems.27-28 The preparation of 
nitrogenous steroids has proven to be of biological interest, with two successful examples 
including dutasteride29 and abiraterone acetate30 (Figure 1.2c). The 4-azasteroids (e.g., 
dutasteride) have attracted interest because many exhibit strong inhibition of the enzyme 5D-
reductase,29 which catalyzes the conversion of testosterone to the more potent androgen 
dihydrotestosterone (DHT), as well as, inhibition of the androgen receptor.31-32 This enzyme and 
receptor both serve as important regulators of male sex hormones, as a result have become 
clinical targets for the treatment of prostate cancer and male physiology-related diseases.33-34 In 
2001, dutasteride was approved by the FDA for the treatment of benign prostatic hyperplasia, 
and was found to be an irreversible inhibitor of 5D-reductase. Dutasteride is semisynthesized 
from testosterone-17-carboxylic acid as shown in Scheme 1.1.35-36 In relation to prostate 
steroidogenesis, abiraterone acetate was marketed in 2011 for the treatment of metastatic 
castration-resistant prostate cancer. On the contrary, abiraterone inhibits cytochrome P450 
C17A1 (CYP17D-hydroxylase and CYP17D-lyase) enzyme, another key enzyme involved in the 
biosynthesis of androgens specifically in the conversion of pregnenolone to 
dehydroepiandrostereone.30, 34 The pyridyl-containing drug was synthesized from readily 
available dehydroepiandrosteron-3-acetate using a palladium-catalyzed cross-coupling reaction 
of 17-enol triflate.37 Abiraterone is an effective binder of CYP17A1 because of the heterocyclic 
nitrogen that coordinates to the heme iron of the target enzyme, which also allows additional 3E-
OH hydrogen-bonding interactions.38 In searches for cancer therapeutics, other D-ring nitrogen-
heterocyclic steroids have been shown to inhibit the CYP17A1 enzyme,26, 38 as well as, to 
possess antiproliferative activities through other mechanisms of action (e.g., antiangiogenic 




Figure 1.2. Representative examples of biologically important steroids. (a) Recent drug 
approvals. (b) Examples of common steroid therapy. (c) Examples of anti-cancer agents, (d) 
Examples of reported 17-azasteroids with biological activities. Agents are shown with emphasis 




Scheme 1.1. Synthesis of dutasteride.a 
 
aReagents and conditions: (a) aq. NaMnO4, NaIO4, tert-butanol, 75 °C, (b) ethylene glycol, NH3, 
180 °C, (c) acetic acid, PtO2, H2/50 psi, (d) MeOH, H2SO4, (e) DDQ, (f) MeOH, H2O, (g) SOCl2, 
aniline, toluene/CH2Cl2/THF, 70 °C.  
 
Scheme 1.2. Synthesis of abiraterone acetate.a   
 
aReagents and conditions: (a) Tf2O, (b) 3-PyBEt2, Pd(PPh3)2Cl2, THF, H2O, Na2CO3, (c) NaOH, 
H2O, MeOH.  
 
Candocuronium iodide is a potent neuromuscular blocker, exemplifying a bioactive 17-
azasteroids.42 Since its discovery, many 17-azasteroids have been investigated for potentially 
useful biological activities such as modulation of GABA receptors43 and 5D-reductase enzyme, 
and for anti-cancer treatments40-41, 44 (Figure 1.2d). These examples of nitrogen-containing 
steroids and related analogs can be found in review papers.27-28 Although a number of nitrogen-
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containing steroid analogs have been synthesized at various steroid positions, rarely have been 
developed into effective drugs.  
 
1.1.3 Late-Stage Functionalization of Steroids  
 Late-stage functionalization has remained a long-standing and important paradigm in 
drug and probe discovery. The concept of late-stage functionalization is defined by the ability of 
a chemist to directly and selectively functionalize natural product-like and drug-like molecules in 
order to rapidly create new structures, and potentially alter their pharmacological profile. 
Particularly, this approach is suitable for research programs that involve rapidly accessing 
molecular diversity, exploring structure-activity relationships, and screening of library 
collections for biological activities.45 Moreover, late-stage functionalization is useful because a 
synthetic route can efficiently generate analogs in few synthetic steps and without extensive 
redesign. However, there are many challenges associated with the direct functionalization of 
complex molecular structures, which include (1) carrying out reactions at one of the many 
identical functional groups (chemoselectivity, site selectivity), (2) controlling or overcoming 
dependence of the reactivity of one functional group, (3) controlling selectivity or overcoming 
substrate bias of product outcome, and (4) difficulty in isolation of pure products from 
mixtures.46-47 Intrinsic to derivatizations of complex molecular frameworks are the numerous 
plausibility of stereoselectivity. In particular, within chiral molecular frameworks, 
diastereoselectivity and regioselectivity are inherent issues that require thoughtful considerations 
to overcome and achieve selective functionalization. Complex natural products continue to be 
quintessential in drug and probe discovery, as a result have been the cornerstone of studies for 
synthetic strategies, including that of late-stage functionalization. These efforts have been tried 
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on famous biologically relevant compounds such as erythromycin, vancomycin, amphotericin, 
digitoxin, and many more.47 The application of late-stage functionalization to selectively modify 
steroids has historical prevalence, and as a biologically relevant framework steroid substrates 
remain under scrutiny to date.  
Late-stage manipulation of steroid scaffolds is a worthwhile strategic advance for seeking 
new and more effective scaffold-related bioactivity, and accessing steroid-based natural products 
and drugs. In fact, the philosophical concepts and implications have been clearly demonstrated 
by early visionaries such as Breslow,48 Barton,49 Arigoni,50 and Corey.51-52 In the early 19th 
century, Corey and Arigoni independently applied the Hofmann-Löffler-Freytag reaction to 
aminosteroid synthesis. The Hofmann-Löffler-Freytag (HLF) reaction is the photochemical 
decomposition of N-haloamines that results in direct functionalization of distal unactivated 
aliphatic C-H bonds. Specifically, the N-X bond homolyzes to form a nitrogen radical capable of 
intramolecular hydrogen atom abstraction; this in turn, provides a carbon radical that recombines 
with the halogen species to undergo nitrogen-mediated nucleophilic displacement. A 
fundamental example by Corey in the total synthesis of alkaloid dihydroconessine showcased 
functionalization of C-18 via the in situ formation of free radical from the decomposition of N-
chloro-20-aminosteroid (Scheme 1.3a).53 Following Corey’s and Arigoni’s investigation on C-18 
functionalization using the HLF reaction, Barton and coworkers reported the semisynthesis of 
aldosterone from corticosterone, the main mineralocorticoid steroid, using the Barton reaction 
(Scheme 1.3b).54 Barton’s work is a photochemical reaction that involves homolytic RO-NO 
cleavage of an alkyl nitrite, followed by hydrogen abstraction, radical recombination, and 
tautomerization to oxime.54 While mechanistically similar to the HLF reaction, together Barton, 
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Corey, and Arigoni were influential in providing the first examples of C-H activation chemistry, 
as well as the concept of late-stage functionalization of bioactive molecules.  
 
Scheme 1.3. Historical examples of late-stage functionalization of steroids. (a) A synthetic step 
from Corey’s synthesis of dihydroconessine. (b) Aldosterone acetate synthesis using the Barton 
reaction.   
 
 
Furthermore, Breslow’s research program pioneered a strategy to imitate nature’s level of 
selective functionalization. Particularly, the concept posed mimicry of enzyme-substrate 
functional selectivity through appropriate geometry, which he termed the synthetic application as 
‘biomimetic’.48 In this aspect, Breslow and coworkers used an oxidant (e.g., benzophenone) 
covalently attached to a substrate to mediate radical-driven functionalization (Figure 1.3). The 
site of C-H functionalization was dependent on the length and location of the tether, and such 
templates have been studied to catalyze remote functionalization at various positions of the 
steroid nucleus.55 In the late 1990s, Breslow fostered the ‘biomimetic’ concept by development 
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of an artificial CYP450 enzyme (metalloporphyrin-based) that performed selective 
hydroxylations with catalytic turnover, unlike reagents that were originally designed and 
attached to the steroid nucleus.55 Indeed, Breslow’s excursion has inspired other researchers to 
develop biomimetic late-stage functionalization, such as Grieco’s reports on related synthetic 
metalloporphyrins.51, 56-57  
 
Figure 1.3. Functionalization of steroid nucleus using attached oxidants.  
 
In recent years, contemporary C-H activation chemistry has exploded as a powerful 
approach to facilitate late-stage functionalization. In this context, C-H functionalization uses 
catalysts that exploit directing groups, or distinct differences in steric, electronic, or 
stereoelectronic properties of C-H bonds. In recent years, numerous research groups have 
developed a number of catalysts for this approach, which are based on small-molecules, 
transition metals,58-59 peptides,47, 60 or enzymes.45, 61-62 Here, I will provide examples on recent 
efforts regarding the (1) late-stage introduction of nitrogen-substituents into complex molecules, 
and (2) late-stage functionalization of nitrogen- and heterocycle-containing substrates. 
Particularly, I will highlight papers that demonstrate modern examples of late-stage 
functionalization of steroid scaffolds.  
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 Although the synthetic versatility of C-H activation chemistry is vast, the direct 
functionalization of natural product-like and drug-like molecules has been relatively limited. 
More promising methodologies further extend their applications towards complex bioactive 
molecules. For example, Hartwig46 and Groves63 have pursued the introduction of azides on 
representative complex molecules because this functionality can be easily converted to a range of 
nitrogen-containing functional groups, as well as, serve as attachment points for various probes 
through Huisgen “click” cycloadditions and Staudinger ligations (Figure 1.4a). Such reactions 
expand the chemistry toolbox for uses in medicinal chemistry settings. As a result, numerous 
developments of selective amination/amidation procedures with various catalytic systems have 
been a focus of intensive research.  
 One main issue in C-H functionalization is that nitrogen or heteroatoms present in 
substrates may bind preferentially to transition-metal catalysts rather than the desired directing 
group or site of functionalization for completion of the desired reaction.64 This issue has 
hindered the application of C-H functionalization in late-stage derivatizations of nitrogen- and 
heterocycle drugs and probes. However, it must be noted that directing groups (including 
amides65 and amines66-67 directing groups) have been exploited as a major advantage and 
successful approach in this field (e.g., Baran, Figure 1.4b).61 Because nitrogen and heterocycles 
are ubiquitous in drug discovery research, others have sought to find methodologies that 
tolerated the presence of such functionalities, and would allow modifications at different 
positions (especially, without the need to install and remove directing groups). For example, 
White and coworkers developed a nitrogen complexation strategy with strong acids, which 
enables remote oxidations of amine and pyridine-containing molecules.68-69 Particularly, the 
authors showed that a salting strategy of amines (i.e., electronic deactivation) in conjunction with 
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iron catalysis effectively facilitates late-stage oxidation of medicinally relevant compounds 
(Figure 1.4b).68-69  
 
Figure 1.4. Modern examples of late-stage functionalization of steroids. (a) Late-stage 
introduction of nitrogen-substituents into complex molecules. (b) Late-stage functionalization of 
nitrogen- and heterocycle-containing substrates.  
 
1.1.4 The Schmidt Reaction of Hydroxyalkyl Azides  
The Beckmann rearrangement and the Schmidt reaction are two common ring-expansion 
transformations employed to insert a nitrogen heteroatom into a carbocyclic skeleton (Scheme 
1.4). In 1886, the Beckmann rearrangement was discovered; it is a two-step transformation 
involving the conversion of a ketone to an oxime, followed by acid-mediated oxime 
rearrangement to afford an amide or lactam.70 In contrast, the Schmidt reaction of ketones is a 
one-step transformation with azide reagents such as hydrazoic acid (HN3) or sodium azide 
(NaN3).71-72 During the 1940–1950s, Briggs,73 Smith,74 and Boyer75-77 individually investigated 
the use of alkyl azides in place of conventional HN3 in order to extend the scope of the Schmidt 
reaction. However, Briggs and Smith failed to achieve the synthesis of N-substituted lactams in 
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this way. Later, Boyer disclosed a limited reaction series between aromatic aldehydes and alkyl 
azides using sulfuric acid (H2SO4) in benzene to afford N-substituted lactams in poor yields. 
Further, Boyer and coworkers discovered that by exchanging an alkyl azide for a hydroxyalkyl 
azide, this transformation provided an efficient route to oxazolines.76 Boyer’s proposed 
mechanism proceeded through intermediate i in Figure 1.5; formed by an initial attack of azide 
onto the activated carbonyl, accompanied by extrusion of molecular nitrogen and water to give 
the oxazoline product. While this finding was a significant advancement, the reaction was 
limited to the use of electron-deficient aromatic aldehydes.  
 
Scheme 1.4. Common nitrogen-ring expansion reactions. (a) The Beckmann rearrangement. (b) 








 In the early 1990s, Aubé and coworkers described the use of boron trifluoride diethyl 
etherate (BF3yOEt2) in dichloromethane (CH2Cl2) to promote the reaction between aldehydes or 
ketones with hydroxyalkyl azides (Figure 1.6).72, 78-81 Compared to that of Boyer’s work, Aubé 
reported superior yields, substantial scope extensions, and a modified mechanism proposal (e.g., 
of ketones; shown in Figure 1.6).81 In this proposed mechanism, initial formation of oxonium ion 
is resultant from an initial attack of the hydroxyl group followed by the loss of water; instead of 
an initial attack onto the activated carbonyl by azide as speculated by Boyer. The formation of 
oxonium ion renders the azide addition intramolecular establishing an azidohydrin-like 
intermediate that rearranges due to extrusion of molecular nitrogen and results in an iminium ion 
intermediate as the primary rearranged product. In the case of an aldehyde, the initial 
intermediate was proposed as a related oxonium ion, and oxazoline or dihydrooxazine (n = 1 or 
2, respectively) ensues from rearrangement and the loss of nitrogen.78 Most often, the isolatable 
iminium ether intermediate from ketone is converted directly to an amide or lactam through an 
overnight stir in either an aqueous saturated solution of sodium bicarbonate (NaHCO3) or 15% 
potassium hydroxide (KOH). Moreover, Forsee at el. showed that acyclic ketones or medium-
sized ketone rings react with hydroxyalkyl azides to afford substituted esters or lactams (Scheme 
1.6).82 However, the outcomes of these reactions are highly dependent on substrate and base 
conditions, taking into account many factors including ring strain and the protonation state of 






Figure 1.6. The Schmidt reaction of ketones with achiral hydroxyalkyl azides.  
 
Scheme 1.5. The Schmidt reaction of medium-sized cycloalkanones with hydroxyalkyl azides. 
 
Particularly relevant to this chapter is the reaction of an iminium ether intermediate with 
various nucleophiles to afford functionalized N-alkyl heterocycles.80, 83-84 In Figure 1.7, the 
iminium ether intermediate is shown to react with nucleophiles at two possible carbon sites, path 
a or path b. The selectivity for path a is rationalized based on the reversibility of the initial 
addition of nucleophile at the formal iminium carbon, which is dependent on the nucleophile. In 
path a, attack occurs at the sp2 carbon (iminium carbon), forming a neutral intermediate that can 
either further convert to final product or revert back to the stable iminium intermediate. In this 
pathway, nucleophiles that behave reversibly ultimately attacks at the distal sp3 carbon adjacent 
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to the oxygen atom in an SN2 fashion (path b). For example, treatment of an iminium ether with 
aqueous hydroxide goes via path a; this was determined by Fenster el al., when the nucleophile 
was 18O-labeled hydroxide showed enrichment of 18O at the carbonyl.84 Towards scope 
extension, Aubé studied a detailed range of nucleophiles in order to exploit the ambident 
electrophilicity of the primary rearranged product, and develop this chemistry as a tool for 
library construction. In these studies, two noteworthy heterocycles that were achievable from 
path a include amine and thioamide formation (under hydrogenation or sodium borohydride 
reducing conditions, and disodium sulfide workup, respectively). Other nucleophiles that add to 
iminium ether afford N-alkylated lactams include azides, sulfides, and halides (via path b). Since 
then, this reaction type has been applied towards library preparation, e.g., of γ-turn-like 
peptidomimetics based on 1,4-diazepin-5-ones.83 Taken together, these protocols explored 
revealed the synthetic versatility and convenience of iminium ethers, which could either be 




Figure 1.7. Nucleophilic addition reactions of iminium ethers.  
 
 
The intermolecular Schmidt reaction between ketones and hydroxyalkyl azides has also 
been applied to the asymmetric synthesis of chiral lactams.79, 85 As shown in Scheme 1.6, 
utilization of a chiral hydroxyalkyl azide afforded diastereotopic lactams in excellent yields and 
stereoselectivities. Sahasrabudhe et al. carried out a systematic study of chiral hydroxyalkyl 
azides in ring expansions of symmetrical cyclohexanones. In sum, many structure-selectivity 
analysis of various chiral azide reagents revealed diastereoselectivities up to 98:2 with 
substituted 3-azidopropanols. However, poorer selectivities were observed with substituted 2-
azidoethanol reagents. The mechanism of the reaction (representative case shown in Figure 1.8), 
and the source of its stereoselectivity have been discussed.85-86 The reaction has also been 
extensively studied by computational methods.86 The specific features pertaining to stereocontrol 
are relevant to the present chapter. In brief, the product outcomes of the asymmetric reaction 
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depend on three following considerations: (1) direction of azide attack relative to pre-existing 
substitution on the ketone reactant, (2) selective formation and reaction of the most stable new 
heterocyclic ring (1,3-oxazinane from 3-azidopropanol, or oxazolidine from 2-azidoethanol), and 
(3) antiperiplanar C→N migration to afford the iminium ether intermediate. All steps prior to the 
actual migration are reversible; the iminium ether intermediate never reverses. In fact, supported 
by density functional theory (DFT) calculations, the barrier for C→N migration is only ca. 2 
kcal/mol higher than reversion to azide and oxonium ion.86   
 





Figure 1.8. Proposed mechanism of the asymmetric Schmidt reaction. The figure was adapted 
from Sahasrabudhe et al.85  
 
 The following discussion focuses on the reactions of substituted cyclohexanones with 3-
azidopropanols. The complex mechanism of this transformation results from a combination of 
three stereochemical and conformational factors (Figure 1.9):85-86  
Factor (1): Direction of azide attack onto ketone. It has been proposed and supported 
by computational methods86 that in the intermediates derived from six-membered rings, 
equatorial azide attack occurs onto the more stable cyclohexanone derivative; where 
stereoselectivity relates to the relative populations of the possible chair conformations of the 
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starting ketones. Attack onto ketones of other ring sizes depend on steric accessibility (specific to 
examples). Since it is not possible to directly observe the spirocyclic intermediate, the direction 
of attack in non-obvious cases may need to be inferred from analyzing the outcomes in the 
context of factors 2 and 3 below.  
Factor (2): Selective formation and reaction of the most stable new heterocycle ring. 
In cases of intermediates derived from monosubstituted 3-azidopropanols, the major products 
afforded from spirocyclic 1,3-oxazinanes containing the substituent in an equatorial orientation. 
It has been reported that 2-aryl or 2-alkoxy substituted 3-azidopropanols lead to products arising 
from spirocyclic 1,3-oxazinanes having the substituent in an axial position. For example, due to a 
π-cation interaction between the aryl group and the N2+ leaving group, which is now in a 1,3-
diaxial relationship.87 In all cases, the heterocyclic ring is presumed to adopt the most stable 
chair-like conformation, and it is worth recognizing that the two chair forms can interconvert 
either by reversion to oxonium ion and azide, or by ring flip between the two chair forms.  
Factor (3): Antiperiplanar migration. In all azido-Schmidt reactions, C→N migrations 
involve concerted antiperiplanar migration to the N2+ leaving group. For spirocyclic 
intermediates from hydroxyalkyl azides, the reaction goes through an axial N2+ group, since if 
this group is equatorial, the only possible antiperiplanar options are a C-O bond (unlikely to 
migrate as it would form a new and weak N-O bond), or a C-C bond (if broken, would lead to an 
unstabilized cation by neighboring an oxygen atom). Additionally, DFT calculations revealed 
that the N2+ is axial in the ground-state conformation.86  
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Figure 1.9. Factors that govern the asymmetric Schmidt reaction. (a) Direction of azide attack 
onto ketone. (b) Selective formation and reaction of the most stable new heterocycle ring. (c) 
Antiperiplanar migration.  
 
1.1.5 Regiochemistry in Nitrogen Ring Expansions  
 Often in nitrogen ring-expansion chemistry of unsymmetrically substituted ketones two 
regioisomers are conceivable, and generally, the product outcomes are determined by electronic 
or steric preferences of the starting substrates. The classic Schmidt or Beckmann reactions 
preferentially proceed to ring-expanded isomers that result from the migration of the more 
substituted carbon, with few known exceptions.70, 72 The regioselectivity of the Beckmann 
reaction generally arises from the preferential formation and regioselective rearrangement of one 
of the two possible oximes, (E)- and (Z)-isomer, as a result of steric interactions. Under acidic or 
protic conditions, interconversions of oxime isomers can take place, which may account for non-




 Alternatively, the photochemical rearrangement of oxaziridines entails a mechanism that 
establishes a stable nitrogen-centered stereoisomer en route to ring-expansion. In contrast to the 
traditional Beckmann, where the carbon anti to the hydroxyl group of the oxime undergoes 
migration, during oxaziridine photolysis the carbon anti the nitrogen lone pair of the oxaziridines 
undergoes migration. Moreover, Aubé has studied stereospecific ring expansions of chiral 
oxaziridines derived from D-methylbenzylamine (D-MBA).88-89 Following stereoselective 
oxaziridine formation, photochemical rearrangement occurs under stereoelectronic control, in 
which the substituent anti to the nitrogen lone pair undergoes migration. Interestingly, by 
switching between (S)- and (R)-MBA reagents, the resultant oxaziridines contain nitrogen 
stereocenters with opposite configurations, thus allowing one synthesize selectively 
regioisomers.  
 Aubé has applied this reagent-directed strategy on simple unsymmetrically substituted 
ketones, as well as, on more challenging cases such as the Wieland-Miescher bicyclic ketone 
(Figure 1.10a).90 In this work, the switchable access to regioisomeric lactams is a nice 
demonstration of group-selectivity concept in asymmetric synthesis. In asymmetric synthesis, 
tools that distinguish between enantio- or diastereotopic methylene groups are important 
methods for stereodifferentiation and stereoselectivity in chemical transformations. Herein, Aubé 
pioneered chiral oxaziridines as tool to differentiate between diastereotopic methylene groups in 
the migration step, thus enacting an asymmetric synthesis of seven-membered nitrogen ring-
expanded products. Interestingly, only a few examples in the literature are reported that use 
asymmetric tools to effect regiochemical control (e.g., Jacobsen’s work on Salen complexes, 
Figure 1.10b, and Miller’s work on peptide catalysts, Figure 1.10c),88, 90-92 and minimally has 
been repurposed for late-stage diversification and functionalizations.47  
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Figure 1.10. Regiochemical control using chiral reagents. (a) Chiral MBA reagents used in 
oxaziridine-photochemical ring expansion of substituted trans-decalone. (b) Jacobsen’s 
regioselective ring opening of enantiomerically enriched epoxides using chiral salen complexes. 
(c) Miller’s catalyst control in Baeyer-Villiger oxidation of functionalized ketones. 
 
However, the above ring-expansion methods are not amendable to library preparation 
because they lack flexible and immediate access to functional diversity. On the other hand, the 
hydroxyalkyl azide variant of the Schmidt reaction encompasses features of functional diversity 
that is practical towards library development. However, this Schmidt reaction variant has not 
been extensively explored in the context of simultaneous regiochemical control and 
diversification.  
 The Aubé laboratory has studied the reaction between of 1,2- or 1,3-hydroxylalkyl azides 
with unsymmetrical cyclohexanones.93 As shown in Figure 1.11, it was determined that the 
reactions of hydroxylalkyl azides with ketones containing methyl or ethyl groups are unselective, 
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however bulkier substituents on ketones may lead to preferential migration of the more 
substituted carbon (similar to the classic Schmidt trend). On the contrary, ketones bearing an 
electron-withdrawing group (e.g., bromine) afforded migration of the unsubstituted methylene 
group. The stereochemical analyses of these reaction intermediates are relevant to our 
understanding of selectivity. The effect of substituent size reflects the differences in the 
nonbonded interactions of the spirocyclic N-diazonium intermediates (Figure 1.11). On 
explanation is that the effect of steric bulk of the 2-substituent on regiochemistry is that the alkyl 
group and the N2+ leaving group experience varying degrees of steric interactions when they are 
in a syn versus anti orientation. Since the leaving group is small, there is not much difference 
between these forms for small alkyl groups, however for larger groups regiochemical preferences 
emerge. For example, presuming equatorial attack of azide on to the oxonium ion intermediate, 
the more substituted carbon (when R = i-Pr, t-Bu) occupies the anti-orientation leading to 
migration of the more highly substituted carbon. However, in the case of bromine, one possible 
explanation is that the electron-withdrawing group deactivates migration of that carbon and, in 





Figure 1.11. The Schmidt reaction of unsymmetrical cyclohexanones with achiral hydroxyalkyl 
azides.   
 
1.1.6 Overview of our Library Design 
 Natural products represent valuable starting points for drug and probe discovery, with 
late-stage diversification as an attractive approach for generating new bioactive agents from 
complex starting scaffolds.7-8 In recent years, relatively few approaches to N-containing steroid 
library collections have been reported.9, 16-17 Because there is paucity of nitrogenous steroids for 
discovery research and these substrates prominently figure in both classic and contemporary 
synthetic approaches, we sought to develop a global approach to the late-stage introduction of 
nitrogen substituents by using ring expansion chemistry. To do so effectively, we needed to 
address the perennial problem of regiochemistry control that accompanies ring expansion 
chemistry, especially of complex structures where there is often substrate biases that dictate the 
regioisomeric outcomes. In this work, we aimed to describe a global approach that uses 
stereoelectronically controlled ring expansions to effect regiochemical control in a complex 
molecular setting, permit directed introduction of a nitrogen-containing group in settings where 
regiochemical control was previously not possible, and overcome strong substrate biases to 
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afford previously inaccessible constitutional isomers (Figure 1.12a). In this chapter, our 
regiodivergent rearrangement strategy describes the uses of chiral reagents to effect regiocontrol 
in chiral natural products, which should become applicable to late-stage natural product 
diversification programs.  
 We focused this chapter on ring-expansions of A and D-rings because the biological 
activities of steroids often depend on the structures of these ring systems. Unfortunately, 
modifications of B and C-rings proved to be relatively problematic (the challenges of these ring 
systems is be discussed in section 1.5). Thus, we present a stereoelectronically controlled ring 
expansion sequence towards selective and flexible access to complementary ring systems derived 
from common steroid substrates of A and D-rings.  
The two limiting cases for regiochemical control are shown in Figure 1.12a. The nitrogen 
ring expansion of a 17-oxosteroid represents a classic case of unidirectional migration in an D-
substituted ketone. Here, this corresponds to migration of the highly substituted C-13 carbon 
versus migration of the less substituted C-16 carbon. Both the Beckmann and Schmidt reactions 
have been carried out on this steroid system, and the standard outcome is the exclusive migration 
of the more substituted C-13.27, 94-95 In contrast, migration of the C-16 carbon is unknown, except 
through multistep sequences.27  
   The challenges of A-ring rearrangement is more severe because the two methylene 
groups attached to the 3-oxosteroid are electronically and sterically similar enough that substrate 
bias may not come in play. In other words, this ketone is only non-symmetrical at a site distal 
from the actual point of chemical reactivity. In fact, reported ring expansion reactions at this 
ketone are known and poorly selective.96-97 A potential solution to this problem is evident from 
previous Aubé laboratory endeavors in ring expansion chemistry. Conceptually, one may embed 
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an achiral cyclohexanone into the chiral context of the A-ring steroid (Figure 1.12b), which now 
renders the two potential migrating methylene groups that were enantiotopic in the monocyclic 
case, diastereotopic. This idea was previously explored in ring-expansion chemistry using chiral 
oxaziridines (Figure 1.10a).  
 As in all approaches for using an asymmetric reaction for the control of product 
regiochemistry (Figure 1.10), it is essential that the substrate be used in enantiomerically pure 
form. This is due to the fact that the stereodifferentiating reaction is designed to favor migration 
of a single enantiotopic methylene group when carried out on an achiral ketone. In a chiral 
ketone substrate, the relevant methylene groups are no longer enantiotopic and are chemically 
non-equivalent (Figure 1.12b). However, due to local asymmetry, they respond to the chiral 
reagent as if they were enantiotopic. Thus, if the reagent is able to distinguish between these 
chemically non-equivalent groups (through the same mechanism as if they were enantiotopic), it 
will afford a single isomeric product only if a given chemically non-equivalent methylene group 
in the molecule maps onto a single “enantiotopic” methylene group from the perspective of the 
added reagent. Another way of thinking about this is that just as the enantiomerically pure ketone 
reacts with racemic hydroxyalkyl azide to give two isomers in a 1:1 ratio because each isomer in 
the racemate enforced the formation of a single stereoisomeric product, a 1:1 mixture would also 
have to resulted if the substrate purities were reversed, i.e., if the hydroxyalkyl azide were 
enantiomerically pure and the ketone substrate were racemic. Therefore, in this work, we studied 
the regiochemistry of the Schmidt reaction between enantioenriched hydroxyalkyl reagents on 




 In this chapter, the library of azasteroids was devised in a systematic manner using the 
hydroxyalkyl azide variant of the Schmidt reaction: (1) I studied the use of achiral and 
enantioenriched hydroxyalkyl azides to effect ring expansion of 3- and 17-oxosteroids, (2) 
determined constitutional isomer selectivity by rationalization of reaction mechanisms, and (3) 
functionalized iminium ether intermediates with various nucleophiles to afford analogs with 





Figure 1.12. Rationale of the project and challenges associated with A- and D-ring late-stage 
functionalization using ring expansion chemistry. (a) Regiochemical issues accompanying ring 
expansion reactions of 3- and 17-oxosteroids. (b) The relationship between enantiotopic group 
migration selectivity in substituted cyclohexanones and regioselectivity in a 3-oxosteroid.  
 
1.2 Synthesis of Hydroxyalkyl Azides  
A variety of 1,2- and 1,3-hydroxyalkyl azides were synthesized for this study; two 
reagents were achiral and eighteen reagents were pairs of enantiomers (Figure 1.13). An 
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attractive aspect of the proposed ring-expansion study was the ready availability of hydroxyalkyl 
azides from commercial starting materials using simple chemical transformations.  
Figure 1.13. Chiral and enantioenriched hydroxyalkyl azides for library preparation. (a) 1,3-
Hydroxyalkyl azides. (b) 1,2-Hydroxyalkyl azides. 
 
 
In general, a simple SN2 reaction of alkyl halides with NaN3 was used to prepare seven 
azide-reagents, which included achiral azides 1.1 and 1.7, racemic azido-1-phenylpropanol 1.2, 
(S)- and (R)-1.2, and (S)- and (R)-3-azido-2-methylpropanol 1.3 (Figure 1.13; representative SN2 
reaction shown in Scheme 1.7). In other cases, the synthesis of enantioenriched 1,3-substituted 
azides required multistep reactions as shown in Scheme 1.7. In one case, enantioenriched 3-
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chloro-1-phenylpropanols were converted to phenyl-containing (S)-1.4 and (R)-1.4 following 
three synthetic steps—displacement of chloride with acetate, Mitsunobu azidation with inversion 
of the benzylic center, and hydrolysis of the acetate protecting group. Similarly, a Mitsunobu 
transformation was used to prepare (S)- and (R)-3-azidobutanol 1.5 following tert-
butyldimethylsilyl (TBS) protection of the less hindered alcohol on the 1,3-butandiol starting 
material. All Mitsunobu procedures were carried out using diphenylphosphoryl azide (DPPA)98 
because this reagent is readily available, nonexplosive, and more stable than HN3.  
The synthesis of a bromophenyl-substituted 3-azido-propanol was desired because of 
potential downstream diversification applications. The enantiomers of 1.6 were synthesized from 
an asymmetric Corey-Bakshi-Shibata reduction99 of 4’-bromo-3-chloropropiophenone and 
subsequent displacement of chloride by NaN3 (Scheme 1.7). Enantioselective reduction was 
achieved using an oxazaborolidine catalyst (Me-CBS) and N,N-diethylaniline borane (DEANB), 
which gave secondary alcohols with selectivity in the range of 96–97% enantiomeric ratio (92–
94% ee). In a similar manner, enantiomers of 2-azido-1-phenylethanol 1.8 were synthesized in 
98–99% enantiomeric ratio (96–98% ee).  
 In general, enantioenriched 1,2-hydroxyalkyl azides were prepared from the 
corresponding amino acids by carbonyl reduction and conversion of the D-amino group to an 
azide.100 In particular, the amino acids leucine, phenylalanine and phenylglycine were reduced 
using refluxing lithium aluminum hydride (LAH) and the resulting amino alcohols were 
converted to the corresponding azides via a diazo transfer using freshly prepared 
trifluoromethanesulfonyl azide (TfN3) (Scheme 1.8). In this way, enantioenriched hydroxyalkyl 




Scheme 1.7. Representative synthesis of 1,3-hydroxyalkyl azides. 
 
Scheme 1.8. Chiral pool synthesis of 1,2-hydroxyalkyl azides from amino acids.  
 
 
1.3 A-Ring Modifications 
1.3.1 Synthesis of 3-Oxosteroids  
 An attractive aspect of the proposed library preparation was the ready availability of 
steroids from commercial sources in enantiopure forms. In the A-ring series, three steroidal 
ketones (3-oxosteroids) were synthesized in one or two steps from either commercial cholesterol 
or testosterone, respectively (Scheme 1.9). We focused on the preparation of 3-oxosteroids for 
several reasons. Firstly, the ketone handle could be easily secured by using straightforward 
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chemistry, which included olefin reductions and oxidation of a secondary alcohol. Secondly, the 
three substrates prepared, 5D-cholestan-3-one 1.13 (3-cholestone), 5D-dihydrotestosterone 1.14 
(5D-DHT), and 5E-dihydrotestosterone 1.15 (5E-DHT), are structurally diverse containing 
variable C-17 side chains and AB junctions. It is interesting that the stereochemical preferences 
of the olefin reduction are sensitive to the steroid substrate and strongly influenced by the 
reducing systems. The stereoselectivity of D,E-unsaturated testosterone is a classic example 
(Figure 1.14). As shown in Figure 1.14, the selectivity of the dissolving metal reduction (lithium 
in ammonia) is under thermodynamic control, whereas Pd/C hydrogenation proceeds with kinetic 
control. In the former case, the trans-product formed is the more stable isomer, and the 
stereochemical outcome is governed by “axial protonation” as originally discussed by Barton101 
and Stork.102 They proposed that the resulting hydrogen is axial because the transition state for 
protonation of the carbanion species has considerable tetrahedral character that allows the 
carbanion orbital to overlap in the unsaturated system; this transition state characteristic is 















Scheme 1.9. Synthesis of 3-oxosteroids from commercial steroids. (a) Synthesis of 5D-
cholestan-3-one. (b) Synthesis of 5D-dihydrotestosterone and 5E-dihydrotestosterone.  
 
Figure 1.14. Kinetic versus thermodynamic hydrogenation. The figure was adapted from Shenvi 
and coworkers.103  
 
 
1.3.2 A Study on the Use of 1,3-Hydroxyalkyl Azides to Effect Ring Expansion on 3-
Oxosteroids, Determination of Constitutional Isomerism Control, and Rationalization of 
Mechanism 
 We aimed to address the problem of A-ring selectivity using a stereocontrolled ring 
expansion to influence the regioselectivity of the N-side chain installation. In this study, readily 
available 3-oxosteroids 1.13–1.15 were reacted with hydroxyalkyl azides 1.1–1.6 (Table 1.1). As 
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expected, the ring expansion of 3-cholestone 1.13 with achiral 3-azidopropanol 1.1 gave little 
selectivity for one ring expansion outcome over the other; 1.16 and 1.17 were observed as a 
38:62 mixture by 1H NMR, and were inseparable by normal phase column chromatography 
(entry 1, Table 1.1). In order to surmount this problem, a reagent control approach was tested 
with a variety of chiral azide reagents 1.2–1.6. For example, enantioenriched (S)- or (R)-3-azido-
1-phenylpropanol, (S)- or (R)-1.2, were reacted separately with 3-cholestone 1.13 and afforded 
spectroscopically pure lactams 1.19 and 1.18, respectively. In each case, the reaction 
demonstrated high regiochemical control (>95:5) and gave excellent yields 88–89% (entries 3 
and 4). As expected, the reaction with racemic 3-azido-1-phenylpropanol (±)-1.2 gave an 
equimolar mixture of 1.18 and 1.19 (entry 2). Compared to the achiral reactant (entry 1) where a 
modest inherent substrate bias was observed, the racemic reactant (entry 2) influenced the non-
selectivity. In this case, each half of the racemate provided a specific regioisomer with high 
selectivity, thus an equimolar mixture of 1.18 and 1.19 was obtained. Generally, the reaction was 
carried out in CH2Cl2 and promoted by 5.0 equiv of BF3yOEt2. These conditions were adapted 
from the asymmetric Schmidt reaction variant.85 However, substantial optimization study was 
carried out for D-ring modifications, which was not done for A-ring modifications. This is 
because A-ring substrates (6-membered ring ketones) readily reacted with azide reagents under 
the standard conditions, while D-ring substrates (5-membered ring ketones) did not proceed in 







Table 1.1. Reaction of 3-oxosteroid 1.13–1.15 with 1,3-hydroxyalkyl azides 1.1–1.6.a  
 
entry steroid azide R3 R4 R5 3-aza: 
4-aza 
ratiob,c 
product(s) isolated  
yield 
(%)d 3-aza 4-aza 
1 1.13 1.1 H H H 38:62e 1.16 + 1.17 92f 
2 1.13 (±)-1.2 (±)-Ph H H 50:50e 1.18 + 1.19 92f 
3 1.13 (S)-1.2 (S)-Ph H H 5:>95 - 1.19 88 
4 1.13 (R)-1.2 (R)-Ph H H >95:5 1.18 - 89 
5 1.13 (S)-1.3 H (S)-Me H 10:90e - 1.20 84 
6 1.13 (R)-1.3 H (R)-Me H 87:13e 1.21 - 71 
7 1.13 (S)-1.4 H H (S)-Ph >95:5 1.22 - 88 
8 1.13 (R)-1.4 H H (R)-Ph 5:>95 - 1.23 87 
9 1.13 (S)-1.5 H H (S)-Me 5:>95 - 1.24 89 
10 1.13 (R)-1.5 H H (R)-Me >95:5 1.25 - 92 
11 1.14 1.1 H H H 40:60e 1.26 + 1.27 95f 
12 1.14 (S)-1.2 (S)-Ph H H 5:>95 - 1.28 88 
13 1.14 (R)-1.2 (R)-Ph H H >95:5 1.29 - 84 
14 1.14 (S)-1.6 (S)-(4-Br)Ph H H 5:>95 - 1.30 86 
15 1.14 (R)-1.6 (R)-(4-Br)Ph H H >95:5 1.31 - 83 
16 1.14 (S)-1.3 H (S)-Me H 13:87e - 1.32 87 
17 1.14 (R)-1.3 H (R)-Me H 87:13e 1.33 - 85 
18 1.14 (S)-1.4 H H (S)-Ph >95:5 1.34 - 89 
19 1.14 (R)-1.4 H H (R)-Ph 5:>95 - 1.35 90 
20 1.14 (S)-1.5 H H (S)-Me 5:>95 - 1.36 85 
21 1.14 (R)-1.5 H H (R)-Me >95:5 1.37 - 85 
22 1.15 (S)-1.2 (S)-Ph H H >95:5 1.38 - 89 
23 1.15 (R)-1.2 (R)-Ph H H 5:>95 - 1.39 83 
24 1.15 (S)-1.4 H H (S)-Ph 5:>95 - 1.40 87 
25 1.15 (R)-1.4 H H (R)-Ph >95:5 1.41 - 90 
aSee Sections 1.7.2 for reaction protocol. bRatio of 3-aza- and 4-aza-A-homo-steroid lactam was 
determined by 1H NMR of the crude reaction mixture. cOnly one regioisomer was observed by 1H NMR 
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of the crude reaction mixture, unless otherwise noted. dIsolated yields of only the major regioisomer, 
unless otherwise noted.  eMixture of regioisomers observed by 1H NMR of the crude reaction mixture.  
fIsolated yields of a mixture of regioisomers.  
  
 Representative mechanisms explaining the regiocontrol for the reaction between 3-
oxosteroid with (R)- or (S)-3-azido-1-phenylpropanol 1.2 are illustrated in Figures 1.15 and 1.16, 
respectively. The mechanism first involves the formation of a pair of spirocyclic 1,3-oxazinanes 
that readily equilibrate prior to rearrangement.85-86 The outcome of the rearrangement is 
governed by three principles: (1) equatorial attack of azide upon the initial oxonium species to 
establish the stereogenicity of the spirocyclic carbon, (2) preferential reaction of the newly 
formed 1,3-oxazinane conformer with the phenyl group in an equatorial position, and (3) the 
stereoelectronically enforced migration of a carbon antiperiplanar to the N2+ leaving group 
(which is axial to allow appropriate arrangement between the migrating and leaving groups). All 
three factors combine to enforce migration of one diastereotopic methylene group over the other, 
which was experimentally observed (Table 1.1). In fact, regiochemical outcome switches when 
the opposite enantiomer of hydroxyalkyl azide is used.  
 It is revealed in Table 1.1 that 3-oxosteroids 1.13–1.15 can be regioselectively converted 
into either desirable lactam in excellent yields by the expedient choice of (S)- or (R)-
azidopropanol reagents. A prominent trend is that the best regioisomer ratios were obtained from 
reactions containing alkyl or aryl substitutions at either the 1 or 3 positions of the hydroxyalkyl 
side chain, whereas a slight erosion in regioselectivity was observed when the 2 position of the 
hydroxyalkyl side chain is substituted. Particularly, in the cases of (S)- or (R)-3-azido-2-
methylpropanol, (S)- or (R)-1.3, 90:10 regioisomer ratios were observed (entries 5 and 6). It 
should be noted that azide reagents substituted at the 2 position (whether 2-alkyl or 2-aryl) have 
been shown to lead to less diastereoselective reactions in the asymmetric Schmidt report.85 On 
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the contrary, high regiochemical control was obtained from the reactions containing methyl or 
phenyl substitution at the 3 position. An instructive pair of examples is shown in Figures 1.17 
and 1.18. Here again, the regiochemical outcomes of these reactions are governed by the 
combination of three principles outlined above.  
 
Figure 1.15. Mechanistic rationale for the ring expansion reaction of a 3-oxosteroid with (R)-3-
azido-1-phenylpropanol (R)-1.2. In this example, E/equatorial attack by the azide is preferred and 
the conformation of the newly formed 1,3-oxazinane ring (i) is anchored by the 1-phenyl 
42 
 
substituent. This leads to migration of the C-2 carbon (blue bond) and following hydrolysis of 
iminium 1.18ii affords isomer 1.18. Differentiation between C-2 and C-4 migration is shown by 
the blue and red bonds, respectively, and key antiperiplanar relationship between the migrating 
group and the N2+ leaving group is indicated by bold bonds.  
 
 
Figure 1.16. Mechanistic rationale for the ring expansion reaction of a 3-oxosteroid with (S)-3-
azido-1-phenylpropanol (S)-1.2. In this example, E/equatorial attack by the azide is preferred and 
the conformation of the newly formed 1,3-oxazinane ring (i) is anchored by the 1-phenyl 
substituent. This leads to migration of the C-4 carbon (red bond) and following hydrolysis of 
iminium 1.19ii affords isomer 1.19. Differentiation between C-2 and C-4 migration is shown by 
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the blue and red bonds, respectively, and key antiperiplanar relationship between the migrating 
group and the N2+ leaving group is indicated by bold bonds.  
 
 
Figure 1.17. Mechanistic rationale for the ring expansion reaction of a 3-oxosteroid with (S)-3-
azido-3-phenylpropanol (S)-1.4. In this example, E/equatorial attack by the azide is preferred and 
the conformation of the newly formed 1,3-oxazinane ring (i) is anchored by the 3-phenyl 
substituent. This leads to migration of the C-2 carbon (blue bond) and following hydrolysis of 
the iminium 1.22ii affords isomer 1.22. Differentiation between C-2 and C-4 migration is shown 
by the blue and red bonds, respectively, and key antiperiplanar relationship between the 




Figure 1.18. Mechanistic rationale for the ring expansion reaction of a 3-oxosteroid with (R)-3-
azido-3-phenylpropanol (R)-1.4. In this example, E/equatorial attack by the azide is preferred and 
the conformation of the newly formed 1,3-oxazinane ring (i) is anchored by the 3-phenyl 
substituent. This leads to migration of the C-4 carbon (red bond) and following hydrolysis of 
iminium 1.23ii affords isomer 1.23. Differentiation between C-2 and C-4 migration is shown by 
the blue and red bonds, respectively, and key antiperiplanar relationship between the migrating 
group and the N2+ leaving group is indicated by bold bonds. 
 
To expand the library, similar reactions to 3-cholestone 1.13 were carried out with 
substrates 5D-DHT 1.14 and 5E-DHT 1.15. Overall yields for these reaction sequences were 
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excellent throughout (see Table 1.1). An additional opportunity was explored with 5D-DHT 1.14, 
in which reactions were carried with a pair of enantioenriched p-bromophenyl azide reagents 
(entries 14 and 15). These analogs were synthesized because the bromo-functionality is a suitable 
handle for downstream cross-coupling activities.  
 An enlightening result during the library expansion was that the nitrogen insertion 
selectivities changed when the stereocontrolled ring expansion reactions were carried out with 
cis-AB steroid, 5E-DHT 1.15 (entries 22–25). When comparing C-5 epimeric steroids, 5D-DHT 
1.14 and 5E-DHT 1.15, opposite nitrogen insertion selectivities were observed. As shown in 
Scheme 1.10 for example, the same chiral reagent (S)-1.2 reverses the overall directionality of 
the nitrogen insertion process and results in opposite regioisomeric lactams 1.28 (4-aza) and 1.38 
(3-aza). This ensues because for trans-AB ring substrates equatorial attack is E, whereas for 
substrates containing a cis-AB ring fusion, equatorial attack is D. A general mechanistic outline 
for the cis-fusion outcome affording analogs 1.38 and 1.39 are shown in Figures 1.19 and 1.20, 
respectively. In this regard, facial selectivities in azide addition onto the oxonium species 
changes the absolute stereochemistry of the newly formed spirocycle stereogenic center, which 
in turn may lead to opposite regiochemical outcomes.  





Figure 1.19. Mechanistic rationale for the ring expansion reaction of 5E-DHT 1.15 with (S)-3-
azido-1-phenylpropanol (S)-1.2. In this example, D/equatorial attack by the azide is preferred and 
the conformation of the newly formed 1,3-oxazinane ring (i) is anchored by the 1-phenyl 
substituent. This leads to migration of the C-2 carbon (blue bond) and following hydrolysis of 
iminium 1.38ii affords isomer 1.38. Differentiation between C-2 and C-4 migration is shown by 
the blue and red bonds, respectively, and key antiperiplanar relationship between the migrating 




Figure 1.20. Mechanistic rationale for the ring expansion reaction of 5E-DHT 1.15 with (R)-3-
azido-1-phenylpropanol (R)-1.2. In this example, D/equatorial attack by the azide is preferred 
and the conformation of the newly formed 1,3-oxazinane ring (i) is anchored by the 1-phenyl 
substituent. This leads to migration of the C-4 carbon (red bond) and following hydrolysis of 
iminium 1.39ii affords isomer 1.39. Differentiation between C-2 and C-4 migration is shown by 
the blue and red bonds, respectively, and key antiperiplanar relationship between the migrating 
group and the N2+ leaving group is indicated by bold bonds. 
 
 Generally, product selectivity was excellent in the reaction sequences between 3-
oxosteroids with enantioenriched azidopropanol derivatives. In this part of our study alone, a 
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total of 22 isomerically pure azasteroid analogs were synthesized in ≥20 milligrams and ≥90% 
purity.  
 
1.3.3 A Study on the Use of 1,2-Hydroxyalkyl Azides to Effect Ring Expansion on 3-
Oxosteroids, Determination of Constitutional Isomerism Control, and Rationalization of 
Mechanism 
In this study, readily available 5D-DHT 1.14 and 5E-DHT 1.15 were reacted with 
hydroxyalkyl azides 1.7–1.9 (Table 1.2). Not surprisingly (see below), the product outcome of 
these reaction sequences with azidoethanol derivatives afforded poorer regiochemistry ratios 
compared to that of the azidopropanol derivatives (Table 1.2, entries 1–3). For entries 1–3, ca. 
40:60 ratios were observed, and regioisomers were difficult to purify chromatographically for 
spectroscopically pure lactams. However, in the remaining entries, the isomeric mixtures were 
separated in moderate yields and allowed trivial characterization of the major isomers. Isolation 
of major regioisomers in moderate yields suggest to poor isomeric mixtures and less selective 
reactions as compared to that of the azidopropanol reagents. Although these reactions were 
somewhat less selective than the azidopropanol reagents, the reactions with enantioenriched 
azidoethanol derivatives still provided isomerically pure 3-azasteroid and 4-azasteroid analogs 
1.42–1.51 for the library collection.  
In regards to the mechanism, the relationship between the migrating and leaving groups 
are less certain due to the presence of a five-membered ring requisite intermediate (i.e., 
uncertainty in assuming antiperiplanar angles for migration). Arguably from these results, a key 
source of regiochemical control is the minimization of steric interactions between the phenyl 
group of the side-chain and the migrating carbon of the steroid A-ring. In comparison to the 
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three-carbon azide reagents, the drop in selectivity associated with the two-carbon azide reagents 
is consistent with the requisite formation of five-membered ring conformers. Our reasoning is 
consistent with the data in Table 1.2.  
 
Table 1.2. Reaction of 3-oxosteroid 1.13–1.14 with 1,2-hydroxyalkyl azides 1.7–1.9.a  
 
entry steroid azide R6 R7 3-aza:4-aza 
ratiob 
product(s) isolated  
yield (%) 3-aza 4-aza 
1 1.13 1.7 H H 37:63c 1.42 + 1.43 95d 
2 1.13 (S)-1.8 (S)-Ph H 46:54 1.44 + 1.45 93d 
3 1.13 (R)-1.8 (R)-Ph H 33:67c 1.46 + 1.47 88d,e 
4 1.13 (S)-1.9 H (S)-CH2Ph ND - 1.48 81f,g 
5 1.13 (R)-1.9 H (R)-CH2Ph ND 1.49 - 65f,h 
6 1.14 (S)-1.9 H (S)-CH2Ph ND - 1.50 76f,i 
7 1.14 (R)-1.9 H (R)-CH2Ph ND 1.51 - 65f 
aSee Section 1.7.2 for reaction protocol. bRatio of 3-aza- and 4-aza-A-homo-steroid lactam was 
determined by 1H NMR of the final product. cMixture of regioisomers observed by 1H NMR of the crude 
reaction mixture, unless otherwise noted. dIsolated yield of a mixture of regioisomers. eIsomeric mixture 
was separated to give 26% isolated yield of 1.46 and 46% isolated yield of 1.47. fIsolated yield of the 
major regioisomer. gIsolated 12% yield (<10.0 mg) of the minor regioisomer, however was not further 
characterized. hIsolated 22% yield (<17.0 mg) of minor regioisomer, however was not further 
characterized. iMinor regioisomer observed in the final product. ND = Not Determined.  
 
 Two of the analogs synthesized, 1.48 and 1.49, provided crystals that were analyzed by 
X-ray crystallography to confirm regiochemistry, which permitted correlation with NMR 
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spectroscopic data for regiochemistry assignments (Figures 1.21 and 1.22). The X-ray crystal 
structures for these analogs are provided in the Cambridge Crystallography Deposit Center 
(CCDC).  
 
Figure 1.21. X-ray crystal structure for analog 1.48 (CCDC 1583534).  
 
 
Figure 1.22. X-ray crystal structure for analog 1.49 (CCDC 1583534).  
 
1.3.4 Functionalization of A-Ring Iminium Ions with Various Nucleophiles 
 The intermediacy of iminium ethers as primary rearrangement products facilitates the 
utility of this reaction in library development. This intermediate permitted a direct route to 
scaffold diversification by reaction with various nucleophiles. Conveniently, prior purification of 
iminium ether intermediates for functionalization was not necessary in these protocols. Using a 
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one-pot, three component reaction protocol, functionalized 3-aza- and 4-azasteroid analogs were 
prepared (Table 1.3). Specifically, readily available 5D-DHT 1.14 and 5E-DHT 1.15 substrates 
were reacted with hydroxyalkyl azides (S)- and (R)-1.2, as well as, (S)- and (R)-1.4, resulting in 
the regioselective formation of iminium ethers that were subsequently functionalized by 
treatment with four nucleophiles: sodium sulfide (Na2S), the reducing agents sodium 
borohydride (NaBH4) or hydrogen gas with Pd/C, NaN3, and 4-methylthiophenoxide. As 
described in the introduction, iminium ethers are known to react with a variety of nucleophiles at 
two possible carbon sites: path a via the formal sp2 iminium carbon and path b via the sp3 carbon 
adjacent to the oxygen atom. In this series, nucleophiles proceeding through path a afforded 
thioamides 1.52–1.57 (via treatment with Na2S) and amines 1.58–1.59 (via treatment with 
NaBH4). Reduction of the iminium ion to access amines was accomplished under very mild 
conditions compared to those typically employed for amide bond conversion to amines (e.g., 
refluxing LAH).  
Conversely, reduction of the iminium ion using hydrogenation conditions proceeded 
through path b, which resulted in a benzylic reduction and removed the regiodirecting 
stereocenter making this a ‘traceless’ process (Table 1.3, analogs 1.60–1.61). Typically, 
nucleophiles associated with path b undergo SN2-type reactions. In this series, azide-containing 
1.62–1.67 and sulfide-containing 1.68–1.73 N-alkylated lactams were synthesized in moderate 
yields (compound collection is shown in Table 1.3). Moreover, we inferred inversion of 
stereochemistry of the analogs containing a phenyl substituent at the sp3 carbon adjacent to the 
oxygen atom when the corresponding iminium intermediate reacted with azide and benzothiolate 
nucleophiles via path b (noted in the footnotes of Table 1.3 as well). It is also worth noting that 
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configuration of the side-chain hydroxyl is retained for analogs that proceed to react via path a 
(based on 18O-labeling studies reported in the literature as discussed in the introduction).84, 104   
 




entry steroid azide  isolated yield (%) 
 
 Z 
   S H  N3 (4-Me)PhSb 
1 1.14 (R)-1.2 85, 1.52 87, 1.58c,d 92, 1.60e 56, 1.62f 66, 1.68 f 
2 1.14 (S)-1.2 45, 1.53 50, 1.59c,g 93, 1.61e 73, 1.63 f 67, 1.69 f 
3 1.14 (R)-1.4 59, 1.54 - 65, 1.64 83, 1.70 
4 1.14 (S)-1.4 80, 1.55 - 60, 1.65 65, 1.71 
5 1.15 (S)-1.2 62, 1.56 - 82, 1.66 f 56, 1.72 f 
6 1.15 (S)-1.4 78, 1.57 - 84, 1.67 76, 1.73 
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aSee Section 1.7.2 for reaction protocols. b0.66 M stock solution of sodium 4-methyl thiophenoxide was 
prepared immediately prior to use by adding sodium (1.0 equiv) to a solution of 4-methylbenzenethiol 
(1.1 equiv) in anhydrous DMF (15.0 mL) at 0 ˚C and stirring at room temperature overnight. cNaBH4, 
MeOH. d51% isolated yield of 1.58 was also obtained from LAH reduction of 1.29. eHydrogenation using 
10% Pd/C, EtOH.  fInversion of stereochemistry. g58% isolated yield of 1.59 was also obtained from LAH 
of 1.28.   
 
 Finally, to further incorporate structural diversity, derivatives lacking the stereochemical 
information that was used to effect the specific ring-expansion reactions were synthesized 
(Scheme 1.11). If necessary, the “parent” lactams of the A-ring steroid are suitable precursors for 
downstream diversification. Removal of the regiodirecting stereocenter was carried out by two 
straightforward synthetic sequences: (1) hydrogenation to remove the benzylic hydroxyl group 
and (2) oxidation of the benzylic hydroxyl group to ketone functionality. As shown in Scheme 
1.11a, 3-azasteroid derivatives 1.18 and 1.29 were converted to analogs 1.74–1.76 lacking 
stereochemical information in the N-side chain; in a similar manner, 4-azasteroid derivatives 
1.77–1.79 were synthesized (Scheme 1.11b). Particularly in Scheme 1.12, oxidation of the side 
chain-benzylic hydroxyl group followed by elimination with sodium hydride (NaH) base 
afforded “parent” constitutional isomers. 3-Cholestone and 5D-DHT ketone derivatives 1.75–
1.76 were converted to 3-azasteroid “parent” lactams 1.80–1.81 in high yields (Scheme 1.12a). 
Accordingly, using similar transformations 4-azasteroid derivatives were converted to its 










Scheme 1.11. Stereoconvergence. (a) Stereoconvergence of 3-azasteroid analogs. (b) 









Scheme 1.12. Synthesis of the ‘parent’ NH A-ring lactams. (a) Synthesis of the ‘parent’ 3-
azsteroid A-ring lactam. (b) Synthesis of the ‘parent’ 4-azsteroid A-ring lactam.  
 
 
1.4 D-Ring Modifications 
1.4.1 Beckmann Rearrangement of 17-Oxosteroids 
 The Beckmann rearrangement for ring expansion chemistry is analogous to the Schmidt 
reaction, and, so similarly, is a useful tool to introduce a nitrogen heteroatom into a carbocyclic 
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framework through the modification of a ketone.70, 105 Although the Beckmann rearrangement of 
17-oxosteroid has been known since 1956,94 the analog was synthesized to demonstrate the 
Beckmann reaction as a complementary method; more importantly, to compare mechanistically 
and spectroscopically the regioisomeric outcome with that of the Schmidt reaction of 
hydroxyalkyl azide. In this work, the stereospecific isomerization of 17-oxime-steroid to give 17-
lactam-steroid warrants discussion because the regiochemical outcome of the Beckmann reaction 
is complementary to that of the Schmidt reaction of azidopropanols.  
 The Beckmann rearrangement requires two synthetic steps. As shown in Scheme 1.13, 
oximes were prepared from starting ketone, trans-androsterone 1.84 and acetate-protected trans-
androsterone 1.85. Then, rearrangement of 17-oxime-steroids 1.86–1.87 was carried out by 
treatment with thionyl chloride (SOCl2) in anhydrous tetrahydrofuran (THF). Unfortunately, the 
conversion to desired lactams 1.88–1.89 proceeded in low yields. A continual challenge for 
carrying out the Beckmann reaction is the requirement of harsh conditions. For example, we used 
10.0 equiv excess of SOCl2 to prepare the lactam products. Despite using excess acid, only one 
isomer of the rearranged product 1.88–1.89 was observed. Generally, the Beckmann 
rearrangement is stereospecific and the observed regiochemical outcome is consequential of the 
preferential formation of the (E)-oxime. Theoretically two constitutional (E)- and (Z)-oximes 
may occur, however biased by the steroid structure, formation of the sterically less hindered (E)-
17-oxime is favorable (Figure 1.23). In contrast, the formation of (Z)-17-oxime is encumbered by 
syn-pentane-like interactions and is very unlikely. As a result, rearrangement proceeds 
exclusively through migration of the C-13 antiperiplanar to the activated OH leaving group 
affording the lactam 1.88. Alternatively, one could rationalize the isolation of the exclusive 
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regioisomer as confirmation to the assignment of the (E)-17-oxime 1.86 as the sole oxime 
isomer.  
 






Figure 1.23. Proposed mechanism for the Beckmann reaction of trans-androsterone 1.84. The 
Beckmann rearrangement has been established and shown70 to occur through selective reaction 
of the sterically least hindered (E)-oxime isomer 1.86 and migration of the trans-antiperiplanar 
bond as depicted in bold blue.  
 
 Although the Beckmann rearrangement gave a clean conversion to one regioisomer, a 
continual restriction of this ring expansion chemistry is the lack of flexibility in providing access 
to either isomers selectively at will. Therefore, in order to find synthetic routes for selective 
preparation of all constitutional isomers other types of chemistry must be explored.  
 
1.4.2 Intramolecular Schmidt Reaction of 17-Oxosteroids 
 The intramolecular Schmidt reaction was used to add to this library collection. First 
introduced in 1991 by Milligan and Aubé, the tethered alkyl azide reacts with ketone under 
acidic conditions in an intramolecular fashion to prepare a fused lactam.106 Since its discovery, 
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the method has been extensively studied and usually leads to the fused lactam isomer. Here, a 
recently improved protocol of the intramolecular Schmidt reaction was applied to the structurally 
complex 17-oxosteroids, trans-androsterone 1.84 and estrone 1.90.107  
 As shown in Scheme 1.14, the 3-hydroxyl group of trans-androsterone 1.84 was 
protected using tert-butyldimethylsilyl chloride (TBSCl) affording 1.91 prior to synthesis of the 
tethered alkyl azide. The C-16 alkylation of the 17-oxosteroidal substrates was carried out by 
deprotonation with lithium di-isopropyl amide (LDA) conditions followed by addition of 1-
chloro-3-iodopropane to provide chloro-alkyl substituted tethers. The Dstereochemistry at the C-
16 position of 1.92 was determined by 1D-NOE NMR experiments, in which the C-16 E-
hydrogen was found to be close to the C-13 methyl substituent. The chloro-alkyl tether 
derivative 1.92 was converted to azide-alkyl tether 1.93 by treatment with NaN3. With 1.93 in 
hand, conversion to fused lactam 1.94 proceeded smoothly in good yields using 1.5 equiv of 
titanium tetrachloride (TiCl4) in HFIP; excess acid facilitated the intramolecular Schmidt 
reaction and the removal of 3-hydroxyl-TBS protecting group. On the other hand, with an azide-
alkyl estrone substrate 1.97, the reaction only required 50 mol% of TiCl4 to directly afford the 
corresponding fused lactam 1.98 in 69% yield. The following methoxy-deprotection of 1.98 with 
boron tribromide (BBr3) reagent gave the 3-phenol-17-fused-lactam analog 1.99.108 Finally, it is 
worth noting that in both examples the intramolecular Schmidt reaction was exclusively selective 
for the fused lactam over the bridge lactam isomer; the fused lactam proceeds via formation of 
the most stable ring fusion (Figure 1.24). Although the intramolecular Schmidt reaction forced 
migration of C-16 over C-13 (compared to the Beckmann reaction), the attachment of an 
azidopropane side chain onto a steroid is a limited solution for late-stage diversification and 
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regiodivergent strategies. In these experiments, three analogs of the interesting pentacyclic 
lactams were synthesized and incorporated in the library collection.  
 












Scheme 1.15. The intramolecular Schmidt reaction of estrone 1.90.  
 
 
Figure 1.24. Proposed mechanism for the intramolecular Schmidt reaction of trans-androsterone 
1.84. The intramolecular Schmidt reaction of a tethered azido ketone entails formation of the 
most stable ring fusion upon azide addition to the TiCl4-activated ketone and subsequent 
migration of a C–C bond antiperiplanar to the N2+ leaving group. In these reactions, the leaving 
group generally occupies an equatorial position and migration of the ring fusion carbon ensues. 
Under special conditions, axial N2+ is possible, leading to bridged adducts, but these cases are 
rare.109 In the case shown, D-addition to C-17 is proposed because the cis bicyclic ring systems 
are generally preferred over the trans version, but the same outcome would be predicted from 





1.4.3 A Study on the Use of 1,3-Hydroxyalkyl Azides to Effect Ring Expansion on 17-
Oxosteroids, Determination of Constitutional Isomerism Control, and Rationalization of 
Mechanism 
To address the problem of D-ring regiochemical divergence, the Schmidt reaction of 
hydroxyalkyl azide (i.e., stereoelectronically controlled ring expansion) was employed to 
influence the N-side chain installation. In this study, readily available 17-oxosteroids 1.84 and 
1.90 were reacted with hydroxyalkyl azides 1.1–1.6. However, prior to the study, optimization 
studies of the reaction condition was carried out. Due to the relatively hindered nature of the D-
ring neopentyl carbonyl, a survey of reaction conditions was explored. The reaction between 
trans-androsterone 1.84 and 3-azidopropanol 1.1 was optimized and these conditions are shown 
in Table 1.4. Generally, this Schmidt reaction variant requires 2.0–5.0 equiv of BF3yOEt2 in 
CH2Cl2 to execute efficient lactam synthesis from simple cyclic ketones. Unfortunately, under 
these conditions starting material remained unconsumed even after 24 hours and with increased 
acid loading to 7.0 equiv (entries 1–3). To address this poor reactivity, a recently improved 
protocol in hexafluoroisopropanol ((CF3)2CHOH or HFIP) was adopted (the details of this 
methodology development are discussed in Chapter 2).110  
Improved results were obtained by carrying out the reaction in HFIP. In surveying some 
protic acids in HFIP (entries 4–6), trifluoromethanesulfonic acid (CF3SO3H or TfOH) gave a 
complete conversion from starting material 1.84 to lactam 1.100 within 24 h and afforded 94% 
yield of exclusively one regioisomer (1.100 isomer observed while 1.100’ isomer not observed). 
From this optimization study, a significant improvement in the minimization of acid equivalence 
resulted from using HFIP as a solvent media. However, a minimal promoter stoichiometry of 1.0 
equiv is necessary to facilitate counterion stabilization of the iminium ether intermediate. To 
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complete this study, the use of TfOH for this reaction was compared in another fluorinated 
alcohol solvent trifluoroethanol (CF3CH2OH or TFE) and the traditional solvent CH2Cl2 (entries 
7 and 8). These results failed to give complete conversions from starting material to lactam, 
which further affirmed the use of HFIP as optimal.   
 
Table 1.4. Optimization of conditions for the reaction between trans-androsterone 1.84 and 3-
azidopropanol 1.1.a  
 








1 3.0 BF3yOEt2 2.0 CH2Cl2 21:79 16 
2 3.0 BF3yOEt2 5.0e CH2Cl2 82:18 80 
3 2.0 BF3yOEt2 7.0e CH2Cl2 89:11 85 
4 2.0 BF3yOEt2 1.1 (CF3)2CHOH 78:22 72 
5 2.0 H2SO4 0.55f (CF3)2CHOH 86:14 78 
6 2.0 CF3SO3H 1.1 (CF3)2CHOH >98:2g 94 
7 2.0 CF3SO3H 1.1 CF3CH2OH 61:39 61 
8 2.0 CF3SO3H 1.1 CH2Cl2 16:84 10 
aSee Section 1.7.4 for reaction protocols. bOnly regioisomer 1.100 was observed by 1H NMR of the crude 
reaction mixture. cProduct conversion was determined by 1H NMR of the crude reaction mixture. 
dIsolated yields of regioisomer 1.100. eCatalyst was added at 0 ˚C. fGenerates 1.1 equiv of proton catalyst. 





Surprisingly, over the course of this study exclusively one constitutional isomer (1.100) 
was observed by crude 1H NMR. The structure of this isomer was confirmed by X-ray crystal 
analysis (Figure 1.25). This result warrants further explanation as the constitutional isomer is 
opposite to that of the Beckmann outcome (C-16 versus C-13 migration).  
 
 
Figure 1.25. X-ray crystal structure of analog 1.100 (CCDC 1583536).  
 
The intermolecular Schmidt reaction between 17-oxosteroid and achiral 3-azidopropanol 
is mechanistically intriguing. To explain this outcome, rationalization of key intermediates and 
transition structures formed in this ring expansion process is pertinent. The regiochemistry of this 
reaction may arise from a combination of two stereochemical and conformational considerations, 
neither of which is obvious based on precedent. The two factors include: (1) D versusE attack 
onto the C-17 oxonium ion and (2) the formation of 1,3-oxazinane ring conformers and favorable 
chair conformations. All possible transformations are assumed to involve antiperiplanar carbon 
migration to an axial N2+ leaving group. As shown in Figure 1.26, the newly formed 1,3-
oxazinane ring can exist in two chair conformations 1.100i and 1.100i’. Upon azide addition, the 
spirocyclic center is attached to C-16 and C-13 of the steroid. The former C-16 is ethyl-like 
(medium substituent, M), and the latter C-13 is fully substituted, therefore tert-butyl-like (large 
substituent, L). Accordingly, C-13 should occupy an equatorial position in preference to the 
65 
 
smaller C-16 methylene group as shown in the figure (boxed). Stereoelectronically enforced 
migration of C-16 occurs through the preferred oxazinane conformer to afford the corresponding 
iminium 1.100ii. Subsequent base treatment of 1.100ii led to the observed product 1.100, which 
was experimentally the exclusive product of the reaction. The matter of D versusE attack is less 
obvious in this example because, in either case, there is a stable chair conformation that would 
lead to the observed regiochemistry. However, this issue clearer in examples with substituents on 





Figure 1.26. Proposed mechanism for the Schmidt reaction between trans-androsterone 1.84 and 
azidopropanol 1.1. Differentiation between the large substituent (C-13, blue bond) and medium 
substituent (C-16, red bond) is denoted as L and M, respectively.  
 
 
 Despite the apparently high substrate bias of the 17-oxosteroids with 3-azidopropanol 1.1 
as indicated by the results in Figure 1.26, it was proved possible to completely divert the reaction 
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outcome using chiral azides as reactants. In Table 1.5, readily available 17-oxosteroidal 
substrates were reacted with chiral hydroxyalkyl azides 1.3 and 1.5. When 1.84 was reacted with 
(S)-1.3, a mixture of regioisomers 1.101 and 1.102 were observed by 1H NMR of the crude 
reaction mixture, whereas when the substrate was treated with (R)-1.3 exclusive migration of C-
16 was observed (analog 1.103, which represented a similar outcome to that observed with using 
achiral 1.1). An instructive pair is the reaction of 1.84 with (S)- and (R)-1.5, because the 
experiments showed an intrinsic preference of the chiral 3-methyl hydroxyalkyl azides over the 
steroid substrate. Remarkably, the opposite migration occurred when the reaction was carried out 
using (S)-1.5, in which the chiral reagent forcibly led to the C-13 migration result over the 
natural substrate preference for C-16 migration affording the regio-diverted analog 1.104. On the 
contrary, rearrangement with reagent (R)-1.5 gave the natural substrate preference and the 
product outcome (analog 1.105) was similar to that of the achiral 1.1. Mechanistic considerations 
of the chiral reagent 1.5-controlled ring expansions of 1.84 are shown in Figures 1.27 and 1.28. 
Here, discussion on the topic of D versusE attack is more fitting. In Figure 1.29, the depicted 
chair conformations reveal that there are variable stable chair conformations that would lead to 
the observed stereochemistry associated with an azide reactant. However, the literature is silent 
on the facial preference of intramolecular spirocycle formation in cases like these (as opposed to 
intermolecular organometallic additions, which prefer D attack away from the C-18 methyl 
group).111 In retrospect, E attack seems more likely with respect to the heterocycle conformers 
because both the steroid and methyl substituents would satisfy more favorably when both are 
occupying the equatorial positions.  
Moreover, C-16 migration was observed when (R)-3-azidobutanol (R)-1.5 was the 
reactant in the reaction (Figure 1.28); whereas, the opposite regiochemistry (C-13 migration) was 
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observed when (S)-3-azidobutanol (S)-1.5 was used as the azide reactant (Figure 1.27). The 
proposed E-attack of azide at C-17 oxonium is uniformly consistent because this mechanism 
clearly proceeds via the favorable formation of the more stable 1,3-oxazinane conformations 
(i.e., methyl substituents occupying equatorial positions in the ring conformer).  
 
Table 1.5. Reactions of 17-oxosteroids 1.84, 1.90, and 1.95 with 1,3-hydroxyalkyl azides 1.1, 
1.3, and 1.5.a  
 





(%)d 17-aza 17a-aza 
1 1.84 1.1 H H >95:5 1.100 - 94 
2 1.84 (S)-1.3 (S)-Me H 56:44e 1.101 + 1.102 53:35f 
3 1.84 (R)-1.3 (R)-Me H >95:5 1.103 - 93 
4 1.84 (S)-1.5 H (S)-Me 5:>95 - 1.104 69 
5 1.84 (R)-1.5 H (R)-Me >95:5 1.105 - 92 
6 1.90 1.1 H H ND 1.106 - 91 
7 1.90 (S)-1.3 (S)-Me H 60:40g 1.107 + 1.108  52:34f 
8 1.90 (R)-1.3 (R)-Me H ND 1.109 - 85 
9 1.90 (S)-1.5 H (S)-Me ND  1.110 68 
10 1.90 (R)-1.5 H (R)-Me ND 1.111 - 86 
11 1.95 1.1 H H ND 1.112 - 93 
aSee Section 1.7.4 for reaction protocols. bRatio of 17-aza- and 17a-aza-D-homo-steroid lactam was 
determined by 1H NMR of the crude reaction mixture. cOnly one 17-aza-regioisomer was observed by 1H 
NMR of the crude reaction mixture, unless otherwise noted. dIsolated yields of only the major 
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regioisomer, unless otherwise noted. eMixture of regioisomers observed by 1H NMR of the crude reaction 
mixture. fIsolated yields of individual regioisomers. gRatio determined by analytical HPLC of the crude 
reaction mixture. ND = Not determined; R3 = H in all cases. 
 
 
Figure 1.27. Proposed mechanism for the regioselectivity of trans-androsterone 1.84 with (S)-3-
azidobutanol (S)-1.5. In this example, it was experimentally shown to lead to the isomer resulting 
from migration of C-13 (red bond). Together, these facts support the assignment of E attack onto 
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the C-17 oxonium ion as shown. Differentiation between the large substituent (C-13, blue bond) 
and medium substituent (C-16, red bond) is denoted as L and M, respectively.  
 
 
Figure 1.28. Proposed mechanism for the regioselectivity of trans-androsterone 1.84 with (R)-3-
azidobutanol (R)-1.5. In this example, the (R)-methyl group and the placement of the large C-13 
into an equatorial substituent clearly favor the 1,3-oxazinane 1.105i conformation as shown, and 
experimentally observed was the isomer resulting from the migration of C-16. Together, these 
facts support the assignment of E attack onto the C-17 oxonium ion as shown. Differentiation 
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between the large substituent (C-13, blue bond) and medium substituent (C-16, red bond) is 
denoted as L and M, respectively. 
 
 
Figure 1.29. Possible ring conformations leadings to C-16 migration. In each case depicted, 
there is a stable chair conformation that would lead to the observed regiochemistry.  
 
 
To further expand the library collection, similar reactions of the trans-androsterone series 
were carried out with the estrone substrates 1.90 and 1.95. The crude regiochemistry of these 
reactions were difficult to examine due to the solubility of estrone derivatives in 
dimethylsulfoxide (DMSO) and not chloroform (CDCl3). However, these additional reactions 
provided 7 new estrone-lactam derivatives for the collection and the regiochemical outcomes 
were analogously selective to that of the trans-androsterone 1.84 substrate discussed (Table 1.5).  
 
1.4.4 A Study on the Use of 1,2-Hydroxyalkyl Azides to Effect Ring Expansion on 17-
Oxosteroids, Determination of Constitutional Isomerism Control, and Rationalization of 
Mechanism 
In this study, readily available 17-oxosteroid substrates were reacted with azidoethanol 
derivatives 1.7–1.11 (Table 1.4). These additional opportunities for isomer control were briefly 
examined. Not surprisingly, these reaction sequences with azidoethanol derivatives afforded 
poorer regiochemical control compared to those of the azidopropanol derivatives. Unfortunately, 
the crude regioisomer ratio for these reactions were difficult to discern, but isolation of major 
regioisomers in moderate yields clearly suggest to poor isomeric mixtures and less selective 
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reactions compared to that of the azidopropanol reagents. Despite this, these experiments still 
provided 15 isomerically pure 17- and 17a-azasteroid 1.113–1.114 for the library collection.  
With respect to the mechanism, the ability of a five-membered ring intermediate to 
assume an antiperiplanar relationship between the migrating and leaving groups are less certain. 
Arguably from these results, a key source of regiochemical control is the minimization of steric 
interactions between the alkyl or phenyl group of the side-chain and the migrating carbon of the 
steroid D-ring. In comparison to the three-carbon azide reagents, the drop in selectivity 
associated with the two-carbon azide reagents is consistent with the requisite formation of five-

















Table 1.6. Reactions of 17-oxosteroids 1.84 and 1.90 with 1,2-hydroxyalkyl azides 1.7 and 1.9–
1.11.a  
 
entry steroid azide R7 17-aza:17a-aza 
ratiob 
product(s) isolated 
yield (%) 17-aza 17a-aza 
1 1.84 1.7 H 30:70c 1.113 + 1.114 96d 
2 1.84 (S)-1.9 (S)-CH2Ph ND - 1.115 89 
3 1.84 (R)-1.9 (R)-CH2Ph ND 1.116 - 82e 
4 1.84 (S)-1.10 (S)-Ph ND - 1.117 77 
5 1.84 (R)-1.10 (R)-Ph ND 1.118 - 51 
6 1.84 (S)-1.11 (S)-CH2CHMe2 ND - 1.119 86 
7 1.84 (R)-1.11 (R)-CH2CHMe2 ND 1.120 - 83e 
8 1.90 1.7 H 30:70f 1.121 + 1.122 94g 
9 1.90 (S)-1.9 (S)-CH2Ph ND - 1.123 91 
10 1.90 (R)-1.9 (R)-CH2Ph ND 1.124 - 72e 
11 1.90 (S)-1.10 (S)-Ph ND - 1.125 51 
12 1.90 (R)-1.10 (R)-Ph ND 1.126 - 56e 
13 1.90 (S)-1.11 (S)-CH2CHMe2 ND - 1.127 86 
14 1.90 (R)-1.11 (R)-CH2CHMe2 ND 1.128 - 68 
aSee Section 1.7.4 for reaction protocols. bRatio of 17-aza- and 17a-aza-D-homo-steroid lactam was 
determined by 1H NMR of the crude reaction mixture, unless otherwise noted. cRatio determined by 1H 
NMR of final compound. dIsolated yield of a mixture of regioisomers. eMinor regioisomer was observed 
in 1H NMR of final compound. fRatio determined by analytical HPLC of crude reaction mixture.  
gIsomeric mixture was separated to give 27% isolated yield of 1.121 and 52% isolated yield of 1.122. ND 






1.4.5 Functionalization of D-Ring Iminium Ions with Various Nucleophiles 
 The intermediacy of an iminium ether as a primary rearrangement product permit their 
versatility for diversification using experimentally straightforward chemistry. In the above 
examples, iminium ethers were hydrolyzed to the corresponding N-alkyl lactams, however, as 
mentioned previously iminium ethers are known to react with a variety of nucleophiles. Thus, a 
small library of diverse 17-aza-D-homo-steroids were prepared using a one-pot three component 
protocol (Table 1.7). Specifically, commercially available trans-androsterone 1.84 and estrone 
1.90 were reacted with achiral 3-azidopropanol 1.1, which resulted in regioselective iminiums 
that were subsequently functioned by treatment with four types of nucleophiles: Na2S, the 
reducing agents NaBH4 or sodium borodeuteride (NaBD4), NaN3, and 4-subsituted 
thiophenoxides. Through path a thioamides, 1.129 trans-androsterone-derived and 1.138 estrone-
derived, were synthesized in moderate yields. Interestingly, path a reduction of D-ring with 
either NaBH4 or NaBD4 stereoselectively led to previously unobserved 1,3-oxazinanes 1.130–
1.131 and 1.139–1.140, trans-androsterone and estrone-derived, respectively. The unusual 
heterocyclic structure of 1.130 was confirmed by X-ray crystallography and shown in Figure 
1.30. Reduction of the D-iminium to access the 1,3-oxazinane structure was accomplished under 
very mild conditions. In past attempts using simpler iminium ether substrates, conditions led to 
fully reduced tertiary amines due to the double addition of the hydride nucleophile. However, 
due to the bulky steroid framework only one addition of the hydride/deuteride species occurred 
despite using heat or excess amounts of reducing agent over an extended period of time.  
 Conversely, nucleophiles that proceed with path b typically undergo SN2-type reactions 
and onto afford N-alkylated lactams. In this way, azide and sulfide N-alkylated lactams, 1.132–
1.137 and 1.138–1.144, were synthesized in moderate yields from 17-oxosteroid substrates. With 
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primary azide handles, analogs 1.132 and 1.141 were subjected to copper-promoted 1,3-dipolar 
Huisgen azide-alkyne cycloaddition reactions for the preparation of triazoles. Using standard 
click chemistry, four additional analogs were prepared with substituted acetylenes as shown in 






















Table 1.7. Three-component reactions for the synthesis of functionalized 17-aza-D-homo-
steroids 1.129–1.144.a  
 
entry steroid nucleophile S, Y or Z product isolated yield (%) 
1 1.84 Na2S S 1.129 52 
2 1.84 NaBH4 H 1.130 85 
3 1.84 NaBD4 D 1.131 64 
4 1.84 NaN3 N3 1.132 86 
5 1.84 NaSAr SC6H5b-c 1.133 71 
6 1.84 NaSAr S(4-Me)C6H4 b-c 1.134 76 
7 1.84 NaSAr S(4-OMe)C6H4 b,d 1.135 65 
8 1.84 NaSAr S(4-Cl)C6H4b,e 1.136 69 
9 1.84 NaSAr S(4-Br)C6H4b,f 1.137 61 
10 1.90 Na2S S 1.138 51 
11 1.90 NaBH4 H 1.139 83 
12 1.90 NaBH4 D 1.140 82 
13 1.90 NaN3 N3 1.141 82 
14 1.90 NaSAr SC6H5b-c 1.142 62 
15 1.90 NaSAr S(4-Me)C6H4b-c 1.143 60 
16 1.90 NaSAr S(4-OMe)C6H4b,d 1.144 63 
aSee Section 1.7.4 for reaction protocols. bStock solutions of sodium thiophenoxides were prepared 
immediately prior to use by adding sodium (1.0 equiv) to a solution of thiophenols (1.1 equiv) in 
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anhydrous DMF (15.0 mL) at 0 ˚C and stirring at room temperature overnight. c0.66 M stock solution. 
d0.67 M stock solution. e0.70 M stock solution. f0.56 M stock solution.  
 
 
Figure 1.30. X-ray crystal structure of analog 1.130 (CCDC 1583518).   
 




 Finally, D-ring analogs that lacked the stereochemical information used to effect the 
specific ring-expansion reactions were synthesized. As shown in Scheme 1.17, the “parent” NH 
lactams of the D-ring steroid were prepared from dissolving metal reduction, in which these 
conditions facilitated cleavage at the benzylic site of the side chains. The establishment of pure 
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“parent” regioisomers further assured the opposing structural features by NMR spectroscopy as 
well as validated the effect of stereoelectronically controlled ring expansion sequence.  
 
Scheme 1.17. Synthesis of the ‘parent’ NH D-ring lactams.  
 
 
1.5 Conclusions and Future Directions 
To summarize, we have demonstrated predictable and selective installation of nitrogen 
into the steroid backbone at four separate positions using stereoelectronically controlled ring 
expansion reactions. We have shown that judicious use of the appropriate azide reagent permits 
regioselective installation of the nitrogen substituent. Achiral and chiral enantioenriched 
hydroxyalkyl azides directed nitrogen insertion in cases where (1) there was minimal migration 
preference (i.e., 3-oxosteroids; C-3 and C-4 were isoelectronic) or, in contrast, (2) there was 
substantial substrate bias for a given regiochemistry (i.e., 17-oxosteroids, C-13 and C-16 were 
not isoelectronic). This work on A- and D-ring late-stage modification featured regiodivergent 
rearrangement, specifically demonstrated the concept of using chiral reagents to effect 
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regiocontrol in chiral natural products. Moreover, by combining the feature of regiochemical 
control with the versatility of iminium ethers as ambident electrophilic intermediates, a 
collection of functionalized analogs was prepared. In sum, 114 isomerically pure analogs with 
spatial and functional diversity were synthesized in >20 milligrams and >90% purity for this 
library collection. This work on reagent-controlled ring expansion should help enhance 
rationalization of the placement of new functional groups onto a natural product backbone and 
application towards library development and diversification programs.  
 
Future Directions  
 Originally, we had aimed to describe a global approach of steroid ring-expansion 
chemistry that incorporated B- and C-ring nitrogenous modifications. Ring-expansion chemistry 
of these steroidal rings are quite rare, therefore represents a unique opportunity to explore the 
effect of reagent-controlled ring expansion in these chiral contexts and produce new steroid-like 
analogs for the library collection. Unfortunately, carrying out any general nitrogen ring-
expansion chemistry at either B- or C-ring is very challenging for a number of reasons.  
 The first challenge is accessing ketone-starting materials. The synthesis of B- and C-ring 
ketones require multiple synthetic steps, which necessitates large-scale chemistry and tedious 
protecting-group manipulations. For example in Scheme 1.18, the preparation of 6-oxosteroid 
and 7-oxosteroid can be visualized through concomitant hydroboration and DMP oxidation, or 
allylic oxidation and enone reduction. Despite having potential access to B-ring oxosteroids, the 
spectroscopic identification of regiochemistry is more accurately represented by comparison both 
types of nitrogen insertion processes, the Beckmann and Schmidt reactions (in fact, may require 
substantial optimization to obtain high-yielding reactions).  
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Scheme 1.18. Synthesis of B-ring oxosteroids. (a) Synthesis of 6-oxosteroid. (b) Synthesis of 





We had envisioned the synthesis of C-ring oxosteroids from readily available steroid 
materials: hydrocortisone, estrone, and cholic acid (Scheme 1.19). Similarly, to access C-ring 
ketones the preparation would require installing/changing the hydroxylation/oxidation states of 
the starting material via a series of protecting-group manipulations. We found this tedious route 
not promising because, based on literature readings, the reactivity of functionalities in those 
positions are quite poor. As a result, a shorter route to obtain carbonyl functionalities in the B- 
and C-ring system might be more promising and amendable towards ring-expansion chemistry 
and library development. This proposal is depicted in Figure 1.31; upon optimization of 
ozonolysis protocols on steroid substrates, this would result in two carbonyl handles on each 
individual steroid for experimentation. Seemingly, the carbonyls at these positions are less 
hindered, which suggests that these sites may be more reactive to ring-expansion studies. 
However, one would have to address the obvious issue of chemoselectivity, which could be 
interesting to study in concurrent with ring-expansion chemistry. Altogether, a strategic redesign 
is necessary to develop an approach for regiodivergent B- and C-ring nitrogenous modifications. 
In this aspect, other natural products such as gibberellic acid and stevioside may also be worthy 
evaluation. Perhaps a strategic redesign that permits a global application of the Schmidt reaction 















Scheme 1.19. Potential routes for accessing C-ring oxosteroids.  
 
 
Figure 1.31. Redesign of B-ring and C-ring carbonyls for late-stage functionalization.  
 
1.6 Experimental Section 
1.6.1 General Information 
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Caution: Although we have not experienced any untoward events with the compounds 
mentioned in this thesis, azides and their precursors are known explosive hazards and should 
be used with appropriate safety precautions. Minimally, careful control of temperature and 
scale should be exercised. We do not recommend distillation of reaction mixtures that may 
contain residues of azide sources.  
 Reactions were performed under inert atmosphere (argon or nitrogen). Reactions were 
carried out in either flame-dried round bottom flasks or glass sample vials (TFE-lined cap). All 
chemicals were purchased from commercial sources and used without further purification. New 
containers of BF3xOEt2, TfOH, and HFIP were used. Anhydrous CH2Cl2, MeOH, DMF and THF 
were purchased from Sigma-Aldrich and used as received. Thin-layer chromatography (TLC) 
was performed using commercial glass-backed silica plates (250 µM) with an organic binder. 
Visualization was accomplished with UV light, Seebach’s stain, or aqueous KMnO4 stain, and 
heating. Purification was carried out by an automated flash chromatography/medium-pressure 
liquid chromatography (MPLC) system using normal phase silica gel flash columns (4, 12, 24, 
40, or 80 g).  
The infrared (IR) spectra were acquired as thin films using a universal ATR sampling 
accessory either on a PerkinElmer Spectrum One FT-IR spectrometer, Thermo Scientific Nicolet 
iS5 FT-IR spectrometer, or Bruker Alpha FT-IR spectrometer; the absorption frequencies are 
reported in cm-1. All nuclear magnetic resonance spectra were recorded on a Varian 400 MHz, 
Varian 500 MHz with a dual carbon/proton cryoprobe, or Bruker 600 MHz with a dual 
carbon/proton cryoprobe instrument. NMR samples were recorded in deuterated chloroform 
(CDCl3) or deuterated dimethylsulfoxide (DMSO-d6). Chemical shifts are reported in parts per 
million (ppm) and referenced to the centerline of solvent (CDCl3: δ 7.26 ppm for 1H NMR and 
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77.16 ppm for 13C NMR; DMSO-d6 δ 2.50 ppm for 1H NMR and 39.52 ppm for 13C NMR). 
Coupling constants are given in hertz (Hz). HRMS data were collected using two instruments. 
(1) Time-of-flight mass spectrometer (TOF) with an electrospray ion source (ESI). (2) Thermo 
LTQ Fourier transform ion cyclotron resonance (FT-ICR, 7T) with a heated electrospray ion 
source (HESI), electrospray ion source (ESI), atmospheric-pressure chemical ionization source 
(APCI), or atmospheric-pressure photoionization (APPI). Purity data were collected using two 
instruments. (1) Waters Acquity H-class UPLC-PDA detector coupled to the Thermo LTQ 
Fourier transform ion cyclotron resonance mass spectrometer (FT-ICR, 7T) with a heated 
electrospray ion source (HESI). Samples were run on analytical Acquity UPLC BEH 2.1 × 50 
mm, 1.7 µm, C18 column, and analytical Acquity UPLC HSS T3, 2.1 × 50 mm, 3.18 µm, C18 
column, at 40 ˚C with mobile phases A (H2O + 0.1% formic acid) and B (MeCN + 0.1% formic 
acid). (2) Agilent 6110 Series LCMS with a UV detector and a single quadrupole mass 
spectrometer. Samples were run on an analytical Agilent Eclipse Plus 4.6 × 50 mm, 1.8 µm, C18 
column at room temperature with mobile phases A (H2O + 0.1% acetic acid) and B (MeOH + 
0.1% acetic acid). Melting points were determined in open capillary tubes using OptiMelt, an 
automated melting point apparatus, and were uncorrected. Compounds that appear in the 
experimental section, but were not discussed in the body of this chapter are given the prefix S 
(supplemental).  
 
General Experimental Procedures for Azasteroid Library Production 
 General procedure A for the preparation of 1.16–1.51. To a solution of steroidal 
ketone 1.13–1.15 (0.124–0.302 mmol, 1.0 equiv) and hydroxyalkyl azide 1.1–1.6 (0.242–0.593 
mmol, 2.0 equiv) in anhydrous CH2Cl2 (0.4 M) in a nitrogen-flushed, two-dram vial at 0 ˚C was 
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added BF3•OEt2 (5.0 equiv) dropwise. The vial was capped, and the reaction mixture was stirred 
at room temperature for 16 h. The solvent was removed under nitrogen, and the residual iminium 
was treated with an aqueous solution of 15% KOH (3.0 mL) and THF (0.5 mL). The biphasic 
mixture was stirred vigorously at room temperature for 24 h. The reaction mixture was diluted 
with CH2Cl2 (50 mL), dried over Na2SO4, filtered, and concentrated. Purification of analogs was 
carried out by an automated MPLC system on normal phase silica gel flash columns.  
 
 General procedure B for the preparation of 1.52–1.73. Step 1—Formation of iminium 
ether intermediate of 1.14 or 1.15: In either a flame-dried, nitrogen-flushed, two-dram vial or 5 
mL-microwave vial was added BF3•OEt2 (62.0–124 µL, 0.500–1.00 mmol, 5.0 equiv) dropwise 
to a solution of 5D-dihydrotestosterone 1.14 (29.0–60.0 mg, 0.100–0.207 mmol, 1.0 equiv) or 
5β-dihydrotestosterone 1.15 (43.9–58.9 mg, 0.151–0.203 mmol, 1.0 equiv) and hydroxyalkyl 
azides (R)-1.2 (44.5–72.7 mg, 0.250–0.410 mmol, 2.0 equiv), (S)-1.2 (36.8–73.5 mg, 0.299–
0.415 mmol, 2.0 equiv), (S)-1.4 (44.3–74.0 mg, 0.250–0.418 mmol, 2.0 equiv), or (R)-1.4 (44.5–
73.4 mg, 0.250–0.414 mmol, 2.0 equiv) in anhydrous CH2Cl2 (0.4 M) at 0 ˚C. The vial was 
capped, and the reaction mixture was stirred at room temperature for 16 h. The solvent was 
removed under nitrogen, and the residual iminium was dried under vacuum before the addition 
of nucleophile.  
 
Step 2— Addition of nucleophiles. 
 2.1. Synthesis of 1.52–1.57 via nucleophilic addition of sulfide: Na2S (65.2–79.8 mg, 
0.835–1.02 mmol, 4.1–5.0 equiv) was added to a solution of iminium ether in anhydrous DMF 
(5.0 mL). The reaction mixture was stirred at 65 ˚C for 24 h. The reaction mixture was diluted 
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with CH2Cl2 (20 mL), and was washed with a saturated solution of NH4Cl (3 × 5 mL), brine (5 
mL), dried over Na2SO4, filtered, and concentrated. Purification of analogs were carried out by 
an automated MPLC system on normal phase silica columns. 
 2.2. Synthesis of 1.58 and 1.59 via nucleophilic addition of hydride: To a solution of 
iminium residue in anhydrous MeOH (2.0 mL) at 0 ˚C was added NaBH4 (30.0 mg, 0.799 mmol, 
4.0 equiv) cautiously. The reaction mixture was stirred at room temperature for overnight. The 
reaction mixture was partitioned between saturated solution of NaHCO3 (5 mL) and CH2Cl2 (20 
mL). The organic layer was separated, dried over Na2SO4, filtered, and concentrated. Purification 
of analogs was carried out by an automated MPLC system on normal phase silica gel flash 
columns.   
 2.3. Synthesis of 1.60 and 1.61 via nucleophilic addition of hydride: 10% Pd/C (10.6–
21.0 mg, 0.100-0.197 mmol, 1.0 equiv) was added to a solution of iminium ether in anhydrous 
EtOH (2.0–4.0 mL). The reaction was stirred under an atmosphere of hydrogen for 24 h. 
Purification of analogs was carried out by an automated MPLC system on normal phase silica 
gel flash columns.  
 2.4. Synthesis of 1.62–1.67 via nucleophilic addition of azide: NaN3 (51.0–52.0 mg, 
0.785–0.802 mmol, 4.0 equiv) was added to a solution of iminium ether in anhydrous DMF (2.0 
mL). The reaction mixture was stirred at 70 ˚C for 24 h. The reaction mixture was partitioned 
between EtOAc (40 mL) and H2O (20 mL). The organic layer was washed with H2O (2 × 5 mL), 
brine (5 mL), dried over Na2SO4, filtered, and concentrated. Purification of analogs were carried 
out by an automated MPLC system on normal phase silica gel columns.  
 2.5. Synthesis of 1.68–1.73 via nucleophilic addition of 4-methylbenzenethiolate: Sodium 
4-methylbenzenethiolate (0.66 M in DMF, 0.60–1.00 mL, 0.375–0.660 mmol, 3.0–4.0 equiv) 
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was added to a solution of iminium ether in anhydrous DMF (2.0 mL). The reaction mixture was 
stirred at 75 ˚C for 24 h. The reaction mixture was partitioned between EtOAc (40 mL) and H2O 
(15 mL). The organic layer was washed with a saturated solution of NaHCO3 (3 × 5 mL), brine 
(5 mL), dried over Na2SO4, filtered, and concentrated to afford crude residue. Purification of 
analogs were carried out by an automated MPLC system on normal phase silica gel columns.  
 
 General procedure C for the PCC oxidation of 1.18–1.19 and 1.28–1.29. To a slurry 
solution of 1.18–1.19 or 1.28–1.29 (53.0–93.0 mg, 0.099–0.212 mmol) in anhydrous CH2Cl2 
(6.0–10.0 mL) and Celite at 0 ˚C was added PCC (43.0–190.0 mg, 0.200–0.880 mmol, 2.0–4.0 
equiv). The brown reaction mixture was allowed to room temperature over 30 min and stirred 
overnight. The reaction mixture was diluted with CH2Cl2, filtered over Celite and concentrated. 
Purification of analogs was carried out by an automated MPLC system on normal phase silica 
gel flash columns.  
  
 General procedure D for the optimization of 1.100. To a solution of trans-
androsterone 1.84 (0.150 mmol, 1.0 equiv) and 3-azidopropanol 1.1 (0.300–0.450 mmol, 2.0–3.0 
equiv) in solvent (0.38 mL, 0.4 M) in a nitrogen-flushed, two-dram vial at room temperature 
(unless otherwise noted) was added acid catalyst (0.0825–1.05 mmol, 0.55–7.0 equiv) dropwise. 
The vial was capped, and the reaction mixture was stirred at room temperature for 24 h. The 
solvent was removed under nitrogen, and an aqueous solution of 15% KOH (3.0 mL) was added 
to the iminium residue. The reaction mixture was vigorously stirred at room temperature for 24 
h. The reaction mixture was diluted with CH2Cl2 (50 mL), dried over anhydrous Na2SO4, 
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filtered, and concentrated. Purification was carried out by an automated MPLC system using a 4 
g normal phase silica gel flash column with gradient elution from 0–5% MeOH/CH2Cl2.  
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
 General procedure E for the preparation of 1.100–1.105 and 1.113–1.120. To a 
solution of trans-androsterone 1.84 (0.125–0.153 mmol, 1.0 equiv) and hydroxyalkyl azide 1.1, 
1.3, 1.5, 1.7, or 1.9–1.11 (0.250–0.302 mmol, 2.0 equiv) in HFIP (0.38 mL, 0.4 M) at room 
temperature or in anhydrous CH2Cl2 (0.50 mL, 0.3 M) at 0 ˚C in a nitrogen-flushed, two-dram 
vial was added TfOH (14.5–26.5 µL, 0.165–0.300 mmol, 1.1–2.0 equiv) or BF3•OEt2 (130 µL, 
1.05 mmol, 7.0 equiv) dropwise. The vial was capped, and the reaction mixture was stirred at 
room temperature for 24 h. The solvent was removed under nitrogen, and the residual iminium 
was treated with an aqueous solution of 15% KOH (3.0 mL) and THF (0.5 mL). The biphasic 
mixture was stirred vigorously at room temperature for 24 h. The reaction mixture was diluted 
with CH2Cl2 (50 mL), dried over Na2SO4, filtered, and concentrated. Purification of analogs was 
carried out by an automated MPLC system on normal phase silica gel flash columns.  
 
 General procedure F for the preparation of 1.106–1.112 and 1.121–1.128. To a 
solution of estrone 1.90 (0.149–0.200 mmol, 1.0 equiv) and hydroxyalkyl azide 1.1, 1.3, 1.5, 1.7, 
or 1.9–1.11 (0.294–0.400 mmol, 2.0 equiv) in HFIP (0.38 mL, 0.4 M) at room temperature or in 
anhydrous CH2Cl2 (0.50 mL, 0.3 M) at 0 ˚C in a nitrogen-flushed, two-dram vial was added 
TfOH (14.5–26.5 µL, 0.165–0.300 mmol, 1.1–2.0 equiv) or BF3•OEt2 (130 µL, 1.05 mmol, 7.0 
equiv) dropwise. The vial was capped, and the reaction mixture was stirred at room temperature 
for 24 h. The solvent was removed under nitrogen, and the residual iminium was treated with an 
aqueous solution of 15% KOH (3.0 mL) and THF (0.5 mL). The biphasic mixture was stirred 
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vigorously at room temperature for 24 h. The reaction mixture was diluted with a saturated 
solution of NH4Cl, and extracted into CH2Cl2 (3 × 15 mL). The combined organic layers were 
washed with brine, dried over Na2SO4, filtered, and concentrated. Purification of analogs was 
carried out by an automated MPLC system on normal phase silica gel flash columns.  
 
 General procedure G for the preparation of 1.129–1.144. Step 1: Formation of 
iminium ether intermediate of 1.84 or 1.90: To a solution of trans-androsterone 1.84 (43.6–145.0 
mg, 0.150–0.500 mmol, 1.0 equiv) or estrone 1.90 (40.6–81.0 mg, 0.150–0.300 mmol, 1.0 equiv) 
and 3-azidopropanol 1.1 (30.1–101 mg, 0.300–1.00 mmol, 2.0 equiv) in HFIP (0.4 M) in either a 
flame-dried, nitrogen-flushed two-dram vial, 20 mL–scintillation vial, or 5 mL-microwave vial 
was added TfOH (14.5–48.5 µL, 0.165–0.550 mmol, 1.1 equiv) dropwise. The vial was capped, 
and the reaction mixture was stirred at room temperature for 24 h. The solvent was removed 
under nitrogen, and the residual iminium was dried under vacuum before the addition of 
nucleophile.  
Step 2: Addition of nucleophiles. 
 2.1. Synthesis of 1.129 and 1.138 via nucleophilic addition of sulfide: Na2S (195–234 mg, 
2.50–3.00 mmol, 10.0 equiv) was added to a solution of iminium ether in anhydrous THF (5.0 
mL). The reaction mixture was stirred at 65 ˚C for 24 h. The reaction mixture was diluted with 
Et2O (20 mL), and was washed with a saturated solution of NH4Cl (3 × 5 mL), brine (5 mL), 
dried over Na2SO4, filtered, and concentrated. Purification of analogs were carried out by an 
automated MPLC system on normal phase silica columns.  
 2.2. Synthesis of 1.130–1.131 and 1.139–1.140 via nucleophilic addition of hydride: To a 
solution of iminium residue in anhydrous MeOH (2.0 mL) at 0 ˚C was added NaBH4 (151 mg, 
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0.400 mmol, 2.0 equiv) or NaBD4 (167 mg, 0.400 mmol, 2.0 equiv) cautiously. The reaction 
mixture was stirred at room temperature for 3 h. The reaction mixture was partitioned between 
saturated solution of NaHCO3 (5 mL) and CH2Cl2 (20 mL). The organic layer was separated, 
dried over Na2SO4, filtered, and concentrated. Purification of analogs was carried out by an 
automated MPLC system on normal phase silica gel flash columns.  
 2.3. Synthesis of 1.132 and 1.141 via nucleophilic addition of azide: NaN3 (39.0–130 mg, 
0.600–2.00 mmol, 4.0 equiv) was added to a solution of iminium ether in anhydrous DMF (2.0–
5.0 mL). The reaction mixture was stirred at 70 ˚C for 24 h. The reaction mixture was partitioned 
between Et2O (40 mL) and H2O (20 mL). The organic layer was washed with H2O (2 × 5 mL), 
brine (5 mL), dried over Na2SO4, filtered, and concentrated. Purification of analogs was carried 
out by an automated MPLC system on normal phase silica gel flash columns.  
 2.4. Synthesis of 1.133–1.137 and 1.142–1.144 via nucleophilic addition of para-
substituted benzenethiolates: Sodium thiobenzolate (0.56–0.70 M in DMF, 0.54–0.67 mL, 2.5 
equiv) was added to a solution of iminium ether in anhydrous DMF (2.0 mL). The reaction 
mixture was stirred at 75 ˚C for 24 h. The reaction mixture was partitioned between EtOAc (40 
mL) and H2O (15 mL). The organic layer was washed with a saturated solution of NaHCO3 (3 × 
5 mL), brine (5 mL), dried over Na2SO4, filtered, and concentrated. Purification of analogs was 
carried out by an automated MPLC system on normal phase silica gel flash columns.  
 
 General procedure H for the preparation of 1.145–1.148. A mixture of steroidal 
azides 1.132 or 1.141 (0.180–0.200 mmol, 1.0 equiv), substituted-acetylene (0.207–0.400 mmol, 
1.0–2.0 equiv), copper sulfate pentahydrate (0.200–0.400 mmol, 1.0–2.0 equiv), and sodium L-
ascorbate (0.400–0.800 mmol, 2.0–4.0 equiv) were dissolved in tBuOH/H2O (1:1, 4.0 mL) at 
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room temperature and stirred overnight. The reaction mixture was diluted with CH2Cl2 (25 mL), 
and the organic layer was washed with aqueous NH4OH (3 x 5 mL), brine (5 mL), dried over 
Na2SO4, filtered, and concentrated. Purification of analogs was carried out by an automated 
MPLC system on normal phase silica gel flash columns.  
 
1.6.2 Experimental Section for 1.2  
 
 3-Azidopropanol, 1.1.78 3-Azidopropanol 1.1 was prepared following a previously 
published procedure. Characterization data were consistent with reported data.  
 
 (±)-3-Chloro-1-phenylpropanol, S1.1112 (±)-3-Chloro-1-phenylpropanol S1.2 was 
prepared following a previously published procedure. Characterization data were consistent with 
reported data.  
 
 (±)-3-Azido-1-phenylpropanol, (±)-1.2. Following a literature procedure85, (±)-3-azido-
1-phenylpropanol (±)-1.2 was prepared as described. A mixture of (±)-3-chloro-1-
phenylpropanol S1.1 (681 mg, 3.99 mmol), NaN3 (780 mg, 12.0 mmol, 3.0 equiv), NaI (899 mg, 
6.00 mmol, 1.5 equiv) in anhydrous DMF (40.0 mL) was stirred for 24 h at 80 ˚C. The reaction 
mixture was partitioned between Et2O and water. The organic layer was washed with brine, dried 
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over anhydrous Na2SO4, filtered, and concentrated under a stream of nitrogen. The crude oil was 
purified by an automated MPLC system using a 24 g normal phase silica column with gradient 
elution of 0–15% EtOAc/hexanes. Concentration of solvents under nitrogen afforded racemic 
product as a colorless oil (619 mg, 3.50 mmol, 88% yield). Rf = 0.25 (10% EtOAc/hexanes); IR 
(neat) 3378, 2089 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.40–7.28 (m, 5H), 4.85 (m, 1H), 3.54–
3.36 (m, 2H), 2.09–1.91 (m, 3H); 13C NMR (101 MHz, CDCl3) δ 144.0, 128.8, 128.1, 125.9, 
72.0, 48.5, 38.0. HRMS (TOF, ESI) m/z: [M – N2 + H]+ calcd for C9H12NO 150.0913, found 
150.0898. HPLC: Chiralcel OD-H, Daicel Chemical Industries, Ltd.; 2–40% i-PrOH/hexanes 
over 60 min; flow rate 1.0 mL/min; UV 220 nm; (S) tR = 10.29 min, (R) tR = 11.03 min.  
 
 (R)-3-Azido-1-phenylpropanol, (R)-1.2.85 (R)-3-Azido-1-phenylpropanol (R)-1.2 was 
prepared following a previously published procedure. Characterization data were consistent with 
reported data.  
 
 (S)-3-Azido-1-phenylpropanol, (S)-1.2. Following a literature procedure85, (S)-3-azido-
1-phenylpropanol (S)-1.2 was prepared as described. A mixture of (S)-3-chloro-1-
phenylpropanol (859 mg, 5.03 mmol), NaN3 (975 mg, 15.0 mmol, 3.0 equiv), NaI (1.12 g, 7.50 
mmol, 1.5 equiv) in anhydrous DMF (45.0 mL) was stirred for 24 h at 80 ˚C. The reaction 
mixture was partitioned between Et2O and water. The organic layer was washed with brine, dried 
over anhydrous Na2SO4, filtered, and concentrated under a stream of nitrogen. The crude oil was 
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purified by an automated MPLC system using a 24 g normal phase silica column with gradient 
elution of 0–15% EtOAc/hexanes. Concentration of solvents under nitrogen afforded product as 
a colorless oil (797 mg, 4.50 mmol, 89% yield) in ≥99.5% ee as determined by analytical HPLC. 
Rf = 0.25 (10% EtOAc/hexanes); IR (neat) 3373, 2092 cm-1; [α]𝐷23 = –35.9 (c 1.09, CHCl3); 1H 
NMR (400 MHz, CDCl3) δ 7.40–7.28 (m, 5H), 4.84 (dd, J = 8.4, 4.7, 1H), 3.54–3.36 (m, 2H), 
2.09–1.91 (m, 3H); 13C NMR (101 MHz, CDCl3) δ 144.0, 128.8, 128.1, 125.9, 72.0, 48.5, 38.0. 
HRMS (TOF, ESI) m/z: [M – N2 + H]+ calcd for 150.0913, found 150.0895. HPLC: Chiralcel 
OD-H, Daicel Chemical Industries, Ltd.; 2–40% i-PrOH/hexanes over 60 min; flow rate 1.0 
mL/min; UV 220 nm; (S) tR = 10.29 min, (R) tR = 11.03 min.  
 
 (R)-3-Azido-2-methylpropanol, (R)-1.3.85 (R)-3-Azido-2-methylpropanol (R)-1.3 was 
prepared following a previously published procedure at an elevated temperature of 45 ˚C for 24 
h. Characterization data were consistent with reported data.  
 
 (S)-3-Azido-2-methylpropanol, (S)-1.3. Following a literature procedure, (S)-3-azido-2-
methylpropanol (S)-1.3 was prepared as described. A mixture of (R)-3-bromo-2-methylpropanol 
(310 µL, 2.96 mmol) and NaN3 (975 mg, 15.0 mmol, 5.0 equiv) in anhydrous DMF (8.0 mL) 
was stirred for 24 h at 45 ˚C. The reaction mixture was partitioned between Et2O and H2O. The 
organic layer was washed with H2O, brine, dried over anhydrous Na2SO4, filtered, and 
concentrated under a stream of nitrogen. The crude oil was purified by an automated MPLC 
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system using a 24 g normal phase silica column with gradient elution of 0–25% EtOAc/hexanes. 
Concentration of solvents under nitrogen afforded product as a colorless oil (315 mg, 2.74 mmol, 
91% yield). Rf = 0.30 (25% EtOAc/hexanes); IR (neat) 3341, 2092 cm-1; [α]𝐷23 = –5.98 (c 1.00, 
CHCl3); 1H NMR (400 MHz, CDCl3) δ 3.58 (m, 2H), 3.35 (m, 2H), 1.93 (m, 1H), 1.65 (s, 1H), 
0.97 (d, J = 6.9, 3H); 13C NMR (101 MHz, CDCl3) δ 65.5, 54.8, 36.0, 14.6. HRMS (TOF, ESI) 
m/z: [2M - H]- calcd for C8H17N6O2 229.1418, found 229.1414.  
 
 (R)-3-Azido-3-phenylpropanol, (R)-1.4.85 (R)-3-Azido-3-phenylpropanol (R)-1.4 was 
prepared following a previously published procedure, in which DPPA and DIAD were used 
instead of HN3 and DEAD, respectively. Characterization data were consistent with reported 
data.  
 
 (R)-3-Hydroxy-3-phenylpropyl acetate, S1.2. Following a literature procedure85, (R)-3-
hydroxy-3-phenylpropyl acetate S1.2 was prepared as described. A mixture of (R)-3-chloro-1-
phenylpropanol (1.03 g, 6.02 mmol), NaOAc (1.48 g, 18.0 mmol, 3.0 equiv) and NaI (1.08 mg, 
7.20 mmol, 1.2 equiv) was heated at 130 ˚C in anhydrous DMF (60.0 mL) for 24 h. The reaction 
was cooled, and partitioned between Et2O and water. The organic layer was washed with brine, 
dried over anhydrous Na2SO4, filtered, and concentrated under a stream of nitrogen. The crude 
oil was purified by an automated MPLC system using a 24 g normal phase silica column with 
gradient elution of 0–15% EtOAc/hexanes. Concentration of solvents under nitrogen afforded 
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product as a colorless oil (758 mg, 3.90 mmol, 65% yield). Rf = 0.30 (20% EtOAc/hexanes); IR 
(neat) 3424, 1728 cm-1; [α]𝐷20 = +22.3 (c 1.03, CHCl3);  1H NMR (400 MHz, CDCl3) δ 7.36 (m, 
4H), 7.29 (m, 1H), 4.80 (m, 1H), 4.33 (m, 1H), 4.13 (m, 1H), 2.20 (m, 1H), 2.14–1.95 (m, 5H); 
13C NMR (101 MHz, CDCl3) δ 171.4, 144.0, 128.7, 127.9, 125.9, 71.4, 61.7, 38.1, 21.1. HRMS 
(FT-ICR, ESI) m/z: [M + Na]+ calcd for C11H14NaO3 217.0835, found 217.0832.  
 
 (S)-3-Azido-3-phenylpropanol, (S)-1.4. Following a literature procedure85, (S)-3-azido-
3-phenylpropan-1-ol (S)-1.4 was prepared as described. A solution of (R)-3-hydroxy-3-
phenylpropyl acetate S1.2 (1.07 g, 5.50 mmol) dissolved in anhydrous THF (55.0 mL) was 
cooled to 0 ˚C. PPh3 (2.17 g, 8.26 mmol, 1.5 equiv), DPPA (2.00 mL, 9.35 mmol, 1.7 equiv), and 
DIAD (1.6 mL, 8.25 mmol, 1.5 equiv) were added sequentially. The reaction mixture was 
warmed to room temperature and stirred for 18 h. The reaction mixture was partitioned between 
Et2O and H2O. The organic layer was washed with H2O, brine, dried over anhydrous Na2SO4, 
filtered, and concentrated under a stream of nitrogen. The crude oil was purified by an automated 
MPLC system using a 24 g normal phase silica column with gradient elution of 0–20% 
EtOAc/hexanes. Concentration of solvents under nitrogen afforded a colorless impure oil (Rf = 
0.73, 20% EtOAc/hexanes). The impure oil was directly hydrolyzed with K2CO3 (1.14 g, 8.25 
mmol, 1.5 equiv) in anhydrous MeOH (45.0 mL) at room temperature for 24 h. MeOH was 
removed under a stream of nitrogen, and the crude residue was purified by an automated MPLC 
system using a 24 g normal phase silica column with gradient elution of 0–20% EtOAc/hexanes. 
Concentration of solvents under nitrogen afforded product as a colorless oil (815 mg, 4.56 mmol, 
83% yield) in 97.0% ee (98.5:1.5 er) as determined by analytical HPLC. Rf = 0.30 (20% 
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EtOAc/hexanes); IR (neat) 3335, 2094 cm-1; [α]𝐷23  = –168.4 (c 1.02, CHCl3); 1H NMR (400 
MHz, CDCl3) δ 7.43–7.26 (m, 5H), 4.71 (dd, J = 8.8, 5.8 Hz, 1H), 3.82–3.67 (m, 2H), 2.11–1.92 
(m, 2H); 13C NMR (101 MHz, CDCl3) δ 139.4, 129.1, 128.6, 127.0, 63.6, 59.8, 38.9. HRMS 
(TOF, ESI) m/z: [M – N2 + H]+ calcd for C9H12NO 150.0913, found 150.0900. HPLC: Chiralcel 
OD-H, Daicel Chemical Industries, Ltd.; 2–40% i-PrOH/hexanes over 60 min; flow rate 1.0 
mL/min; UV 220 nm; (R) tR = 11.29 min, (S) tR = 12.77 min.  
 
 (S)-4-((tert-Butyldimethylsilyl)oxy)butan-2-ol, S1.3. Following a literature 
procedure113, (S)-4-((tert-butyldimethylsilyl)oxy)butan-2-ol S1.3 was prepared as described. 
Imidazole (1.36 g, 20.0 mmol, 2.0 equiv) and DMAP (31.0 mg, 25.0 mmol, 2.5 equiv) were 
added to (S)-1,3-butandiol (900 µL, 10.0 mmol) in anhydrous DMF (25.0 mL, 0.4 M). The 
mixture was cooled to 0 ˚C and TBDMSCl (1.66 g, 11.0 mmol, 1.1 equiv) in anhydrous CH2Cl2 
(12.0 mL) was added. The solution was stirred at 0 ˚C for 2 h and then stirred at room 
temperature overnight. The reaction mixture was diluted with H2O and extracted with Et2O (4 x 
20 mL). The combined organic layers were dried over anhydrous Na2SO4, filtered, and 
concentrated under a stream of nitrogen. The crude oil was purified by an automated MPLC 
system using a 24 g normal phase silica column with gradient elution of 0–10% EtOAc/hexanes. 
Concentration of solvents under nitrogen afforded product as a colorless oil (1.82 g, 8.89 mmol, 
89% yield). Rf = 0.32 (10% EtOAc/hexanes); IR (neat) 3388 cm-1; [α]𝐷22  = –4.31 (c 1.02, 
CHCl3); 1H NMR (400 MHz, CDCl3) δ 4.03 (m, 1H), 3.89 (m, 1H), 3.81 (m, 1H), 1.65 (m, 2H), 
1.19 (d, J = 6.24 Hz, 3H), 0.90 (s, 9H), 0.081 (s, 6H); 13C NMR (101 MHz, CDCl3) δ 68.5, 62.9, 
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40.1, 26.0, 23.5, 18.3, -5.38, -5.43. HRMS (FT-ICR, ESI) m/z: [M + Na]+ calcd for 
C10H24NaO2Si 227.1438, found 227.1434.  
 
 (R)-(3-Azidobutoxy)(tert-butyl)dimethylsilane, S1.4. Following a literature 
procedure85, (R)-(3-azidobutoxy)(tert-butyl)dimethylsilane S1.4 was prepared as described. A 
solution of (S)-4-((tert-butyldimethylsilyl)oxy)butan-2-ol S1.3 (1.02 g, 5.00 mmol) in anhydrous 
THF (50.0 mL) was cooled to 0 ˚C. PPh3 (1.57 g, 6.00 mmol, 1.2 equiv), DPPA (1.60 mL, 7.42 
mmol, 1.48 equiv), and DIAD (1.20 mL, 6.09 mmol, 1.2 equiv) were added sequentially. The 
reaction mixture was warmed to room temperature and stirred for 18 h. The reaction mixture was 
partitioned between Et2O and H2O. The organic layer was washed with H2O, brine, dried over 
anhydrous Na2SO4, filtered, and concentrated under nitrogen atmosphere. The crude oil was 
purified by an automated MPLC system using a 24 g normal phase silica column with gradient 
elution of 100% hexanes. Concentration of solvents under nitrogen afforded product as a 
colorless oil (857 mg, 3.74 mmol, 75% yield). Rf = 0.75 (10% EtOAc/hexanes); IR (neat) 2098 
cm-1; [α]𝐷23 = –55.8 (c 1.00, CHCl3); 1H NMR (400 MHz, CDCl3) δ 3.68 (m, 3H), 1.66 (m, 2H), 
1.28 (d, J = 6.60 Hz, 3H), 0.90 (s, 9H), 0.062 (s, 3H), 0.057 (s, 3H); 13C NMR (101 MHz, 
CDCl3) δ 59.7, 54.9, 39.2, 26.1, 19.8, 18.4, -5.26. HRMS (TOF, ESI) m/z: [M – N2 + H]+ calcd 




 (R)-3-Azidobutanol, (R)-1.5. Following a literature procedure85, (R)-3-azidobutanol (R)-
1.5 was prepared as described. A solution of (R)-(3-azidobutoxy)(tert-butyl)dimethylsilane S1.4 
(573 mg, 2.50 mmol) in anhydrous THF (50.0 mL) was treated with TBAF (1.0 M in THF, 2.75 
mL, 2.75 mmol, 1.1 equiv). After stirring at room temperature for 30 min, the reaction was 
partitioned between Et2O and H2O. The organic layer was washed with a saturated solution of 
NH4Cl, brine, dried over anhydrous Na2SO4, filtered, and concentrated under a stream of 
nitrogen. The crude oil was purified by an automated MPLC system using a 12 g normal phase 
silica column with gradient elution of 0–45% EtOAc/hexanes. Concentration of solvents under 
nitrogen afforded product as a colorless oil (234 mg, 2.03 mmol, 81% yield). Rf = 0.33 (25% 
EtOAc/hexanes); IR (neat) 3341, 2094 cm-1; [α]𝐷23  = –107.3 (c 1.00, CHCl3); 1H NMR (400 
MHz, CDCl3) δ 3.81–3.68 (m, 3H), 1.72 (m, 2H), 1.32 (d, J = 6.56, 3H); 13C NMR (101 MHz, 
CDCl3) δ 60.0, 55.5, 38.7, 19.7. HRMS (TOF, ESI) m/z: [2M - H]- calcd for C8H17N6O2 
229.1418, found 229.1446.    
 
 (R)-4-((tert-Butyldimethylsilyl)oxy)butan-2-ol, S1.5.113 (R)-4-((tert-
Butyldimethylsilyl)’oxy butan-2-ol S1.5 was prepared following a previously published 
procedure. Characterization data were consistent with reported data.  
 
 (S)-(3-Azidobutoxy)(tert-butyl)dimethylsilane, S1.6. Following a literature procedure85, 
(S)-(3-azidobutoxy)(tert-butyl)dimethylsilane S1.6 was prepared as described. A solution of (R)-
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4-((tert-butyldimethylsilyl)oxy)butan-2-ol S1.5 (1.02 g, 5.00 mmol) in anhydrous THF (50.0 
mL) was cooled to 0 ˚C. PPh3 (1.57 g, 6.00 mmol, 1.2 equiv), DPPA (1.60 mL, 7.42 mmol, 1.48 
equiv), and DIAD (1.20 mL, 6.09 mmol, 1.21 equiv) were added sequentially. The reaction 
mixture was warmed to room temperature and stirred for 18 h. The reaction mixture was 
partitioned between Et2O and H2O. The organic layer was washed with H2O, brine, dried over 
anhydrous Na2SO4, filtered, and concentrated under a stream of nitrogen. The crude oil was 
purified by an automated MPLC system using a 24 g normal phase silica column with gradient 
elution of 100% hexanes. Concentration of solvents under nitrogen afforded product as a 
colorless oil (897 mg, 3.91 mmol, 78% yield). Rf = 0.75 (10% EtOAc/hexanes); IR (neat) 2098 
cm-1; [α]𝐷23 = +58.1 (c 1.02, CHCl3); 1H NMR (400 MHz, CDCl3) δ 3.69 (m, 3H), 1.66 (m, 2H), 
1.28 (d, J = 6.56, 3H), 0.90 (s, 9H), 0.062 (s, 3H), 0.057 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 
59.7, 55.0, 39.3, 26.0, 19.8, 18.4, -5.27. HRMS (TOF, ESI) m/z: [M – N2 + H]+ calcd for 
C10H24NOSi 202.1622, found 202.1597.  
 
 (S)-3-Azidobutanol, (S)-1.5. Following a literature procedure85, (S)-3-azidobutanol (S)-
1.5 was prepared as described. A solution of (S)-(3-azidobutoxy)(tert-butyl)dimethylsilane S1.6 
(520 mg, 2.27 mmol) in anhydrous THF (45.0 mL) was treated with TBAF (1.0 M in THF, 2.50 
mL, 2.50 mmol, 1.1 equiv). After stirring at room temperature for 30 min, the reaction was 
partitioned between Et2O and H2O. The organic layer was washed with a saturated solution of 
NH4Cl, brine, dried over anhydrous Na2SO4, filtered, and concentrated under a stream of 
nitrogen. The crude oil was purified by an automated MPLC system using a 12 g normal phase 
silica column with gradient elution of 0–45% EtOAc/hexanes. Concentration of solvents under 
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nitrogen afforded product as a colorless oil (178 mg, 1.55 mmol, 68% yield). Rf = 0.32 (25% 
EtOAc/hexanes); IR (neat) 3341, 2094 cm-1; [α]𝐷23 = +91.7 (c 1.00, CHCl3); 1H NMR (400 MHz, 
CDCl3) δ 3.81–3.74 (m, 3H), 1.71 (m, 2H), 1.32 (d, J = 6.56 Hz, 3H); 13C NMR (101 MHz, 
CDCl3) δ 60.0, 55.5, 38.8, 19.7. HRMS (ESI) m/z calcd for C4H10N3O [M + H]+ 116.0824, found 
116.0485.   
 
 (R)-1-(4-Bromophenyl)-3-chloropropanol, S1.7. Following a literature procedure99, 
(R)-1-(4-bromophenyl)-3-chloropropanol S1.7 was prepared as described. A flame-dried, three-
neck 25 mL round bottom equipped with a thermocouple was charged with (R)-(+)-2-methyl-
CBS-oxazaborolidine solution (1.0 M in toluene, 900 µL, 0.900 mmol, 0.15 equiv). Borane N,N-
diethylaniline complex (1.60 mL, 9.00 mmol, 1.5 equiv), and was heated to 30 ˚C. 4′-Bromo-3-
chloropropiophenone (1.48 g, 6.00 mmol) in anhydrous toluene (4.0 mL) was added dropwise to 
the reaction mixture using a syringe pump (0.07 mL/min) over 60 min. After ketone addition, the 
reaction mixture was stirred for an additional 1 h at 30 ˚C. The reaction mixture was allowed to 
25 ˚C, and carefully quenched with MeOH (3.0 mL), followed by addition of 1.0 N HCl (5.0 
mL) and stirred for 15–20 min. The aqueous layer was extracted with Et2O (4 x 10 mL). The 
combined organic layers were washed with 1.0 N HCl (2 x 10 mL), H2O, brine, dried over 
anhydrous Na2SO4, filtered, and concentrated. The crude oil was purified by an automated 
MPLC system using a 24 g normal phase silica column with gradient elution of 0–10% 
EtOAc/hexanes. Concentration of solvents under nitrogen afforded product as a colorless oil 
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(1.25 g, 5.02 mmol, 84% yield) in 92.2% ee (96.1:3.9 er) as determined by analytical HPLC. Rf = 
0.30 (10% EtOAc/hexanes); IR (neat) 3366 cm-1; [α]𝐷23 = +7.25 (c 1.00, CHCl3); 1H NMR (400 
MHz, CDCl3) δ 7.50 (m, 2H), 7.25 (m, 2H), 4.94 (m, 1H), 3.74 (m, 1H), 3.55 (m, 1H), 2.20 (m, 
1H), 2.05 (m, 1H), 1.95 (br s, 1H); 13C NMR (101 MHz, CDCl3) δ 142.8, 131.9, 127.6, 121.8, 
70.8, 41.6, 41.5. HRMS (TOF, ESI) m/z: [M + HCOO]– calcd for C10H11BrClO3 292.9580, found 
292.9571. HPLC: Chiralcel OJ-H, Daicel Chemical Industries, Ltd.; 2–40% i-PrOH/hexanes 
over 60 min; flow rate 1.0 mL/min; UV 220 nm; (S) tR = 11.57 min, (R) tR = 12.89 min. 
 
 (R)-3-Azido-1-(4-bromophenyl)propanol, (R)-1.6. Following a literature procedure85, 
(R)-3-azido-1-(4-bromophenyl)propanol (R)-1.6 was prepared as described. A mixture of (R)-1-
(4-bromophenyl)-3-chloropropanol S1.7 (999 mg, 4.00 mmol), NaN3 (780 mg, 12.0 mmol, 3.0 
equiv), NaI (899 mg, 6.00 mmol, 1.5 equiv) in anhydrous DMF (40.0 mL) was stirred for 24 h at 
80 ˚C. The reaction mixture was partitioned between Et2O and H2O. The organic layer was 
washed brine, dried over anhydrous Na2SO4, filtered, and concentrated under a stream of 
nitrogen. The crude oil was purified by an automated MPLC system using a 24 g normal phase 
silica column with gradient elution of 0–20% EtOAc/hexanes. Concentration of solvents under 
nitrogen afforded product as a colorless oil (902 mg, 3.52 mmol, 88% yield) in 92.7% ee 
(96.4:3.6 er) as determined by analytical HPLC. Rf = 0.20 (10% EtOAc/hexanes); IR (neat) 
3386, 2092 cm-1; [α]𝐷20 = +18.3 (c 1.00, CHCl3); 1H NMR (400 MHz, CDCl3) δ 7.49 (m, 2H), 
7.24 (m, 2H), 4.82 (dd, J = 8.5, 4.5, 1H), 3.52 (m, 1H), 3.38 (m, 1H), 2.09 (br s, 1H), 2.06–1.84 
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(m, 2H); 13C NMR (101 MHz, CDCl3) δ 143.0, 131.9, 127.6, 121.8, 76.8, 48.4, 38.0. HRMS 
(FT-ICR, APPI) m/z: [M – N2 + H]+ calcd for C9H11BrNO 228.0019, found 228.0019. HPLC: 
Chiralpak IA, Daicel Chemical Industries, Ltd.; 8% EtOH/hexanes over 60 min; flow rate 1.0 
mL/min; UV 220 nm; (S) tR = 11.56 min, (R) tR = 13.74 min.  
 
 (S)-1-(4-Bromophenyl)-3-chloropropanol, S1.8. Following a literature procedure99, (S)-
1-(4-bromophenyl)-3-chloropropanol S1.8 was prepared as described. A flame-dried, three-neck 
25 mL round bottom equipped with a thermocouple was charged with (R)-(+)-2-methyl-CBS-
oxazaborolidine solution (1.0 M in toluene, 900 µL, 0.900 mmol, 0.15 equiv). Borane N,N-
diethylaniline complex (1.60 mL, 9.00 mmol, 1.5 equiv), and was heated to 30 ˚C. 4′-Bromo-3-
chloropropiophenone (1.48 g, 6.00 mmol) in anhydrous toluene (4.0 mL) was added dropwise to 
the reaction mixture using a syringe pump (0.07 mL/min) over 60 min. After ketone addition, the 
reaction mixture was stirred for an additional 1 h at 30 ˚C. The reaction mixture was allowed to 
25 ˚C, and carefully quenched with MeOH (3.0 mL), followed by addition of 1.0 N HCl (5.0 
mL) and stirred for 15–20 min. The aqueous layer was extracted with Et2O (4 x 10 mL). The 
combined organic layers were washed with 1.0 N HCl (2 x 10 mL), H2O, brine, dried over 
anhydrous Na2SO4, filtered, and concentrated. The crude oil was purified by an automated 
MPLC system using a 24 g normal phase silica column with gradient elution of 0–10% 
EtOAc/hexanes. Concentration of solvents under nitrogen afforded product as a colorless oil 
(1.20 g, 4.80 mmol, 80% yield) in 93.8% ee (96.9:3.1 er) as determined by analytical HPLC. Rf = 
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0.30 (10% EtOAc/hexanes); IR (neat) 3366 cm-1; [α]𝐷23  = –6.00 (c 1.00, CHCl3). 
Characterization data were consistent with reported data.114 HPLC: Chiralcel OJ-H, Daicel 
Chemical Industries, Ltd.; 2–40% i-PrOH/hexanes over 60 min; flow rate 1.0 mL/min; UV 220 
nm; (S) tR = 11.57 min, (R) tR = 12.89 min.  
 
 (S)-3-Azido-1-(4-bromophenyl)propanol, (S)-1.6. Following a literature procedure85, 
(S)-3-azido-1-(4-bromophenyl)propanol (S)-1.6 was prepared as described. A mixture of (S)-1-
(4-bromophenyl)-3-chloropropanol S1.8 (1.04 g, 4.16 mmol), NaN3 (780 mg, 12.5 mmol, 3.0 
equiv), NaI (890 mg, 6.24 mmol, 1.5 equiv) in anhydrous DMF (40.0 mL) was stirred for 24 h at 
80 ˚C. The reaction mixture was partitioned between Et2O and H2O. The organic layer was 
washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated under a stream of 
nitrogen. The crude oil was purified by an automated MPLC system using a 24 g normal phase 
silica column with gradient elution of 0–20% EtOAc/hexanes. Concentration of solvents under 
nitrogen afforded product as a colorless oil (1.01 g, 3.97 mmol, 95% yield) in 93.2% ee (96.6:3.4 
er) as determined by analytical HPLC. Rf = 0.20 (10% EtOAc/hexanes); IR (neat) 3385, 2092 
cm-1; [α]𝐷20 = –18.1 (c 1.00, CHCl3); 1H NMR (400 MHz, CDCl3) δ 7.49 (m, 2H), 7.24 (m, 2H), 
4.81 (dd, J = 8.4, 4.5 Hz, 1H), 3.51 (m, 1H), 3.38 (m, 1H), 2.14 (br s, 1H), 2.05–1.83 (m, 2H); 
13C NMR (101 MHz, CDCl3) δ 142.9, 131.9, 127.6, 121.8, 71.4, 48.4, 38.0. HRMS (FT-ICR, 
APPI) m/z: [M – N2 + H]+ calcd for C9H11BrNO 228.0019, found 228.0019. HPLC: Chiralpak 
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IA, Daicel Chemical Industries, Ltd.; 8% EtOH/hexanes over 60 min; flow rate 1.0 mL/min; UV 
220 nm; (S) tR = 11.56 min, (R) tR = 13.74 min. 
 
 2-Azidoethanol, 1.7.78 2-Azidoethanol 1.7 was prepared following a previously 
published procedure. Characterization data were consistent with reported data.  
 
 (S)-2-Chloro-1-phenylethanol, S1.9. Following a literature procedure99, (S)-2-chloro-1-
phenylethanol S1.9 was prepared as described. A flame-dried, three-neck 25 mL round bottom 
equipped with a thermocouple was charged with (S)-(+)-2-methyl-CBS-oxazaborolidine solution 
(1.0 M in toluene, 1.65 mL, 1.65 mmol, 0.1 equiv). Borane N,N-diethylaniline complex (3.0 mL, 
1.01 mmol, 1.01 equiv), and was heated to 32 ˚C. 2-Chloroacetophenone (2.55 g, 16.5 mmol) in 
anhydrous toluene (6.0 mL) was added dropwise to the reaction mixture using a syringe pump 
(0.10 mL/min) over 90 min. After ketone addition, the reaction mixture was stirred for an 
additional 1 h at 32 ˚C. The reaction mixture was allowed to 25 ˚C, and carefully quenched with 
MeOH (5.0 mL), followed by addition of 1.0 N HCl (10.0 mL) and stirred for 15–20 min. The 
aqueous layer was extracted with Et2O (4 x 15 mL). The combined organic layers were washed 
with 1.0 N HCl (2 x 10 mL), H2O, brine, dried over anhydrous Na2SO4, filtered, and 
concentrated. The crude oil was purified by an automated MPLC system using a 24 g normal 
phase silica column with gradient elution of 0–5% EtOAc/hexanes. Concentration of solvents 
under nitrogen afforded product as a colorless oil (2.09 g, 13.3 mmol, 81% yield) in 97.8% ee 
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(98.9:1.1 er) as determined by analytical HPLC. Rf = 0.40 (10% EtOAc/hexanes); IR (neat) 3379 
cm-1; [α]𝐷22 = +57.3 (c 1.00, CHCl3). Characterization data were consistent with reported data.115 
HPLC: Chiralcel OD-H, Daicel Chemical Industries, Ltd.; 2–40% i-PrOH/hexanes over 60 min; 
flow rate 1.0 mL/min; UV 220 nm; (S) tR = 9.75 min, (R) tR = 10.83 min.  
 
 (S)-2-Azido-1-phenylethanol, (S)-1.8. Following a literature procedure85, (S)-2-azido-1-
phenylethanol (S)-1.8 was prepared as described. A mixture of (S)-2-chloro-1-phenylethanol 
S1.9 (313 mg, 2.00 mmol), NaN3 (520 mg, 8.00 mmol, 4.0 equiv), and NaI (599 g, 4.00 mmol, 
2.0 equiv) in anhydrous DMF (20.0 mL) was stirred for 30 h at 85 ˚C. The reaction mixture was 
partitioned between Et2O and H2O. The organic layer was washed with brine, dried over 
anhydrous Na2SO4, filtered, and concentrated under a stream of nitrogen. The crude oil was 
purified by an automated MPLC system using a 24 g normal phase silica column with gradient 
elution of 0–10% EtOAc/hexanes. Concentration of solvents under nitrogen afforded product as 
a colorless oil (292 mg, 1.79 mmol, 90% yield) in ≥99.5% ee as determined by analytical HPLC. 
Rf = 0.25 (10% EtOAc/hexanes); IR (neat) 3396, 2096 cm-1; [α]𝐷22 = +87.9 (c 1.03, CHCl3); 1H 
NMR (400 MHz, CDCl3) δ 7.45–7.29 (m, 5H), 4.89 (m, 1H), 3.47 (m, 2H), 2.32 (d, J = 3.2 Hz, 
1H); 13C NMR (101 MHz, CDCl3) δ 140.7, 128.9, 128.6, 126.1, 73.6, 58.3. HRMS (TOF, ESI) 
m/z: [M – N2 + H]+ calcd for C8H10NO 136.0757, found 136.0719. HPLC: Chiralcel OJ-H, 
Daicel Chemical Industries, Ltd.; 2% i-PrOH/hexanes over 60 min; flow rate 1.0 mL/min; UV 




 (R)-2-Chloro-1-phenylethanol, S1.10. Following a literature procedure99, (R)-2-chloro-
1-phenylethanol S1.10 was prepared as described. A flame-dried, three-neck 25 mL round 
bottom equipped with a thermocouple was charged with (R)-(+)-2-methyl-CBS-oxazaborolidine 
solution (1.0 M in toluene, 1.65 mL, 1.65 mmol, 0.1 equiv). Borane N,N-diethylaniline complex 
(3.0 mL, 1.01 mmol, 1.01 equiv), and was heated to 32 ˚C. 2-Chloroacetophenone (2.55 g, 16.5 
mmol) in anhydrous toluene (6.0 mL) was added dropwise to the reaction mixture using a 
syringe pump (0.10 mL/min) over 90 min. After ketone addition, the reaction mixture was stirred 
for an additional 1 h at 32 ˚C. The reaction mixture was allowed to 25 ˚C, and carefully 
quenched with MeOH (5.0 mL), followed by addition of 1.0 N HCl (10.0 mL) and stirred for 15–
20 min. The aqueous layer was extracted with Et2O (4 x 15 mL). The combined organic layers 
were washed with 1.0 N HCl (2 x 10 mL), H2O, brine, dried over anhydrous Na2SO4, filtered, 
and concentrated. The crude oil was purified by an automated MPLC system using a 24 g normal 
phase silica column with gradient elution of 0–5% EtOAc/hexanes. Concentration of solvents 
under nitrogen afforded product as a colorless oil (2.12 g, 13.5 mmol, 82% yield) in 96.0% ee 
(49:1 er) as determined by analytical HPLC. Rf = 0.40 (10% EtOAc/hexanes); IR (neat) 3383 cm-
1; [α]𝐷22 = –53.3 (c 1.00, CHCl3). Characterization data were consistent with reported data.114 
HPLC: Chiralcel OD-H, Daicel Chemical Industries, Ltd.; 2–40% i-PrOH/hexanes over 60 min; 




 (R)-2-Azido-1-phenylethanol, (R)-1.8. Following a literature procedure85, (R)-2-azido-1-
phenylethanol (R)-1.8 was prepared as described. A mixture of (R)-2-chloro-1-phenylethanol 
S1.11 (472 mg, 3.01 mmol), NaN3 (683 mg, 10.5 mmol, 3.5 equiv), and NaI (899 mg, 6.00 
mmol, 2.0 equiv) in anhydrous DMF (30.0 mL) was stirred for 24 h at 85 ˚C. The reaction 
mixture was partitioned between Et2O and H2O. The organic layer was washed with brine, dried 
over anhydrous Na2SO4, filtered, and concentrated under a stream of nitrogen. The crude oil was 
purified by an automated MPLC system using a 24 g normal phase silica column with gradient 
elution of 0–10% EtOAc/hexanes. Concentration of solvents under nitrogen afforded product as 
a colorless oil (406 mg, 2.49 mmol, 83% yield) in ≥99.5% ee as determined by analytical HPLC. 
Rf = 0.25 (10% EtOAc/hexanes); IR (neat) 3392, 2097 cm-1; [α]𝐷22 = –87.4 (c 1.02, CHCl3); 1H 
NMR (400 MHz, CDCl3) δ 7.43–7.29 (m, 5H), 4.89 (m, 1H), 3.48 (m, 2H), 2.31 (br s, 1H); 13C 
NMR (101 MHz, CDCl3) δ 140.7, 128.9, 128.5, 126.1, 73.6, 58.3. HRMS (TOF, ESI) m/z: [M – 
N2 + H]+ calcd for C8H10NO 136.0757, found 136.0747. HPLC: Chiralcel OJ-H, Daicel 
Chemical Industries, Ltd.; 2% i-PrOH/hexanes over 60 min; flow rate 1.0 mL/min; UV 220 nm; 
(R) tR = 24.41 min, (S) tR = 29.05 min.  
 
 (S)-2-Azido-3-phenylpropanol, (S)-1.9.100 (S)-2-Azido-3-phenylpropanol (S)-1.9 was 
prepared following a previously published procedure. Characterization data were consistent with 




 (R)-2-Azido-3-phenylpropanol, (R)-1.9.100 (R)-2-Azido-3-phenylpropanol (R)-1.9 was 
prepared following a previously published procedure. Characterization data were consistent with 
reported data.  
 
 (S)-2-Azido-2-phenylethanol, (S)-1.10. Following the literature procedure100, 116, (S)-2-
azido-2-phenylethanol (S)-1.10 was obtained as a yellow oil (376 mg, 2.31 mmol, 58% yield) in 
94.9% ee (39:1 er) as determined by analytical HPLC. Purification was carried out by an 
automated MPLC system using a 24 g normal phase silica column with gradient elution of 0–
10% EtOAc/hexanes. Rf = 0.22 (10% EtOAc/hexanes); IR (neat) 3356, 2094 cm-1; [α]𝐷22  = 
+199.4 (c 0.98, CHCl3); 1H NMR (400 MHz, CDCl3) δ 7.43–7.32 (m, 5H), 4.68 (dd, J = 7.1, 5.7 
Hz, 1H), 3.80–3.72 (m, 2H); 13C NMR (101 MHz, CDCl3) δ 136.4, 129.1, 128.9, 127.3, 68.0, 
66.7. HRMS (TOF, ESI) m/z: [M – N2 + H]+ calcd for C8H10NO 136.0757, found 136.0749. 
HPLC: Chiralpak IA, Daicel Chemical Industries, Ltd.; 2–30% EtOH/hexanes over 60 min; flow 
rate 1.0 mL/min; UV 220 nm; (S) tR = 13.38 min, (R) tR = 15.38 min.   
 
 (R)-2-Azido-2-phenylethanol, (R)-1.10.117 (R)-2-Azido-2-phenylethanol (R)-1.10 was 
prepared following a previously published procedure. Characterization data were consistent with 




 (S)-2-Azido-4-methylpentanol, (S)-1.11.100 (S)-2-Azido-4-methylpentanol (S)-1.11 was 
prepared following a previously published procedure. Characterization data were consistent with 
reported data.  
 
 (R)-2-Azido-4-methylpentanol, (R)-1.11. Following the literature procedure100, 116, (R)-
2-azido-4-methylpentanol (R)-1.11 was obtained as a yellow oil (363 mg, 2.56 mmol, 63% 
yield). Purification was carried out by an automated MPLC system using a 24 g normal phase 
silica column with gradient elution of 0–15% EtOAc/hexanes. Rf = 0.42 (10% EtOAc/hexanes); 
IR (neat) 3356, 2101 cm-1; [α]𝐷22 = +5.0 (c 1.00, CHCl3); 1H NMR (400 MHz, CDCl3) δ 3.73–
3.67 (m, 1H), 3.57–3.50 (m, 2H), 1.83–1.73 (m, 1H), 1.49–1.42 (m, 1H), 1.32–1.25 (m, 1H), 
0.96 (dd, J = 6.6, 0.8 Hz, 6H); 13C NMR (101 MHz, CDCl3) δ 65.8, 62.7, 39.6, 25.1, 23.1, 22.2. 
HRMS (TOF, ESI) m/z: [M – N2 + H]+ calcd for C8H10NO 116.1070, found 116.1035.  
 
1.6.3 Experimental Section for 1.3 




 5α-Cholestan-3-ol, 1.12.118 To a solution of cholesterol (2.03 g, 5.25 mmol) in 
anhydrous EtOH (55.0 mL, 0.1 M) was added 10% Pd/C (220 mg, 2.07 mmol, 0.40 equiv) under 
argon. The reaction mixture was degassed and charged with hydrogen. The reaction mixture was 
stirred under balloon-pressure hydrogen overnight. The reaction mixture was filtered over Celite 
and concentrated. Purification was carried out by an automated MPLC system using a 40 g 
normal phase silica column with gradient elution from 0–10% EtOAc/hexanes to afford S1 as a 
white amorphous solid (1.86 g, 4.79 mmol, 91% yield). Characterization data were consistent 
with reported data.   
 
 5α-Cholestan-3-one, 1.13.119 To a solution of 1.12 (1.57 g, 4.04 mmol) in anhydrous 
CH2Cl2 (50.0 mL) was added Celite and PCC (1.31 g, 6.07 mmol, 1.5 equiv) at 0 ˚C. The 
reaction mixture was allowed to room temperature and stirred overnight. The reaction mixture 
was filtered through a short pad of Celite and concentrated. Purification was carried out by an 
automated MPLC system using a 40 g normal phase silica column with gradient elution from 0–
10% EtOAc/hexanes to afford 1.13 as a white amorphous solid (1.45 g, 3.75 mmol, 93% yield). 




 5α-Dihydrotestosterone, 1.14.120 Following a literature procedure121, 5α-
Dihydrotestosterone 1.14 was prepared as described. To a solution of testosterone (570 mg, 1.98 
mmol) in anhydrous THF (6.0 mL) was condensed liquid NH3 (~30 mL) at –78 ˚C. To the 
cooled solution was added pieces of lithium wire (83.0 mg, 12.0 mmol, 6.0 equiv). The blue 
solution was stirred at –78 ˚C for 20 min, and was allowed to –35 ˚C and stirred for an additional 
2 h. The reaction mixture was quenched by adding solid NH4Cl slowly (until the disappearance 
of blue). The resulting mixture was diluted with H2O and EtOAc. The organic layer was washed 
with brine, dried over anhydrous Na2SO4, filtered, and concentrated. Purification was carried out 
by an automated MPLC system using a 24 g normal phase silica column with gradient elution 
from 0–30% EtOAc/hexanes to afford 1.14 as a white amorphous solid (331 mg, 1.14 mmol, 
58% yield). Characterization data were consistent with reported data; mp 179–181 ˚C.  
 
 5β-Dihydrotestosterone, 1.15.122 To a solution of testosterone (2.30 g, 8.00 mmol) in 
anhydrous THF (80.0 mL, 0.1 M) was added 10% Pd/C (341 mg, 3.20 mmol, 0.40 equiv) under 
argon. The reaction mixture was degassed and charged with hydrogen. The reaction mixture was 
stirred under balloon-pressure hydrogen overnight. The reaction mixture was filtered over Celite 
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and concentrated. Purification was carried out by an automated MPLC system using an 80 g 
normal phase silica column with gradient elution from 0–20% EtOAc/hexanes to afford 1.15 as a 
colorless amorphous solid (1.51 g, 5.20 mmol, 65% yield) and 2 as a white amorphous solid (414 
mg, 1.43 mmol, 18% yield). Characterization data were consistent with reported data.  
 
Experimental section for 1.3.2 
 
 5α-Cholestane-derived A-Ring Lactams, 1.16 and 1.17. Following the general 
procedure A, 3-azidopropanol 1.1 (30.5 mg, 0.301 mmol, 2.0 equiv) was reacted with 5α-
cholestan-3-one 1.13 (58.0 mg, 0.150 mmol) to give an inseparable mixture (38:62) of 
regioisomers 1.16 and 1.17 as a white amorphous solid (63.4 mg, 0.138 mmol, 92% yield). 
Purification was carried out by an automated MPLC system using a 4 g normal phase silica 
column with gradient elution from 0–5% MeOH/CH2Cl2. Rf = 0.43 (5% MeOH/CH2Cl2); IR 
(neat) 3318, 1625 cm-1; key 1H NMR (600 MHz, CDCl3) δ 3.67–3.61 (m, 2H), 2.96 (ddd, J = 
15.7, 6.5, 1.8 Hz, 1H), 2.79 (dd, J = 14.3, 10.6 Hz, 1H), 2.65 (t, J = 13.1 Hz, 1H), 2.34 (dd, J = 
14.5, 7.6 Hz, 1H), 2.00–1.93 (m, 2H), 1.91–1.77 (m, 3H); 13C NMR (151 MHz, CDCl3) δ 177.3, 
177.2, 58.10, 58.06, 56.5, 56.3, 54.2, 54.0, 52.0, 48.9, 45.4, 44.8, 44.5, 44.0, 42.44, 42.40, 41.0, 
40.04, 40.01, 39.98, 39.6, 38.5, 38.3, 36.3, 35.9, 35.1, 34.9, 32.12, 32.06, 31.9, 31.0, 30.32, 
30.28, 28.5, 28.4, 28.1, 24.3, 24.0, 22.9, 22.7, 21.4, 21.1, 18.77, 18.75, 12.21, 12.15. Note: 
Missing carbon signals due to signal overlap of regioisomers. HRMS (FT-ICR, ESI) m/z: [M + 




 5α-Cholestane-derived A-Ring Lactams, 1.18 and 1.19. Following the general 
procedure A, (±)-3-azido-1-phenylpropanol (±)-1.2 (44.3 mg, 0.250 mmol, 2.0 equiv) was 
reacted with 5α-cholestan-3-one 1.13 (48.3 mg, 0.125 mmol) to give a 50:50 mixture of 
regioisomers 1.18 and 1.19 as a white amorphous solid (61.4 mg, 0.115 mmol, 92% yield). 
Purification was carried out by an automated MPLC system using a 12 g normal phase column 
0–5% MeOH/CH2Cl2. The mixture was intentionally not separated by column chromatography. 
Rf = 0.40 (5% MeOH/CH2Cl2); IR (neat) 3376, 1617 cm-1; key 1H NMR (400 MHz, CDCl3) δ 
4.67–4.62 (m, 2H), 4.15–4.03 (m, 2H), 3.73–3.63 (m, 2H), 3.15–3.07 (m, 2H), 3.01 (m, 1H), 
2.71 (dd, J = 14.2, 10.4 Hz, 1H), 2.61–2.52 (m, 2H, contains d, 2.54, J = 15.6 Hz, 1H), 2.40–2.35 
(m, 1H); 13C NMR (101 MHz, CDCl3) δ 177.21, 177.1, 144.3, 144.26, 128.47, 128.43, 127.2, 
127.1, 125.7, 127.6, 70.0, 56.5, 56.4, 56.32, 56.30, 54.5, 54.3, 52.5, 49.6, 45.9, 45.7, 44.2, 42.5, 
42.4, 41.2, 40.11, 40.05, 39.9, 39.65, 36.63, 38.5, 38.4, 38.1, 37.9, 36.3, 36.1, 35.9, 35.1, 34.9, 
32.21, 32.17, 32.0, 31.0, 28.5, 28.3, 28.1, 24.29, 24.25, 23.9, 22.9, 22.7, 21.4, 21.1, 18.79, 18.76, 
12.2, 12.1. Note: Missing carbon signals due to signal overlap of regioisomers. HRMS (FT-ICR, 




 5α-Cholestane-derived A-Ring Lactam, 1.18. Following the general procedure A, (R)-
3-azido-1-phenylpropanol (R)-1.2 (44.5 mg, 0.251 mmol, 2.0 equiv) was reacted with 5α-
cholestan-3-one 1.13 (48.4 mg, 0.125 mmol) to give 1.18 as a white amorphous solid (59.5 mg, 
0.111 mmol, 89% yield). Purification was carried out by an automated MPLC system using a 12 
g normal phase silica column 0–40% EtOAc/hexanes. Rf = 0.54 (50% EtOAc/hexanes); mp 178–
182 ˚C; IR (neat) 3373, 1613 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.39–7.33 (m, 4H), 7.31–7.25 
(m, 1H), 4.65 (dd, J = 9.8, 3.2 Hz, 1H), 4.07 (ddd, J = 14.6, 10.6, 4.2 Hz, 1H), 3.66 (dd, J = 15.7, 
11.8 Hz, 1H), 3.12 (dt, J = 14.2, 4.6 Hz, 1H), 3.01 (dd, J = 15.6, 6.2 Hz, 1H), 2.71 (dd, J = 14.1, 
10.4 Hz, 1H), 2.00–1.77 (complex, 4H, contains d, J = 14.2 Hz, 1H), 1.69–1.65 (m, 1H), 1.59–
0.93 (complex, 24H), 0.94–0.85 (complex, 12H, contains s, 0.91, 3H; s, 0.89, 3H; d, 0.87, J = 1.8 
Hz, 3H; d, 0.85, J = 1.9 Hz, 3H), 0.75–0.65 (m, 4H, contains s, 3H); 13C NMR (101 MHz, 
CDCl3) δ 177.2, 144.3, 128.4 (2C), 127.2, 125.7 (2C), 70.1, 56.5, 56.3, 54.5, 45.9 45.7, 44.2, 
42.4, 41.8, 40.1, 40.07, 39.6, 38.5, 37.9, 36.3, 35.9, 34.9, 32.0, 31.0, 28.3, 28.1, 24.3, 24.0, 22.9, 
22.7, 21.4, 18.9, 12.2, 12.1. HRMS (FT-ICR, ESI) m/z: [M + H]+ calcd for C36H58NO2 536.4462, 
found 536.4463.  
 
 5α-Cholestane-derived A-Ring Lactam, 1.19. Following the general procedure A, (S)-
3-azido-1-phenylpropanol (S)-1.2 (86.6 mg, 0.500 mmol, 2.0 equiv) was reacted with 5α-
cholestan-3-one 1.13 (96.6 mg, 0.250 mmol) to give 1.19 as a white amorphous solid (118 mg, 
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0.220 mmol, 88% yield). Purification was carried out by an automated MPLC system using a 12 
g normal phase silica column 0–40% EtOAc/hexanes. Rf = 0.42 (50% EtOAc/hexanes); mp 194–
199 ˚C; IR (neat) 3378, 1619 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.37–7.33 (m, 4H) 7.26 (m, 
1H), 4.64 (dd, J = 9.8, 3.2 Hz, 1H), 4.10 (ddd, J = 14.6, 10.7, 4.3 Hz, 1H), 3.70 (dd, J = 15.5, 8.5 
Hz, 1H), 3.11 (dt, J = 14.1, 4.5 Hz, 1H), 2.61–2.52 (m, 2H, contains d, 2.54, J = 15.5 Hz, 1H), 
2.39 (m, 1H), 2.04–1.72 (complex, 6H), 1.61–1.47 (complex, 3H), 1.39–0.94 (complex, 19H), 
0.91–0.85 (complex, 12H, contains s, 0.91, 3H; s, 0.89, 3H; d, 0.87, J = 1.9 Hz, 3H; d, 0.85, J = 
1.9 Hz, 3H), 0.74–0.65 (m, 4H, contains s, 0.65, 3H); 13C NMR (101 MHz, CDCl3) δ 177.1, 
144.4, 128.5 (2C), 127.1, 125.6 (2C), 70.1, 56.5, 56.3, 54.3, 52.5, 49.6, 45.9, 42.5, 40.0, 39.7, 
38.4, 38.1, 36.3, 36.2, 35.9, 35.2, 32.2, 28.5, 28.3, 28.1, 24.3, 24.0, 22.9, 22.7, 21.1, 18.8, 12.2. 
Note: Missing two carbon signals due to signal overlap of methyl groups. HRMS (FT-ICR, 
HESI) m/z: [M + H]+ calcd for C36H58NO2 536.4462, found 536.4449.  
 
 5α-Cholestane-derived A-Ring Lactam, 1.20. Following the general procedure A, (S)-
3-azido-2-methylpropanol (S)-1.3 (34.7 mg, 0.300 mmol, 2.0 equiv) was reacted with 5α-
cholestan-3-one 1.13 (58.0 mg, 0.150 mmol) to give 1.20 as a white amorphous solid (59.5 mg, 
0.126 mmol, 84% yield). Purification was carried out twice by an automated MPLC system first 
using a 12 g normal phase silica column with gradient elution from 0–40% EtOAc/Et2O, and 
second using a 4 g column normal phase silica column with gradient elution from 0–5% 
MeOH/CH2Cl2. Rf = 0.35 (2% MeOH/CH2Cl2); mp 186–187 ˚C; IR (neat) 3417, 1623 cm-1; 1H 
NMR (400 MHz, CDCl3) δ 3.68 (dd, J = 13.9, 10.1 Hz, 1H), 3.58 (m, 1H), 3.41 (dd, J = 11.9, 3.1 
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Hz, 1H), 3.28 (dd, J = 11.8, 3.7 Hz, 1H), 2.84 (dd, J = 13.9, 4.4 Hz, 1H), 2.64 (t, J = 14.0 Hz, 
1H), 2.45 (d, J = 15.3 Hz, 1H), 2.33 (m, 1H), 1.95 (m, 1H), 1.88–1.65 (complex, 4H), 1.57–1.42 
(m, 3H), 1.37–0.90 (complex, 22H, contains d, 0.95, J = 6.9 Hz, 3H), 0.88–0.80 (complex, 12H, 
contains d, 0.85, J = 1.9 Hz, 3H; d, 0.83, J = 1.9 Hz, 3H), 0.69 (m, 1H), 0.62 (s, 3H); 13C NMR 
(101 MHz, CDCl3) δ 177.2, 63.2, 56.5, 56.3, 54.0, 52.2, 50.9, 48.4, 42.5, 40.0, 39.6, 38.3, 36.3, 
35.9, 35.8, 35.1, 34.3, 32.1, 31.9, 28.6, 28.3, 28.1, 24.3, 23.9, 22.9, 22.7, 21.1, 18.7, 15.2, 12.3, 
12.1. HRMS (FT-ICR, ESI) m/z: [M + H]+ calcd for C31H56NO2 474.4306, found 474.4305. 
 
 5α-Cholestane-derived A-Ring Lactam, 1.21. Following the general procedure A, (R)-
3-azido-2-methylpropanol (R)-1.3 (34.4 mg, 0.300 mmol, 2.0 equiv) was reacted with 5α-
cholestan-3-one 1.13 (58.1 mg, 0.150 mmol) to give 1.21 as a white amorphous solid (50.2 mg, 
0.106 mmol, 71%). Purification was carried out by an automated MPLC system using a 12 g 
normal phase silica with gradient elution from 0–5% MeOH/CH2Cl2. Rf = 0.27 (2% 
MeOH/CH2Cl2 run twice); mp 160–162 ˚C; IR (neat) 3347, 1616 cm-1; 1H NMR (400 MHz, 
CDCl3) δ 3.67 (dd, J = 13.9, 10.2 Hz, 1H), 3.57 (dd, J = 15.5, 11.7 Hz, 1H), 3.43 (dd, J = 11.8, 
3.1 Hz, 1H), 3.30 (dd, J = 11.9, 3.6 Hz, 1H), 2.95 (m, 1H), 2.85–2.76 (m, 2H), 1.99–1.92 (m, 2H,  
contains d, 1.94, J = 14.4 Hz, 1H), 1.85–1.61 (complex, 4H), 1.58–0.92 (complex, 25H, contains 
d, 0.96, J = 6.9 Hz, 3H), 0.90–0.84 (complex, 12H, contains t, 0.88, J = 3.3 Hz, 6H; d, 0.85, J = 
2.0 Hz, 3H; d, 0.84, J = 1.9 Hz, 3H), 0.70 (m, 1H), 0.63 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 
177.2, 63.2, 56.5, 56.4, 54.3, 50.5, 45.5, 43.8, 42.4, 40.4, 40.08, 40.05, 39.6, 38.5, 36.2, 35.9, 
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34.9, 34.2, 32.1, 31.0, 28.3, 28.1, 24.2, 23.9, 22.9, 22.7, 21.4, 18.8, 15.3, 12.2, 12.1. HRMS (FT-
ICR, ESI) m/z: [M + H]+ calcd for C31H56NO2 474.4306, found 474.4306.  
 
 5α-Cholestane-derived A-Ring Lactam, 1.22.  Following the general procedure A, (S)-
3-azido-3-phenylpropanol (S)-1.4 (44.2 mg, 0.249 mmol, 2.0 equiv) was reacted with 5α-
cholestan-3-one 1.13 (48.4 mg, 0.125 mmol) to give 1.22 as a cream-colored amorphous solid 
(59.1 mg, 0.110 mmol, 88% yield). Purification was carried out by an automated MPLC system 
using a 12 g normal phase silica column with gradient elution from 0–50% EtOAc/hexanes. Rf = 
0.39 (50% EtOAc/hexanes); mp 149–152 ˚C; IR (neat) 3416, 1618 cm-1; 1H NMR (400 MHz, 
CDCl3) δ 7.36–7.24 (m, 5H), 5.88 (dd, J = 12.4, 3.3 Hz, 1H), 3.70 (m, 1H), 3.40 (m, 1H), 3.18 
(dd, J = 15.3, 11.6 Hz, 1H), 2.82 (m, 2H), 2.13–2.02 (m, 2H, contains d, 2.06, J = 14.9 Hz, 1H), 
1.95–1.74 (m, 3H), 1.66–1.43 (m, 5H), 1.37–0.87 (complex, 18H), 0.84 (dd, J = 6.5, 2.2 Hz, 9H), 
0.77 (s, 3H), 0.57 (s, 3H), 0.47 (m, 1H), 0.38 (m, 1H); 13C NMR (101 MHz, CDCl3) δ 177.5, 
139.1, 128.63 (2C), 128.55 (2C), 127.9, 58.5, 56.38, 56.32, 54.2, 52.5, 43.6, 42.3, 40.6, 40.4, 
40.0, 39.6, 39.2, 38.1, 36.2, 35.8, 34.8, 32.0, 31.0. 28.3, 28.1, 24.2, 23.9, 22.9, 22.6, 21.1, 18.7, 




 5α-Cholestane-derived A-Ring Lactam, 1.23. Following the general procedure A, (R)-
3-azido-3-phenylpropanol (R)-1.4 (44.3 mg, 0.250 mmol) was reacted with 5α-cholestan-3-one 
1.13 (48.3 mg, 0.125 mmol) to give 1.23 as a white amorphous solid (58.4 mg, 0.109 mmol, 87% 
yield). Purification was carried out by an automated MPLC system using a 12 g normal phase 
silica column with gradient elution from 0–50% EtOAc/hexanes. Rf = 0.43 (50% 
EtOAc/hexanes); mp 187–189 ˚C; IR (neat) 3409, 1620 cm-1; 1H NMR (400 MHz, CDCl3) δ 
7.37–7.28 (m, 5H), 5.92 (dd, J = 12.5, 3.1 Hz, 1H), 3.72 (m, 1H), 3.42 (td, J = 11.7, 2.8 Hz, 1H), 
3.18 (dd, J = 15.2, 9.0 Hz, 1H), 2.69 (t, J = 14.0 Hz, 1H), 2.47 (dd, J = 15.0, 7.4 Hz, 1H), 2.35 
(d, J = 15.3 Hz, 1H), 2.09 (m, 1H), 1.95–1.83 (m, 3H), 1.79–1.71 (m, 1H), 1.53–0.82 (complex, 
29 H), 0.77 (s, 3H), 0.58 (s, 3H), 0.52–0.43 (m, 2H), 0.34–0.23 (m, 2H); 13C NMR (126 MHz, 
CDCl3) δ 177.2, 139.1, 129.0 (2C), 128.5 (2C), 128.1, 58.5, 56.4 (2C), 54.0, 52.8, 48.8, 45.4, 
42.4, 40.0, 39.6, 38.0, 36.3, 36.1, 35.9, 35.1, 32.6, 32.3, 31.6, 28.3, 28.1, 27.4, 24.2, 23.9, 22.9, 
22.7, 21.0, 18.8, 12.10, 12.06. HRMS (FT-ICR, HESI) m/z: [M + H]+ calcd for C36H58NO2 
536.4462, found 436.4456.  
 
 5α-Cholestane-derived A-Ring Lactam, 1.24. Following the general procedure A, (S)-
3-azidobutanol (S)-1.5 (28.5 mg, 0.248 mmol, 2.0 equiv) was reacted with 5α-cholestan-3-one 
1.13 (48.6 mg, 0.126 mmol) to give 1.24 as a white amorphous (52.8 mg, 0.111 mmol, 88% 
yield). Purification was carried out by an automated MPLC system using a 12 g normal phase 
silica column with gradient elution from 0–5% MeOH/CH2Cl2. Rf = 0.37 (5% MeOH/CH2Cl2); 
mp 145–149 ˚C; IR (neat) 3338, 1620 cm-1; 1H NMR (400 MHz, CDCl3) δ 4.78 (m, 1H), 3.51 
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(ddd, J = 12.1, 5.1, 2.5 Hz, 1H), 3.29–3.21 (m, 2H), 2.68 (t, J = 14.1 Hz, 1H), 2.50–2.40 (m, 2H, 
contains d, J = 2.48, 15.6 Hz, 1H), 1.98 (m, 1H), 1.91–1.77 (m, 2H), 1.74–1.44 (complex, 5H), 
1.38–0.81 (complex, 35H), 0.70 (m, 1H), 0.64 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 177.5, 
58.6, 56.5, 56.3, 54.1, 49.9, 45.6, 44.4, 42.5. 40.0, 39.7, 38.4, 36.8, 36.3, 35.93, 35.92, 35.2, 32.5, 
32.0, 28.4, 28.2, 27.6, 24.3, 24.0, 23.0, 22.7, 21.1, 18.9, 18.8, 12.3, 12.2. HRMS (FT-ICR, ESI) 
m/z: [M + H]+ calcd for C31H56NO2 474.4306, found 474.4313.  
 
 5α-Cholestane-derived A-Ring Lactam, A5. Following the general procedure A, (R)-3-
azidobutanol (R)-1.5 (29.5 mg, 0.256 mmol, 2.0 equiv) was reacted with 5α-cholestan-3-one 1.13 
(48.9 mg, 0.126 mmol) to give 1.25 as a white amorphous solid (54.7 mg, 0.115 mmol, 92% 
yield). Purification was carried out by an automated MPLC system using a 12 g normal phase 
silica with gradient elution from 0–5% MeOH/CH2Cl2. Rf = 0.43 (5% MeOH/CH2Cl2); mp 142–
146 ˚C; IR (neat) 3403, 1620 cm-1; 1H NMR (400 MHz, CDCl3) δ 4.76 (m, 1H), 3.52 (ddd, J = 
12.0, 5.0, 2.5 Hz, 1H), 3.30–3.20 (m, 2H), 2.98 (m, 1H), 2.82 (dd, J = 15.0, 10.8 Hz, 1H), 2.04 
(d, J = 15.0 Hz, 1H), 1.97 (m, 1H), 1.87–1.77 (m, 2H), 1.73–1.64 (m, 2H), 1.59–0.85 (complex, 
38H), 0.74–0.67 (m, 1H), 0.65 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 177.7, 58.6, 56.5, 56.4, 
54.4, 45.6, 43.8, 42.4, 42.0, 40.3, 40.1, 39.6, 38.5, 38.1, 36.6, 36.3, 35.9, 34.9, 32.1, 31.0, 28.4, 
28.2, 24.3, 24.0, 23.0, 22.7, 21.4, 18.9, 18.8, 12.3, 12.2. HRMS (FT-ICR, ESI) m/z: [M + H]+ 




 17β-Hydroxy-5α-androstane-derived A-Ring Lactams, 1.26 and 1.27. Following the 
general procedure A, 3-azidopropanol 1.1 (30.6 mg, 0.303 mmol, 2.0 equiv) was reacted with 
5α-DHT 1.14 (43.6 mg, 0.150 mmol) to give a 40:60 mixture of regioisomers 1.26 and 1.27 as a 
white amorphous solid (51.6 mg, 0.142 mmol, 95% yield, UPLC/HRMS purity: ≥99.5%). 
Purification was carried out by an automated MPLC system using a 12 g normal phase silica 
column with gradient elution from 0–5% MeOH/CH2Cl2. Rf = 0.27 (5% MeOH/CH2Cl2); IR 
(neat) 3325, 1618, 1603 cm-1; key 1H NMR (400 MHz, CDCl3) δ 2.91 (ddd, J = 15.6, 6.5, 1.8 
Hz, 1H), 2.73 (dd, J = 14.2, 10.4 Hz, 1H), 2.59 (t, J = 13.0 Hz, 1H), 2.44 (d, J = 15.4 Hz, 1H), 
2.29 (dd, J = 14.9, 6.9 Hz, 1H), 2.04–1.93 (m, 2H), 1.91–1.72 (m, 4H, contains d, J = 14.3 Hz, 
1H); 13C NMR (126 MHz, CDCl3) δ 177.2, 177.1, 81.90, 81.86, 77.4, 77.2, 76.9, 58.11, 58.06, 
54.4, 54.1, 52.0, 51.02, 51.01, 48.9, 45.3, 44.8, 44.5, 44.0, 42.9, 42.8, 41.1, 40.0, 38.6, 38.4, 36.8, 
36.7, 36.0, 35.1, 34.9, 32.1, 31.6, 31.5, 30.9, 30.7, 30.6, 30.32, 30.29, 28.4, 23.4, 21.0, 20.7, 
12.24, 12.19, 11.25, 11.23. Note: Missing carbon signals due to signal overlap of regioisomers. 




 17β-Hydroxy-5α-androstane-derived A-Ring Lactam, 1.28. Following the general 
procedure A, (S)-3-azido-1-phenylpropanol (S)-1.2 (44.3 mg, 0.250 mmol, 2.0 equiv) was 
reacted with 5α-DHT 1.14 (36.1 mg, 0.124 mmol) to give 1.28 as a cream-colored amorphous 
(48.1 mg, 0.109 mmol, 88% yield, UPLC/HRMS purity: ≥99.5%). Purification was carried out 
by an automated MPLC system using a 12 g normal phase silica column with gradient elution 
from 0–5% MeOH/CH2Cl2. Rf = 0.35 (5% MeOH/CH2Cl2); mp 155–157 ˚C; IR (neat) 3321, 
1622 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.37–7.32 (m, 4H), 7.26 (m, 1H), 4.63 (dd, J = 9.8, 3.2 
Hz, 1H), 4.09 (ddd, J = 14.6, 10.6, 4.3 Hz, 1H), 3.69 (m, 1H), 3.64 (t, J = 8.6 Hz, 1H), 3.11 (dt, J 
= 14.2, 4.5 Hz, 1H), 2.61–2.52 (m, 2H, contains d, 2.54, J = 15.6 Hz, 1H), 2.11–2.02 (m, 1H), 
1.95–1.72 (complex, 5H), 1.68–1.55 (complex, 2H), 1.48–1.19 (complex, 9H), 1.06 (m, 1H), 
0.98–0.84 (complex, 5H, contains s, 0.92, 3H), 0.75–0.68 (complex, 4H, contains s, 0.74, 3H); 
13C NMR (101 MHz, CDCl3) δ 177.1, 144.3, 128.5 (2C), 127.2, 125.6 (2C), 81.9, 70.0, 54.4, 
52.4, 51.1, 49.6, 45.9, 42.9, 38.5, 38.0, 36.7, 36.2, 35.2, 32.1, 31.8, 30.6, 28.4, 23.5, 20.7, 12.2, 





 17β-Hydroxy-5α-androstane-derived A-Ring Lactam, 1.29. Following the general 
procedure A, (R)-3-azido-1-phenylpropanol (R)-1.2 (44.1 mg, 0.250 mmol, 2.0 equiv) was 
reacted with 5α-DHT 1.14 (36.2 mg, 0.125 mmol) to give 1.29 as a cream-colored amorphous 
solid (46.0 mg, 0.105 mmol, 84% yield, UPLC/HRMS purity: 95.7%). Purification was carried 
out by an automated MPLC system using a 12 g normal phase silica column with gradient 
elution from 0–5% MeOH/CH2Cl2. Rf = 0.33 (5% MeOH/CH2Cl2); mp 155–157 ˚C; IR (neat) 
3348, 1622 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.39–7.36 (m, 4H), 7.26 (m, 1H), 4.65 (dd, J = 
9.9, 3.5 Hz, 1H), 4.06 (ddd, J = 14.6, 10.5, 4.4 Hz, 1H), 3.69–3.61 (m, 2H), 3.12 (dt, J = 14.5, 
4.7 Hz, 1H), 3.02 (m, 1H), 2.72 (dd, J = 14.1, 10.3 Hz, 1H), 2.11–1.78 (complex, 6H, contains d, 
1.98, J = 1.9 Hz, 1H), 1.70–1.65 (m, 1H), 1.62–1.54 (m, 2H), 1.51–1.15 (complex, 8H), 1.06 (m, 
1H), 0.98–0.85 (complex, 5H, contains s, 0.90, 3H), 0.73–0.68 (complex, 4H, contains s, 0.73, 
3H); 13C NMR (126 MHz, CDCl3) δ 177.1, 144.2, 128.4 (2C), 127.2, 125.7 (2C), 81.9, 70.0, 
54.5, 51.0, 45.8, 45.7, 44.2, 42.8, 41.9, 40.0, 38.6, 37.8, 36.8, 34.9, 31.6, 30.9, 30.7, 23.4, 21.0, 






 17β-Hydroxy-5α-androstane-derived A-Ring Lactam, 1.30. Following the general 
procedure A, (S)-3-azido-1-(4-bromophenyl)propanol (S)-1.6 (65.8 mg, 0.257 mmol, 2.0 equiv) 
was reacted with 5α-DHT 1.14 (35.9 mg. 0.124 mmol) to give 1.30 as a white amorphous solid 
(54.9 mg, 0.106 mol, 86% yield, UPLC/HRMS purity: ≥99.5%). Purification was carried out by 
an automated MPLC system using a 12 g normal phase silica column with gradient elution from 
0–2% MeOH/CH2Cl2. Rf = 0.38 (4% MeOH/CH2Cl2); mp 195–199 ˚C; IR (neat) 3334, 1615, 
1598 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.47 (d, J = 8.4 Hz, 2H), 7.23 (d, J = 8.3 Hz, 2H), 4.58 
(dd, J = 9.9, 3.1 Hz, 1H), 4.10 (dd, J = 14.6, 10.9, 3.9 Hz, 1H), 3.71 (m, 1H), 3.64 (t, J = 8.6 Hz, 
1H), 3.08 (dt, J = 14.3, 4.4 Hz, 1H), 2.62–2.52 (m, 2H), 2.38 (m, 1H), 2.07 (m, 1H), 2.00–1.55 
(complex, 6H), 1.49–1.20 (complex, 9H), 1.06 (m, 1H), 0.99–0.83 (m, 5H, contains s, 0.91, 3H), 
0.74–0.67 (m, 4H, contains s, 0.74, 3H); 13C NMR (101 MHz, CDCl3) δ 177.2, 143.3, 131.5 
(2C), 127.4 (2C), 120.9, 81.9, 69.4, 54.5, 52.5, 51.1, 49.8, 45.8, 42.9, 38.5, 38.0, 36.7, 36.2, 35.2, 
32.1, 31.8, 30.6, 28.4, 23.5, 20.8, 12.2, 11.3. HRMS (FT-ICR, HESI) m/z: [M + H]+ calcd for 




 17β-Hydroxy-5α-androstane-derived A-Ring Lactam, 1.31. Following the general 
procedure A, (R)-3-azido-1-(4-bromophenyl)propanol (R)-1.6 (64.1 mg, 0.250 mmol, 2.0 equiv) 
was reacted with 5α-DHT 1.14 (36.5 mg, 0.126 mmol) to give 1.31 as a white amorphous solid 
(53.9 mg, 0.104 mol, 83% yield, UPLC/HRMS purity: ≥99.5%). Purification was carried by an 
automated MPLC system using a 12 g normal phase silica column with gradient elution from 0–
2% MeOH/CH2Cl2. Rf = 0.43 (4% MeOH/CH2Cl2); mp 213–217 ˚C; IR (neat) 3348, 1621 cm-1; 
1H NMR (400 MHz, CDCl3) δ 7.46 (m, 2H), 7.25 (m, 2H), 4.59 (dd, J = 10.0, 3.2, 1H), 4.06 
(ddd, J = 14.6, 10.8, 4.0 Hz, 1H), 3.72–3.62 (m, 2H), 3.10 (dt, J = 14.2, 4.6 Hz, 1H), 3.02 (m, 
1H), 2.73 (dd, J = 14.1, 10.4 Hz, 1H), 2.11–2.00 (m, 1H), 1.99 (d, J = 14.2 Hz, 1H), 1.94–1.55 
(complex, 7H), 1.57–1.03 (complex, 9H), 0.98–0.83 (m, 5H, contains s, 0.93, 3H), 0.74–0.67 (m, 
4H, contains s, 0.74, 3H); 13C NMR (101 MHz, CDCl3) δ 177.3, 143.3, 131.5 (2C), 127.5 (2C), 
120.9, 81.9, 69.4, 54.6, 51.0, 46.0, 45.7, 44.2, 43.0, 41.9, 40.0, 38.6, 37.9, 36.8, 35.0, 31.6, 30.9, 
30.7, 23.4, 21.0, 12.2, 11.2. HRMS (FT-ICR, HESI) m/z: [M + H]+ calcd for C28H41NO3 
518.2264, found 518.2319.  
 
 17β-Hydroxy-5α-androstane-derived A-Ring Lactam, 1.32. Following the general 
procedure A, (S)-3-azido-2-methylpropanol (S)-1.3 (27.4 mg, 0.238 mmol, 2.0 equiv) 5α-DHT 
1.14 (36.2 mg, 0.125 mmol) was reacted with to give 1.32 as an off-white amorphous solid (41.0 
mg, 0.109 mol, 87% yield, UPLC/HRMS purity: ≥99.5%). Purification was carried out by an 
automated MPLC system using a 12 g normal phase silica column with gradient elution from 
50–100% EtOAc/hexanes. Rf = 0.28 (4% MeOH/CH2Cl2); mp 196–200 ˚C; IR (neat) 3312, 1607 
125 
 
cm-1; 1H NMR (400 MHz, CDCl3) δ 3.71 (dd, J = 14.0, 10.1, 1H), 3.65–3.58 (m, 2H), 3.43 (dd, J 
= 11.8, 3.1 Hz, 1H), 3.30 (dd, J = 11.8, 3.8 Hz, 1H), 2.86 (dd, J = 13.9, 4.4 Hz, 1H), 2.67 (t, J = 
13.9 Hz, 1H), 2.50 (d, J = 15.3 Hz, 1H), 2.37 (dd, J = 14.8, 7.5 Hz, 1H), 2.05 (m, 1H), 1.88 (m, 
1H), 1.81 (m, 1H), 1.75–1.18 (complex, 13H), 1.04 (m, 1H), 0.97 (d, J = 6.9 Hz, 3H), 0.85–0.86 
(m, 4H, contains s, 0.91, 3H), 0.76–0.70 (m, 4H, contains s, 0.73, 3H); 13C NMR (126 MHz, 
CDCl3) δ 177.2, 81.9, 63.3, 54.2, 52.3, 51.1, 50.7, 48.4, 42.9, 38.5, 36.8, 35.9, 35.2, 34.3, 32.1, 
31.5, 30.6, 28.5, 23.5, 20.7, 15.2, 12.4, 11.3. HRMS (FT-ICR, HESI) m/z: [M + H]+ calcd for 
C23H40NO3 378.3003, found 378.2996.  
 
 17β-Hydroxy-5α-androstane-derived A-Ring Lactam, 1.33. Following the general 
procedure A, (R)-3-azido-2-methylpropanol (R)-1.3 (28.3 mg, 0.246 mmol, 2.0 equiv) was 
reacted with 5α-DHT 1.14 (36.4 mg, 0.125 mmol) to give 1.33 as a white crystalline solid (40.3 
mg, 0.107 mol, 85% yield, UPLC/HRMS purity: ≥99.5%). Purification was carried by an 
automated MPLC system using a 12 g normal phase silica column with gradient elution from 0–
6% MeOH/CH2Cl2. Rf = 0.47 (5% MeOH/CH2Cl2); mp 215–218 ˚C; IR (neat) 3354, 1617 cm-1; 
1H NMR (400 MHz, CDCl3) δ 3.71–3.65 (dd, J = 13.9, 10.1 Hz, 1H), 3.64–3.56 (m, 2H), 3.44 
(dd, J = 11.8, 3.1 Hz, 1H), 3.31 (dd, J = 11.8, 3.8 Hz, 1H), 2.97 (m, 1H), 2.87–2.78 (m, 2H), 
2.10–2.00 (m, 1H), 1.97 (d, J = 14.6 Hz, 1H), 1.83–1.18 (complex, 13H), 1.05 (m, 1H), 0.97 (d, 
J = 7.0 Hz, 3H), 0.94–0.82 (complex, 5H, contains s, 0.91, 3H), 0.77–0.70 (m, 4H, contains s, 
0.73, 3H); 13C NMR (151 MHz, CDCl3) δ 177.3, 82.0, 63.3, 54.4, 51.1, 50.7, 45.6, 43.9, 42.9, 
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40.4, 40.0, 38.7, 36.9, 35.0, 34.3, 31.6, 30.9, 30.7, 23.5, 21.1, 15.3, 12.3, 11.2. HRMS (FT-ICR, 
HESI) m/z: [M + H]+ for C23H40NO3 378.3003, found 378.2996.  
 
 17β-Hydroxy-5α-androstane-derived A-Ring Lactam, 1.34. Following the general 
procedure A, (S)-3-azido-3-phenylpropanol (S)-1.4 (44.1 mg, 0.249 mmol, 2.0 equiv) was 
reacted with 5α-DHT 1.14 (36.4 mg, 0.125 mmol) to give 1.34 as a cream-colored amorphous 
solid (48.6 mg, 0.111 mmol, 89% yield, UPLC/HRMS purity: ≥99.5%). Purification was carried 
out by an automated MPLC system using a 12 g normal phase silica column with gradient 
elution from 0–5% MeOH/CH2Cl2. Rf = 0.40 (5% MeOH/CH2Cl2); mp 197–202 ˚C; IR (neat) 
3441, 3356, 1597 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.38–7.28 (m, 5H), 5.89 (dd, J = 12.4, 3.2 
Hz, 1H), 3.72 (ddd, J = 12.1, 5.1, 2.5 Hz, 1H), 3.57 (t, J = 8.4 Hz, 1H), 3.40 (td, J = 11.7, 2.8 Hz, 
1H), 3.20 (dd, J = 15.4, 11.7, 1H), 2.87–2.80 (m, 2H), 2.14–1.98 (m, 3H, contains d, 2.09, J = 
14.8 Hz, 1H), 1.93 (m, 1H), 1.71–1.63 (m, 2H), 1.56–1.04 (complex, 10H), 0.97–0.80 (complex, 
6H, contains s, 0.80, 3H), 0.67 (s, 3H), 0.49 (m, 1H), 0.40 (m, 1H); 13C NMR (101 MHz, CDCl3) 
δ 177.5, 139.1, 128.7 (2C), 128.6 (2C), 128.0, 81.9, 58.5, 54.3, 52.6, 50.9, 43.6, 42.8, 40.7, 40.4, 
39.2, 38.3, 36.7, 34.9, 32.0, 31.6, 30.9, 30.7, 23.4, 20.8, 12.1, 11.1. HRMS (FT-ICR, HESI) m/z: 





 17β-Hydroxy-5α-androstane-derived A-Ring Lactam, 1.35. Following the general 
procedure A, (R)-3-azido-3-phenylpropanol (R)-1.4 (44.4 mg, 0.251 mmol, 2.0 equiv) was 
reacted with 5α-DHT 1.14 (36.3 mg, 0.125 mmol) to give 1.35 as a cream-colored amorphous 
solid (49.5 mg, 0.113 mmol, 90% yield, UPLC/HRMS purity: ≥99.5%). Purification was carried 
by an automated MPLC system using a 12 g normal phase silica column with gradient elution 
from 0–4% MeOH/CH2Cl2. Rf = 0.40 (5% MeOH/CH2Cl2); mp 248–254 ˚C; IR (neat) 3344, 
1613 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.37–7.28 (m, 5H), 5.92 (ddd, J = 12.0, 5.1, 2.5 Hz, 
1H), 3.57 (t, J = 8.5 Hz, 1H), 3.42 (td, J = 11.7, 2.9 Hz, 1H), 3.19 (dd, J = 15.3, 9.0 Hz, 1H), 
2.69 (m, 1H), 2.49 (m, 1H), 2.37 (d, J = 15.4 Hz, 1H), 2.12–1.84 (complex, 4H), 1.76 (m, 1H), 
1.59–1.08 (complex, 8H), 1.03–0.74 (m, 7H, contains s, 0.78, 3H), 0.66 (s, 3H) 0.52–0.44 (m, 
2H), 0.37–0.22 (m, 2H); 13C NMR (101 MHz, CDCl3) δ 177.2, 139.0, 129.0 (2C), 128.5 (2C), 
128.1, 81.9, 58.5, 54.1, 52.8, 50.9, 48.8, 45.4, 42.8, 38.1, 36.7, 36.1, 35.1, 32.5, 32.2, 31.2, 30.6, 
27.2, 23.4, 20.6, 12.1, 11.2. HRMS (FT-ICR, HESI) m/z: [M + H]+ calcd for C28H42NO3 





 17β-Hydroxy-5α-androstane-derived A-Ring Lactam, 1.36. Following the general 
procedure A, (S)-3-azidobutanol (S)-1.5 (29.5 mg, 0.256 mmol, 2.0 equiv) was reacted with 5α-
DHT 1.14 (36.5 mg, 0.126 mmol) to give 1.36 as a white amorphous solid (40.3 mg, 0.107 
mmol, 85% yield, UPLC/HRMS purity: 96.3%). Purification was carried out by an automated 
MPLC system using a 12 g normal phase silica column with gradient elution from 0–5% 
MeOH/CH2Cl2. Rf = 0.20 (80% EtOAc/hexanes); mp 217–219 ˚C; IR (neat) 3357, 1620 cm-1; 1H 
NMR (400 MHz, CDCl3) δ 4.78 (m, 1H), 3.63 (t, J = 8.7 Hz, 1H), 3.51 (m, 1H), 3.29–3.22 (m, 
2H), 2.69 (t, J = 14.2 Hz, 1H), 2.51–2.42 (m, 2 H, contains d, 2.49, J = 15.3 Hz, 1H), 2.49 (m, 
1H), 1.89 (dd, J = 14.1, 7.5 Hz, 1H), 1.81 (dt, J = 12.3, 3.4 Hz, 1H), 1.75–1.53 (m, 4H), 1.48–
1.12 (complex, 13H, contains d, 1.17, J = 8.1 Hz, 3H), 1.04 (m, 1H), 0.97–0.84 (m, 5H, contains 
s, 0.91, 3H), 0.75–0.68 (m, 4H, contains s, 0.73, 3H); 13C NMR (101 MHz, CDCl3) δ 177.4, 81.9, 
58.6, 54.2, 51.1, 50.0, 45.6, 44.4, 42.9, 38.5, 36.7, 36.0, 35.5, 32.5, 31.6, 30.6, 27.5, 23.5, 20.7, 
18.9, 12.3, 11.3. Note: Missing one carbon signal due to signal overlap. HRMS (FT-ICR, HESI) 






 17β-Hydroxy-5α-androstane-derived A-Ring Lactam, 1.37. Following the general 
procedure A, (R)-3-azidobutanol (R)-1.2 (27.9 mg, 0.242 mmol, 2.0 equiv) was reacted with 5α-
DHT 1.14 (36.0 mg, 0.124 mmol) to give 1.37 as a white amorphous solid (39.7 mg, 0.105 
mmol, 85% yield, UPLC/HRMS purity: 98.9%). Purification was carried out by an automated 
MPLC system using a 12 g normal phase silica column with gradient elution from 0–5% 
MeOH/CH2Cl2. Rf = 0.40 (5% MeOH/CH2Cl2); mp 179–184 ˚C; IR (neat) 3408, 3330, 1607 cm-
1; 1H NMR (400 MHz, CDCl3) δ 4.74 (m, 1H), 3.62 (t, J = 8.6 Hz, 1H), 3.52 (ddd, J = 12.0, 5.0, 
2.5 Hz, 1H), 3.29–3.20 (m, 2H), 2.98 (m, 1H), 2.83 (dd, J = 15.0, 10.8 Hz, 1H), 2.10–2.01 (m, 
2H, contains d, J = 15.0 Hz, 1H), 1.88–1.78 (m, 2H), 1.70–1.04 (complex, 17H, contains d, 1.18, 
J = 6.9 Hz, 1H), 0.96–0.83 (complex, 6H, contains s, 0.90, 3H), 0.75–0.68 (complex, 5H, 
contains s, 0.73, 3H); 13C NMR (101 MHz, CDCl3) δ 177.5, 81.9, 58.5, 54.5, 51.1, 45.5, 43.8, 
42.9, 42.1, 40.4, 38.6, 38.0, 36.8, 36.6, 35.0, 31.7, 30.9, 30.7, 23.5, 21.0, 18.9, 12.3, 11.2. HRMS 






 17β-Hydroxy-5β-androstane-derived A-Ring Lactam, 1.38. Following the general 
procedure A, (S)-3-azido-1-phenylpropanol (S)-1.2 (105 mg, 0.593 mmol, 2.0 equiv) was reacted 
with 5β-DHT 1.15 (87.6 mg, 0.302 mmol) to give 1.38 a white amorphous solid (117 mg, 0.267 
mmol, 89% yield, UPLC/HRMS purity: 97.6%). Purification was carried out by an automated 
MPLC system using a 12 g normal phase silica column with gradient elution from 0–2% 
MeOH/CH2Cl2. Rf = 0.35 (4% MeOH/CH2Cl2); mp 79–101 ˚C; IR (neat) 3374, 1616 cm-1; 1H 
NMR (400 MHz, CDCl3) δ 7.38–7.30 (m, 4H), 7.25–7.22 (m, 1H), 4.63 (dd, J = 9.8, 3.2 Hz, 
1H), 4.04 (ddd, J = 14.5, 10.5, 4.2 Hz, 1H), 3.66 (t, J = 8.5 Hz, 1H), 3.53 (dd, J = 15.4, 10.5 Hz, 
1H), 3.15 (dt, J = 14.1, 4.7 Hz, 1H), 3.08–2.97 (m, 2H), 2.13–2.03 (m, 2H, contains d, J = 14.4 
Hz, 1H), 1.99-1.75 (complex, 5H), 1.60 (m, 1H), 1.48–1.21 (complex, 10H), 1.15–1.01 (m, 5H, 
contains s, 1.01, 3H), 0.95–0.83 (m, 1H), 0.75 (s, 3H); 13C NMR (151 MHz, CDCl3) δ 176.8, 
144.3, 128.5 (2C), 127.2, 125.7 (2C), 82.0, 70.2, 51.1, 45.9, 44.5, 43.2, 42.2, 41.0, 40.0, 39.3, 
37.6, 37.1, 37.0, 36.0, 30.8, 29.9, 25.7, 24.2, 23.5, 21.0, 11.3. HRMS (FT-ICR, HESI) m/z: [M + 





 17β-Hydroxy-5β-androstane-derived A-Ring Lactam, 1.39. Following the general 
procedure A, (R)-3-azido-1-phenylpropanol (R)-1.2 (44.3 mg, 0.250 mmol, 2.0 equiv) was 
reacted with 5β-DHT 1.15 (36.6 mg, 0.126 mmol) to give 1.39 as a white amorphous solid (45.9 
mg, 0.104 mmol, 83% yield, UPLC/HRMS purity: ≥99.5%). Purification was carried out by an 
automated MPLC system using a 12 g normal phase silica column with gradient elution from 0–
3.5% MeOH/CH2Cl2. Rf = 0.44 (5% MeOH/CH2Cl2); mp 79–101 ˚C; IR (neat) 3367, 1626 cm-1; 
1H NMR (400 MHz, CDCl3) δ 7.36–7.32 (m, 4H), 7.27–7.23 (m, 1H), 4.63 (dd, J = 9.6, 3.4 Hz, 
1H), 4.10–4.01 (m, 2H), 3.66 (t, J = 8.5 Hz, 1H), 3.14 (dt, J = 14.1, 4.7 Hz, 1H), 2.74 (d, J = 15.4 
Hz, 1H), 2.56 (dd, J = 15.0, 11.8 Hz, 1H), 2.29 (m, 1H), 2.07 (m, 1H), 1.95–1.79 (complex, 5H), 
1.62–1.21 (complex, 11H), 1.18–1.09 (m, 1H), 1.06–0.99 (m, 4H, contains s, 1.02, 3H), 0.91–
0.75 (m, 5H, contains s, 0.75, 3H); 13C NMR (151 MHz, CDCl3) δ177.2, 144.2, 128.5 (2C), 
127.3, 125.7 (2C), 81.9, 70.3, 52.4, 51.0, 45.9, 45.6, 43.2, 37.9, 37.1, 37.0, 36.0, 34.4, 30.7, 28.8, 
26.6, 24.3, 23.5, 20.7, 11.3. Note: Missing two carbon signals due to signal overlap. HRMS (FT-





 17β-Hydroxy-5β-androstane-derived A-Ring Lactam, 1.40. Following the general 
procedure A, (S)-3-azido-3-phenylpropanol (S)-1.4 (44.0 mg, 0.248 mmol, 2.0 equiv) was 
reacted with 5β-DHT 1.15 (36.6 mg, 0.126 mmol) to give 1.40 as a white amorphous solid (48.1 
mg, 0.109 mmol, 87% yield, UPLC/HRMS purity: 98.8%). Purification was carried out by an 
automated MPLC system using a 12 g normal phase silica column with gradient elution from 0–
5% MeOH/CH2Cl2. Rf = 0.38 (5% MeOH/CH2Cl2); mp 223–227 ˚C; IR (neat) 3355, 1633 cm-1; 
1H NMR (400 MHz, CDCl3) δ 7.36–7.27 (m, 5H), 5.87 (dd, J = 12.2, 3.3 Hz, 1H), 3.73 (ddd, J = 
12.1, 5.0, 2.6 Hz, 1H), 3.64–3.56 (m, 2H), 3.42 (td, J = 11.6, 2.9 Hz, 1H), 2.67 (dd, J = 15.3, 
12.3 Hz, 1H), 2.57 (d, J = 15.2 Hz, 1H), 2.36 (dd, J = 15.4, 8.2 Hz, 1H), 2.11–1.79 (complex, 
5H), 1.54–0.94 (complex, 13H), 0.79 (s, 3H), 0.69–0.53 (m, 5H, contains s, 0.69, 3H); 13C NMR 
(151 MHz, CDCl3) δ 177.5, 138.8, 128.6 (2C), 128.4 (2C), 127.9, 81.7, 58.2, 52.7, 50.8, 44.9, 
44.4, 43.0, 41.1, 36.7, 35.6, 34.1, 31.8, 30.7, 30.4, 27.4, 26.2, 24.2, 23.2, 20.3, 11.0. Note: 
Missing one carbon signal due to signal overlap. HRMS (FT-ICR, HESI) m/z: [M + H]+ calcd for 





 17β-Hydroxy-5β-androstane-derived A-Ring Lactam, 1.41. Following the general 
procedure A, (R)-3-azido-3-phenylpropanol (R)-1.4 (43.8 mg, 0.247 mmol, 2.0 equiv) was 
reacted with 5β-DHT 1.15 (36.1 mg, 0.124 mmol) to give 1.41 as a white amorphous solid (49.1 
mg, 0.112 mmol, 90% yield, UPLC/HRMS purity: 97.7%). Purification was carried out by an 
automated MPLC system using a 12 g normal phase silica column with gradient elution from 0–
5% MeOH/CH2Cl2. Rf = 0.38 (5% MeOH/CH2Cl2); IR (neat) 3369, 1615 cm-1; mp decomposed; 
1H NMR (400 MHz, CDCl3) δ 7.37–7.26 (m, 5H), 5.97 (dd, J = 12.4, 3.3 Hz, 1H), 3.72 (ddd, J = 
12.0, 5.1, 2.6 Hz, 1H), 3.63 (t, J = 8.5 Hz, 1H), 3.44 (td, J = 11.6, 2.9 Hz, 1H), 3.17 (dd, J = 15.5, 
11.9 Hz, 1H), 3.03 (dd, J = 15.2, 8.0 Hz, 1H), 2.45 (br s, 1H),  2.27 (d, J = 15.4 Hz, 1H), 2.18–
2.01 (m, 2H), 1.97–1.75 (m, 4H), 1.61–1.53 (m, 1H), 1.49–0.97 (complex, 12H), 0.94–0.77 (m, 
5H, contains s, 0.82, 3H), 0.69 (s, 3H); 13C NMR (151 MHz, CDCl3) δ 176.7, 138.9, 128.7, 
128.5, 127.9, 81.9, 58.6, 52.8, 51.0, 43.1, 42.7, 40.2, 39.6, 38.9, 38.2, 36.9, 36.7, 35.9, 31.9, 30.7, 
29.7, 25.6, 23.4, 20.9, 11.3. Note: Missing one carbon signal due to signal overlap. HRMS (FT-






Experimental section for 1.3.3 
 
 5α-Cholestane-derived A-Ring Lactams, 1.42 and 1.43. Following the general 
procedure A, 2-azidoethanol 1.7 (26.6 mg, 0.306 mmol, 2.0 equiv) was reacted with 5α-
cholestan-3-one 1.13 (58.4 mg, 0.151 mmol) to give a 37:63 mixture of regioisomer 1.42 and 
1.43 as a white amorphous solid (63.8 mg, 0.143 mmol, 95% yield). Purification was carried out 
by an automated MPLC system using a 4 g normal phase column with gradient elution from 0–
5% MeOH/CH2Cl2. Rf = 0.30 (5% MeOH/CH2Cl2); IR (neat) 3391, 1623 cm-1; key 1H NMR 
(400 MHz, CDCl3) δ 3.04 (ddd, J = 15.6, 6.4, 1.7 Hz, 1H), 2.79 (dd, J = 14.3, 10.8 Hz, 1H), 2.65 
(t, J = 13.2 Hz, 1H), 2.58 (d, J = 15.5 Hz, 1H), 2.34 (ddd, J = 14.6, 7.7, 1.3 Hz, 1H); 13C NMR 
(101 MHz, CDCl3) δ 177.34, 177.26, 61.9, 56.5, 56.3, 54.1, 53.9, 53.1, 52.0, 51.8, 48.7, 46.6, 
43.7, 42.40, 42.37, 41.0, 40.2, 40.02, 40.00, 39.6, 38.4, 38.2, 36.2, 35.9, 35.8, 35.1, 34.8, 32.3, 
32.1, 31.9, 31.0, 28.4, 28.3, 28.1, 24.2, 23.9, 22.9, 22.6, 21.3, 21.1, 18.7, 12.2, 12.12, 12.09. 
Note: Missing carbon signals due to signal overlap of regioisomers. HRMS (FT-ICR, ESI) m/z: 




 5α-Cholestane-derived A-Ring Lactams, 1.44 and 1.45.  Following the general 
procedure A, (S)-2-azido-1-phenylethanol (S)-1.8 (41.0 mg, 0.251 mmol, 2.0 equiv) was reacted 
with 5α-cholestan-3-one 1.13 (48.3 mg, 0.125 mmol) to give a 46:54 mixture of regioisomer 1.44 
and 1.45 as a white amorphous solid (60.4 mg, 0.116 mmol, 93% yield). Purification was carried 
out by an automated MPLC system using a 12 g normal phase column with gradient elution from 
0–5% MeOH/CH2Cl2. Rf = 0.47 (4% MeOH/CH2Cl2); IR (neat) 3303, 1615 cm-1; key 1H NMR 
(400 MHz, CDCl3) δ 7.40–7.32 (m, 8H), 7.30–7.26 (m, 2H), 5.10 (d, J = 4.8 Hz, 1H), 4.99–4.93 
(m, 2H), 4.55 (d, J = 4.3 Hz, 1H), 3.78–3.71 (m, 2H), 3.68–3.55 (m, 3H), 3.45 (dd, J = 15.8, 11.8 
Hz, 1H), 2.80–2.68 (m, 2H), 2.61 (t, J = 13.8 Hz, 1H), 2.38–2.34 (m, 1H), 2.31 (d, J = 14.9 Hz, 
1H), 1.98–1.94 (m, 3H); 13C NMR (101 MHz, CDCl3) δ 178.8, 178.5, 142.7, 142.6, 128.6 (2C), 
128.5 (2C), 127.62, 127.60, 126.0 (2C), 125.9 (2C), 74.5, 74.2, 59.8, 58.4, 56.6, 56.5, 56.4, 54.8, 
54.1, 53.8, 47.9, 47.6, 43.6, 42.5, 42.4, 40.9, 40.10, 40.07, 40.03, 39.7, 38.4, 38.0, 36.3, 35.91, 
35.90, 35.6, 35.0, 34.9, 32.2, 32.1, 31.6, 31.0, 28.34, 28.31, 28.1, 24.3, 23.96, 23.95, 23.0, 22.7, 
21.3, 21.1, 18.8, 12.15, 12.13. Note: Missing one carbon signal due to signal overlap. HRMS 
(FT-ICR, ESI) m/z: [M + H]+ calcd for C35H56NO2 522.4306, found 522.4306.  
 
 5α-Cholestane-derived A-Ring Lactams, 1.46 and 1.47. Following the general 
procedure A, (R)-2-azido-1-phenylethanol (R)-1.5 (41.0 mg, 0.251 mmol, 2.0 equiv) was reacted 
with 5α-cholestan-3-one 1.13 (49.0 mg, 0.127 mmol) to give a 33:67 mixture of regioisomer 1.46 
and 1.47 as a white amorphous solid (58.1 mg, 0.111 mmol, 88% yield). Purification was carried 
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out by an automated MPLC system using a 12 g normal phase column with gradient elution from 
0–5% MeOH/CH2Cl2. The mixture of isomers was separated by using a 12 g normal phase 
column with 0–50% EtOAc/hexanes to give 1.47 as a white amorphous solid (32.2 mg, 0.0617 
mmol, 49% yield) as the major regioisomer and 1.46 as a white amorphous solid (17.0 mg, 
0.0326 mmol, 26% yield) as the minor regioisomer. 1.47: Rf = 0.25 (50% EtOAc/hexanes); mp 
210–213 ˚C; IR (neat) 3346, 1611 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.39–7.33 (m, 4H), 7.31–
7.25 (m, 1H), 4.93 (m, 1H), 4.32 (d, J = 4.3 Hz, 1H), 3.64 (m, 2H), 3.54 (m, 1H), 2.62 (t, J = 
13.4 Hz, 1H), 2.39–2.29 (m, 2H, contains d, 2.31, J = 15.7 Hz, 1H), 1.96 (m, 1H), 1.89–1.77 (m, 
2H), 1.69–1.62 (m, 2H), 1.58–1.46 (m, 3H), 1.38–0.91 (complex, 17H), 0.90–0.83 (complex, 
12H, contains d, 0.89, J = 6.5 Hz, 3H; d, 0.87, J = 1.9 Hz, 3H; d, 0.85, J = 1.9 Hz, 3H; s, 0.83, 
3H), 0.71–0.65 (m, 1H), 0.63 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 178.3, 142.5, 128.6 (2C), 
127.3, 126.0 (2C), 74.3, 58.8, 56.5, 56.4, 54.5, 53.9, 48.6, 42.5, 40.0, 39.7, 38.2, 36.3, 35.9, 35.7, 
35.1, 32.2, 31.8, 28.6, 28.3, 28.2, 24.3, 24.0, 23.0, 22.7, 21.1, 18.8, 12.2. Note: Missing one 
carbon signal due to signal overlap. HRMS (FT-ICR, ESI) m/z: [M + H]+ calcd for C35H56NO2 
522.4306, found 522.4310. 1.46: Rf = 0.36 (50% EtOAc/hexanes); mp 162–165 ˚C; IR (neat) 
3358, 1621 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.40–7.33 (m, 4H), 7.28–7.24 (m, 1H), 4.92 (m, 
1H), 4.83 (m, 1H), 3.73–3.62 (m, 2H), 3.55 (dd, J = 14.3, 2.6 Hz, 1H), 2.85 (m, 1H), 2.76 (m, 
1H), 1.97–1.92 (m, 2H, contains d, 1.94, J = 14.6 Hz, 1H), 1.86–1.77 (m, 1H), 1.65 (m, 1H), 
1.56–0.93 (complex, 21H), 0.89–0.82 (complex, 12H, contains d, 0.89, J = 6.4 Hz, 3H; d, 0.87, J 
= 2.0 Hz, 3H; d, 0.85, J = 2.0 Hz, 3H; 0.82, s, 3H) 0.72–0.66 (m, 1H), 0.62 (s, 3H), 0.61–0.54 
(m, 1H); 13C NMR (101 MHz, CDCl3) δ 178.6, 142.7, 128.6 (2C), 127.6, 126.0 (2C), 74.2, 59.2, 
56.6, 56.4, 54.1, 48.0, 43.4, 42.4, 40.1, 39.9, 39.7, 38.3, 36.3, 35.9, 34.8, 32.1, 31.0, 29.8, 28.4, 
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28.1, 24.3, 24.0, 22.9, 22.7, 21.3 18.8, 12.19, 12.12. HRMS (FT-ICR, ESI) m/z: [M + H]+ calcd 
for C35H56NO2 522.4306, found 522.4308.  
 
 5α-Cholestane-derived A-Ring Lactam, 1.48. Following the general procedure A, (S)-
2-azido-3-phenylpropanol (S)-1.9 (53.4 mg, 0.301 mmol, 2.0 equiv) was reacted with 5α-
cholestan-3-one 1.13 (58.1 mg, 0.150 mmol) to give 1.48 as a white amorphous solid (65.1 mg, 
0.121 mmol, 81% yield) as the major regioisomers, in addition an uncharacterized, impure minor 
product was obtained  (10.0 mg, 0.019 mmol, 12% yield). Purification was carried out by an 
automated MPLC system using a 12 g normal phase column with gradient elution from 0–5% 
MeOH/CH2Cl2. Rf = 0.23 (2% MeOH/CH2Cl2); mp 203–204 ˚C; IR (neat) 3415, 1618 cm-1; 1H 
NMR (400 MHz, CDCl3) δ 7.31–7.26 (m, 2H), 7.24–7.20 (m, 3H), 4.64 (br s, 1H), 3.74 (dd, J = 
11.6, 3.6 Hz, 1H), 3.64 (dd, J = 11.6, 7.7 Hz, 1H), 3.34 (dd, J = 15.6, 9.2 Hz, 1H), 2.89 (m, 2H), 
2.61 (t, J = 13.8 Hz, 1H), 2.44 (d, J = 15.6 Hz, 1H), 2.33 (dd, J = 15.0, 7.2 Hz, 1H), 1.93 (m, 
1H), 1.85–1.74 (m, 4H), 1.37–0.94 (complex, 20H), 0.91–0.81 (complex, 9H, contains s, 0.89, 
3H; d, 0.87, J = 2.1 Hz, 3H; d, 0.85, J = 1.9 Hz, 3H), 0.79 (s, 3H), 0.74–0.67 (m, 1H), 0.61 (s, 
3H), 0.42 (m, 1H); 13C NMR (126 MHz, CDCl3) δ 177.6, 138.2, 128.8 (2C), 128.6 (2C), 126.6, 
64.1, 56.4, 56.3, 53.8, 48.4, 42.4, 39.9, 39.6, 37.9, 36.2, 35.9, 35.7, 35.03, 34.99, 33.0, 31.7, 28.3, 
28.2, 28.1, 24.2, 23.9, 23.0, 21.0, 18.7, 12.13, 12.12. Note: Missing three carbon signals due to 
signal overlap. X-ray crystal structure of this analog is provided in the CCDC (CCDC 1583535). 
HRMS (FT-ICR, HESI) m/z: [M + H]+ calcd for C36H58NO2 536.4462, found 536.4489. 
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Table 1.8. Selected crystallographic and refinement parameters for 1.48. 
compound 1.48 
CCDC deposition number 1583535 
empirical formula  C36H57NO2 
formula weight 535.82 
temperature 100(2) K 
wavelength  1.54178 Å 
crystal system orthorhombic 
space group P 21 21 21 
unit cell dimensions a = 7.1041(9) Å, D= 90° 
b = 8.9377(11) Å, E= 90° 
c = 50.231(6) Å, J = 90° 
Z 4 
volume   3189.4(7) Å3 
density 1.116 Mg/m3 
absorption coefficient 0.509 µ mm-1 
F(000) 1184 
crystal size 0.200 × 0.120 × 0.020 mm3 
Theta range for data collection  3.519 to 67.727°   
index ranges -8<=h<=8, -10<=k<=6, -56<=l<=57 
reflections collected 14336 
independent reflections 5254 [R(int) = 0.0413] 
completeness to theta = 66.000° 96.1% 
absorption correction multi-scan 
max. and min. transmission 1.000 and 0.762 
refinement method full-matrix least-squares on F2 
data/restraints/parameters 5254/0/580 
Goodness-of-fit F2 1.124 
final R indices [I>2sigma(I)] R1 = 0.0512, wR2 = 0.1349 
R indices (all data) R1 = 0.0543, wR2 = 0.1368 
absolute structure parameter -0.09(18) 
largest diff. peak and hole 0.169 and -0.246 e.Å-3 
 
 
 5α-Cholestane-derived A-Ring Lactam, 1.49. Following the general procedure A, (R)-
2-azido-3-phenylpropanol (R)-1.9 (53.5 mg, 0.302 mmol, 2.0 equiv) was reacted with 5α-
cholestan-3-one 1.13 (57.9 mg, 0.150 mmol) to give 1.49 as a white amorphous solid (52.4 mg, 
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0.0978 mmol, 65% yield) as the major regioisomers; an uncharacterized, impure minor product 
was also obtained in this case (17.8 mg, 0.033 mmol, 22% yield). Purification was carried out by 
an automated MPLC system using a 12 g normal phase column with gradient elution from 0–
100% EtOAc/Ether. The major isomer was subjected to a second purification using a 4 g normal 
phase column with gradient elution from 0–5% MeOH/CH2Cl2. Rf = 0.29 (25% EtOAc/Ether); 
mp 191–194 ˚C; IR (neat) 3415, 1620 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.31–7.26 (m, 2H), 
7.23–7.18 (m, 3H), 4.38 (br s, 1H), 3.71 (m, 2H), 3.31 (dd, J = 15.7, 11.7 Hz, 1H), 2.99–2.73 (m, 
3H), 2.75 (m, 1H), 1.95–1.89 (m, 2H, contains d, 1.91, J = 14.3 Hz, 1H), 1.80 (m, 1H), 1.65–
1.46 (m, 4H), 1.42–0.93 (complex, 19H),  0.89–0.83 (complex, 11H, contains d, 0.88, J = 6.4 
Hz, 3H; 0.86, d, J = 2.0 Hz, 3H; 0.85, d, J = 2.0 Hz, 3H), 0.79 (s, 3H), 0.61 (s, 3H), 0.50 (m, 
1H); 13C NMR (126 MHz, CDCl3) δ 177.7, 138.5, 129.1 (2C), 128.6 (2C), 126.5, 64.0, 56.4, 
56.3, 54.2, 43.6, 42.4, 41.2, 40.9, 40.0, 39.6, 38.2, 36.2, 35.9, 35.0, 34.8, 32.1, 31.0, 28.3, 28.1, 
24.2, 23.9, 22.9, 22.7, 21.3, 18.7, 12.2, 12.1. Note: Missing two carbon signals due to signal 
overlap. X-ray crystal structure of this analog is provided in the CCDC (CCDC 1583534). 
HRMS (FT-ICR, ESI) m/z: [M + H]+ calcd for C36H58NO2 536.4462, found 536.4471.  
 
Table 1.9. Selected crystallographic and refinement parameters for 1.49. 
compound 1.49 
CCDC deposition number 1583534 
empirical formula  C36H57NO2 
formula weight 535.82  
temperature 100(2) K 
Wavelength Å 1.54178 
crystal system orthorhombic 
space group P 21 21 21 
unit cell dimensions a = 6.9681(10) Å, D= 90° 
b = 8.9956(12) Å, E= 90° 
c = 50.221(7) Å, J = 90° 
Z 4 
volume   3148.0(7) Å3 
density 1.131 Mg/m3 
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absorption coefficient 0.515 µ mm-1 
F(000) 1184 
crystal size 0.450 × 0.180 × 0.020 mm3 
Theta range for data collection  3.520 to 67.956°   
index ranges -8<=h<=8, -10<=k<=7, -58<=l<=58 
reflections collected 20015 
independent reflections 5136 [R(int) = 0.0435] 
completeness to theta = 66.000° 96.1% 
absorption correction multi-scan 
max. and min. transmission 1.000 and 0.836 
refinement method full-matrix least-squares on F2 
data/restraints/parameters 5136/0/578 
Goodness-of-fit F2 1.235 
final R indices [I>2sigma(I)] R1 = 0.0491, wR2 = 0.1160 
R indices (all data) R1 = 0.0535, wR2 = 0.1180 
absolute structure parameter -0.03(9) 
largest diff. peak and hole 0.184 and -0.196 e.Å-3 
 
 
 17β-Hydroxy-5α-androstane-derived A-Ring Lactam, 1.50. Following the general 
procedure A, (S)-2-azido-3-phenylpropanol (S)-1.9 (45.8 mg, 0.458 mmol, 2.0 equiv) was 
reacted with 5α-DHT 1.14 (36.5 mg, 0.126 mmol) to give 1.50 as a white amorphous solid (42.0 
mg, 0.096 mmol, 76% yield, LCMS purity: 96.0%) containing a slight impurity of minor 
regioisomer. Purification was carried out by an automated MPLC system using a 12 g normal 
phase silica column with gradient elution from 0–4% MeOH/CH2Cl2. Rf = 0.28 (4% 
MeOH/CH2Cl2); mp 157–159 ˚C; IR (neat) 3390, 1621 cm-1; 1H NMR (400 MHz, CDCl3) δ 
7.32–7.27 (m, 2H), 7.24–7.19 (m, 2H), 4.68 (br s, 1H), 3.74 (dd, J = 11.6, 3.6 Hz, 1H), 3.67–
3.58 (m, 2H), 3.39 (dd, J = 15.6, 9.3 Hz, 1H), 2.992.82 (m, 2H), 2.66 (t, J = 13.9 Hz, 1H), 2.49–
2.39 (m, 2H), 2.26 (m, 2H), 2.09–1.99 (m, 1H), 1.82–1.74 (m, 2H), 1.64–1.50 (m, 3H), 1.46–
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1.36 (m, 1H), 1.32–0.95 (complex, 7H), 0.89–0.76 (m, 4H, contains s, 0.81, 3H), 0.76–0.65 (m, 
4H, contains s, 0.69, 3H), 0.42 (m, 1H); 13C NMR (151 MHz, CDCl3) δ 178.0, 138.0, 128.8, 
128.7, 126.7, 81.9, 64.1, 54.0, 51.0, 48.4, 42.9, 38.1, 36.7, 35.7, 35.0, 34.9, 32.6, 31.3, 30.6, 28.1, 
23.4, 20.6, 12.2, 11.2. Note: Missing carbon two carbon signals due to signal overlap. HRMS 
(FT-ICR, HESI) m/z: [M + H]+ calcd for C28H42NO3 440.3159, found 440.3154.   
 
 17β-Hydroxy-5α-androstane-derived A-Ring Lactam, 1.51. Following the general 
procedure A, (R)-2-azido-3-phenylpropanol (R)-1.9 (44.7 mg, 0.252 mmol, 2.0 equiv) was 
reacted with 5α-DHT 1.14 (35.9 mg, 0.124 mmol) to give 1.51 as a white amorphous solid (35.1 
mg, 0.080 mmol, 65% yield, LCMS purity: 97.3%). Purification was carried out by an automated 
MPLC system using a 12 g normal phase silica column with gradient elution from 0–4% 
MeOH/CH2Cl2 over 50 min. Rf = 0.32 (4% MeOH/CH2Cl2); IR (neat) 3375, 1619 cm-1; mp 172–
174 ˚C; 1H NMR (400 MHz, CDCl3) δ 7.32–7.26 (m, 2H), 7.24–7.19 (m, 3H), 3.78–3.68 (m, 
2H), 3.61 (t, J = 8.5 Hz, 1H), 3.34 (dd, J = 15.9, 11.8 Hz, 1H), 3.02–2.85 (m, 3H), 2.81–2.75 (m, 
1H), 2.09–1.99 (m, 4H), 1.77 (dt, J = 12.5, 3.4 Hz, 1H), 1.68–1.52 (m, 3H), 1.48–1.14 (complex, 
7H), 1.02–0.79 (complex, 7H, contains s, 0.82, 3H), 0.70 (s, 3H), 0.53 (m, 1H); 13C NMR (101 
MHz, CDCl3) δ 177.8, 138.5, 129.1 (2C), 128.7 (2C), 126.6, 81.9, 64.3, 54.4, 51.0, 43.7, 42.8, 
41.3, 40.8, 38.4, 36.8, 35.0, 34.9, 31.6, 30.8, 30.7, 23.4, 20.9, 12.2, 11.2. Note: Missing two 
carbon signals due to signal overlap. HRMS (FT-ICR, HESI) m/z: [M + H]+ calcd for C28H42NO3 




Experimental section for 1.3.4 
 
 17β-Hydroxy-5α-androstane-derived A-Ring Thioamide, 1.52. Following the general 
procedure B, (R)-3-azido-1-phenylpropanol (R)-1.2 (72.1 mg, 0.407 mmol, 2.0 equiv) was 
reacted with 5α-DHT 1.14 (58.3 mg, 0.201 mmol) to give 1.52 as an off-white solid (77.3 mg, 
0.170 mmol, 85% yield, UPLC/HRMS purity: 98.9%). Purification was carried out by an 
automated MPLC system using a 12 g normal phase silica column with gradient elution from 0–
45% EtOAc/hexanes. Rf = 0.38 (50% EtOAc/hexanes); mp 236–239 ˚C; IR (neat) 3331, 1529 
cm-1; 1H NMR (400 MHz, CDCl3) δ 7.39–7.33 (m, 4H), 7.29–7.27 (m, 1H), 4.73 (m, 1H), 4.68 
(m, 1H), 3.91 (dd, J = 15.3, 11.9 Hz, 1H), 3.75 (m, 2H), 3.63 (t, J = 8.6 Hz, 1H), 3.36 (m, 1H), 
3.10 (dd, J = 14.1, 9.7 Hz, 1H), 2.79 (d, J = 14.1 Hz, 1H), 2.21–1.78 (m, 3H), 1.88 (dd, J = 14.5, 
6.4 Hz, 1H), 1.81 (dt, J = 12.4, 3.4 Hz, 1H), 1.69 (m, 1H), 1.63–1.17 (complex, 10 H), 1.05 (m, 
1H), 0.99 (m, 4H, contains s, 0.91, 3H), 0.74–0.67 (m, 4H, contains s, 0.73, 3H); 13C NMR (151 
MHz, CDCl3) δ 206.2, 143.9, 128.6 (2C), 127.6, 125.7 (2C), 81.9, 70.4, 54.6, 54.0, 51.0, 50.0, 
49.8, 45.6, 42.9, 40.6, 38.4, 36.9, 36.8, 34.9, 31.6, 30.7, 23.4, 21.0, 12.6, 11.2. Note: Missing one 
carbon signal due to signal overlap. HRMS (FT-ICR, HESI) m/z: [M + H]+ calcd for C28H42NO2S 




 17β-Hydroxy-5α-androstane-derived A-Ring Thioamide, 1.53. Following the general 
procedure B, (S)-3-azido-1-phenylpropanol (S)-1.2 (71.2 mg, 0.402 mmol, 2.0 equiv) was 
reacted with 5α-DHT 1.14 (58.6 mg, 0.202 mmol) to give 1.53 as a white amorphous solid (41.2 
mg, 0.090 mmol, 45% yield, UPLC/HRMS purity: 97.6%). Purification was carried out by an 
automated MPLC system using a using 12 g normal phase silica column with gradient elution 
from 0–40% EtOAc/hexanes. Rf = 0.42 (50% EtOAc/hexanes); mp 229–233 ˚C; IR (neat) 3428, 
3302, 1520 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.36 (m, 4H), 7.28 (m, 1H), 4.80 (ddd, J = 13.4, 
10.1, 4.9 Hz, 1H), 4.73 (m, 1H), 3.96 (m, 2H), 3.70–3.62 (m, 2H), 3.21 (dd, J = 14.2, 7.1 Hz, 
1H), 2.97 (t, J = 13.3 Hz, 1H), 2.88 (d, J = 15.1 Hz, 1H), 2.11–2.02 (m, 4H), 1.84–1.72 (m, 2H), 
1.66–1.55 (m, 2H), 1.50–1.19 (complex, 7H), 1.05 (m, 1H), 0.97–0.84 (m, 5H, contains s, 0.92, 
3H), 0.76–0.69 (m, 4H, contains s, 0.74, 3H); 13C NMR (151 MHz, CDCl3) δ 206.2, 143.9, 128.6 
(2C), 127.4, 125.5 (2C), 81.8, 70.1, 56.1, 54.4, 54.1, 51.0, 48.3, 42.9, 42.2, 38.2, 37.4, 37.3, 36.6, 
35.1, 31.6, 30.6, 28.2, 23.4, 20.6, 12.6, 11.3. HRMS (FT-ICR, HESI) m/z: [M + H]+ calcd for 




 17β-Hydroxy-5α-androstane-derived A-Ring Thioamide, 1.54. Following the general 
procedure B, (R)-3-azido-3-phenylpropanol (R)-1.4 (73.4 mg, 0.414 mmol, 2.0 equiv) was 
reacted with 5α-DHT 1.14 (58.9 mg, 0.203 mmol) to give 1.54 as a pale yellow amorphous solid 
(54.5 mg, 0.120 mmol, 59% yield, UPLC/HRMS purity: ≥99.5%). Purification was carried out 
using 12 g silica column with gradient elution from 0–50% EtOAc/hexanes. Rf = 0.34 (50% 
EtOAc/hexanes); IR (neat) 3410, 3310, 1495, 1451 cm-1; mp 243–245 ˚C; 1H NMR (400 MHz, 
CDCl3) δ 7.43–7.31 (m, 5H), 7.14 (dd, J = 12.0, 3.2 Hz, 1H), 3.74 (m, 1H), 3.60–3.45 (m, 3H), 
3.36 (dd, J = 14.8, 7.8 Hz, 1H), 3.01 (m, 1H), 2.72 (dd, J = 14.9 Hz, 1H), 2.18 (m, 1H), 2.11–
1.96 (m, 2H), 1.88 (m, 1H), 1.75 (dt, J = 12.3, 3.4 Hz, 1H), 1.56–1.07 (complex, 9H), 1.00–0.73 
(complex, 6H, contains s, 0.78, 3H), 0.63 (s, 3H), 0.40 (m, 3H), 0.18 (m, 1H); 13C NMR (151 
MHz, CDCl3) δ 206.4, 138.1, 128.8 (2C), 128.7, 128.6 (2C), 81.9, 61.1, 58.1, 54.2, 50.8, 49.6, 
47.9, 42.8, 42.3, 37.8, 37.2, 36.6, 35.0, 32.5, 31.1, 30.5, 27.1, 23.3, 20.5, 12.4, 11.2. HRMS (FT-
ICR, HESI) m/z: [M + H]+ calcd for C28H42NO2S 456.2931, found 456.2920.  
 
 17β-Hydroxy-5α-androstane-derived A-Ring Thioamide, 1.55. Following the general 
procedure B, (S)-3-azido-3-phenylpropanol (S)-1.4 (74.0 mg, 0.418 mmol, 2.1 equiv) was 
reacted with 5α-DHT 1.14 (58.8 mg, 0.202 mmol) to give 1.55 as an off-white amorphous solid 
(73.6 mg, 0.162 mmol, 80% yield, UPLC/HRMS purity: 90.3%). Purification was carried out by 
an automated MPLC system using a using 12 g normal phase silica column with gradient elution 
from 0–50% EtOAc/hexanes. Rf = 0.32 (50% EtOAc/hexanes); mp 249–251 ˚C; IR (neat) 3338, 
1488, 1454 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.41–7.31 (m, 5H), 7.12 (dd, J = 12.0, 3.3 Hz, 
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1H), 3.79–3.71 (m, 1H), 3.57 (m, 1H), 3.52–3.44 (m, 3H), 3.25–3.12 (m, 2H), 2.96 (d, J = 14.6 
Hz, 1H), 2.24–2.16 (m, 1H), 2.12–1.99 (m, 2H), 1.69–1.63 (m, 2H), 1.60–1.52 (m, 2H), 1.44–
1.02 (complex, 9H), 0.96–0.81 (m, 3H), 0.81 (s, 3H), 0.66 (s, 3H), 0.41 (m, 1H), 0.21 (m, 1H); 
13C NMR (151 MHz, CDCl3) δ 207.0, 138.0, 128.9 (2C), 128.6, 128.3 (2C), 81.9, 61.0, 58.1, 
54.2, 50.8, 49.9, 44.9, 43.7, 42.8, 39.7, 38.0, 36.6, 34.8, 32.3, 31.5, 30.8, 30.7, 23.4, 20.7, 12.5, 
11.1. HRMS (FT-ICR, HESI) m/z: [M + H]+ calcd for C28H42NO2S [M + H]+ 456.2931, found 
456.2929.  
 
 17β-Hydroxy-5β-androstane-derived A-Ring Thioamide, 1.56. Following the general 
procedure B, (S)-3-azido-1-phenylpropanol (S)-1.2 (73.5 mg, 0.415 mmol, 2.1 equiv) was 
reacted with 5β-DHT 1.15 (58.9 mg, 0.203 mmol) to give 1.56 as a pale yellow foam solid (57.7 
mg, 0.127 mmol, 62% yield, UPLC/HRMS purity: 98.0%). Purification was carried out using 12 
g silica column with gradient elution from 0–50% EtOAc/hexanes. Rf = 0.33 (50% 
EtOAc/hexanes); IR (neat) 3425, 3312, 1495, 1451 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.38–
7.32 (m, 4H), 7.29–7.25 (m, 1H), 4.75–4.64 (m, 2H), 3.85 (m, 2H), 3.74 (m, 1H), 3.65 (m, 1H), 
3.46 (dd, J = 13.8, 11.2 Hz, 1H), 3.26 (dd, J= 15.2, 7.0 Hz, 1H), 2.92 (d, J = 13.8 Hz, 1H), 2.16–
1.89 (complex, 4H), 1.85 (m, 1H), 1.77 (m, 1H), 1.64–1.02 (complex, 11H), 1.00 (s, 3H), 0.86 
(m, 2H), 0.75 (s, 3H); 13C NMR (151 MHz, CDCl3) δ 206.2, 143.9, 128.6 (2C), 127.5, 125.7 
(2C), 82.0, 70.3, 53.9, 51.1, 49.2, 48.6, 43.2, 42.8, 41.6 (br), 38.4, 37.1, 37.0, 36.9, 35.9, 30.8, 
30.2, 25.7, 24.8 (br), 23.5, 21.0, 11.3. Note: Two broad carbon signals were consistently 
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observed amongst cis-AB analogs. HRMS (FT-ICR, HESI) m/z: [M + H]+ calcd for C28H42NO2S 
456.2931, found 456.2920.  
 
 17β-Hydroxy-5β-androstane-derived A-Ring Thioamide, 1.57. Following the general 
procedure B, (S)-3-azido-3-phenylpropanol (S)-1.4 (72.0 mg, 0.406 mmol, 2.0 equiv) was 
reacted with 5β-DHT 1.15 (58.2 mg, 0.200 mmol) to give 1.57 as a pale-yellow amorphous solid 
(71.6 mg, 0.156 mmol, 78% yield, UPLC/HRMS purity: ≥99.5%). Purification was carried out 
using 12 g silica column with gradient elution from 0–40% EtOAc/hexanes. Rf = 0.28 (50% 
EtOAc/hexanes); mp 226 ˚C (decomposed); IR (neat) 3366, 1501, 1446 cm-1; 1H NMR (400 
MHz, CDCl3) δ 7.41–7.31 (m, 5H), 7.08 (dd, J = 10.7, 4.4 Hz, 1H), 3.85 (dd, J = 14.8, 10.2 Hz, 
1H), 3.74 (m, 1H), 3.61 (m, 2H), 3.50 (m, 1H), 3.21 (dd, J = 15.1, 8.3 Hz, 1H), 2.98 (dd, J = 
15.0, 11.8 Hz, 1H), 2.92 (d, J = 14.8 Hz, 1H), 2.21–1.99 (m, 3H), 1.93 (dd, J = 15.1, 8.4 Hz, 
1H), 1.03 (m, 1H), 1.55–0.83 (complex, 11H), 0.74 (s, 3H), 0.72–0.57 (m, 2H), 0.69 (s, 3H), 
0.39 (m, 1H); 13C NMR (151 MHz, CDCl3) δ 207.0, 138.2, 128.8 (2C), 128.7, 128.4 (2C), 81.9, 
61.2, 58.3, 51.0, 49.5, 44.0, 43.2, 41.5, 40.9, 36.9, 36.6, 35.8, 34.9, 32.4, 30.6, 27.5, 26.3, 24.4, 
23.4, 20.6, 11.2. Note: Two broad carbon signals were consistently observed amongst cis-AB 





 17β-Hydroxy-5α-androstane-derived A-Ring Amine, 1.58. Method 1: Following the 
general procedure B, (R)-3-azido-1-phenylpropanol (R)-1.2 (72.7 mg, 0.410 mmol, 2.0 equiv) 
was reacted with 5α-DHT 1.14 (58.0 mg, 0.200 mmol) to give 1.58 as pale yellow sticky solid 
(73.6 mg, 0.173 mmol, 87% yield, UPLC/HRMS purity: ≥99.5%). Purification was carried out 
by an automated MPLC system using a 12 g normal phase silica column using MeOH/CH2Cl2. 
Rf = 0.15 (4% MeOH/CH2Cl2). HRMS (FT-ICR, HESI) m/z: [M + H]+ calcd for C28H44NO2 [M + 
H]+ 426.3367, found 426.3356. Method 2: 1.29 (110.0 mg, 0.250 mmol) was added to a stirring 
suspension of LAH (1M THF, 0.500 mL, 0.500 mmol, 2.0 equiv) in anhydrous THF (14 mL) at 
0 ˚C. The reaction mixture was allowed to room temperature, stirred for 4 h and then refluxed for 
24 h. The reaction mixture was allowed to room temperature and quenched with a saturated 
aqueous solution of sodium potassium tartarate (5 mL). The biphasic mixture was stirred 
overnight. The biphasic mixture was diluted CH2Cl2 (50 mL). The organic layer was washed 
with aqueous solution of sodium potassium tartarate (2 × 5 mL), brine (5 mL), dried over 
Na2SO4, filtered, and concentrated. Purification was carried out by an automated MPLC system 
using a 12 g normal phase silica column using MeOH/CH2Cl2 to give 1.58 as white foam solid 
(53.9 mg, 0.127 mmol, 51% yield, UPLC/HRMS purity: ≥99.5%). mp decomposed; IR (neat) 
3357, 2918, 2846, 1449 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.36 (m, 4H), 7.23 (m, 1H), 4.99 
(dd, J = 7.9, 3.2 Hz, 1H), 3.61 (t, J = 8.6 Hz, 1H), 2.91 (m, 1H), 2.76 (m, 3H), 2.56 (m, 2H), 2.05 
(m, 1H), 1.90 (m, 1H) 1.79 (m, 2H), 1.66–1.51 (complex, 4H), 1.03 (m, 1H), 0.90 (m, 2H), 0.83 
(s, 3H), 0.76–0.73 (complex, 4H, contains s, 0.73, 3H); 13C NMR (151 MHz, CDCl3) δ 145.2, 
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128.3 (2C), 127.0, 125.7 (2C), 82.1, 75.5, 58.3, 54.7, 54.0, 51.3, 50.7, 46.2, 42.9, 38.5, 37.0, 
35.3, 34.1, 31.7, 31.0, 30.7, 29.9, 23.6, 21.5, 13.3, 11.3. Note: Missing one carbon signal due to 
signal overlap. HRMS (FT-ICR, HESI) m/z: [M + H]+ calcd for C28H44NO2 [M + H]+ 426.3367, 
found 426.3357.   
 
 17β-Hydroxy-5α-androstane-derived A-Ring Amine, 1.59. Method 1: Following the 
general procedure B, (S)-3-azido-1-phenylpropanol (S)-1.2 (71.1 mg, 0.401 mmol, 2.0 equiv) 
was reacted with 5α-DHT 1.14 (58.9 mg, 0.203 mmol) to give 1.59 as pale yellow sticky solid 
(43.1 mg, 0.101 mmol, 50% yield, UPLC/HRMS purity: ≥99.5%). Purification was carried out 
by an automated MPLC system using a 12 g normal phase silica column using MeOH/CH2Cl2. 
Rf = 0.15 (4% MeOH/CH2Cl2). HRMS (FT-ICR, HESI) m/z: [M + H]+ calcd for C28H44NO2 [M + 
H]+ 426.3367, found 426.3357. Method 2: 1.28 (97.0 mg, 0.221 mmol) was added to a stirring 
suspension of LAH (1M THF, 0.43 mL, 0.430 mmol, 2.0 equiv) in anhydrous THF (10 mL) at 0 
˚C. The reaction mixture was allowed to room temperature, stirred for 4 h and then refluxed for 
24 h. The reaction mixture was allowed to room temperature and quenched with a saturated 
aqueous solution of sodium potassium tartarate (5 mL). The biphasic mixture was stirred 
overnight. The biphasic mixture was diluted CH2Cl2 (50 mL). The organic layer was washed 
with aqueous solution of sodium potassium tartarate (2 × 5 mL), brine (5 mL), dried over 
Na2SO4, filtered, and concentrated. Purification was carried out by an automated MPLC system 
using a 12 g normal phase silica column using MeOH/CH2Cl2 to give 1.59 as white foam solid 
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(54.7 mg, 0.129 mmol, 58% yield, UPLC/HRMS purity: ≥99.5%). mp decomposed; IR (neat) 
3337, 2920, 2848, 1448 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.36 (m, 4H), 7.23 (m, 1H), 4.95 
(dd, J = 6.9, 4.7 Hz, 1H), 3.63 (t, J = 8.5 Hz, 1H), 2.86–2.61 (complex, 5H), 2.35 (d, J = 13.6 Hz, 
1H), 2.05 (m, 1H), 1.83–1.18 (complex, 17H), 1.04 (m, 1H), 0.98–0.82 (complex, 5H, contains s, 
0.82, 3H), 0.76–0.67 (complex, 4H, contains s, 0.73, 3H); 13C NMR (101 MHz, CDCl3) δ 145.4, 
128.3 (2C), 126.9, 125.7 (2C), 82.1, 75.7, 58.3, 57.5, 55.3, 53.5, 51.3, 45.7, 43.0, 40.0, 38.3, 
37.1, 35.4, 34.6, 31.7, 30.8, 28.9, 23.5, 22.0, 21.4, 14.0, 11.3. HRMS (FT-ICR, HESI) m/z: [M + 
H]+ calcd for C28H44NO2 [M + H]+ 426.3367, found 426.3356.  
 
 17β-Hydroxy-5α-androstane-derived A-Ring Lactam 1.60. Following the general 
procedure B, (R)-3-azido-1-phenylpropanol (R)-1.2 (70.5 mg, 0.398 mmol, 1.9 equiv) was 
reacted with 5α-DHT 1.14 (60.0 mg, 0.207 mmol) to give 1.60 as white foam solid (80.9 mg, 
0.191 mmol, 92% yield, UPLC/HRMS purity: ≥99.5%). Purification was carried out by an 
automated MPLC system using a 12 g normal phase silica column with gradient elution from 0–
3% MeOH/CH2Cl2. Rf = 0.38 (4% MeOH/CH2Cl2); mp decomposed; IR (neat) 3214, 1626 cm-1; 
1H NMR (400 MHz, CDCl3) δ 7.29 (m, 2H), 7.18 (m, 3H), 3.59 (m, 2H), 3.48–3.31 (m, 2H), 
2.95 (dd, J = 15.5, 6.3 Hz, 1H), 2.74 (dd, J = 14.3, 10.1 Hz, 1H), 2.62 (td, J = 7.4, 2.5 Hz, 2H), 
2.04 (m, 1H), 1.93 (d, J = 14.3 Hz, 1H), 1.96–1.77 (m, 4H), 1.68–1.56 (complex, 4H), 1.48–1.14 
(complex, 6H), 1.03 (m, 1H), 0.95–0.83 (complex, 6H, contains s, 0.88, 3H), 0.73–0.66 
(complex, 4H, contains s, 0.73, 3H); 13C NMR (101 MHz, CDCl3) δ 175.4, 141.9, 128.52 (2C), 
128.46 (2C), 126.0, 82.0, 54.5, 51.1, 47.9, 44.9, 43.9, 42.9, 41.6, 40.5, 38.5, 36.8, 35.0, 33.4, 
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31.7, 30.9, 30.7, 30.1, 23.5, 21.0, 12.2, 11.2. HRMS (FT-ICR, HESI) m/z: [M + H]+ calcd for 
C28H42NO2 [M + H]+ 424.3210, found 424.3203.  
 
 17β-Hydroxy-5α-androstane-derived A-Ring Lactam, 1.61. Following the general 
procedure B, (S)-3-azido-1-phenylpropanol (S)-1.2 (36.8 mg, 0.208 mmol, 2.1 equiv) was 
reacted with 5α-DHT 1.14 (29.0 mg, 0.100 mmol) to give 1.61 as white foam solid (39.6 mg, 
0.093 mmol, 93% yield, UPLC/HRMS purity: ≥99.5%). Purification was carried out by an 
automated MPLC system using a 12 g normal phase silica column with gradient elution from 0–
3% MeOH/CH2Cl2. Rf = 0.38 (4% MeOH/CH2Cl2); mp decomposed; IR (neat) 3212, 1621 cm-1; 
1H NMR (400 MHz, CDCl3) δ 7.34 (m, 2H), 7.25 (m, 3H), 3.67 (m, 2H), 3.47 (m, 2H), 2.68 (m, 
3H), 2.55 (d, J = 15.5 Hz, 1H), 2.39 (m, 1H), 2.11 (m, 1H), 1.97–1.83 (complex, 4H), 1.79–1.59 
(complex, 4H), 1.10 (m, 1H), 1.02–0.90 (complex, 5H, contains s, 0.95, 3H), 0.83–0.72 
(complex, contains s, 0.79, 3H); 13C NMR (101 MHz, CDCl3) δ 175.3, 141.9, 128.5 (2C), 128.4 
(2C), 126.0, 81.9, 54.2, 51.5, 51.1, 49.1, 48.0, 42.8, 38.3, 36.8, 36.0, 35.2, 33.4, 32.5, 31.5, 30.6, 
30.3, 28.4, 23.4, 20.7, 12.2, 11.2. HRMS (FT-ICR, HESI) m/z: [M + H]+ calcd for C28H42NO2 [M 




 17β-Hydroxy-5α-androstane-derived A-Ring Lactam, 1.62. Following the general 
procedure B, (R)-3-azido-1-phenylpropanol (R)-1.2 (71.6 mg, 0.404 mmol, 2.0 equiv) was 
reacted with 5α-DHT 1.14 (57.7 mg, 0.199 mmol) to give 1.62 as a yellow amorphous solid 
(52.0 mg, 0.112 mmol, 56% yield, UPLC/HRMS purity: 97.9%). Purification was carried out by 
an automated MPLC system using a 12 g normal phase silica column with gradient elution from 
0–50% EtOAc/hexanes. Rf = 0.32 (50% EtOAc/hexanes); mp 160–163 ˚C; IR (neat) 3378, 2093, 
1624 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.40–7.30 (m, 5H), 4.46 (t, J = 7.2 Hz, 1H), 3.62 (t, J 
= 8.5 Hz, 1H), 3.56–3.45 (m, 2H), 3.32 (m ,1H), 2.92 (m, 1H), 2.67 (dd, J = 14.3, 10.3 Hz, 1H), 
2.05 (m, 1H), 1.97 (q, J = 7.3 Hz, 2H), 1.91 (d, J = 8.96 Hz, 1H), 1.82–1.77 (m, 2H), 1.69–1.63 
(m, 1H), 1.62–1.16 (complex, 10H), 1.05 (m, 1H), 0.96–0.83 (m, 5H, contains s, 3H), 0.74–0.68 
(m, 4H, contains s, 3H); 13C NMR (101 MHz, CDCl3) δ 175.6, 139.3, 129.0 (2C), 128.6, 127.0 
(2C), 82.0, 64.4, 54.4, 51.1, 45.7, 45.2, 43.8, 42.9, 41.3, 40.3, 38.5, 36.8, 35.0, 34.7, 31.7, 30.9, 
30.7, 23.5, 21.0, 12.2, 11.2. HRMS (FT-ICR, HESI) m/z: [M + H]+ calcd for C28H41N4O2 
465.3224, found 465.3212.  
 
 17β-Hydroxy-5α-androstane-derived A-Ring Lactam, 1.63. Following the general 
procedure B, (S)-3-azido-1-phenylpropanol (S)-1.2 (71.0 mg, 0.401 mmol, 2.0 equiv) was 
reacted with 5α-DHT 1.14 (58.3 mg, 0.201 mmol) to give 1.63 as a yellow amorphous solid 
(67.9 mg, 0.146 mmol, 73% yield, UPLC/HRMS purity: ≥99.5%). Purification was carried out 
by an automated MPLC system using a using 12 g normal phase silica column with gradient 
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elution from 0–80% EtOAc/hexanes. Rf = 0.34 (50% EtOAc/hexanes); mp 148–150 ˚C; IR (neat) 
3353, 2094, 1624 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.39–7.28 (m, 5H), 4.44 (t, J = 7.1 Hz, 
1H), 3.61 (t, J = 8.5 Hz, 1H), 3.57–3.50 (m, 2H), 3.26 (dt, J = 13.7, 7.0 Hz, 1H), 2.51 (m, 1H), 
2.44 (d, J = 15.4 Hz, 1H), 2.29 (m, 1H), 2.03 (m, 1H), 1.95 (q, J = 7.3 Hz, 2H), 1.87–1.67 
(complex, 4H), 1.64–1.52 (m, 2H), 1.47–1.17 (complex, 7H), 1.03 (m, 1H), 0.96–0.87 (m, 2H), 
0.85 (s, 3H), 0.72–0.66 (complex, 4H, contains s, 3H); 13C NMR (101 MHz, CDCl3) δ 175.4, 
139.2, 129.0 (2C), 128.5, 127.0 (2C), 81.8, 64.3, 54.1, 51.8, 51.0, 49.0, 45.9, 42.8, 38.2, 36.7, 
35.9, 35.1, 34.6, 32.3, 31.4, 30.5, 28.4, 23.4, 20.7, 12.2, 11.2. HRMS (FT-ICR, HESI) m/z: [M + 
H]+ calcd for C28H41N4O2 465.3224, found 465.3223.  
 
 17β-Hydroxy-5α-androstane-derived A-Ring Lactam, 1.64. Following the general 
procedure B, (R)-3-azido-3-phenylpropanol (R)-1.4 (71.6 mg, 0.404 mmol, 2.0 equiv) was 
reacted with 5α-DHT 1.14 (58.0 mg, 0.200 mmol) to give 1.64 as an orange amorphous solid 
(60.5 mg, 0.130 mmol, 65% yield, UPLC/HRMS purity: 94.4%). Purification was carried out by 
an automated MPLC system using a 12 g silica column with gradient elution from 0–60% 
EtOAc/hexanes. Rf = 0.28 (50% EtOAc/hexanes); mp 228–235 ˚C;  IR (neat) 3275, 2091, 1611 
cm-1; 1H NMR (400 MHz, CDCl3) δ 7.34–7.28 (m, 5H), 5.93 (t, J = 7.7 Hz, 1H), 3.56 (t, J = 8.5 
Hz, 1H), 3.42–3.25 (m, 3H), 2.64 (m, 1H), 2.49–2.42 (m, 2H, contains d, 1.57, J = 15.2 Hz, 1H), 
2.14 (q, J = 7.5 Hz, 2H), 2.00 (m, 1H), 1.83 (m, 1H), 1.75 (m, 1H), 1.57–1.32 (m, 4H), 1.21–1.08 
(m, 4H), 1.02–0.91 (m, 2H), 0.81–0.73 (m, 4H), 0.66 (s, 3H), 0.56 (m, 1H), 0.39 (m, 1H), 0.34–
0.20 (m, 2H); 13C NMR (101 MHz, CDCl3) δ 175.6, 139.2, 128.7 (2C), 128.3 (2C), 128.1, 81.9, 
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54.1, 53.2, 50.9, 49.1, 48.7, 45.2, 42.8, 38.1, 36.7, 36.1, 35.1, 32.6, 31.2, 30.6, 29.5, 27.6, 23.4, 
20.6, 12.1, 11.2. HRMS (FT-ICR, HESI) m/z: [M + H]+ calcd for C28H41N4O2 465.3224, found 
465.3217.  
 
 17β-Hydroxy-5α-androstane-derived A-Ring Lactam, 1.65. Following the general 
procedure B, (S)-3-azido-3-phenylpropanol (S)-1.4 (71.1 mg, 0.401 mmol, 2.0 equiv) was 
reacted with 5α-DHT 1.14 (57.0 mg, 0.196 mmol) to give 1.65 as a pale yellow crystalline solid 
(54.6 mg, 0.118 mmol, 60% yield, LCMS purity: ≥99.5%). Purification was carried out by an 
automated MPLC system using a 12 g normal phase silica column with gradient elution from 0–
50% EtOAc/hexanes. Rf = 0.32 (50% EtOAc/hexanes); mp decomposed; IR (neat) 3394, 2096, 
1624 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.38–7.28 (m, 5H), 5.88 (dd, J = 8.9, 6.6 Hz, 1H), 3.57 
(t, J = 8.6 Hz, 1H), 3.42–3.25 (m, 3H), 2.96 (m, 1H), 2.78 (m, 1H), 2.63 (m, 1H), 2.20–2.12 (m, 
2H), 2.09–1.98 (m, 2H), 1.71–1.05 (complex, 11H), 0.96–0.80 (complex, 6H, contains s, 0.81, 
3H), 0.67 (s, 3H), 0.44 (m, 1H), 0.30 (m, 1H); 13C NMR (101 MHz, CDCl3) δ 175.9, 139.1, 
128.9 (2C), 128.1 (2C), 128.0, 82.0, 54.2, 53.4, 50.9, 49.1, 43.6, 42.8, 40.9, 40.5, 39.1, 38.2, 
36.7, 34.9, 31.5, 30.9, 30.7, 29.4, 23.4, 20.8, 12.1, 11.2. HRMS (FT-ICR, HESI) m/z: [M + H]+ 




 17β-Hydroxy-5β-androstane-derived A-Ring Lactam, 1.66. Following the general 
procedure B, (S)-3-azido-1-phenylpropanol (S)-1.2 (69.9 mg, 0.394 mmol, 2.0 equiv) was 
reacted with 5β-DHT 1.15 (58.2 mg, 0.200 mmol) to give 1.66 as a cream-colored amorphous 
solid (76.1 mg, 0.164 mmol, 82% yield, UPLC/HRMS purity: 98.8%). Purification was carried 
out by an automated MPLC system using a 12 g normal phase silica column with gradient 
elution from 0–50% EtOAc/hexanes. Rf = 0.25 (50% EtOAc/hexanes); mp 137–142 ˚C; IR (neat) 
3393, 2094, 1628 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.41–7.30 (m, 5H), 4.45 (t, J = 7.2 Hz, 
1H), 3.65 (t, J = 8.6 Hz, 1H), 3.62–3.55 (m, 1H), 3.37 (dd, J = 15.2, 10.2 Hz, 1H), 3.26 (m, 1H), 
3.02–2.92 (m, 2H), 2.12–2.03 (m, 2H, contains d, 2.06, J = 14.7 Hz, 1H), 1.97 (q, J = 7.3 Hz, 
2H), 1.92–1.82 (m, 2H), 1.73 (m, 1H), 1.63–1.58 (m, 1H), 1.47–1.20 (complex, 10H), 1.13–0.96 
(m, 5H, contains s, 0.98, 3H), 0.92–0.82 (m, 1H), 0.74 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 
175.0, 139.4, 129.0 (2C), 128.5, 127.0 (2C), 82.0, 64.4, 51.0, 45.9, 44.0, 43.2 (br), 42.6, 40.6, 
39.7, 39.6, 37.0, 36.9, 36.0, 34.5, 30.8, 29.9, 25.7, 23.8 (br), 23.5, 21.0, 11.3. Note: Two broad 
carbon signals were consistently observed amongst cis-AB analogs. HRMS (FT-ICR, HESI) m/z: 
[M + H]+ calcd for C28H41N4O2 465.3224, found 465.3254.  
 
 17β-Hydroxy-5β-androstane-derived A-Ring Lactam, 1.67. Following the general 
procedure B, (S)-3-azido-3-phenylpropanol (S)-1.4 (69.7 mg, 0.393 mmol, 2.0 equiv) was 
reacted with 5β-DHT 1.15 (58.2 mg, 0.200 mmol) to give 1.67 as an orange amorphous solid 
(77.9 mg, 0.168 mmol, 84% yield, UPLC/HRMS purity: ≥99.5%). Purification was carried out 
by an automated MPLC system using a 12 g normal phase silica column with gradient elution 
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from 0–40% EtOAc/hexanes. Rf = 0.22 (50% EtOAc/hexanes); mp 174–178 ˚C; IR (neat) 3396, 
2095, 1628 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.35–7.27 (m, 5H), 5.88 (m, 1H), 3.70 (dd, J = 
15.3, 10.1 Hz, 1H), 3.63 (t, J = 8.5 Hz, 1H), 3.41 (m, 1H), 3.29 (m, 1H), 2.68–2.58 (m, 2H), 2.32 
(dd, J = 14.9, 8.5 Hz, 1H), 2.21–2.11 (m, 2H), 2.04 (m, 1H), 1.88–1.79 (m, 2H), 1.56–0.93 
(complex, 13H), 0.85–0.79 (m, 4H, contains s, 0.77, 3H), 0.69 (s, 3H), 0.53 (m, 1H); 13C NMR 
(101 MHz, CDCl3) δ 175.8, 139.1, 128.7 (2C), 128.2 (2C), 128.1, 81.9, 53.6, 51.0, 49.1, 45.1, 
44.7, 43.2, 41.4 (br), 36.94, 36.97, 35.9, 34.2, 31.1, 30.7, 29.5, 27.9, 26.4, 24.1 (br), 23.4, 20.6, 
11.2. Note: Two broad carbon signals were consistently observed amongst cis-AB analogs. 
HRMS (FT-ICR, HESI) m/z: [M + H]+ calcd for C28H41N4O2 465.3224, found 465.3213.  
 
 17β-Hydroxy-5α-androstane-derived A-Ring Lactam, 1.68. Following the general 
procedure B, (R)-3-azido-1-phenylpropanol (R)-1.2 (44.5 mg, 0.250 mmol, 2.0 equiv) was 
reacted with 5α-DHT 1.14 (36.3 mg, 0.125 mmol) to give 1.68 as a yellow crystalline solid (45.2 
mg, 0.0828 mmol, 66% yield, UPLC/HRMS purity: 97.0%). Purification was carried out by an 
automated MPLC system using a 12 g normal phase silica column with gradient elution from 0–
60% EtOAc/hexanes. Rf = 0.30 (50% EtOAc/hexanes); mp 182–186 ˚C; IR (neat) 3395, 1632 
cm-1; 1H NMR (400 MHz, CDCl3) δ 7.27–7.17 (m, 5H), 7.12 (m, 2H), 6.99 (m, 2H), 4.05 (t, J = 
7.4 Hz, 1H), 3.62 (t, J = 8.6 Hz, 1H), 3.44–3.28 (m, 3H), 2.83 (m, 1H), 2.58 (dd, J = 14.2, 10.4 
Hz, 1H), 2.28 (s, 3H), 2.13 (q, J = 7.3 Hz, 2H), 2.04 (m, 1H), 1.85 (d, J = 14.3 Hz, 1H), 1.82–
1.71 (m, 2H), 1.67–0.98 (complex, 11H), 0.94–0.80 (m, 5H, contains s, 0.83, 3H), 0.72 (s, 3H), 
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0.69–0.62 (m, 1H); 13C NMR (126 MHz, CDCl3) δ 175.4, 141.8, 137.6, 133.3 (2C), 130.8, 129.6 
(2C), 128.5 (2C), 127.9 (2C), 127.3, 82.0, 54.3, 51.8, 51.0, 46.6, 45.0, 43.8, 42.8, 41.4, 40.4, 
38.4, 36.8, 34.9, 34.3, 31.6, 30.9, 30.7, 23.4, 21.3, 21.0, 12.1, 11.2. HRMS (FT-ICR, HESI) m/z: 
[M + H]+ calcd for C35H48NO2S [M + H]+ 546.3400, found 546.3420.  
 
 17β-Hydroxy-5α-androstane-derived A-Ring Lactam, 1.69. Following the general 
procedure B, (S)-3-azido-1-phenylpropanol (S)-1.2 (53.4 mg, 0.301 mmol, 2.0 equiv) was 
reacted with 5α-DHT 1.14 (45.7 mg, 0.157 mmol) to give 1.69 as a yellow amorphous solid 
(57.3 mg, 0.105 mmol, 67% yield, UPLC/HRMS purity: 94.2%). Purification was carried out by 
an automated MPLC system using a using 12 g normal phase silica column with gradient elution 
from 0–40% EtOAc/hexanes. Rf = 0.22 (50% EtOAc/hexanes); mp 149–153 ˚C; IR (neat) 3390, 
1632 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.26–7.16 (m, 5H), 7.11 (m, 2H), 7.00 (m, 2H), 4.04 
(t, J = 7.2 Hz, 1H), 4.62 (t, J = 8.6 Hz, 1H), 3.46–3.52 (m, 3H), 2.46–2.35 (m, 2H), 2.28–2.22 
(m, 4H, contains s, 2.28, 3H), 2.15-2.00 (m, 3H, contains q, 2.12, J = 7.3 Hz, 2H), 1.84–1.77 (m, 
2H), 1.70–1.53 (complex, 5H), 1.47–1.16 (complex, 10H), 1.06–0.98 (m, 1H), 0.95–0.82 (m, 4H, 
contains s, 3H, 0.83), 0.72 (s, 3H), 0.66 (m, 1H); 13C NMR (101 MHz, CDCl3) δ 175.4, 141.8, 
137.7, 133.4 (2C), 130.6, 129.6 (2C), 128.5 (2C), 127.9 (2C), 127.3, 81.9, 54.1, 51.7, 51.1, 49.0, 
46.9, 42.9, 38.3, 36.8, 35.9, 35.2, 34.3, 32.3, 31.4, 30.6, 28.4, 23.5, 21.3, 20.7, 12.2, 11.2. Note: 
Missing one carbon signal due to signal overlap. HRMS (FT-ICR, HESI) m/z: [M + H]+ calcd for 




 17β-Hydroxy-5α-androstane-derived A-Ring Lactam, 1.70. Following the general 
procedure B, (R)-3-azido-3-phenylpropanol (R)-1.4 (44.5 mg, 0.250 mmol, 2.0 equiv) was 
reacted with 5α-DHT 1.14 (36.3 mg, 0.125 mmol) to give 1.70 as a cream-colored amorphous 
solid (57.0 mg, 0.104 mmol, 83% yield, UPLC/HRMS purity: 97.5%). Purification was carried 
out using 12 g silica column with gradient elution from 0–50% EtOAc/hexanes. Rf = 0.27 (50% 
EtOAc/hexanes); IR (neat) 3400, 1625 cm-1; mp decomposed; 1H NMR (400 MHz, CDCl3) δ 
7.30–7.21 (m, 7H), 7.07–7.05 (m, 2H), 5.89 (dd, J = 9.3, 6.1 Hz, 1H), 3.53 (t, J = 8.5 Hz, 1H), 
3.19 (dd, J = 15.5, 8.9 Hz, 1H), 2.93–2.86 (m, 1H), 2.78–2.71 (m, 1H), 2.59 (t, J = 13.6 Hz, 1H), 
2.42–2.37 (m, 1H), 2.28 (s, 3H), 2.19–2.05 (m, 2H), 1.98–1.93 (m, 1H), 1.79 (m, 1H), 1.71 (m, 
1H), 1.53–1.05 (complex, 8H), 0.97–0.85 (m, 2H), 0.78–0.69 (m, 4H, contains s, 0.74, 3H), 0.62 
(s, 3H), 0.52 (m, 1H), 0.34 (m, 1H), 0.23 (m, 2H); 13C NMR (101 MHz, CDCl3) δ 175.4, 139.6, 
136.5, 132.5, 130.5, 129.9, 128.6, 128.4, 127.9, 81.9, 54.9, 54.1, 50.9, 48.7, 45.1, 42.8, 38.0, 
36.7, 36.2, 35.1, 32.7, 31.5, 31.2, 30.6, 30.2, 27.6, 23.4, 21.1, 20.6, 12.1, 11.1. HRMS (FT-ICR, 




 17β-Hydroxy-5α-androstane-derived A-Ring Lactam, 1.71. Following the general 
procedure B, (S)-3-azido-3-phenylpropanol (S)-1.4 (44.2 mg, 0.249 mmol, 2.0 equiv) was 
reacted with 5α-DHT 1.14 (36.3 mg, 0.125 mmol) to give 1.71 as a white amorphous solid (44.3 
mg, 0.081 mmol, 65% yield, UPLC/HRMS purity: 97.2%). Purification was carried out by an 
automated MPLC system using a using 12 g normal phase silica column with gradient elution 
from 0–40% EtOAc/hexanes. Rf = 0.53 (50% EtOAc/hexanes); mp 181–183 ˚C; IR (neat) 3313, 
1613 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.34–7.24 (m, 7H), 7.10–7.08 (m, 2H), 5.87 (dd, J = 
9.6, 5.9 Hz, 1H), 3.56 (t, J = 8.6 Hz, 1H), 3.23 (dd, J = 15.6, 11.5 Hz, 1H), 2.96–2.87 (m, 2H), 
2.81–2.73 (m, 2H), 2.31 (s, 3H), 2.24–2.10 (m, 2H), 2.07–1.98 (m, 2H, contains d, 2.04, J = 14.3 
Hz, 1H), 1.70–1.04 (complex, 13H), 0.95–0.76 (m, 5H, contains s, 0.79, 3H), 0.67 (s, 3H), 0.41 
(m, 1H), 0.27 (m, 1H); 13C NMR (101 MHz, CDCl3) δ 175.7, 139.6, 136.5, 132.5, 130.5 (2C), 
129.8 (2C), 128.6 (2C), 128.2 (2C), 127.8, 81.9, 55.0, 54.2, 50.9, 43.6, 42.8, 40.9, 40.6, 38.9, 
38.2, 36.7, 34.9, 31.58, 31.55, 30.9, 30.7, 30.2, 23.4, 21.1, 20.8, 12.1, 11.1. HRMS (FT-ICR, 
HESI) m/z: [M + H]+ calcd for C35H48NO2S [M + H]+ 546.3400, found 546.3396.  
 
 17β-Hydroxy-5β-androstane-derived A-Ring Lactam, 1.72. Following the general 
procedure B, (S)-3-azido-1-phenylpropanol (S)-1.2 (53.0 mg, 0.299 mmol, 2.0 equiv) was 
reacted with 5β-DHT 1.15 (43.9 mg, 0.151 mmol) to give 1.72 as a white crystalline solid (46.1 
mg, 0.084 mmol, 56% yield, UPLC/HRMS purity: 98.6%). Purification was carried out using 12 
g silica column with gradient elution from 0–40% EtOAc/hexanes. Rf = 0.33 (50% 
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EtOAc/hexanes); IR (neat) 3380, 1621 cm-1; mp 142–147 ˚C; 1H NMR (400 MHz, CDCl3) δ 
7.26–7.17 (m, 5H), 7.13 (m, 2H), 7.00 (m, 2H), 4.04 (t, J = 7.2 Hz, 1H), 3.65 (t, J = 8.5 Hz, 1H), 
3.46–3.29 (m, 2H), 3.23 (dd, J = 10.4, 15.2 Hz, 1H), 2.90–2.81 (m, 2H), 2.28 (s, 3H), 2.18–2.04 
(m, 3H), 1.99 (d, J = 14.6 Hz, 1H), 1.89–1.75 (m, 3H), 1.68–1.54 (m, 2H), 1.47–0.94 (complex, 
11H), 0.94 (s, 3H), 0.91–0.78 (m, 1H), 0.73 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 175.0, 
141.8, 137.8, 133.6 (2C), 130.7, 129.6 (2C), 128.5 (2C), 127.9 (2C), 127.3, 82.0, 52.0, 51.1, 
47.0, 43.8, 43.2, 42.3 (br), 40.5, 39.6, 39.5, 37.0, 36.9, 35.9, 34.0, 30.8, 29.8, 25.7, 23.8 (br), 
23.5, 21.3, 21.0, 11.3. Note: Two broad carbon signals were consistently observed amongst cis-
AB analogs. HRMS (FT-ICR, HESI) m/z: [M + H]+ calcd for C35H48NO2S 546.3400, found 
546.3394.  
 
 17β-Hydroxy-5β-androstane-derived A-Ring Lactam, 1.73. Following the general 
procedure B, (S)-3-azido-3-phenylpropanol (S)-1.4 (51.0 mg, 0.288 mmol, 2.0 equiv) was 
reacted with 5β-DHT 1.15 (46.6 mg, 0.160 mmol) to give 1.73 as a white crystalline solid (66.8 
mg, 0.122 mmol, 76% yield, UPLC/HRMS: 99.0%). Purification was carried out using 12 g 
silica column with gradient elution from 0–40% EtOAc/hexanes. Rf = 0.20 (40% 
EtOAc/hexanes); mp 212–215 ˚C; IR (neat) 3406, 1628 cm-1; 1H NMR (400 MHz, CDCl3) δ 
7.32–7.23 (m, 7H), 7.09 (m, 2H), 5.89 (m, 1H), 3.67–3.61 (m, 2H), 2.94 (m, 1H), 2.79 (m, 1H), 
2.64–2.57 (m, 2H), 2.42–2.31 (m, 4H contains s, 2.31, 3H), 2.24–2.12 (m, 2H), 2.05 (m, 1H), 
1.87–1.79 (m, 3H), 1.57–0.95 (complex, 11H), 0.88–0.74 (m, 4H, contains s, 0.76, 3H), 0.70–
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0.60 (4H, contains s, 0.70, 3H), 0.49 (m, 1H); 13C NMR (101 MHz, CDCl3) δ 175.8, 139.4, 
136.4, 132.4, 130.4 (2C), 129.9 (2C), 128.6 (2C), 128.2 (2C), 128.0, 82.0, 55.3, 51.1, 45.0, 44.6, 
43.2, 41.5 (br), 37.0, 36.9, 35.9, 34.1, 31.4, 30.9, 30.7, 30.1, 27.9, 26.4, 24.0 (br), 23.5, 21.2, 
20.6, 11.2. Note: Two broad carbon signals were consistently observed amongst cis-AB analogs. 
HRMS (FT-ICR, HESI) m/z: [M + H]+ calcd for C35H48NO2S 546.3400, found 546.3414.  
 
 5α-Cholestane-derived A-Ring Lactam, 1.74. A solution of 1.18 (53.6 mg, 0.100 
mmol), 10% Pd/C (42.6 mg, 0.400 mmol, 4.0 equiv), and acetic acid (2.0 mL) in anhydrous 
EtOH (15.0 mL) was placed under hydrogen atmosphere (40 psi) via a shaker-Parr 
hydrogenation apparatus over 24 h. The solution was filtered over Celite and concentrated. The 
crude residue was purified by an automated MPLC system using a 12 g normal phase silica 
column with gradient elution from 0–60% EtOAc/hexanes. Concentration of solvents afforded 
product 1.74 as white amorphous solid (48.6 mg, 0.0935 mmol, 94% yield). Rf = 0.68 (50% 
EtOAc/hexanes); mp 146–147 ˚C; IR (neat) 1624 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.31–7.27 
(m. 2H), 7.20–7.16 (m, 3H), 3.58 (dd, J = 11.7, 15.6 Hz, 1H), 3.46–3.33 (m, 2H), 2.95 (dd, J = 
15.4, 6.2 Hz, 1H), 2.74 (dd, J = 14.2, 10.3 Hz, 1H), 2.62 (m, 2H), 1.98–1.91 (m, 2H, contains d, 
J = 14.3 Hz, 1H), 1.87–1.75 (m, 3H), 1.67–1.63 (m, 2H), 1.59–0.92 (complex, 22H), 0.89–0.84 
(complex, 12H), 0.71–0.64 (m, 4H, contains s, 0.64, 3H); 13C NMR (101 MHz, CDCl3) δ 175.5, 
142.0 128.52 (2C), 128.46 (2C), 126.0, 56.5. 56.4, 54.3, 47.9, 45.0, 43.8, 42.5, 41.5, 40.5, 40.1, 
39.7, 38.4, 36.3, 35.9, 34.9, 33.5, 32.1, 31.1, 30.1, 28.4, 28.1, 24.3, 23.9, 22.9, 22.7, 21.4, 18.8, 
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12.18, 12.16. HRMS (FT-ICR, ESI) m/z: [M + H]+ calcd for C36H57NO 520.4513, found 
520.4523.  
 
 5α-Cholestane-derived A-Ring Lactam, 1.75. Following the general procedure C, 1.18 
(530 mg, 0.099 mmol) was oxidized to give product 1.75 as a white amorphous solid (41.2 mg, 
0.077 mmol, 78% yield). Purification was carried out by an automated MPLC system using a 12 
g normal phase silica column with gradient elution from 0–25% EtOAc/hexanes. Rf = 0.63 (50% 
EtOAc/hexanes); mp 209–214 ˚C; IR (neat) 1683, 1642 cm-1; 1H NMR (400 MHz, CDCl3) δ 
7.98 (m, 2H), 7.56 (m, 1H), 7.47 (m, 2H), 3.79 (dt, J = 13.4, 6.7 Hz, 1H), 3.72–3.61 (m, 2H), 
3.26 (m, 2H), 3.19 (m, 1H), 2.74 (dd, J = 14.2, 10.2 Hz, 1H), 1.98–1.93 (m, 1H), 1.90 (d, J = 
14.3 Hz, 1H), 1.85–1.76 (m, 2H), 1.66–0.91 (complex, 23H), 0.83–0.90 (complex, 12H), 0.68–
0.61 (m, 4H, contains s, 0.64, 3H); 13C NMR (101 MHz, CDCl3) δ 199.4, 175.9, 136.9, 133.4, 
128.8 (2C), 128.4 (2C), 56.5, 56.4, 54.3, 46.7, 45.4, 43.7, 42.5, 41.4, 40.5, 40.1, 39.7, 38.4, 37.8, 
36.3, 35.9, 34.9, 32.1, 31.1, 28.4, 28.1, 24.3, 24.0, 23.9, 22.9, 22.7, 21.4, 18.8, 12.2. HRMS (FT-
ICR, ESI) m/z: [M + H]+ calcd for C36H56NO2 534.4306, found 534.4313.  
 
 17β-Hydroxy-5α-androstane-derived A-Ring Lactam, 1.76. Following the general 
procedure C, 1.29 (75.0 mg, 0.170 mmol) was oxidized to give 1.76 as a white amorphous solid 
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(50 mg, 0.115 mmol, 68% yield, UPLC/HRMS purity: ≥99.5%). Purification was carried out by 
an automated MPLC system using a 12 g normal phase silica column with gradient elution from 
0–2% MeOH/CH2Cl2. Concentration of solvents afforded a slightly impure azasteroid, which 
was subjected to a second purification on a 4 g normal phase silica column with gradient elution 
0–80% EtOAc/hexanes. Rf = 0.20 (50% EtOAc/hexanes); mp 209–212 ˚C; IR (neat) 1726, 1673, 
1645, 1628 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.97 (m, 2H), 7.56 (m, 1H), 7.46 (m, 2H), 3.82–
3.62 (m, 3H), 3.31–3.20 (m, 3H), 2.75 (dd, J = 14.3, 9.9 Hz, 1H), 2.43 (m, 1H), 2.06 (m, 1H), 
1.96–1.89 (m, 2H, contains d, J = 14.4 Hz, 1H), 1.82–1.75 (m, 3H), 1.68–1.63 (m, 1H), 1.53–
1.14 (complex, 9H), 1.04–0.91 (m, 1H), 0.89 (s, 3H), 0.84 (s, 3H), 0.71 (m, 1H); 13C NMR (101 
MHz, CDCl3) δ 221.1, 199.3, 175.7, 136.8, 133.5, 128.8 (2C), 128.3 (2C), 54.3, 51.4, 47.6, 46.6, 
45.3, 43.7, 41.4, 40.3, 38.6, 37.8, 36.0 34.5, 31.6, 30.9, 30.7, 21.8, 20.7, 13.9, 12.2. HRMS (FT-
ICR, HESI) m/z: [M + H]+ calcd for C28H38NO3 [M + H]+ 436.2846, found 436.2823.  
 
 5α-Cholestane-derived A-Ring Lactam, 1.77. A solution of 1.19 (53.6 mg, 0.100 
mmol), 10% Pd/C (21.3 mg, 0.200 mmol, 2.00 equiv), and acetic acid (200 µL) in anhydrous 
EtOH (15.0 mL) was placed under hydrogen atmosphere (40 psi) via a shaker-Parr 
hydrogenation apparatus over 24 h. The solution was filtered over Celite and concentrated. The 
crude residue was purified by purified by an automated MPLC system using a 12 g normal phase 
silica column with gradient elution from 0–60% EtOAc/hexanes. Concentration of solvents 
afforded product 1.77 as white amorphous solid (36.0 mg, 0.0692 mmol, 69% yield). Rf = 0.75 
(50% EtOAc/hexanes); mp 155–157 ˚C; IR (neat) 1624 cm-1; 1H NMR (400 MHz, CDCl3) δ 
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7.31–7.27 (m, 2H), 7.20–7.16 (m, 3H), 3.60 (dd, J = 15.4, 8.5 Hz, 1H), 3.40 (m, 2H), 2.66–2.56 
(m, 3H), 2.48 (d, J = 15.4 Hz, 1H), 2.34 (dd, J = 14.4, 7.5 Hz, 1H), 1.97 (m, 1H), 1.88–1.43 
(complex, 8H), 1.34–0.93 (complex, 19H), 0.92–0.85 (complex, 12H), 0.71–0.64 (m, 4H, 
contains s, 0.64, 3H); 13C NMR (101 MHz, CDCl3) δ 175.4, 142.0, 128.53 (2C), 128.45 (2C), 
126.0, 56.5, 56.4, 54.1, 51.6, 49.1, 48.0, 42.5, 40.1, 39.7, 38.2. 36.3, 36.0, 35.9, 35.2, 33.5, 32.6, 
32.0, 30.1, 28.6, 28.4, 28.2, 24.3, 24.0, 22.9, 22.7, 21.1, 18.8, 12.2, 12.16. HRMS (FT-ICR, ESI) 
m/z: [M + H]+ calcd for C36H57NO 520.4513, found 520.4513.  
 
 5α-Cholestane-derived A-Ring Lactam, 1.78. Following the general procedure C, 1.19 
(536 mg, 0.100 mmol) was oxidized to give 1.78 as a white amorphous solid (426 mg, 0.080 
mmol, 80% yield). Purification was carried out by an automated MPLC system using a 12 g 
normal phase silica column with gradient elution from 0–25% EtOAc/hexanes. Rf = 0.25 (25% 
EtOAc/hexanes); mp 177–179 ˚C; IR (neat) 1678, 1641 cm-1; 1H NMR (500 MHz, CDCl3) δ 
7.98 (m, 2H), 7.56 (m, 1H), 7.47 (m, 2H), 3.82 (dt, J = 13.5, 6.7 Hz, 1H), 3.78–3.60 (m, 2H), 
3.25 (m, 2H), 2.75 (d, J = 15.4 Hz, 1H), 2.59 (t, J = 13.1 Hz, 1H), 2.30 (dd, J = 13.9, 7.2 Hz, 
1H), 1.95 (dt, J = 12.6, 3.4 Hz, 1H), 1.86–1.76 (m, 2H), 1.69–1.64 (m, 3H), 1.56–1.47 (m, 3H), 
1.43–0.77 (complex, 29H), 0.64–0.59 (m, 4H, contains s, 0.63, 3H); 13C NMR (126 MHz, 
CDCl3) δ 199.3, 175.9, 136.8, 133.4, 128.8 (2C), 128.3 (2C), 56.5, 56.3, 54.0, 53.2, 49.1, 45.4, 
42.4, 40.0, 39.6, 38.2, 37.8, 36.3, 35.9, 35.8, 35.1, 32.5, 31.9, 28.4, 28.1, 24.3, 24.0, 23.0, 22.7, 
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21.1, 18.8, 12.2, 12.1. Note: Missing one carbon signal due to signal overlap. HRMS (FT-ICR, 
HESI) m/z: [M + H]+ calcd for C36H57NO2 534.4306, found 534.4307.  
 
 17β-Hydroxy-5α-androstane-derived A-Ring Lactam, 1.79. Following the general 
procedure C, 1.28 (93.0 mg, 0.212 mmol) was oxidized to give 1.79 as a white amorphous solid 
(68.6 mg, 0.157 mmol, 74% yield, UPLC/HRMS purity: 96.1%). Purification was carried out by 
an automated MPLC system using a 12 g normal phase silica column with gradient elution from 
0–2% MeOH/CH2Cl2. Concentration of solvents afforded a slightly impure azasteroid, which 
was subjected to a second purification on a 4 g normal phase silica column with gradient elution 
0–80% EtOAc/hexanes. Rf = 0.20 (50% EtOAc/hexanes); mp 217–221 ˚C; IR (neat) 1723, 1676, 
1644 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.98 (m, 2H), 7.57 (m, 1H), 7.47 (m, 2H), 3.82 (dt, J = 
13.3, 6.6 Hz, 1H), 3.73–3.65 (m, 2H), 3.33–3.20 (m, 2H), 2.81 (d, J = 15.5 Hz, 1H), 2.60 (m, 
1H), 2.43 (dd, J = 19.9, 8.3 Hz, 1H), 2.33 (dd, J = 14.4, 7.7 Hz, 1H), 2.10–2.01 (m, 1H), 1.94–
1.75 (complex, 4H), 1.72–1.67 (m, 1H), 1.54–1.43 (complex, 3H), 1.38–1.16 (complex, 6H), 
0.97–0.89 (m, 4H, contains s, 0.89, 3H), 0.84 (s, 3H), 0.69 (1H); 13C NMR (101 MHz, CDCl3) δ 
221.0, 199.2, 175.7, 136.9, 133.5, 128.8 (2C), 128.3 (2C), 54.1, 53.2, 51.4, 49.1, 47.6, 45.4, 38.4, 
37.9, 36.0, 35.8, 34.7, 32.4, 31.6, 30.7, 28.0, 21.9, 20.4, 13.9, 12.3. HRMS (FT-ICR, HESI) m/z: 




 5α-Cholestane-derived A-Ring Lactam, 1.80. A solution of 1.75 (54.3 mg, 0.102 
mmol) and sodium hydride (60% dispersion in mineral oil, 20.0 mg, 0.814 mmol, 4.8 equiv) in 
anhydrous THF (8.0 mL) was heated at 65 ˚C for 2 h. The reaction was cooled to room 
temperature and quenched with a saturated solution of NH4Cl (5 mL). The reaction mixture was 
diluted with CH2Cl2 (20 mL) and washed with saturated solution of NH4Cl (2 x 5 mL), H2O (5 
mL) and brine (5 mL). The combined organic layer was dried over anhydrous Na2SO4 filtered, 
and concentrated. The crude residue was purified by an automated MPLC system using a 12 g 
normal phase silica column with gradient elution from 0–5% MeOH/CH2Cl2. Concentration of 
solvents afforded product 1.80 as white amorphous solid (29.2 mg, 0.073 mmol, 72% yield). Rf = 
0.23 (2% MeOH/CH2Cl2); mp 287–290 ˚C (decomposed); IR (neat) 3315, 3193, 1676, 1628 cm-
1; 1H NMR (400 MHz, CDCl3) δ 5.77 (br s, 1H), 3.39 (m, 1H), 2.98 (m, 1H), 2.75 (dd, J = 14.3, 
11.0 Hz, 1H), 1.97 (dt, J = 12.6, 3.4 Hz, 1H), 1.88–1.77 (m, 3H), 1.66 (m, 1H), 1.57–0.94 
(complex, 20H), 0.93–0.85 (complex, 14H), 0.74 (m, 1H), 0.65 (s, 3H); 13C NMR (101 MHz, 
CDCl3) δ 178.6, 56.5, 56.3, 54.2, 43.4, 42.4, 42.2, 40.1, 39.74, 39.65, 39.0, 38.1, 36.3, 35.9, 34.8, 
32.2, 31.2, 28.4, 28.2, 24.3, 24.0, 23.0, 22.7, 21.4, 18.8, 12.16, 12.11. HRMS (FT-ICR, ESI) m/z: 




 17β-Hydroxy-5α-androstane-derived A-Ring Lactam, 1.81. A solution of 1.76 (87.0 
mg, 0.200 mmol) and sodium hydride (60% dispersion in mineral oil, 38.0 mg, 1.60 mmol, 4.8 
equiv) in anhydrous THF (8.0 mL) was heated at 65 ˚C for 2 h. The reaction was cooled to room 
temperature and quenched with a saturated solution of NH4Cl (5 mL). The reaction mixture was 
diluted with CH2Cl2 (20 mL) and washed with saturated solution of NH4Cl (2 x 5 mL), H2O (5 
mL) and brine (5 mL). The combined organic layer was dried over anhydrous Na2SO4 filtered, 
and concentrated. The crude residue was purified by an automated MPLC system using a 12 g 
normal phase silica column with gradient elution from 0–5% MeOH/CH2Cl2. Concentration of 
solvents afforded product 1.76 as white amorphous solid (44.0 mg, 0.145 mmol, 73% yield, 
UPLC/HRMS purity: ≥99.5%). Rf = 0.25 (3% MeOH/CH2Cl2); mp 283–285 ˚C; IR (neat) 3303, 
3219, 1736, 1668 cm-1. 1H NMR (400 MHz, CDCl3) δ 5.77 (br s, 1H), 3.40 (ddd, J = 15.9, 11.8, 
4.4 Hz, 1H), 3.00 (m, 1H), 2.77 (dd, J = 14.3, 11.0 Hz, 1H), 2.44 (dd, J = 19.4, 8.8 Hz, 1H), 2.08 
(m, 1H), 1.97–1.78 (complex, 4H), 1.70 (m, 1H), 1.60–1.22 (complex, 10H), 1.03 (m, 1H), 0.94 
(s, 3H), 0.89–0.78 (complex, 5H, contains s, 0.86, 3H); 13C NMR (151 MHz, CDCl3) δ 221.0, 
178.3, 54.3, 51.5, 47.6, 43.4, 42.2, 39.7, 39.2, 38.0, 36.0, 34.4, 31.7, 31.0, 30.8, 21.9, 20.7, 13.9, 
12.1. HRMS (FT-ICR, HESI) m/z: [M + H]+ calcd for C19H20NO2 304.2271, found 304.2267.  
 
 5α-Cholestane-derived A-Ring Lactam, 1.82. A solution of 1.78 (88.6 mg, 0.166 
mmol) and sodium hydride (60% dispersion in mineral oil, 35.0 mg, 0.879 mmol, 5.3 equiv) in 
anhydrous THF (14.0 mL) was heated at 65 ˚C for 2 h. The reaction was cooled to room 
temperature and quenched with a saturated solution of NH4Cl (5 mL). The reaction mixture was 
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diluted with CH2Cl2 (20 mL) and washed with saturated solution of NH4Cl (2 x 5 mL), H2O (5 
mL) and brine (5 mL). The combined organic layer was dried over anhydrous Na2SO4 filtered, 
and concentrated. The crude residue was purified by an automated MPLC system using a 12 g 
normal phase silica column with gradient elution from 0–5% MeOH/CH2Cl2. Concentration of 
solvents afforded product 1.82 as white amorphous solid (51.7 mg, 0.129 mmol, 78% yield). Rf = 
0.28 (3% MeOH/CH2Cl2); mp 301–304 ˚C (decomposed); IR (neat) 3190, 1672, 1627 cm-1; 1H 
NMR (400 MHz, CDCl3) δ 5.60 (br s, 1H), 3.37 (m, 1H), 2.63–2.50 (m, 2H), 2.25 (m, 1H), 1.98 
(m, 1H), 1.92–1.77 (m, 2H), 1.69 (m, 1H), 1.60–1.48 (m, 3H), 1.38–0.93 (complex, 18H), 0.90–
0.85 (complex, 13H), 0.73 (m, 1H), 0.65 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 178.7, 56.6, 
56.4, 53.9, 49.8, 44.7, 42.5, 40.1, 39.7, 38.8, 36.3, 35.9, 35.4, 35.2, 31.9, 31.5, 28.4, 28.2, 27.9, 
24.3, 24.0, 23.0, 22.7, 21.2, 18.8, 12.20, 12.18. HRMS (FT-ICR, ESI) m/z: [M + H]+ calcd for 
C27H48NO 402.3730, found 402.3732. 
 
 17β-Hydroxy-5α-androstane-derived A-Ring Lactam, 1.83. A solution of 1.79 (87.0 
mg, 0.200 mmol) and sodium hydride (60% dispersion in mineral oil, 38.0 mg, 1.60 mmol, 4.8 
equiv) in anhydrous THF (8.0 mL) was heated at 65 ˚C for 2 h. The reaction was cooled to room 
temperature and quenched with a saturated solution of NH4Cl (5 mL). The reaction mixture was 
diluted with CH2Cl2 (20 mL) and washed with saturated solution of NH4Cl (2 x 5 mL), H2O (5 
mL) and brine (5 mL). The combined organic layer was dried over anhydrous Na2SO4 filtered, 
and concentrated. The crude residue was purified by an automated MPLC system using a 12 g 
normal phase silica column with gradient elution from 0–4% MeOH/CH2Cl2. Concentration of 
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solvents afforded product 1.83 as white amorphous solid (46.7 mg, 0.153 mmol, 76% yield, 
UPLC/HRMS purity: ≥99.5%). Rf = 0.25 (4% MeOH/CH2Cl2); mp decomposed; IR (neat) 3202, 
3091, 1732, 1647 cm-1. 1H NMR (400 MHz, CDCl3) δ 6.02 (br s, 1H), 3.39 (m, 1H), 2.60 (m, 
2H), 2.44 (dd, J = 19.2, 8.9 Hz, 1H), 2.27 (m, 1H), 2.07 (m, 1H), 1.96–1.21 (complex, 16H), 
1.00–0.79 (complex, 5H, contains s, 0.94, 3H; s, 0.86, 3H); 13C NMR (151 MHz, CDCl3) δ 
220.9, 178.5, 54.0, 51.5, 49.8, 47.6, 44.6, 39.0, 36.0, 35.4, 34.8, 31.7, 31.4, 30.7, 27.6, 21.9, 20.4, 
13.9, 12.2. HRMS (FT-ICR, HESI) m/z: [M + H]+ calcd for C19H30NO2 304.2271, found 
304.2270.   
 
1.6.4 Experimental Section for 1.4 
Experimental section for 1.4.1 
 
Synthesis of 1.88  
 Intermediate 1.86 was prepared following a previously published procedure94, 123. 
Characterization data were consistent with reported data.124 UPLC/HRMS purity: ≥99.5%.   
 
 3β-Hydroxy-5α-androstane-derived D-Ring Lactam, 1.88.125 Following the literature 
procedure44, to a solution of 1.86 (106 mg, 0.349 mmol) in anhydrous THF (7.0 mL, 0.05 M) at 0 
˚C was added SOCl2 (0.25 mL, 10.0 equiv). The reaction mixture was stirred for 2 h at 0 ˚C, and 
stirred at room temperature overnight. The reaction mixture was terminated with a saturated 
aqueous solution of NaHCO3 (20 mL) and H2O (15 mL). The aqueous layer was extracted with 
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CH2Cl2, and the combined organic layers were washed with a solution of saturated NaHCO3, 
H2O, brine, dried over Na2SO4, filtered, and concentrated. Purification was carried out by an 
automated MPLC system using a 12 g normal phase silica column with gradient elution of 0–5% 
MeOH/CH2Cl2. Concentration of appropriate fractions afforded product as a cream-colored 
amorphous solid (53.0 mg, 0.174 mmol, 50% yield, UPLC/HRMS purity: ≥99.5%). Rf = 0.19 
(3% MeOH/CH2Cl2); mp 286–294 ˚C (decomposed); IR (neat) 3155, 3038, 1654 cm-1; 1H NMR 
(400 MHz, CDCl3) δ 6.18 (s, 1H), 3.59 (m, 1H), 2.50–2.29 (m, 2H), 2.24 (br s, 1H), 1.95–1.76 
(m, 3H), 1.73–1.63 (m, 3H), 1.59 (m, 1H), 1.50–1.16 (complex, 9H), 1.17–1.07 (complex, 4H, 
contains s, 1.14, 3H), 1.02–0.80 (complex, 3H), 0.79 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 
172.2, 71.2, 54.79, 53.82, 47.8, 44.4, 40.2, 38.0, 36.9, 35.9, 35.7, 31.5, 30.9, 30.6, 28.5, 22.3, 
21.3, 19.9, 12.4. HRMS (FT-ICR, HESI) m/z: [M + H]+ calcd for C19H32NO2 306.2428, found 
306.2424.  
 
Synthesis of 1.89 





 3β-Acetoxy-5α-hydroxyandrostan-17-one Oxime, 1.87.  Intermediate 1.87 was 
prepared following a previously published procedure94, 123 as described. To a solution of 1.85 
(598 mg, 1.80 mmol), NH2OH•HCl (500 mg, 7.20 mmol, 4.0 equiv), NaOAc (591 mg, 7.20 
mmol, 4.0 equiv) in anhydrous EtOH (9.0 mL, 0.2 M) was refluxed for 6 h. EtOH was removed 
under a stream of nitrogen, and the residual crude was dissolved in H2O (40 mL). The aqueous 
layer was extracted with Et2O (3 x 15 mL), filtered, and concentrated. Purification was carried by 
an automated MPLC system using a 24 g normal phase silica column with gradient elution of 0–
30% EtOAc/hexanes. Concentration of fractions afforded product as a white amorphous solid 
(548 mg, 1.58 mmol, 88% yield, UPLC/HRMS purity: ≥99.5%). Rf = 0.44 (30% 
EtOAc/hexanes); mp 186–188 ˚C; IR (neat) 3456, 1714 cm-1; 1H NMR (400 MHz, CDCl3) δ 
4.68 (m, 1H), 2.62–2.45 (m, 2H), 2.03–1.99 (complex, 4H, contains s, 2.02, 3H), 1.86–1.80 (m, 
3H), 1.76–1.71 (m, 2H), 1.67–1.59 (m, 2H), 1.55–1.15 (complex, 9H), 1.09–0.91 (complex, 5H, 
contains s, 0.93, 3H), 0.84 (s, 3H), 0.76–0.70 (m, 1H); 13C NMR (101 MHz, CDCl3) δ 173.9, 
170.8, 73.7, 54.3, 54.0, 44.7, 36.8, 35.8, 34.9, 34.1, 33.9, 31.5, 28.4, 27.6, 26.1, 23.1, 21.6, 20.8, 
17.1, 12.3. Note: Missing one carbon signal due to signal overlap. HRMS (FT-ICR, HESI) m/z: 
[M + H]+ calcd for C21H34NO3 348.2533, found 348.2528.  
 
 3β-Hydroxy-5α-androstane-derived D-Ring Lactam, 1.89. Following a literature 
procedure44, to a solution of 1.87 (139 mg, 0.400 mmol) in anhydrous THF (5.0 mL) at 0 ˚C was 
added SOCl2 (0.29 mL, 10.0 equiv). The reaction mixture was stirred for 2 h at 0 ˚C, and stirred 
at room temperature overnight. The reaction mixture was terminated with saturated aqueous 
solution of NaHCO3 (20 mL) and H2O (15 mL). The aqueous layer was extracted with CH2Cl2, 
and the combined organic layers were washed with a solution of saturated NaHCO3, H2O, brine, 
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dried over Na2SO4, filtered, and concentrated. Purification was carried out by an automated 
MPLC system using a 12 g normal phase silica column with gradient elution of 0–2% 
MeOH/CH2Cl2. Concentration of fractions afforded product as a cream-colored amorphous solid 
(60.9 mg, 0.175 mmol, 44% yield, UPLC/HRMS purity: 98.0%). Rf = 0.25 (2% MeOH/CH2Cl2); 
mp decomposed; IR (neat) 3186, 3055, 1731, 1673 cm-1; 1H NMR (400 MHz, CDCl3) δ 5.91 (br 
s, 1), 4.69 (m, 1H), 2.50–2.30 (m, 2H), 2.02 (s, 3H), 1.96–1.61 (complex, 7H), 1.55–1.17 
(complex, 10H), 1.15 (s, 3H), 1.04 (m, 1H), 0.96–0.79 (complex, 5H, contains s, 0.81, 3H); 13C 
NMR (101 MHz, CDCl3) δ 172.0, 170.8, 73.5, 54.70 53.7, 47.7, 44.3, 40.2, 36.6, 35.9, 35.7, 
33.9, 30.8, 30.7, 28.4, 27.5, 22.4, 21.6, 21.3, 19.9, 12.3. HRMS (FT-ICR, HESI) m/z: [M + H]+ 
calcd for C21H34NO3 348.2533, found 348.2532.  
 
Experimental section for 1.4.2 
Synthesis of 1.94  
 Intermediate 3β-(tert-butyldimethylsilyl)oxy)-epiandrosterone 1.91 was prepared 
following a previously published procedure.127-128 Characterization data were consistent with 




 3β-((tert-Butyldimethylsilyl)oxy)-16α-(3′-chloropropyl)-5α-androstan-17-one, 1.92. 
Following a literature procedure107, 1.92 was prepared as described: To a cooled 1.0 M LDA 
solution (260 µL, 1.82 mmol, 1.2 equiv) in anhydrous THF (15.0 mL, 0.1 M) at –78 ˚C was 
added 1.91 (609 mg, 1.51 mmol) cautiously. The reaction mixture was allowed to –10 ˚C and 
stirred for 1 h. To the pale yellow solution, HMPA (1.10 mL, 6.32 mmol, 4.2 equiv) was added 
followed by 1-chloro-3-iodopropane (240 µL, 2.24 mmol, 1.5 equiv). The pale yellow solution 
was stirred at –10 ˚C for 1 h, warmed to room temperature, and stirred overnight. The reaction 
mixture was quenched with a solution of saturated NH4Cl (40 mL) and H2O (20 mL). The 
aqueous layer was extracted with Et2O (3 × 30 mL). The combined organic layer was washed 
with brine (15 mL), dried over Na2SO4, filtered, and concentrated. Purification was carried out 
by an automated MPLC system using a 24 g normal phase silica column with gradient elution of 
0–40% CH2Cl2/hexanes. Fractions containing mixtures of 1.91 and 1.92 were subjected to a 
second automated purification using the same gradient. Concentration of fractions afforded 
product as a white amorphous solid (578 mg, 1.20 mmol, 80% yield). Rf = 0.80 (100% CH2Cl2); 
Rf = 0.58 (30% CH2Cl2/hexanes); IR (neat) 1736 cm-1; 1H NMR (400 MHz, CDCl3) δ 3.58–3.48 
(m, 3H), 2.42 (m, 1H), 1.93–1.16 (complex, 18H), 1.08 (m, 1H), 0.99–0.77 (complex, 19H, 
contains s, 0.89, 3H; s, 0.88, 9H; s, 0.82, 3H), 0.66 (m, 1H), 0.05 (s, 6H); 13C NMR (101 MHz, 
CDCl3) δ 222.1, 72.1, 54.7, 49.5, 48.7, 45.2, 45.0, 44.2, 38.8, 37.3, 35.9, 35.2, 32.0, 31.9, 31.3, 
31.0, 28.8, 28.6, 28.0, 26.1 (3C), 20.5, 18.4, 14.7, 12.5, -4.4 (2C). HRMS (FT-ICR, APCI) m/z: 




 16α-(3′-Azidopropyl)-3β-((tert-butyldimethylsilyl)oxy)-5α-androstan-17-one, 1.93.  
Following a literature procedure107, 1.93 was prepared as described. A mixture of 1.92 (482 mg, 
1.00 mmol), NaI (300 mg, 2.00 mmol, 2.0 equiv), NaN3 (195 mg, 3.00 mmol, 3.0 equiv) in 
anhydrous DMF (10.0 mL, 1.0 M) was stirred at 80 ˚C overnight. The reaction mixture was 
quenched with H2O (50 mL). The aqueous layer was extracted with Et2O (3 × 30 mL). The 
combined organic layer was washed with H2O (3 × 15 mL), brine (15 mL), dried over Na2SO4, 
filtered, and concentrated. Purification was carried out by an automated MPLC system using a 24 
g normal phase silica column with gradient elution of 0–6% EtOAc/hexanes. Concentration of 
fractions afforded product as a white amorphous solid (433 mg, 0.887 mmol, 89% yield) 
containing a minor unidentified impurity. The intermediate was used in the next step without 
further purification. Rf = 0.36 (4% EtOAc/hexanes); mp 82–86 ˚C; IR (neat) 2092, 1733 cm-1; 1H 
NMR (400 MHz, CDCl3) δ 3.54 (m, 1H), 3.33–3.20 (m, 2H), 2.41 (m, 1H), 1.82–1.16 (complex, 
18H), 1.08 (m, 1H), 0.99–0.87 (complex, 16H, contains s, 0.89, 3H; s, 0.88, 9H), 0.82 (s, 3H), 
0.66 (m, 1H), 0.05 (s, 6H); 13C NMR (101 MHz, CDCl3) δ 222.0, 72.1, 54.7, 51.5, 49.5, 48.6, 
45.2, 44.4, 38.7, 37.3, 35.8, 35.2, 32.0, 31.9, 31.0, 28.6, 28.5, 27.9, 27.6, 26.1 (3C), 20.5, 18.4, 
14.7, 12.5, -4.397, -4.405. HRMS (FT-ICR, APCI) m/z: [M – N2 + H]+ calcd for C22H50N3O2Si 




 3β-Hydroxy-5α-androstane-derived D-Ring Lactam, 1.94. Following a literature 
procedure107, 1.94 was prepared as described. To a solution of 1.93 (48.5 mg, 0.099 mmol) in 
HFIP (0.5 mL) at 0 ˚C under nitrogen atmosphere was added TiCl4 (1.0 M in CH2Cl2, 149 µL, 
0.149 mmol, 1.5 equiv). The vial was capped, and the reaction mixture was stirred at room 
temperature for 24 h. The reaction mixture was concentrated under a stream of nitrogen. The 
residue was diluted with CH2Cl2, washed with a solution of saturated NH4Cl (2 × 5 mL), solution 
of saturated NaHCO3 (5 mL), brine (5 mL), dried over Na2SO4, filtered, and concentrated. 
Purification was carried out by an automated MPLC system using a 12 g normal phase silica 
column with gradient elution of 0–4% MeOH/CH2Cl2. Concentration of fractions afforded 
product as a white amorphous solid (28.7 mg, 0.083 mmol, 84% yield, UPLC/HRMS purity: 
96.5%). Rf = 0.25 (2% MeOH/CH2Cl2); mp 199–209 ˚C; IR (neat) 3393, 1621 cm-1; 1H NMR 
(400 MHz, CDCl3) δ 3.63–3.51 (m, 3H), 3.37 (m, 1H), 2.12–2.01 (m, 2H), 1.93–1.54 (complex, 
9H), 1.51–1.16 (complex, 9H), 1.12–0.93 (complex, 5H, contains s, 1.03, 3H), 0.90–0.79 
(complex, 4H, contains s, 0.79, 3H), 0.65 (m, 1H); 13C NMR (101 MHz, CDCl3) δ 176.3, 71.4, 
53.9, 53.2, 44.7, 44.3, 43.3, 40.3, 38.1, 37.2, 36.9, 35.6, 35.5, 33.9, 31.6, 31.2, 28.7, 28.5, 22.1, 






Synthesis of 1.99  
 Intermediate 1.95 was prepared following a previously published procedure.129 
Characterization data were consistent with reported data (mp 168–173 ˚C).129-130  
 
16α-(3′-Chloropropyl)-3-methoxy-estrone, 1.96. Following a literature procedure, 1.96 was 
prepared as described. To a cooled 1.0 M LDA solution (260 µL, 1.82 mmol, 1.2 equiv) in 
anhydrous THF (20.0 mL) at –78 ˚C was added mestrone 1.95 (425 mg, 1.50 mmol) cautiously. 
The reaction mixture was allowed to –10 ˚C and stirred for 1 h. To the pale yellow solution, 
HMPA (1.10 mL, 6.32 mmol, 4.2 equiv) was added followed by 1-chloro-3-iodopropane (240 
µL, 2.24 mmol, 1.5 equiv). The pale yellow solution was stirred at –10 ˚C for 1 h, warmed to 
room temperature, and stirred overnight. The reaction mixture was quenched with a solution of 
saturated NH4Cl (40 mL) and H2O (20 mL). The aqueous layer was extracted with Et2O (3 × 30 
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mL). The combined organic layer was washed with brine (15 mL), dried over Na2SO4, filtered, 
and concentrated. Purification was carried out by an automated MPLC system using a 24 g 
normal phase silica column with gradient elution of 0–10% Et2O/hexanes. Fractions containing 
mixtures of 1.95 and 1.96 were subjected to a second automated purification using the same 
gradient. Concentration of appropriate fractions afforded desired product as a yellow oil/solid 
(426 mg, 1.17 mmol, 78% yield) containing a minor unidentified impurity. The intermediate was 
used in the next step without further purification. Rf = 0.40 (10% EtOAc/hexanes); IR (neat) 
1730 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.20 (m, 1H), 6.73 (dd, J = 8.6, 2.8 Hz, 1H), 6.65 (d, J 
= 2.8 Hz, 1H), 3.78 (s, 3H), 3.61–3.46 (m, 2H), 2.92–2.89 (m, 2H), 2.49 (m, 1H), 2.39 (m, 1H), 
2.25 (m, 1H), 2.01–1.82 (complex, 5H), 1.79–1.71 (m, 1H), 1.66–1.38 (complex, 7H), 0.95 (s, 
3H). 13C NMR (101 MHz, CDCl3) δ 221.6, 157.7, 137.9, 132.1, 126.5, 114.0, 111.7, 55.4, 48.8, 
48.4, 44.9, 44.3, 44.1, 38.5, 31.8, 31.4, 30.0, 28.8, 27.8, 26.6, 26.0, 14.8. HRMS (FT-ICR, APCI) 
m/z: [M + H]+ C22H30ClO2 calcd for [M + H]+ 361.1929, found 361.1929. 
 
 16α-(3′-Azidopropyl)-3-methoxy-estrone, 1.97. Following a literature procedure107, 
1.97 was prepared as described. A mixture of 1.96 (419 mg, 1.16 mmol), NaI (348 mg, 2.32 
mmol, 2.0 equiv), NaN3 (226 mg, 3.48 mmol, 3.0 equiv) in anhydrous DMF (12.0 mL, 1.0 M) 
was stirred at 80 ˚C overnight. The reaction mixture was quenched with H2O (50 mL). The 
aqueous layer was extracted with Et2O (3 × 30 mL). The combined organic layer was washed 
with H2O (3 × 15 mL), brine (15 mL), dried over Na2SO4, filtered, and concentrated. Purification 
was carried out by an automated MPLC system using a 24 g normal phase silica column with 
gradient elution of 0–10% EtOAc/hexanes. Concentration of fractions afforded desired product 
as a white oil (391 mg, 1.06 mmol, 92% yield) containing a minor unidentified impurity. The 
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intermediate was used in the next step without further purification. Rf = 0.29 (10% 
EtOAc/hexanes); IR (neat) 2091, 1733 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.20 (d, J = 8.6 Hz, 
1H), 6.72 (dd, J = 8.6, 2.8 Hz, 1H), 6.65 (d, J = 2.7 Hz, 1H), 3.78 (s, 3H), 3.36–3.24 (m, 2H), 
2.92–2.89 (m, 2H), 2.49 (m, 1H), 2.39 (m, 1H), 2.25 (m, 1H), 2.02–1.32 (complex, 13H), 0.95 (s, 
3H). 13C NMR (101 MHz, CDCl3) δ 221.6, 157.7, 137.9, 132.1, 126.5, 114.0, 111.7, 55.4, 51.5, 
48.8, 48.4, 44.5, 44.1, 38.5, 31.8, 29.8, 28.5, 27.72, 27.68, 26.6, 26.0, 14.7. HRMS (FT-ICR, 
HESI) m/z: [M – N2 + H]+ calcd for C22H30N3O2 340.2271, found 340.2267.  
 
 3-Methoxy-1,3,5-estratriene-derived D-Ring Lactam, 1.98. Following a literature 
procedure107, 1.98 was prepared as described. To a solution of 1.97 (95.7 mg, 0.260 mmol) in 
HFIP (2.0 mL) at 0 ˚C under nitrogen atmosphere was added TiCl4 (1.0 M in CH2Cl2, 130 µL, 
0.130 mmol, 0.5 equiv). The vial was capped, and the reaction mixture was stirred at room 
temperature for 24 h. The reaction mixture was concentrated under nitrogen. The residue was 
diluted with CH2Cl2, washed with a solution of saturated NH4Cl (2 × 8 mL), solution of saturated 
NaHCO3 (8 mL), brine (8 mL), dried over Na2SO4, filtered, and concentrated. Purification was 
carried out by an automated MPLC system using a 12 g normal phase silica column with 
gradient elution of 0–70% EtOAc/hexanes. Concentration of fractions afforded product as a 
white amorphous solid (61.3 mg, 0.181 mmol, 69% yield, UPLC/HRMS purity: 97.7%). Rf = 
0.25 (50% EtOAc/hexanes); mp 144–149 ˚C; IR (neat) 1612 cm-1; 1H NMR (400 MHz, CDCl3) δ 
7.24 (d, J = 8.7 Hz, 1H), 6.73 (dd, J = 8.6, 2.8 Hz, 1H), 6.62 (d, J = 2.7 Hz, 1H), 3.78 (s, 3H), 
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3.61 (m, 2H), 3.41 (m, 1H), 2.85 (m, 2H), 2.37 (m, 1H), 2.27–2.11 (m, 2H), 2.05–1.89 (m, 3H), 
1.81–1.68 (m, 3H), 1.58–1.24 (complex, 6H), 1.08 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 
176.3, 157.7, 137.7, 132.4, 126.6, 113.7, 111.8, 55.4, 54.0, 44.9, 42.7, 42.0, 40.7, 40.4, 35.6, 
33.9, 30.2, 28.4, 26.6, 26.0, 22.2, 15.2. HRMS (FT-ICR, HESI) m/z: [M + H]+ calcd for 
C22H30NO2 340.2271, found 340.2269.  
 
 3-Hydroxy-1,3,5-estratriene-derived D-Ring Lactam, 1.99. To a solution of 1.98 (51.5 
mg, 0.152 mmol) in anhydrous CH2Cl2 (5.0 mL) at –78 ˚C was added BBr3 (1.0 M in CH2Cl2, 
1.20 mL, 1.20 mmol, 8.0 equiv). The reaction mixture was stirred at –78 ˚C for 1 h, warmed to 
room temperature over 4 h, and continued stirring at room temperature for 1 h (pinkish-orange 
suspension). The reaction mixture was quenched with two drops of water and MeOH (2 mL). 
The solvent was removed under nitrogen, the residue was redissolved in MeOH, and loaded on 
silica gel for purification. Purification was carried out by an automated MPLC system using a 12 
g normal phase silica column with gradient elution of 0–3% MeOH/CH2Cl2. Concentration of 
fractions afforded 1.99 as a white amorphous solid (38.1 mg, 0.117 mmol, 77% yield, 
UPLC/HRMS purity: ≥99.5%). Rf = 0.20 (2% MeOH/CH2Cl2); mp 283–300 ˚C (decomposed); 
IR (neat) 3303, 1621, 1606 cm-1; 1H NMR (600 MHz, DMSO-d6) δ 8.99 (s, 1H), 7.07 (d, J = 8.5 
Hz, 1H), 6.51 (d, J = 9.4 Hz, 1H), 6.43 (m, 1H), 3.59 (m, 1H), 3.40 (m, 1H), 3.20 (m, 1H), 2.70 
(m, 2H), 2.27 (m, 1H), 2.09 (m, 2H), 1.93 (m, 3H), 1.81 (m, 1H), 1.67 (m, 2H), 1.56–1.37 (m, 
2H), 1.29–1.18 (m, 4H), 0.98 (s, 3H); 13C NMR (151 MHz, DMSO-d6) δ 174.6, 155.0, 137.0, 
130.1, 126.1, 114.6, 112.8, 53.1, 44.1, 42.1, 41.3, 40.0934, 40.0933, 34.8, 33.9, 29.4, 27.5, 25.9, 




Experimental section for 1.4.3 
 
 3β-Hydroxy-5α-androstane-derived D-Ring Lactam, 1.100. Following the general 
procedure E, 3-azidopropanol 1.1 (30.3 mg, 0.300 mmol, 2.0 equiv) was reacted with trans-
androsterone 1.84 (43.6 mg, 0.150 mmol) to give 1.100 as a white amorphous solid (51.0 mg, 
0.141 mmol, 94% yield, UPLC/HRMS purity: ≥99.5%). Purification was carried out by an 
automated MPLC system using a 12 g normal phase silica column with gradient elution from 0–
5% MeOH/CH2Cl2. Rf = 0.35 (5% MeOH/CH2Cl2); mp 177–181 ˚C; IR (neat) 3237, 1625 cm-1; 
1H NMR (400 MHz, CDCl3) δ 3.69–3.55 (m, 2H), 3.49–3.39 (m, 2H), 3.32–3.17 (m, 3H), 2.60 
(br s, 2H), 2.19 (m, 1H), 1.94 (m, 1H), 1.89–1.22 (complex, 17H), 1.13–1.06 (m, 4H, contains s, 
1.12, 3H), 1.00–0.93 (m, 1H), 0.91–0.62 (m, 1H), 0.80 (s, 3H), 0.68 (m, 1H); 13C NMR (101 
MHz, CDCl3) δ 178.3, 71.3, 57.9, 53.4, 47.1, 45.9, 44.4, 43.0, 41.3, 38.1, 36.8, 35.7, 34.8, 34.6, 
31.6, 31.0, 29.3, 28.6, 21.0, 20.3, 18.6, 12.4. Note: X-ray crystal structure of this analog is 
provided in the CCDC (CCDC 1583536). HRMS (FT-ICR, HESI) m/z: [M + H]+ calcd for 




Table 1.10. Selected crystallographic and refinement parameters for 1.100. 
compound 1.100 
CCDC deposition number 1583536 
empirical formula  C22H37NO3 
formula weight 363.53  
temperature 100(2) K 
wavelength Å 1.54178 Å 
crystal system orthorhombic 
space group P 2(1)2(1)2(1) 
unit cell dimensions a = 6.8941(7) Å, D= 90° 
b = 11.1491(12) Å, E= 90° 
c = 25.762(3) Å, J = 90° 
Z 4 
volume   1980.1(4) Å3 
density 1.219 Mg/m3 
absorption coefficient 0.624 µ mm-1 
F(000) 800 
crystal size 0.08 × 0.07 × 0.06 mm3 
Theta range for data collection  4.32 to 68.53°   
index ranges -8<=h<=8, -12<=k<=13, -25<=l<=31 
reflections collected 12012 
independent reflections 3476 [R(int) = 0.0278] 
completeness to theta = 66.000° 99.7% 
absorption correction multi-scan 
max. and min. transmission 1.000 and 0.875 
refinement method full-matrix least-squares on F2 
data/restraints/parameters 3476/0/384 
Goodness-of-fit F2 1.047 
final R indices [I>2sigma(I)] R1 = 0.0324, wR2 = 0.0823 
R indices (all data) R1 = 0.0347, wR2 = 0.0840 
absolute structure parameter 0.1(2) 
extinction coefficient 0.0032(3) 
largest diff. peak and hole 0.159 and -0.172 e.Å-3 
 
 
 3β-Hydroxy-5α-androstane-derived D-Ring Lactams, 1.101 and 1.102. Following the 
general procedure E, (S)-3-azido-2-methylpropanol (S)-1.3 (34.6 mg, 0.300 mmol, 2.0 equiv) 
was reacted with trans-androsterone 1.84 (43.7 mg, 0.151 mmol) to give 1.101 as a white 
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amorphous solid to afford a separable mixture of two regioisomeric lactams 1.101 (30.3 mg, 
0.0803 mmol, 53% yield, UPLC/HRMS purity: 98.7%) and 1.102 (19.9 mg, 0.053 mmol, 35%, 
UPLC/HRMS purity: ≥99.5%). A 56:44 regioisomeric ratio was observed by 1H NMR of crude 
reaction mixture. Purification was carried out by an automated MPLC system using a 12 g 
normal phase silica column with gradient elution from 0–20% EtOAc/Ether. Concentration of 
fractions afforded slightly impure 1.101 and 1.102. A second purification of separated 
regioisomers using a 4 g column with gradient elution from 0–5% MeOH/DCM afforded pure 
regioisomers. 1.101: Rf = 0.26 (50% EtOAc/Ether); IR (neat) 3440, 3283, 1632 cm-1; mp 174–
177 ˚C; 1H NMR (400 MHz, CDCl3) δ 3.65–3.53 (m, 2H), 3.35 (dd, J = 11.9, 3.3 Hz, 1H), 3.27 
(m, 3H), 2.90 (dd, J = 13.9, 4.3 Hz), 2.16 (m, 1H), 1.93–1.51 (complex, 7H), 1.43–1.19 
(complex. 9H), 1.10–1.03 (m, 4H, contains s, 1.10, 3H), 0.98–0.80 (m, 5H, contains d, J = 7.0 
Hz, 3H), 0.78 (s, 3H), 0.66 (m, 1H); 13C NMR (400 MHz, CDCl3) δ 178.3, 71.2, 63.1, 53.3, 49.7, 
48.6, 46.2, 44.4, 41.4, 38.0, 36.8, 35.7, 34.85, 34.79, 33.7, 31.5, 30.9, 28.6, 21.0, 20.3, 18.5, 15.3, 
12.3. HRMS (FT-ICR, HESI) m/z: [M + H]+ calcd for C23H40NO3 378.3003, found 378.2991. 
1.102: Rf = 0.11 (50% EtOAc/Ether); IR (neat) 3443, 3309, 1603 cm-1; mp 196–198 ˚C; 1H NMR 
(126 MHz, CDCl3) δ 3.83 (dd, J = 14.8, 11.4 Hz, 1H), 3.58 (tt, J = 11.0, 4.8 Hz, 1H), 3.48–3.44 
(m, 1H), 3.33 (dd, J = 11.9, 2.9 Hz, 1H) 3.03 (dd, J = 14.7, 4.6 Hz, 1H), 2.58–2.42 (m, 2H), 1.95 
(m, 1H), 1.89 (m, 1H), 1.83–1.70 (complex, 4H), 1.58 (m, 1H), 1.52 (td, J = 12.8, 3.9 Hz, 1H), 
1.41–1.18 (complex, 8H), 1.17 (s, 3H), 1.14–1.04 (m, 1H), 1.00–0.94 (m, 4H, contains d, J = 6.9 
Hz, 3H), 0.91–0.80 (m, 1H), 0.76–0.71 (m, 4H, contains s, 0.76, 3H); 13C NMR (126 MHz, 
CDCl3) δ 172.3, 71.1, 62.7, 59.1, 52.7, 48.4, 44.2, 42.7, 37.9, 37.8, 37.5, 36.8, 36.1, 35.5, 31.4, 
30.8, 30.2, 28.5, 21.8, 21.6, 20.1, 15.6, 12.2. HRMS (FT-ICR, HESI) m/z: [M + H]+ calcd for 




 3β-Hydroxy-5α-androstane-derived D-Ring Lactam, 1.103. Following the general 
procedure E, (R)-3-azido-2-methylpropanol (R)-1.3 (34.8 mg, 0.302 mmol, 2.0 equiv) was 
reacted with trans-androsterone 1.84 (43.9 mg, 0.151 mmol) to give 1.103 as a white amorphous 
solid (53.2 mg, 0.141 mmol, 93% yield, UPLC/HRMS purity: ≥99.5%). Purification was carried 
out by an automated MPLC system using a 12 g normal phase silica column with gradient 
elution from 0–5% MeOH/CH2Cl2. Rf = 0.33 (5% MeOH/CH2Cl2); mp 168–171 ˚C; IR (neat) 
3380, 1614 cm-1; 1H NMR (400 MHz, CDCl3) δ 3.89 (dd, J = 13.8, 11.0 Hz, 1H), 3.58 (tt, J = 
10.7, 4.8 Hz, 1H), 3.41–3.27 (m, 3H), 3.18 (m, 1H), 2.77 (br s, 2H), 2.53 (dd, J = 13.9, 4.3 Hz, 
1H), 2.18 (m, 1H), 1.93 (m, 1H), 1.88–1.18 (complex, 15H), 1.11–1.05 (m, 4H, contains s, 1.11, 
3H), 1.00–0.96 (m, 4H, contains d, J = 7.0 Hz, 3H), 0.94–0.80 (m, 1H), 0.79 (s, 3H), 0.67 (m, 
1H); 13C NMR (101 MHz, CDCl3) δ 178.2, 71.1, 63.1, 53.3, 49.1, 47.7, 45.5, 44.4, 41.3, 38.0, 
36.8, 35.6, 34.7, 34.4, 33.5, 31.4, 30.9, 28.8, 21.0, 30.2, 18.5, 15.4, 12.3. HRMS (FT-ICR, HESI) 
m/z: [M + H]+ calcd for C23H41NO3 378.3008 found 378.2995.  
 
 3β-Hydroxy-5α-androstane-derived D-Ring Lactam, 1.104. Following the general 
procedure E, (S)-3-azidobutanol (S)-1.5 (34.6 mg, 0.300 mmol 2.0 equiv) was reacted with trans-
androsterone 1.84 (43.6 mg, 0.150 mmol) to give 1.104 as a white amorphous solid (38.8 mg, 
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0.103 mmol, 69% yield, UPLC/HRMS purity: 97.2%). Purification was carried out by an 
automated MPLC system using a 12 g normal phase silica column with gradient elution from 0–
5% MeOH/CH2Cl2. Rf = 0.26 (5% MeOH/CH2Cl2); IR (neat) 3352, 1612, 1594 cm-1; mp 242–
245 ˚C; 1H NMR (400 MHz, CDCl3) δ 3.73–3.67 (m, 2H), 3.64–3.56 (m, 2H), 2.52 (dd, J = 18.3, 
6.5 Hz, 1H), 2.41–2.32 (m, 1H), 2.28–2.16 (m, 4H), 2.06–1.98 (m, 1H), 1.93–1.68 (complex, 
4H), 1.59 (m, 1H), 1.46–1.20 (complex, 12H, contains d, J = 6.6 Hz, 3H), 1.18 (s, 3H), 1.14–
1.06 (m, 1H), 1.02–0.83 (m, 2H), 0.78–0.71 (m, 4H, contains s, 0.78, 3H); 13C NMR (101 MHz, 
CDCl3) δ 171.6, 71.2, 61.9, 60.3, 53.1, 49.6, 48.0, 44.3, 38.5, 37.9, 37.6, 36.8, 36.2, 35.6, 33.3, 
31.4, 31.0, 28.6, 21.9, 19.1, 18.9, 18.4, 12.3. HRMS (FT-ICR, HESI) m/z: [M + H]+ calcd for 
C23H40NO3 378.3003 found 378.2995.   
 
 
 3β-Hydroxy-5α-androstane-derived D-Ring Lactam, 1.105. Following the general 
procedure E, (R)-3-azidobutanol (R)-1.5 (34.4 mg, 0.299 mmol, 2.0 equiv) was reacted with 
trans-androsterone 1.84 (44.4 mg, 0.153 mmol) to give 1.105 as a white amorphous solid (52.9 
mg, 0.140 mmol, 92% yield, UPLC/HRMS purity: 97.4%). Purification was carried out by an 
automated MPLC system using a 12 g normal phase silica column with gradient elution from 0–
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4% MeOH/CH2Cl2. Rf = 0.31 (5% MeOH/CH2Cl2); mp 214–217 ˚C; IR (neat) 3380, 3291, 1596 
cm-1; 1H NMR (400 MHz, CDCl3) δ 4.87 (m, 1H), 3.59 (tt, J = 10.7, 4.8, 1H), 3.51 (ddd, J = 
12.1, 5.0, 2.4 Hz, 1H), 3.27 (td, J = 11.8, 2.6, 1H), 3.19–3.03 (m, 2H), 2.59 (br s, 2H), 2.19 (m, 
1H), 1.96 (m, 1H), 1.89–1.22 (complex, 16H), 1.18 (dd, J = 7.1 Hz, 3H), 1.13–1.05 (m, 1H), 
0.97 (m, 1H), 0.91–0.82 (m, 1H), 0.80 (s, 3H), 0.68 (m, 1H); 13C NMR (101 MHz, CDCl3) δ 
178.4, 71.3, 58.6, 53.5, 45.6, 44.5, 44.3, 41.9, 40.2, 38.1, 36.8, 36.2, 35.7, 34.7, 34.6, 31.6, 31.0, 
28.6, 20.6, 20.3, 18.8, 18.4, 12.4. HRMS (FT-ICR, HESI) m/z: [M + H]+ calcd for C23H40NO3 
378.3003 found 378.2995.   
 
 
 3-Hydroxy-1,3,5-estratriene-derived D-Ring Lactam, 1.106. Following the general 
procedure F, 3-azidopropanol 1.1 (30.5 mg, 0.302 mmol, 2.0 equiv) was reacted with estrone 
1.90 (40.6 mg, 0.150 mmol) to give 1.106 as a white amorphous solid (46.7 mg, 0.136 mmol, 
91% yield, UPLC/HRMS purity: ≥99.5%). Purification was carried out by an automated MPLC 
system using a 4 g normal phase silica column with gradient elution from 0–5% MeOH/CH2Cl2. 
Rf = 0.35 (5% MeOH/CH2Cl2); mp 228–235 ˚C; IR (neat) 3124, 1599 cm-1; 1H NMR (400 MHz, 
DMSO-d6) δ 9.00 (s, 1H), 7.06 (d, J = 8.4 Hz, 1H), 6.51 (dd, J = 8.4, 2.6, 1H), 6.44 (d, J = 2.6 
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Hz, 1H), 3.39–3.22 (complex, 8H), 3.20–3.13 (m, 1H), 2.72 (m, 2H), 2.28 (m, 1H), 2.11 (m, 2H), 
1.99 (m, 1H), 1.63–1.15 (complex, 6H), 1.02 (s, 3H); 13C NMR (126 MHz, DMSO-d6) δ 175.2, 
155.0, 137.0, 130.2, 125.9, 114.6, 112.8, 58.3, 46.3, 43.9, 43.4, 42.3, 40.4, 38.1, 34.4, 29.8, 29.3, 
25.7, 25.5, 20.4, 17.9. HRMS (FT-ICR, HESI) m/z: [M + H]+ calcd for C21H30NO3 344.2220, 
found 344.2214.  
 
 3-Hydroxy-1,3,5-estratriene-derived D-Ring Lactams, 1.107 and 1.108. Following the 
general procedure F, (S)-3-azido-2-methylpropanol (S)-1.3 (46.0 mg, 0.400 mmol, 2.0 equiv) 
was reacted with estrone 1.90 (54.0 mg, 0.200 mmol) to afford a separable mixture of two 
regioisomeric lactams 1.107 (37.1 mg, 0.104 mmol, 52% yield, UPLC/HRMS purity: ≥99.5%) 
and 1.108 (24.2 mg, 0.068 mmol, 34% yield, UPLC/HRMS purity: ≥99.5%). A 60:40 
regioisomeric ratio was observed by analytical HPLC of crude reaction mixture: Chiralpak IA, 
Daicel Chemical Industries, Ltd.; 0–30% EtOH/hexanes over 60 min; flow rate 1.0 mL/min; UV 
220 nm; 1.107 = 40.48 min, 1.108 = 48.09 min. Purification was carried out by an automated 
MPLC system using a 12 g normal phase silica column with gradient elution from 0–80% 
EtOAc/hexanes. 1.107: Rf = 0.48 (80% EtOAc/hexanes); mp 189–200 ˚C; IR (neat) 3197, 1615, 
1602 cm-1; 1H NMR (400 MHz, DMSO-d6) δ 9.00 (s, 1H), 7.06 (d, J = 8.4 Hz, 1H), 6.51 (dd, J = 
8.4, 2.6 Hz, 1H), 6.44 (d, J = 2.5 Hz, 1H) 4.42 (t, J = 5.5 Hz, 1H), 3.37–3.19 (complex, 6H), 3.00 
(dd, J = 13.2, 7.3 Hz, 1H), 2.72 (m, 2H), 2.27 (m, 1H), 2.17–2.08 (m, 2H), 1.98 (m, 1H), 1.88 
(m, 1H), 1.65–1.15 (complex, 6H), 1.03 (s, 3H), 0.79 (dd, J = 6.8 Hz, 3H); 13C NMR (126 MHz, 
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DMSO-d6) δ 175.6, 155.0, 137.0, 130.2, 126.0, 114.7, 112.8, 63.7, 48.9, 46.9, 43.9, 42.3, 40.6, 
38.2, 34.5, 33.6, 29.4, 25.8, 25.6, 20.5, 18.1, 14.9. HRMS (FT-ICR, HESI) m/z calcd for 
C22H32NO3 [M + H]+ 358.2377, found 358.2372. 1.108: Rf = 0.29 (80% EtOAc/hexanes); mp 
255–268 ˚C; IR (neat) 3135, 1569 cm-1; 1H NMR (400 MHz, DMSO-d6) δ 9.02 (s, 1H), 7.06 (d, 
J = 8.4 Hz, 1H), 6.52 (dd, J = 8.4, 2.6 Hz, 1H), 6.45 (d, J = 2.6 Hz, 1H), 4.43 (t, J = 5.5 Hz, 1H), 
3.38 (dd, J = 14.0, 8.0 Hz, 1H), 3.28–3.16 (m, 3H), 2.72 (m, 2H), 2.40–2.33 (m, 3H), 2.26 (m, 
1H), 2.16 (m, 1H), 2.04–1.92 (m, 2H), 1.84 (h, J = 6.9, 6.2 Hz, 1H), 1.65 (m, 1H), 1.55–1.36 (m, 
2H), 1.29–1.15 (m, 3H), 1.12 (s, 3H), 0.79 (d, J = 6.8 Hz, 3H); 13C NMR (126 MHz, DMSO-d6) 
δ 170.4, 155.1, 137.0, 129.9, 126.0, 114.6, 112.8, 64.3, 59.5, 46.7, 42.9, 41.8, 40.1, 37.5, 37.0, 
31.0, 29.4, 26.6, 25.8, 19.5, 19.2, 15.3. HRMS (FT-ICR, HESI) m/z: [M + H]+ calcd for 
C22H33NO3 358.2377, found 358.2370.  
 
 3-Hydroxy-1,3,5-estratriene-derived D-Ring Lactam, 1.109. Following the general 
procedure F, (R)-3-azido-2-methylpropanol (R)-1.3 (34.5 mg, 0.300 mmol, 2.0 equiv) was 
reacted with estrone 1.90 (40.6 mg, 0.150 mmol) to give 1.109 as a white amorphous solid (45.8 
mg, 0.128 mmol, 85% yield, UPLC/HRMS purity: 96.4%). Purification was carried out by an 
automated MPLC system using a 12 g normal phase silica column with gradient elution from 0–
50% EtOAc/hexanes. Rf = 0.15 (50% EtOAc/hexanes); mp 219–222 ˚C; IR (neat) 3514, 1602 
cm-1; 1H NMR (400 MHz, DMSO-d6) δ 9.00 (s, 1H), 7.06 (d, J = 8.4 Hz, 1H), 6.51 (dd, J = 8.4, 
2.6 Hz, 1H), 6.44 (d, 2.6 Hz, 1H), 4.37 (m, 1H), 3.36–3.16 (complex, 5H), 2.95 (dd, J = 13.3, 7.2 
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Hz, 1H), 2.72 (m, 2H), 2.28 (m, 1H), 2.17–2.09 (m, 2H), 1.99 (m, 2H), 1.88 (h, J = 6.8 Hz, 1H), 
1.61–1.15 (complex, 6H), 3.02 (s, 3H), 0.81 (d, J = 6.8 Hz, 3H); 13C NMR (151 MHz, DMSO-
d6) δ 175.7, 155.0, 137.0, 130.2, 126.0, 114.7, 112.8, 63.8, 49.0, 46.9, 43.8, 42.3, 40.6, 38.1, 
34.5, 33.5, 29.4, 25.8, 25.6, 20.4, 18.1, 14.9. HRMS (FT-ICR, HESI) m/z: [M + H]+ calcd for 
C22H32NO3 358.2377, found 358.2371.   
 
 3-Hydroxy-1,3,5-estratriene-derived D-Ring Lactam, 1.110. Following the general 
procedure F, (S)-3-azidobutanol (S)-1.5 (34.6 mg, 0.300 mmol, 2.0 equiv) was reacted with 
estrone 1.90 (40.5 mg, 0.150 mmol) to give 1.110 as an off-white amorphous solid (36.7 mg, 
0.103 mmol, 68% yield, UPLC/HRMS purity: 96.1%). Purification was carried out by an 
automated MPLC system using a 12 g normal phase silica column with gradient elution from 0–
6% MeOH/CH2Cl2. Rf = 0.13 (4% MeOH/CH2Cl2); mp 248–255 ˚C; IR (neat) 3328, 3114, 1620 
cm-1; 1H NMR (600 MHz, DMSO-d6) δ 8.96 (s, 1H), 7.05 (d, J = 8.6 Hz, 1H), 6.52 (dd, J = 8.5, 
2.6 Hz, 1H), 6.45 (d, J = 2.6 Hz, 1H), 4.33 (t, J = 5.0 Hz, 1H), 3.62 (m, 1H), 3.45–3.34 (m, 2H), 
2.73 (m, 2H), 2.39–2.19 (complex, 5H), 2.12–2.02 (m, 2H), 1.86 (m, 2H), 1.55 (m, 1H), 1.44–
1.33 (m, 2H), 1.30 (d, J = 6.5 Hz, 3H), 1.27–1.20 (m, 3H), 1.15 (s, 3H); 13C NMR (151 MHz, 
DMSO-d6) δ 168.8, 155.0, 136.9, 129.9, 125.8, 114.5, 112.8, 60.6, 58.5, 47.7, 46.6, 42.0, 39.3, 
38.4, 36.9, 33.0, 29.2, 26.9, 25.9, 18.61, 18.56, 18.1. HRMS (FT-ICR, HESI) m/z: [M + H]+ 




 3-Hydroxy-1,3,5-estratriene-derived D-Ring Lactam, 1.111. Following the general 
procedure F, (R)-3-azidobutanol (R)-1.5 (33.8 mg, 0.294 mmol, 2.0 equiv) was reacted with 
estrone 1.90 (40.4 mg, 0.149 mmol) to give 1.111 as a white amorphous solid (46.2 mg, 0.129 
mmol, 86% yield, UPLC/HRMS purity: 97.9%). Purification was carried out by an automated 
MPLC system using a 12 g normal phase silica column with gradient elution from 0–4% 
MeOH/CH2Cl2. Rf = 0.38 (5% MeOH/CH2Cl2); mp 246–242 ˚C; IR (neat) 3160, 1585 cm-1; 1H 
NMR (600 MHz, DMSO-d6) δ 8.95 (s, 1H), 7.05 (d, J = 8.5 Hz, 1H), 6.52 (dd, J = 8.4, 2.6 Hz, 
1H), 6.44 (d, J = 2.6 Hz, 1H), 4.57 (m, 1H), 4.27 (t, J = 5.4 Hz, 1H), 3.30 (m, 1H), 3.21–3.10 (m, 
2H), 2.73 (m, 1H), 2.27 (m, 1H), 2.16–1.98 (complex, 4H), 1.64 (m, 1H), 1.55–1.41 (complex, 
4H), 1.34–1.15 (complex, 3H), 1.06 (d, J = 6.9 Hz, 3H), 1.02 (s, 3H); 13C NMR (151 MHz, 
DMSO-d6) δ 175.2, 154.9, 136.9, 130.2, 125.8, 114.6, 112.7, 58.1, 44.8, 43.6, 42.2, 40.8, 38.1, 
36.1, 34.5, 29.2, 25.7, 25.5, 20.3, 18.0, 17.3. Note: Missing one carbon signal due to signal 
overlap. HRMS (FT-ICR, HESI) m/z: [M + H]+ calcd for C22H32NO3 358.2377, found 358.2371.   
 
 3-Methoxy-1,3,5-estratriene-derived D-Ring Lactam, 1.112. Following the general 
procedure F, 3-azidopropanol 1.1 (30.6 mg, 0.303 mmol 2.0 equiv) was reacted with estrone 3-
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methyl ether 1.95 (42.7 mg, 0.150 mmol) to give 1.112 as an off-white amorphous solid (50.0 
mg, 0.140 mmol, 93% yield, UPLC/HRMS purity: 97.8%). Purification was carried out by an 
automated MPLC system using a 12 g normal phase silica column with gradient elution from 0–
5% MeOH/CH2Cl2. Rf = 0.35 (5% MeOH/CH2Cl2); mp 142–145 ˚C; IR (neat) 3354, 1601 cm-1; 
1H NMR (400 MHz, CDCl3) δ 7.22 (d, J = 8.6 Hz, 1H), 6.73 (dd, J = 8.6, 2.8 Hz, 1H), 6.63 (d, J 
= 2.6 Hz, 1H), 4.20 (br s, 1H), 3.77 (s, 3H), 3.68 (ddd, J = 14.0, 8.2, 4.6 Hz, 1H), 3.52–3.41 (m, 
2H), 3.89–3.25 (m, 3H), 2.87 (m, 2H), 2.41–2.32 (m, 2H), 2.30–2.21 (m, 1H), 2.06 (m, 2H), 
1.79–1.21 (complex, 8H), 1.16 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 178.2, 157.8, 137.6, 
132.3, 126.4, 113.7, 111.8, 58.0, 55.3, 47.0, 44.7, 43.0, 42.9, 41.4, 38.5, 34.6, 30.0, 29.4, 26.4, 
25.9, 21.0, 18.5. HRMS (FT-ICR, HESI) m/z: [M + H]+ calcd for C22H32NO3 358.2377, found 
358.2371.  
Experimental section for 1.4.4 
 
 3β-Hydroxy-5α-androstane-derived D-Ring Lactams, 1.113 and 1.114. Following the 
general procedure E, azidoethanol 1.7 (26.1 mg, 0.300 mmol, 2.0 equiv) was reacted with trans-
androsterone 1.84 (43.6 mg, 0.150 mmol) to give an inseparable mixture (30:70) of regioisomers 
1.113 and 1.114 as a white amorphous solid (50.4 mg, 0.144 mmol, 96% yield, UPLC/HRMS 
purity: ≥99.5%). Purification was carried out by an automated MPLC system using a 12 g 
normal phase silica column with gradient elution from 0–5% MeOH/CH2Cl2. Rf = 0.26 (5% 
MeOH/CH2Cl2); IR (neat) 3328, 1600 cm-1; key 1H NMR (400 MHz, CDCl3) δ 4.46 (br s, 1H), 
3.86 (m, 1H), 3.77 (m, 2H), 3.65–3.56 (complex, 4H), 3.37 (m, 1H), 3.26 (m, 1H), 2.52 (m, 1H), 
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2.44 (m, 1H); 13C NMR (151 MHz, CDCl3) δ 179.5, 173.7, 71.3, 71.2, 65.0, 62.2, 60.5, 53.4, 
53.0, 51.4, 48.8, 48.7, 45.7, 44.9, 44.4, 44.3, 41.3, 38.2, 38.1, 38.0, 36.9, 36.3, 35.7, 35.6, 34.8, 
34.5, 31.7, 31.6, 31.5, 31.0, 30.9, 28.6, 28.5, 21.6, 21.2, 20.3, 19.3, 19.0, 18.5, 12.4, 12.3. Note: 
Missing one carbon signal due to signal overlap of regioisomers. HRMS (FT-ICR, HESI) m/z: 
[M + H]+ calcd for C21H36NO3 350.2690, found 350.2683.   
 
 3β-Hydroxy-5α-androstane-derived D-Ring Lactam, 1.115. Following the general 
procedure E, (S)-2-azido-3-phenylpropanol (S)-1.9 (53.2 mg, 0.300 mmol, 2.0 equiv) was reacted 
with trans-androsterone 1.84 (43.6 mg, 0.150 mmol) to give 1.115 as a white amorphous solid 
(58.9 mg, 0.134 mmol, 89% yield, UPLC/HRMS purity: 96.9%). Purification was carried out by 
an automated MPLC system using a 12 g normal phase silica column with gradient elution from 
50–100% EtOAc/hexanes. Rf = 0.26 (80% EtOAc/hexanes); mp 236–240 ˚C; IR (neat) 3332, 
1596 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.31–7.18 (m, 5H), 3.76–3.68 (m, 2H), 3.63–3.49 (m, 
3H), 2.99 (m, 1H), 2.56 (m, 1H), 2.42 (ddd, J = 18.6, 10.2, 8.0 Hz, 1H), 1.98 (m, 1H), 1.92–1.79 
(m, 3H), 1.71–1.65 (m, 2H), 1.61–1.56 (m, 1H), 1.44–1.03 (complex, 13H), 1.00–0.80 (m, 4H, 
contains s, 0.88, 3H), 0.76–0.68 (m, 4H, contains s, 0.74, 3H); 13C NMR (101 MHz, CDCl3) δ 
173.3, 140.0, 129.7 (2C), 128.6 (2C), 126.6, 71.2, 65.6, 62.0, 59.7, 53.0, 49.8, 44.3, 37.9, 37.8, 
36.8, 36.2, 35.6, 34.6, 33.1, 31.4, 31.1, 28.5, 21.7, 18.8, 18.3, 12.2. HRMS (FT-ICR, HESI) m/z: 




 3β-Hydroxy-5α-androstane-derived-derived D-Ring Lactam, 1.116. Following the 
general procedure E, (R)-2-azido-3-phenylpropanol (R)-1.9 (53.2 mg, 0.300 mmol, 2.0 equiv) 
was reacted with trans-androsterone 1.84 (43.7 mg, 0.150 mmol) to give 1.116 as a white 
amorphous solid (54.0 mg, 0.123 mmol, 82% yield, UPLC/HRMS purity: 97.2%) containing a 
minor uncharacterized regioisomer (regioisomer ratio 89:11). Purification was carried out by an 
automated MPLC system using a 12 g normal phase silica column with gradient elution from 0–
5% MeOH/CH2Cl2 over 40 min. Rf = 0.30 (80% EtOAc/hexanes); mp 109–118 ˚C; IR (neat) 
3426, 3280, 1603 cm-1; key 1H NMR (400 MHz, CDCl3) δ 7.31–7.24 (m, 2H), 7.22–7.18 (m, 
3H), 4.06 (m, 1H), 3.95 (m, 1H), 3.83–3.71 (m, 2H), 3.61–3.53 (m, 2H), 3.13–3.05 (m, 2H), 
2.96–2.89 (m, 2H), 2.12 (m, 1H); 13C NMR (101 MHz, CDCl3) δ 178.8, 138.7, 129.2 (2C), 128.5 
(2C), 126.5, 71.3, 64.1, 53.3, 46.9, 45.1, 44.4, 41.7, 38.1, 36.8, 35.7, 34.79, 34.78, 33.9, 31.6, 
30.9, 29.8, 28.6, 21.2, 20.3, 18.1, 12.3. Note: Characterization above only denotes peaks of the 





 3β-Hydroxy-5α-androstane-derived D-Ring Lactam, 1.117. Following the general 
procedure E, (S)-2-azido-2-phenylethanol (S)-1.10 (40.8 mg, 0.250 mmol, 2.0 equiv) was reacted 
with trans-androsterone 1.84 (36.3 mg, 0.125 mmol) to give 1.117 as a white amorphous solid 
(40.8 mg, 0.0959 mmol, 77% yield, UPLC/HRMS purity: 97.8%). Purification was carried out 
by an automated MPLC system using a 12 g normal phase silica column with gradient elution 
from 50–100% EtOAc/hexanes. Rf = 0.38 (5% MeOH/CH2Cl2); mp 212–217 ˚C; IR (neat) 3352, 
3235, 1608 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.33–7.28 (m, 4H), 7.24–7.19 (m, 1H), 4.75 (m, 
1H), 4.41 (dd, J = 11.9, 5.3 Hz, 1H), 4.03 (dd, J = 11.9, 2.4 Hz, 1H), 3.60 (m, 1H), 2.62 (ddd, J = 
18.8, 7.3, 1.6 Hz, 1H), 2.48 (ddd, J = 18.8, 10.5, 8.4 Hz, 1H), 2.16 (m, 1H), 1.99–1.91 (m, 2H), 
1.83–1.68 (m, 4H), 1.62–1.19 (complex, 11H), 1.15 (s, 3H), 1.12–0.88 (m, 3H), 0.82–0.76 (m, 
4H, contains s, 0.77, 3H); 13C NMR (101 MHz, CDCl3) δ 173.0, 138.3, 128.4 (2C), 127.2 (2C), 
126.7, 71.1, 66.1, 62.2, 59.7, 53.0, 49.9, 44.3, 38.4, 37.9, 36.9, 36.4, 35.6, 32.9, 31.4, 31.1, 28.5, 
22.0, 19.3, 19.1, 12.3. HRMS (FT-ICR, HESI) m/z: [M + H]+ calcd for C27H39NO3 426.3003, 
found 426.2983.   
 
 3β-Hydroxy-5α-androstane-derived D-Ring Lactam, 1.118. Following the general 
procedure E, (R)-2-azido-2-phenylethanol (R)-1.10 (40.8 mg, 0.250 mmol, 2.0 equiv) was 
reacted with trans-androsterone 1.84 (36.2 mg, 0.125 mmol) to give 1.118 as a yellow 
amorphous solid (27.0 mg, 0.0634 mmol, 51% yield, UPLC/HRMS purity: 98.9%). Purification 
was carried out by an automated MPLC system using a 12 g normal phase silica column with 
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gradient elution from 50–100% EtOAc/hexanes. Rf = 0.36 (4% MeOH/CH2Cl2); IR (neat) 3364, 
1601 cm-1; mp 212–214 ˚C; 1H NMR (400 MHz, CDCl3) δ 7.35–7.19 (m, 5H), 5.66 (t, J = 7.1 
Hz, 1H), 4.10 (d, J = 7.1 Hz, 2H), 3.57 (m, 1H), 3.21 (ddd, J = 12.4, 7.3, 2.0 Hz, 1H), 2.82 (ddd, 
J = 12.4, 10.6, 7.1 Hz, 1H), 2.21 (m, 1H), 1.87–1.18 (complex, 17H), 1.15 (s, 3H), 1.10–0.91 (m, 
2H), 0.85–0.74 (m, 4H, contains s, 0.78, 3H), 0.67 (m, 1H); 13C NMR (126 MHz, CDCl3) δ 
179.0, 137.0, 128.7 (2C), 128.0 (2C), 127.8, 71.2, 62.1, 59.0, 53.2, 45.1, 44.4, 42.9, 41.9, 38.0, 
36.8, 35.6, 34.91, 34.86, 31.4, 30.8, 28.5, 21.0, 20.3, 18.3, 12.3. HRMS (FT-ICR, HESI) m/z: [M 
+ H]+ calcd for C27H40NO3 426.3003, found 426.2985.   
 
 3β-Hydroxy-5α-androstane-derived D-Ring Lactam, 1.119. Following the general 
procedure E, (S)-2-azido-4-methylpentanol (S)-1.11 (43.2 mg, 0.302 mmol, 2.0 equiv) was 
reacted with trans-androsterone 1.84 (43.9 mg, 0.151 mmol) to give 1.119 as a white amorphous 
solid (52.6 mg, 0.130 mmol, 86% yield, UPLC/HRMS purity: ≥99.5%). Purification was carried 
out by an automated MPLC system using a 12 g normal phase silica column with gradient 
elution from 0–80% EtOAc/hexanes. Rf = 0.33 (80% EtOAc/hexanes); mp 164–168 ˚C; IR (neat) 
3317, 1604 cm-1; 1H NMR (400 MHz, CDCl3) δ 5.68 (d, J = 9.3 Hz, 1H), 3.82 (m, 1H), 3.67–
3.56 (m, 2H), 3.51 (m, 1H), 2.64 (ddd, J = 13.6, 11.1, 4.0 Hz, 1H), 2.50 (ddd, J = 18.6, 7.0, 1.5 
Hz, 1H), 2.37 (ddd, J = 18.8, 11.0, 8.1 Hz, 1H), 2.10 (dt, J = 12.3, 3.6 Hz, 1H), 1.93–1.06 
(complex, 20H, contains s, 1.18, 3H), 1.02–0.84 (complex, 10H, contains dd, 0.94, J = 6.6, 1.3 
Hz, 6H), 0.79–0.71 (complex, 4H, contains s, 0.78, 3H); 13C NMR (101 MHz, CDCl3) δ 172.8, 
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71.1, 64.9, 61.9, 55.1, 53.0, 49.7, 44.3, 37.9, 37.5, 36.8, 36.0, 35.6, 33.0, 31.4, 31.0, 25.5, 24.1, 
21.9, 21.8, 18.9, 18.8, 12.3. Note: Missing two carbons signal due to signal overlap. HRMS (FT-
ICR, HESI) m/z: [M + H]+ calcd for C25H44NO3 406.3316, found 406.3296.  
 
 3β-Hydroxy-5α-androstane-derived D-Ring Lactam, 1.120. Following the general 
procedure E, (R)-2-azido-4-methylpentanol (R)-1.11 (43.2 mg, 0.302 mmol, 2.0 equiv) was 
reacted with trans-androsterone 1.84 (43.9 mg, 0.151 mmol) to give 1.11 as a white amorphous 
solid (51.0 mg, 0.126 mmol, 83% yield, UPLC/HRMS purity: 92.4%). Purification was carried 
out by an automated MPLC system using a 12 g normal phase silica column with gradient 
elution from 0–5% MeOH/CH2Cl2 over 50 min. Rf = 0.27 (5% MeOH/CH2Cl2); IR (neat) 3364, 
1611 cm-1; mp 97–115 ˚C; key 1H NMR (400 MHz, CDCl3) δ 4.30 (m, 1H), 3.67 (dd, J = 11.5, 
3.8 Hz, 1H), 3.64–3.55 (m, 2H), 2.16 (m, 1H), 1.95 (m, 1H); 13C NMR (101 MHz, CDCl3) δ 
179.0, 71.3, 64.1, 55.8, 53.4, 45.4, 44.5, 43.3, 41.8, 38.1, 36.9, 35.7, 34.97, 34.95, 31.6, 31.0, 
28.6, 25.1, 23.3, 22.5, 21.2, 20.4, 18.2, 12.4. Note: Missing one carbon signal due to signal 
overlap; characterization above only denotes peaks of the major regioisomer. HRMS (FT-ICR, 




 3-Hydroxy-1,3,5-estratriene-derived D-Ring Lactams, 1.121 and 1.122. Following the 
general procedure F, 2-azidoethanol 1.7 (26.1 mg, 0.300 mmol, 2.0 equiv) was reacted with 
estrone 1.95 (40.6 mg, 0.150 mmol) to give a mixture of 1.121:1.122 as an off-white amorphous 
solid (46.3 mg, 0.141 mmol, 94% yield). Purification was carried out by an automated MPLC 
system using a 12 g normal phase silica column with gradient elution from 0–5% 
MeOH/CH2Cl2. A 30:70 regioisomeric ratio was observed by analytical HPLC of crude reaction 
mixture: Chiralpak IB, Daicel Chemical Industries, Ltd.; 0–30% EtOH/hexanes over 60 min; 
flow rate 1.0 mL/min; UV 220 nm; 1.121 = 28.03 min, 1.122 = 34.55 min. The mixture was 
subjected to a second purification using Chiralpak IB prep HPLC with gradient elution from 0–
5% EtOH/hexanes over 60 min to give 1.121 (36.1 mg, 0.110 mmol, 27% yield, UPLC/HRMS 
purity: 98.1%) as a white amorphous solid and 1.122 (68.9 mg, 0.209 mmol, 52% yield, 
UPLC/HRMS purity: 99.0%) as a white amorphous solid. 1.121 + 1.122 mixture: Rf = 0.38 (5% 
MeOH/CH2Cl2); IR (neat) 3334, 1596, 1567 cm-1. 1.121: mp decomposed; IR (neat) 3479, 3309, 
1595 cm-1; 1H NMR (400 MHz, DMSO-d6) δ 9.03 (s, 1H), 7.06 (d, J = 8.5 Hz, 1H), 6.51 (dd, J = 
8.4, 2.7 Hz, 1H), 6.44 (d, J = 2.6 Hz, 1H), 4.64 (m, 1H), 3.49–3.16 (complex, 5H), 2.72 (m, 2H), 
2.28 (m, 1H), 2.17–2.07 (m, 2H), 1.97 (m, 2H), 1.60–1.14 (complex, 7H), 1.02 (s, 3H); 13C NMR 
(126 MHz, DMSO-d6) δ 175.2, 155.1, 137.0, 130.2, 126.0, 114.7, 112.8, 58.6, 49.2, 47.7, 43.8, 
42.4, 40.5, 38.1, 34.5, 29.4, 25.8, 25.6, 20.5, 18.1. HRMS (FT-ICR, HESI) m/z: [M + H]+ calcd 
for C20H28NO3 330.2064, found 330.2059. 1.122: mp 259–262 ˚C; IR (neat) 3332, 1566 cm-1; 1H 
NMR (400 MHz, DMSO-d6) δ 9.02 (s, 1H), 7.06 (d, J = 8.5 Hz, 1H), 6.52 (dd, J = 8.4, 2.6 Hz, 
1H), 6.44 (d, J = 2.6 Hz, 1H), 4.67 (t, J = 5.4 Hz, 1H), 3.58–3.45 (m, 2H), 3.33 (m, 1H), 3.13 (m, 
1H), 2.72 (m, 2H), 2.41–2.15 (complex, 5H), 2.03 (m, 1H), 1.92 (m, 1H), 1.59 (m, 1H), 1.49–
1.35 (m, 2H), 1.30–1.19 (m, 3H), 1.11 (s, 3H); 13C NMR (126 MHz, DMSO-d6) δ 169.7, 155.1, 
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137.0, 129.9, 126.1, 114.6, 112.9, 60.0, 59.2, 46.9, 43.4, 42.0, 39.6, 37.4, 31.3, 29.4, 26.7, 25.8, 
18.9, 18.6. HRMS (FT-ICR, HESI) m/z: [M + H]+ calcd for C20H28NO3 330.2064, found 
330.2059. 
 
 3-Hydroxy-1,3,5-estratriene-derived D-Ring Lactam, 1.123. Following the general 
procedure F, (S)-2-azido-3-phenylpropanol (S)-1.9 (53.2 mg, 0.300 mmol, 2.0 equiv) was reacted 
with estrone 1.90 (40.6 mg, 0.150 mmol) to give 1.123 as a white amorphous solid (57.3 mg, 
0.137 mmol, 91% yield, UPLC/HRMS purity: 96.8%). Purification was carried out by an 
automated MPLC system using a 12 g normal phase silica column with gradient elution from 0–
80% EtOAc/hexanes. Rf = 0.21 (50% EtOAc/hexanes); mp 246–253 ˚C; IR (neat) 3247, 1602 
cm-1; 1H NMR (400 MHz, DMSO-d6) δ 9.01 (s, 1H), 7.27 (m, 2H), 7.17 (3H), 7.01 (d, J = 8.5 
Hz, 1H), 6.50 (dd, J = 8.4, 2.6 Hz, 1H), 6.42 (d, J = 2.6 Hz, 1H), 4.98 (m, 1H), 3.72 (m, 2H), 
3.50 (m, 1H), 3.27 (m, 1H), 3.09 (dd, J = 13.2, 5.9 Hz, 1H), 2.67 (m, 2H), 2.43–2.24 (m, 3H), 
2.16 (m, 1H), 2.07 (m, 1H), 1.97 (m, 1H), 1.83 (m, 1H), 1.61 (m, 1H), 1.39 (m, 1H), 1.26–1.04 
(m, 4H), 0.47 (s, 3H); 13C NMR (126 MHz, DMSO-d6) δ 170.6, 155.1, 140.5, 137.0, 129.8, 
129.5 (2C), 128.2 (2C), 126.1, 126.0, 114.6, 112.8, 63.4, 60.4, 59.7, 47.6, 42.0, 39.6, 37.1, 34.4, 
32.7, 29.3, 26.7, 25.9, 18.5, 17.6. HRMS (FT-ICR, HESI) m/z: [M + H]+ calcd for C27H34NO3 




 3-Hydroxy-1,3,5-estratriene-derived D-Ring Lactam, 1.124. Following the general 
procedure F, (R)-2-azido-3-phenylpropanol (R)-1.9 (53.2 mg, 0.300 mmol, 2.0 equiv) was 
reacted with estrone 1.95 (41.2 mg, 0.152 mmol) to give 1.124 as a white crystalline solid (45.6 
mg, 0.109 mmol, 72% yield, UPLC/HRMS purity: 98.5%) containing a minor uncharacterized 
regioisomer. Purification was carried out by an automated MPLC system using a 12 g normal 
phase silica column with gradient elution from 0–5% MeOH/CH2Cl2. Rf = 0.40 (5% 
MeOH/CH2Cl2); IR (neat) 3298, 1609 cm-1; mp 115–134 ˚C; 1H NMR (400 MHz, DMSO-d6) δ 
9.00 (s, 1H), 7.25 (m, 2H), 7.18 (m, 3H), 7.03 (d, J = 8.5 Hz, 1H), 6.50 (dd, J = 8.4, 2.6 Hz, 1H), 
6.42 (d, J = 2.7 Hz, 1H), 4.73 (m, 1H), 3.57 (m, 1H), 3.48 (m, 1H), 3.14 (m, 2H), 2.82 (m, 2H), 
2.69 (m, 3H), 2.21 (m, 1H), 2.00–1.86 (m, 3H), 1.40–1.03 (complex, 7H), 0.94 (s, 3H); 13C NMR 
(151 MHz, DMSO-d6) δ 175.6, 155.0, 138.9, 137.0, 130.2, 128.9 (2C), 128.0 (2C), 125.93, 
125.90, 114.6, 112.8, 61.0, 43.1, 42.4, 40.7, 38.2, 34.7, 33.7, 29.3, 25.8, 25.5, 20.4, 17.5. Note: 
Missing two carbon signals due to signal overlap; characterization above only denote peaks of 
the major regioisomer. HRMS (FT-ICR, HESI) m/z: [M + H]+ calcd for C27H34NO3 420.2533, 




 3-Hydroxy-1,3,5-estratriene-derived D-Ring Lactam, 1.125. Following the general 
procedure F, (S)-2-azido-2-phenylethanol (S)-1.10 (64.6 mg, 0.396 mmol, 2.0 equiv was reacted 
with estrone 1.90 (54.5 mg, 0.201 mmol) to give 1.125 as a white amorphous solid (41.5 mg, 
0.102 mmol, 51% yield, UPLC/HRMS purity: ≥99.5%). Purification was carried out by an 
automated MPLC system using a 12 g normal phase silica column with gradient elution from 0–
2% MeOH/CH2Cl2. Rf = 0.23 (2% MeOH/CH2Cl2); mp 254–259 ˚C; IR (neat) 3233, 1734 cm-1; 
1H NMR (400 MHz, CDCl3) δ 9.02 (s, 1H), 7.36 (d, J = 7.7 Hz, 2H), 7.25 (m, 2H), 7.15 (m, 1H), 
7.07 (d, J = 8.5 Hz, 1H), 6.53 (dd, J = 8.4, 2.7 Hz, 1H), 6.45 (d, J = 2.6 Hz, 1H), 5.02 (t, J = 5.4 
Hz, 1H), 4.16 (m, 1H), 4.03 (m, 1H), 2.74 (m, 1H), 2.43–2.27 (m, 5H), 2.07–2.05 (m, 1H), 1.99–
1.92 (m, 1H), 1.78 (m, 1H), 1.60–1.44 (m, 2H), 1.33–1.21 (m, 4H), 1.14 (s, 3H); 13C NMR (101 
MHz, CDCl3) δ 170.1, 155.1, 141.0, 137.0, 129.9, 127.5, 127.2, 126.0, 125.7, 114.6, 112.8, 65.4, 
64.9, 61.1, 59.2, 47.8, 42.0, 37.5, 32.5, 29.3, 27.0, 26.0, 19.2, 18.6, 15.1. Note: Missing one 
carbon signal due to signal overlap. HRMS (FT-ICR, HESI) m/z: [M + H]+ calcd for C26H32NO3 
406.2377, found 406.2370.  
 
 3-Hydroxy-1,3,5-estratriene-derived D-Ring Lactam, 1.126. Following the general 
procedure F, (R)-2-azido-2-phenylethanol (R)-1.10 (41.7 mg, 0.256 mmol, 2.0 equiv) was 
reacted with estrone 1.90 (34.5 mg, 0.128 mmol) to give 1.126 as a yellow solid/oil (29.1 mg, 
0.072 mmol, 56% yield, UPLC/HRMS purity: ≥99.5%) containing a minor uncharacterized 
regioisomer. Purification was carried out by an automated MPLC system using a 12 g normal 
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phase silica column with gradient elution from 0–2% MeOH/CH2Cl2. Rf = 0.17 (2% 
MeOH/CH2Cl2, run twice); IR (neat) 3414, 3344, 1591 cm-1; 1H NMR (400 MHz, DMSO-d6) δ 
8.99 (s, 1H), 7.34 (m, 2H), 7.26 (m, 3H), 7.05 (d, J = 8.5 Hz, 1H), 6.51 (dd, J = 8.4, 2.6 Hz, 1H), 
6.43 (d, J = 2.6 Hz, 1H), 5.63 (t, J = 7.3 Hz, 1H), 4.87 (t, J = 5.5 Hz, 1H), 3.92 (m, 1H), 3.83 (m, 
1H), 2.84 (m, 1H), 2.70 (m, 2H), 2.28 (m, 1H), 2.13 (m, 1H), 1.93 (m, 1H), 1.58–1.11 (complex, 
8H), 1.08 (s, 3H); 13C NMR (101 MHz, DMSO-d6) δ 175.8, 155.0, 138.5, 137.0, 130.2, 128.3 
(2C), 127.7 (2C), 126.9, 125.9, 114.6, 112.8, 59.7, 56.4, 43.3, 42.1, 41.1, 40.9, 38.4, 34.8, 29.3, 
25.7, 25.6, 20.4, 17.8. Note: Characterization above only denotes peaks of the major 
regioisomer. HRMS (FT-ICR, HESI) m/z: [M + H]+ calcd for C26H32NO3 406.2377, found 
406.2376.  
 
 3-Hydroxy-1,3,5-estratriene-derived D-Ring Lactam, 1.127. Following the general 
procedure F, (S)-2-azido-4-methylpentanol (S)-1.11 (43.0 mg, 0.300 mmol, 2.0 equiv) was 
reacted with estrone 1.90 (0.0411 mg, 0.152 mmol to give 1.127 as a white amorphous solid 
(50.6 mg, 0.131 mmol, 86% yield, UPLC/HRMS purity: ≥99.5%). Purification was carried out 
by an automated MPLC system using a 12 g normal phase silica column with gradient elution 
from 0–80% EtOAc/hexanes. Rf = 0.25 (50% EtOAc/hexanes); mp 233–236 ˚C; IR (neat) 3152, 
1598, 1571 cm-1; 1H NMR (400 MHz, DMSO-d6) δ 9.02 (s, 1H), 7.06 (d, J = 8.4 Hz, 1H), 6.52 
(dd, J = 8.4, 2.6 Hz, 1H), 6.44 (d, J = 2.6 Hz, 1H), 4.96 (dd, J = 6.7, 4.4 Hz, 1H), 3.75 (m, 1H), 
3.56 (m, 1H), 3.42 (m, 1H), 2.73 (m, 2H), 2.40–2.15 (complex, 6H), 2.03 (m, 1H), 1.88 (m, 1H), 
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1.64 (m, 2H), 1.48–1.15 (complex 9H, contains s, 1.15, 3H), 0.90 (dd, J = 18.9, 6.5 Hz, 6H); 13C 
NMR (126 MHz, DMSO-d6) δ 170.2, 155.1, 136.9, 129.9, 125.9, 114.6, 112.8, 63.7, 60.7, 54.9, 
47.5, 41.9, 39.5, 37.3, 32.5, 29.3, 26.9, 25.9, 25.4, 23.7, 22.3, 18.9, 18.5. Note: Missing one 
carbon signals due to signal overlap. HRMS (FT-ICR, HESI) m/z: [M + H]+ calcd for C24H36NO3 
386.2690, found 386.2683.  
 
 3-Hydroxy-1,3,5-estratriene-derived D-Ring Lactam, 1.128. Following the general 
procedure F, (R)-2-azido-4-methylpentanol (R)-1.1 (43.4 mg, 0.303 mmol, 2.0 equiv) was 
reacted with estrone 1.90 (41.6 mg, 0.153 mmol) to give 1.128 as a white crystalline solid (40.2 
mg, 0.104 mmol, 68% yield, UPLC/HRMS purity: 98.8%). Purification was carried out by an 
automated MPLC system using a 12 g normal phase silica column with gradient elution from 0–
5% MeOH/CH2Cl2. Rf = 0.17 (5% MeOH/CH2Cl2); IR (neat) 3247, 1601 cm-1; mp 117–142 ˚C; 
1H NMR (400 MHz, CDCl3) δ 9.00 (s, 1H), 7.05 (d, J = 8.5 Hz, 1H), 6.51 (dd, J = 8.5, 2.5 Hz, 
1H), 6.44 (d, J = 2.6 Hz, 1H), 4.58 (t, J = 5.6 Hz, 1H), 4.48 (m, 1H), 3.42–3.24 (m, 3H), 3.09 (m, 
1H), 2.72 (m, 2H), 2.29–2.25 (m, 1H), 2.17–2.08 (m, 2H), 2.00–1.97 (m, 2H), 1.56–1.45 
(complex, 9H), 1.02 (s, 3H), 0.87 (dd, J = 8.5, 6.3 Hz, 6H); 13C NMR (151 MHz, CDCl3) δ 
175.6, 155.0, 137.0, 130.3, 125.9, 114.6, 112.8, 61.8, 43.6, 42.3, 40.9, 38.4, 36.2, 34.9, 29.4, 
25.7, 25.6, 24.4, 23.5, 21.9, 20.5, 17.8. Note: Missing two carbon signals due to signal overlap. 
HRMS (FT-ICR, HESI) m/z: [M + H]+ calcd for C24H36NO3 386.2690, found 386.2684.  




 3β-Hydroxy-5α-androstane-derived D-Ring Thioamide, 1.129. Following the general 
procedure G, 1.129 was prepared as a white amorphous solid (49.1 mg, 0.129 mmol, 52% yield, 
UPLC/HRMS purity: 98.6%). Purification was carried out by an automated MPLC system using 
a 12 g normal phase silica column with gradient elution from 0–1.5% MeOH/CH2Cl2. Rf = 0.33 
(5% MeOH/CH2Cl2); mp 212–216 ˚C; IR (neat) 3241, 1519 cm-1; 1H NMR (400 MHz, CDCl3) δ 
4.46 (dt, J = 13.3, 6.6 Hz, 1H), 3.88 (dt, J = 13.4, 5.9 Hz, 1H), 3.62–3.47 (m, 3H), 3.44–3.31 (m, 
2H), 2.74 (m, 1H), 2.05 (m, 1H), 1.90–1.53 (complex, 7H), 1.46–1.22 (complex, 9H), 1.18 (s, 
3H), 1.09 (m, 1H), 0.97 (m, 1H), 0.85 (m, 1H), 0.79 (s, 3H), 0.65 (m, 1H); 13C NMR (101 MHz, 
CDCl3) δ 211.7, 71.3, 58.1, 53.0, 51.7, 50.6, 46.4, 44.6, 44.4, 39.7, 38.0, 36.8, 36.0, 35.6, 31.6, 
31.0, 29.6, 28.6, 21.3, 21.2, 12.3. Note: Missing one carbon signal due to signal overlap. HRMS 
(FT-ICR, HESI) m/z: [M + H]+ calcd for C22H38NO2S 380.2618, found 380.2612.   
 
 3β-Hydroxy-5α-androstane-derived D-Ring Oxazinane, 1.130. Following the general 
procedure G, 1.130 was prepared as a white amorphous solid (59.4 mg, 0.171 mmol, 85% yield, 
LCMS Purity: ≥99.5%). Purification was carried out by an automated MPLC system using a 12 g 
normal phase silica column with gradient elution from 0–10% MeOH (0.5% NH4OH)/CH2Cl2. Rf 
= 0.25 (5% MeOH (0.5% NH4OH)/CH2Cl2); mp 178–184 ˚C; IR (neat) 3350, 2929, 2848 cm-1; 
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1H NMR (400 MHz, CDCl3) δ 4.00 (m, 1H), 3.58 (m, 1H), 3.38 (m, 1H), 2.96–2.81 (m, 3H), 
2.11–1.94 (m, 3H), 1.83–1.71 (m, 4H), 1.61–1.18 (complex, 11H), 1.10–1.01 (m, 1H), 0.99–0.88 
(m, 5H, contains s, 0.95, 3H), 0.83–0.72 (m, 5H, contains s, 0.78, 3H), 0.65 (m, 1H); 13C NMR 
(101 MHz, CDCl3) δ 102.3, 71.4, 67.9, 54.8, 54.6, 53.9, 49.4, 44.6, 38.3, 37.9, 37.0, 35.9, 35.7, 
34.5, 31.6, 31.0, 28.7, 25.9, 23.7, 20.2, 13.6, 12.4. HRMS (FT-ICR, HESI) m/z: [M + H]+ calcd 
for C22H38NO2 348.2897, found 348.2890. Note: X-ray crystal structure of this analog is 
provided in the CCDC (CCDC 1583518).  
 
Table 1.11. Selected crystallographic and refinement parameters for 1.130. 
compound 1.130 
CCDC deposition number 1583518 
empirical formula  C22H41NO4 
formula weight 383.56  
temperature 200(2) K 
wavelength Å 1.54178 Å 
crystal system orthorhombic 
space group P 212121 
unit cell dimensions a = 7.4276(3) Å, D= 90° 
b = 10.1060(12) Å, E= 90° 
c = 28.7302(12) Å, J = 90° 
Z 4 
volume   2156.58(15) Å3 
density 1.219 Mg/m3 
absorption coefficient 0.629 µ mm-1 
F(000) 848 
crystal size 0.150 × 0.150 × 0.020 mm3 
Theta range for data collection  3.076 to 69.815°   
index ranges -8<=h<=8, -10<=k<=12, -32<=l<=33 
reflections collected 18686 
independent reflections 3675 [R(int) = 0.0545] 
completeness to theta = 66.000° 98.4% 
absorption correction multi-scan 
max. and min. transmission 1.000 and 0.718 
refinement method full-matrix least-squares on F2 
data/restraints/parameters 3675/0/408 
Goodness-of-fit F2 1.028 
final R indices [I>2sigma(I)] R1 = 0.0385, wR2 = 0.1012 
R indices (all data) R1 = 0.0418, wR2 = 0.1031 
absolute structure parameter 0.12(12) 





 3β-Hydroxy-5α-androstane-derived D-Ring Oxazinane, 1.131. Following the general 
procedure G, 1.131 was prepared as a white amorphous solid (45.0 mg, 0.128 mmol, 64% yield, 
LCMS Purity: ≥99.5%). Purification was carried out by an automated MPLC system using a 12 g 
normal phase silica column with gradient elution from 0–10% MeOH (0.5% NH4OH)/CH2Cl2. Rf 
= 0.25 (5% MeOH (0.5% NH4OH)/CH2Cl2); mp 178–184 ˚C; IR (neat) 3519, 3243, 2930, 2847 
cm-1; 1H NMR (400 MHz, CDCl3) δ 4.01 (m, 1H), 3.58 (m, 1H), 3.38 (m, 1H), 2.96–2.82 (m, 
2H), 2.13–1.95 (m, 3H), 1.83–1.71 (m, 3H), 1.58–1.18 (complex, 12H), 1.10–1.03 (m, 1H), 
0.99–0.91 (m, 5H, contains s, 0.96, 3H), 0.84–0.72 (m, 5H, contains s, 0.78, 3H), 0.65 (m, 1H); 
13C NMR (101 MHz, CDCl3) δ 71.4, 67.5, 54.7, 54.5, 53.8, 49.3, 44.5, 38.2, 38.0, 36.9, 35.83, 
35.80, 35.7, 34.4, 31.6, 31.0, 28.7, 25.6, 23.4, 20.1, 13.4, 12.4. HRMS (FT-ICR, HESI) m/z: [M 
+ H]+ calcd for C22H37DNO2 349.2960, found 349.2952.  
 
 3β-Hydroxy-5α-androstane-derived D-Ring Lactam, 1.132. Following the general 
procedure G, 1.132 was prepared as an off-white amorphous solid (166 mg, 0.429 mmol, 86% 
yield, UPLC/HRMS purity: ≥99.5%). Purification was carried out by an automated MPLC 
system using a 12 g normal phase silica column with gradient elution from 0–75% 
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EtOAc/hexanes. Rf = 0.25 (50% EtOAc/hexanes); mp 135–139 ˚C; IR (neat) 3469, 3330, 2092, 
1607 cm-1; 1H NMR (400 MHz, CDCl3) δ 3.59 (m, 1H), 3.49 (m, 1H), 3.35–3.18 (complex, 5H), 
2.18 (m, 1H), 1.95–1.72 (complex, 6H), 1.66–1.49 (m, 3H), 1.45–1.19 (complex, 9H), 1.13–1.05 
(m, 4H, contains s, 1.09, 3H), 0.97 (m, 1H), 0.91–0.82 (m, 1H), 0.80 (s, 3H); 13C NMR (101 
MHz, CDCl3) δ 176.8, 71.3, 53.4, 49.5, 47.6, 46.0, 44.9, 44.5, 41.2, 38.1, 36.9, 35.7, 34.9, 34.6, 
31.9, 31.0, 28.6, 36.7, 21.2, 20.3. 18.4, 12.4. HRMS (FT-ICR, HESI) m/z: [M + H]+ calcd for 
C22H37N4O2 389.2911, found 389.2904.  
 
 3β-Hydroxy-5α-androstane-derived D-Ring Lactam, 1.133. Following the general 
procedure G, 1.133 was prepared as a white amorphous solid (48.7 mg, 0.107 mmol, 71% yield, 
UPLC/HRMS purity: 98.6%). Purification was carried out by an automated MPLC system using 
a 12 g normal phase silica column with gradient elution from 0–50% EtOAc/hexanes. Rf = 0.48 
(50% EtOAc/hexanes); mp 133–136 ˚C; IR (neat) 3367, 1617 cm-1; 1H NMR (400 MHz, CDCl3) 
δ 7.36–7.25 (m, 4H), 7.17 (m, 1H), 3.63–3.48 (m, 2H), 3.30–3.15 (m, 3H), 2.29–2.86 (m, 2H), 
2.18 (m, 1H), 1.92–1.21 (complex, 18H), 1.12–1.05 (m, 4H, contains s, 1.08, 3H), 1.00–0.91 (m, 
1H), 0.89–0.80  (m, 1H), 0.79 (s, 3H) 0.66 (m, 1H); 13C NMR (101 MHz, CDCl3) δ 176.7, 136.6, 
129.3 (2C), 129.0 (2C), 126.1, 71.3, 53.4, 47.3, 46.2, 46.0, 44.5, 41.2, 38.1, 36.9, 35.7, 34.9, 
34.6, 31.6, 31.3, 31.0, 28.6, 27.0, 21.2, 20.3, 18.4, 12.4. HRMS (FT-ICR, HESI) m/z: [M + H]+ 




 3β-Hydroxy-5α-androstane-derived D-Ring Lactam, 1.134. Following the general 
procedure G, 1.134 was prepared as a white amorphous solid (53.1 mg, 0.113 mmol, 76% yield, 
UPLC/HRMS purity: 99.0%). Purification was carried out by an automated MPLC system using 
a 12 g normal phase silica column with gradient elution from 0–60% EtOAc/hexanes. Rf = 0.24 
(50% EtOAc/hexanes); mp 171–175 ˚C; IR (neat) 3413, 1614 cm-1; 1H NMR (400 MHz, CDCl3) 
δ 7.24 (m, 3H), 7.09 (m, 2H), 3.59 (m, 1H), 3.51 (m, 1H), 3.29–3.14 (m, 3H), 2.85 (m, 2H), 2.31 
(s, 3H), 2.17 (m, 1H), 1.92–1.21 (complex, 18H), 1.12–1.05 (m, 4H, contains s, 1.07, 3H), 1.02–
0.93 (m, 1H), 0.89–0.82 (m, 1H), 0.79 (s, 3H), 0.66 (m, 1H); 13C NMR (101 MHz, CDCl3) δ 
176.7, 136.3, 132.7, 130.2 (2C), 129.8 (2C), 71.3, 53.4, 47.3, 46.2, 45.9, 44.5, 41.2, 38.1, 36.9, 
35.7, 34.9, 34.6, 32.0, 31.6, 31.0, 28.6, 27.0, 21.2, 21.1, 20.3, 18.5, 12.4. HRMS (FT-ICR, HESI) 
m/z: [M + H]+ calcd for C29H44NO2S 470.3087, found 470.3078.  
 
 3β-Hydroxy-5α-androstane-derived D-Ring Lactam, 1.135. Following the general 
procedure G, 1.135 was prepared as a white amorphous solid (47.4 mg, 0.0976 mmol, 65% yield, 
UPLC/HRMS purity: 98.5%). Purification was carried out by an automated MPLC system using 
a 12 g normal phase silica column with gradient elution from 0–55% EtOAc/hexanes. Rf = 0.27 
(50% EtOAc/hexanes); mp 152–155 ˚C; IR (neat) 3402, 1612 cm-1; 1H NMR (400 MHz, CDCl3) 
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δ 7.33 (m, 2H), 6.84 (m, 2H), 3.79 (s, 3H), 3.59 (m, 1H), 3.49 (m, 1H), 3.28–3.13 (m, 3H), 2.78 
(m, 2H), 2.17 (m, 1H), 1.91–1.21 (complex, 18H), 1.12–1.04 (m, 4H, contains s, 1.07, 3H), 
1.00–0.93 (m, 1H), 0.90–0.80 (m, 1H), 0.79 (s, 3H), 0.66 (m, 1H); 13C NMR (101 MHz, CDCl3) 
δ 176.6, 159.1, 133.3 (2C), 126.6, 114.7 (2C), 71.3, 55.5, 53.2, 47.3, 46.1, 45.9, 44.5, 41.2, 38.1, 
36.8, 35.7, 34.8, 34.6, 33.5, 31.6, 31.0, 28.6, 27.0, 21.2, 20.3, 18.4, 12.3. HRMS (FT-ICR, HESI) 
m/z: [M + H]+ calcd 486.3036, found 486.3028.  
 
 3β-Hydroxy-5α-androstane-derived D-Ring Lactam, 1.136. Following the general 
procedure G, 1.136 was prepared as a white amorphous solid (51.0 mg, 0.104 mmol, 69% yield, 
UPLC/HRMS purity: 96.6%). Purification was carried out by an automated MPLC system using 
a 12 g normal phase silica column with gradient elution from 0–65% EtOAc/hexanes. Rf = 0.28 
(50% EtOAc/hexanes); mp 188–196 ˚C; IR (neat) 3393, 1613 cm-1; 1H NMR (400 MHz, CDCl3) 
δ 7.24 (m, 4H), 3.63–3.48 (m, 2H), 3.29–3.15 (m, 3H), 2.89 (m, 2H), 2.17 (m, 1H), 1.92–1.21 
(complex, 18H), 1.12–1.05 (m, 4H, contains s, 1.07, 3H), 0.96 (m, 1H), 0.89–0.80 (m, 1H), 0.79 
(s, 3H), 0.66 (m, 1H); 13C NMR (101 MHz, CDCl3) δ 176.8, 135.1, 132.1, 130.7 (2C), 129.2 
(2C), 71.3, 53.4, 47.3, 46.2, 45.9, 44.5, 41.2, 38.1, 36.9, 35.7, 34.8, 34.6, 31.5850, 31.5849, 31.0, 
28.6, 26.9, 21.2, 20.3, 18.5, 12.4. HRMS (FT-ICR, HESI) m/z: [M + H]+ calcd for 




 3β-Hydroxy-5α-androstane-derived D-Ring Lactam, 1.137. Following the general 
procedure G, 1.137 was prepared as a white amorphous solid (48.9 mg, 0.0913 mmol, 61% yield, 
UPLC/HRMS purity: 98.9%). Purification was carried out by an automated MPLC system using 
a 12 g normal phase silica column with gradient elution from 0–60% EtOAc/hexanes. Rf = 0.29 
(50% EtOAc/hexanes); mp 196–199 ˚C; IR (neat) 3408, 1610 cm-1; 1H NMR (400 MHz, CDCl3) 
δ 7.39 (m, 2H), 7.18 (m, 2H), 3.59 (m, 1H), 3.56–3.49 (m, 1H), 3.30–3.15 (m, 3H), 2.87 (m, 2H), 
2.18 (m, 1H), 1.91–1.21 (complex, 18H), 1.13–1.05 (m, 4H, contains s, 1.08, 3H), 0.97 (m, 1H), 
0.90–0.80 (m, 1H), 0.79 (s, 3H). 0.67 (m, 1H); 13C NMR (101 MHz, CDCl3) δ 176.8, 135.9, 
132.1 (2C), 130.8 (2C), 119.9, 71.3, 53.4, 47.3, 46.2, 45.9, 44.5, 41.2, 38.1, 36.9, 35.7, 34.8, 
34.6, 31.6, 31.4, 31.0, 28.6, 26.8, 21.2, 20.3, 18.5, 12.4. HRMS (FT-ICR, HESI) m/z: [M + H]+ 
calcd for C28H41BrNO2S 534.2036, found 534.2028.   
 
 3-Hydroxy-1,3,5-estratriene-derived D-Ring Thioamide, 1.138. Following the general 
procedure G, 1.138 was prepared as a white amorphous solid (55.1 mg, 0.153 mmol, 51% yield, 
UPLC/HRMS purity: 92.0%). Purification was carried out by an automated MPLC system using 
a 12 g normal phase silica column with gradient elution from 0–1.5% MeOH/CH2Cl2. Rf = 0.40 
(5% MeOH/CH2Cl2); mp 216–219 ˚C; IR (neat) 3227, 1531, 1501 cm-1; 1H NMR (400 MHz, 
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DMSO-d6) δ 8.99 (s, 1H), 7.06 (d, J = 8.5 Hz, 1H), 6.52 (d, J = 8.5 Hz, 1H), 6.44 (s, 1H), 4.50 
(m, 1H), 4.02 (m, 1H), 3.78 (m, 1H), 3.63 (m, 1H), 3.51 (m, 1H), 3.43 (m, 2H), 2.70 (m, 3H), 
2.31 (m, 1H), 2.07 (m, 3H), 1.81 (m, 2H), 1.64–1.15 (complex, 6H), 1.08 (s, 3H); 13C NMR (126 
MHz, DMSO-d6) δ 207.8, 155.0, 137.0, 130.2, 126.0, 114.7, 112.8, 58.5, 52.2, 50.6, 45.2, 42.3, 
41.9, 39.3, 29.4, 28.2, 26.4, 25.8, 20.6, 20.4. Note: Missing one carbon signal due to signal 
overlap. HRMS (FT-ICR, HESI) m/z: [M + H]+ calcd for C21H30NO2S 360.1992, found 
360.1990.  
 
 3-Hydroxy-1,3,5-estratriene-derived D-Ring Oxazinane, 1.139. Following the general 
procedure G, 1.139 was prepared as a white amorphous solid (54.2 mg, 0.166 mmol, 83% yield, 
LCMS purity: ≥99.5%). Purification was carried out by an automated MPLC system using a 12 g 
normal phase silica column with gradient elution from 0–8% MeOH (0.5% NH4OH)/CH2Cl2. Rf 
= 0.20 (5% MeOH (0.5% NH4OH)/CH2Cl2); mp 206–212 ˚C; IR (neat) 2936, 2851, 1609, 1509 
cm-1; 1H NMR (400 MHz, DMSO-d6) δ 8.97 (s, 1H), 7.03 (d, J = 8.6 Hz, 1H), 6.50 (dd, J = 8.4, 
2.6 Hz, 1H), 6.42 (d, J = 2.6 Hz, 1H), 3.93 (m, 1H), 3.29 (m, 1H), 2.83–2.67 (m, 4H), 2.21 (m, 
1H), 2.12 (m, 1H), 2.05–1.90 (m, 3H), 1.84–1.68 (m, 2H), 1.56 (m, 1H), 1.40 (m, 1H), 1.30–1.10 
(complex, 6H), 1.03–0.96 (m, 1H), 0.89 (s, 3H); 13C NMR (126 MHz, DMSO-d6) δ 154.9, 137.0, 
130.4, 125.9, 114.7, 112.8, 101.1, 66.5, 53.9, 53.6, 47.3, 42.8, 37.9, 37.7, 35.5, 29.4, 25.7, 25.6, 





 3-Hydroxy-1,3,5-estratriene-derived D-Ring Oxazinane, 1.140. Following the general 
procedure G, 1.140 was prepared as a white amorphous solid (53.9 mg, 0.164 mmol, 82% yield, 
LCMS purity: ≥99.5%). Purification was carried out by an automated MPLC system using a 12 g 
normal phase silica column with gradient elution from 0–10% MeOH (0.5% NH4OH)/CH2Cl2. Rf 
= 0.20 (5% MeOH (0.5% NH4OH)/CH2Cl2); mp 212–215 ˚C; IR (neat) 2936, 2855, 1610, 1505 
cm-1; 1H NMR (400 MHz, DMSO-d6) δ 8.97 (s, 1H), 7.03 (d, J = 8.3 Hz, 1H), 6.50 (dd, J = 8.4, 
2.6 Hz, 1H), 6.42 (d, J = 2.6 Hz, 1H), 3.93 (m, 1H), 3.30 (m, 1H), 2.83 (m, 1H), 2.75–2.68 (m, 
3H), 2.21 (m, 1H), 2.12 (m, 1H), 2.05–1.89 (m, 3H), 1.84–1.68 (m, 2H), 1.55 (m, 1H), 1.40 (m, 
1H), 1.30–1.05 (complex, 5H), 1.02–0.96 (m, 1H), 0.89 (s, 3H); 13C NMR (126 MHz, DMSO-d6) 
δ 154.9, 137.0, 130.4, 125.9, 114.7, 112.8, 101.1, 66.5, 53.9, 53.6, 47.3, 42.8, 37.9, 37.6, 35.5, 
29.4, 25.7, 25.6, 25.4, 23.0, 13.6. HRMS (FT-ICR, HESI) m/z: [M + H]+ calcd for C21H29DNO2 
329.2334, found 329.2329.  
 
 3-Hydroxy-1,3,5-estratriene-derived D-Ring Lactam, 1.141. Following the general 
procedure G, 1.141 was prepared as an off-white amorphous solid (45.2 mg, 0.123 mmol, 82% 
yield, UPLC/HRMS purity: 94.5%). Purification was carried out by an automated MPLC system 
using a 4 g normal phase silica column with gradient elution from 0–30% EtOAc/hexanes. Rf = 
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0.50 (50% EtOAc/hexanes); mp 204–210 ˚C; IR (neat) 3323, 2098, 1619, 1607 cm-1; 1H NMR 
(400 MHz, DMSO-d6) δ 9.00 (s, 1H), 7.06 (d, J = 8.4 Hz, 1H), 6.51 (dd, J = 8.4, 2.7 Hz, 1H), 
6.43 (d, J = 2.6 Hz, 1H), 3.40–3.14 (complex, 6H), 2.72 (m, 2H), 2.28 (m, 1H), 2.11 (m, 2H), 
2.00 (m, 2H), 1.72 (p, J = 6.9 Hz, 2H), 1.61–1.11 (complex, 6H), 1.02 (s, 3H); 13C NMR (101 
MHz, DMSO-d6) δ 175.1, 155.0, 137.0, 130.2, 125.8, 114.6, 112.8, 48.6, 46.3, 43.8, 43.7, 42.3, 
40.5, 38.1, 34.4, 29.3, 25.9, 25.7, 25.5, 20.4, 17.9. HRMS (FT-ICR, HESI) m/z: [M + H]+ calcd 
for C21H29N4O2 369.2285, found 369.2283.  
 
 3-Hydroxy-1,3,5-estratriene-derived D-Ring Lactam, 1.142. Following the general 
procedure G, 1.142 was prepared as an off-white amorphous solid (40.6 mg, 0.0932 mmol, 62% 
yield, UPLC/HRMS purity: 97.8%). Purification was carried out by an automated MPLC system 
using a 12 g normal phase silica column with gradient elution from 0–60% EtOAc/hexanes. Rf = 
0.63 (50% EtOAc/hexanes); mp 209–215 ˚C; IR (neat) 3053, 1560, 1585 cm-1; 1H NMR (400 
MHz, DMSO-d6) δ 9.01 (s, 1H), 7.32 (m, 4H), 7.19 (m, 1H), 7.05 (d, J = 8.5 Hz, 1H), 6.51 (dd, J 
= 8.4, 2.6 Hz, 1H), 6.44 (d, J = 2.6 Hz, 1H), 3.41 (m, 1H), 3.32–3.19 (m, 4H), 2.91 (m, 2H), 2.72 
(m, 2H), 2.26 (m, 1H), 2.10 (m, 2H), 1.98 (m, 1H), 1.76 (p, J = 7.2 Hz, 2H), 1.57–1.14 
(complex, 6H), 1.01 (s, 3H); 13C NMR (126 MHz DMSO-d6) δ 175.2, 155.0, 137.0, 136.3, 130.2, 
129.1 (2C), 128.0 (2C), 126.0, 125.6, 114.7, 112.8, 46.5, 45.4, 43.8, 42.3, 40.5, 38.1, 34.4, 29.7, 
29.4, 26.3, 25.8, 25.6, 20.4, 18.0. HRMS (FT-ICR, HESI) m/z: calcd for C27H34NO2S [M + H]+ 




 3-Hydroxy-1,3,5-estratriene-derived D-Ring Lactam, 1.143. Following the general 
procedure G, 1.143 was prepared as a white amorphous solid (40.2 mg, 0.0894 mmol, 60% yield, 
UPLC/HRMS purity: 99.0%). Purification was carried out by an automated MPLC system using 
a 12 g normal phase silica column with gradient elution from 0–50% EtOAc/hexanes. Rf = 0.50 
(50% EtOAc/hexanes); mp 208–212 ˚C; IR (neat) 3282, 1602 cm-1; 1H NMR (400 MHz, DMSO-
d6) δ 9.00 (s, 1H), 7.22 (m, 2H), 7.13 (m, 2H), 7.05 (d, J = 8.4 Hz, 1H), 6.51 (dd, J = 8.4, 2.6 Hz, 
1H), 6.44 (d, J = 2.6 Hz, 1H), 3.39 (m, 1H), 3.29–3.16 (m, 3H), 2.86 (m, 2H), 2.72 (m, 2H), 
2.32–2.25 (m, 4H, contains s, 2.26, 3H), 2.10 (m, 2H), 1.97 (m, 2H), 1.72 (p, J = 7.2 Hz, 2H), 
1.60–1.14 (complex, 6H), 1.00 (s, 3H); 13C NMR (126 MHz, DMSO-d6) δ 175.1, 155.0, 137.0, 
135.3, 132.4, 130.2, 129.7 (2C), 128.9 (2C), 126.0, 114.7, 112.8, 46.4, 45.4, 43.8, 42.3, 40.5, 
38.1, 34.4, 30.4, 29.4, 26.4, 25.8, 25.6, 20.5, 20.4, 18.0. HRMS (FT-ICR, HESI) m/z: [M + H]+ 
calcd for C28H36NO2S 450.2461, found 450.2458.  
 
 3-Hydroxy-1,3,5-estratriene-derived D-Ring Lactam, 1.144. Following the general 
procedure G, 1.144 was prepared as an off-white crystalline solid (44.0 mg, 0.0945 mmol, 63% 
yield, UPLC/HRMS purity: ≥99.5%). Purification was carried out by an automated MPLC 
system using a 12 g normal phase silica column with gradient elution from 0–80% 
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EtOAc/hexanes. Rf = 0.38 (50% EtOAc/hexanes); mp 206–209 ˚C; IR (neat) 3301, 1618, 1606 
cm-1; 1H NMR (400 MHz, DMSO-d6) δ 9.00 (s, 1H), 7.32 (m, 2H), 7.05 (d, J = 8.4 Hz, 1H), 6.91 
(m, 2H), 6.51 (dd, J = 8.4, 2.6 Hz, 1H), 6.44 (d, J = 2.6 Hz, 1H), 3.74 (s, 3H), 3.37 (m, 1H), 
3.29–3.16 (m, 3H), 2.78 (m, 2H), 2.72 (m, 2H), 2.27 (m, 1H), 2.11 (m, 2H), 1.98 (m, 2H), 1.69 
(p, J = 7.2 Hz, 2H), 1.59–1.16 (complex, 6H), 1.00 (s, 3H); 13C NMR (126 MHz, DMSO-d6) δ 
175.1, 158.3, 155.0, 137.0, 132.2 (2C), 130.2, 125.97 (2C), 125.91, 114.8, 114.7, 112.8, 55.2, 
46.4, 45.3, 43.8, 42.3, 40.5, 38.1, 34.4, 32.0, 29.4, 26.4, 25.8, 25.6, 20.4, 18.0. HRMS (FT-ICR, 
HESI) m/z: [M + H]+ calcd for C28H36NO3S 466.2410, found 466.2408. 
 
 3β-Hydroxy-5α-androstane-derived D-Ring Lactam, 1.145. Following the general 
procedure H, 1.145 was prepared as a white amorphous solid (81.7 mg, 0.167 mmol, 83% yield, 
UPLC/HRMS purity: 98.9%). Purification was carried out by an automated MPLC system using 
a 12 g normal phase silica column with gradient elution from 0–5% MeOH/CH2Cl2. Rf = 0.25 
(3% MeOH/CH2Cl2); mp 197–202 ˚C; IR (neat) 3400, 1619 cm-1; 1H NMR (400 MHz, CDCl3) δ 
7.93 (s, 1H), 7.84 (m, 2H), 7.41 (m, 2H), 7.32 (m, 1H), 4.40 (m, 2H), 3.58 (m, 1H), 3.42 (m, 
2H), 3.30–3.15 (m, 2H), 2.36–2.13 (m, 3H), 1.87 (m, 1H), 1.69 (m, 2H), 1.72–1.10 (complex, 
12H), 1.06–0.98 (m, 4H, contains s, 1.06, 3H), 2.93 (s, 3H) 0.50 (m, 1H); 13C NMR (101 MHz, 
CDCl3) δ 172.3, 147.7, 130.8, 128.9 (2C), 128.2, 125.9 (2C), 120.4, 71.3, 53.1, 48.5, 47.3, 45.6, 
44.8, 44.3, 41.2, 38.1, 36.7, 35.6, 34.8, 34.5, 31.5, 30.9, 28.6, 27.7, 21.0, 20.2, 18.4, 12.3. HRMS 




 3β-Hydroxy-5α-androstane-derived D-Ring Lactam, 1.146. Following the general 
procedure H, 1.146 was prepared as a white amorphous solid (74.9 mg, 0.152 mmol, 84% yield, 
UPLC/HRMS purity: 97.9%). Purification was carried out by an automated MPLC system using 
a 12 g normal phase silica column with gradient elution from 0–5% MeOH/CH2Cl2. Rf = 0.16 
(5% MeOH/CH2Cl2); mp 190–194 ˚C; IR (neat) 3353, 1640, 1609 cm-1; 1H NMR (400 MHz, 
CDCl3) δ 9.04 (s, 1H), 8.57 (m, 1H), 8.19 (m, 1H), 8.08 (s, 1H), 7.36 (ddd, J = 7.9, 4.8, 0.8 Hz,) 
4.42 (m, 2H), 3.59 (m, 1H), 3.50–3.17 (m, 4H), 2.34–2.12 (m, 3H), 1.91 (m, 1H), 1.83 (m, 1H), 
1.71 (m, 2H), 1.62–1.15 (complex, 11H), 1.08–0.99 (m, 4H, contains s, 1.08, 3H), 0.95–0.79 (m, 
2H), 0.77 (s, 3H), 0.54 (m, 1H); 13C NMR (101 MHz, CDCl3) δ 177.4, 149.3, 147.3, 144.6, 
133.1, 127.0, 123.8, 120.9, 71.2, 53.2, 48.5, 47.3. 45.7, 44.6, 44.4, 41.3, 38.1, 36.8, 35.6, 34.8, 
34.6, 31.5, 30.9, 28.6, 27.8, 21.1, 20.2, 18.5, 12.3. HRMS (FT-ICR, HESI) m/z: [M + H]+ calcd 
for C29H42N5O2 492.3333, found 492.3322.   
 
 3β-Hydroxy-5α-androstane-derived D-Ring Lactam, 1.147. Following the general 
procedure H, 1.147 was prepared as a white foam/crystalline solid (81.5 mg, 0.164 mmol, 91% 
yield, UPLC/HRMS purity: 95.9%). Purification was carried out by an automated MPLC system 
using a 12 g normal phase silica column with gradient elution from 0–5% MeOH/CH2Cl2. Rf = 
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0.35 (5% MeOH/CH2Cl2); mp 140–144 ˚C; IR (neat) 3345, 1622 cm-1; 1H NMR (500 MHz, 
CDCl3) δ 7.83 (s, 1H), 7.68 (m, 1H), 7.46 (m, 1H), 7.37 (m, 1H), 4.38 (m, 2H), 3.59 (tt, J = 10.7, 
4.8 Hz, 1H), 3.41 (m, 2H), 3.28–3.15 (m, 2H), 2.28 (m, 1H), 2.16 (m, 2H), 1.88 (m, 1H), 1.82–
1.67 (m, 3H), 1.60–1.18 (complex, 11H), 1.12 (m, 1H), 1.06–1.00 (m, 4H, contains s, 1.06, 3H), 
0.91 (m, 1H), 0.85–0.78 (m, 1H), 0.76 (s, 3H), 0.50 (m, 1H); 13C NMR (126 MHz, CDCl3) δ 
177.3 143.9, 132.0, 126.4, 126.0, 121.1, 120.2, 71.3, 53.0, 48.5, 47.3, 45.5, 44.8, 44.3, 41.1, 38.1, 
36.7, 35.6, 34.7, 34.5, 31.5, 30.9, 28.6, 27.6, 21.0, 20.2, 18.4, 12.3. HRMS (FT-ICR, HESI) m/z: 
[M + H]+ calcd for C28H41N4O2S 497.2945, found 497.2936.   
 
 3-Hydroxy-1,3,5-estratriene-derived D-Ring Lactam, 1.148. Following the general 
procedure H, 1.148 was prepared as a white crystalline/amorphous solid (58.8 mg, 0.125 mmol, 
63% yield, UPLC/HRMS purity: ≥99.5%). Purification was carried out by an automated MPLC 
system using a 12 g normal phase silica column with gradient elution from 30–85% 
EtOAc/hexanes. Rf = 0.30 (80% EtOAc/hexanes); mp 217–223 ˚C; IR (neat) 3363, 1593 cm-1; 1H 
NMR (400 MHz, DMSO-d6) δ 9.00 (s, 1H), 8.60 (s, 1H), 7.84 (m, 2H), 7.44 (m, 2H), 7.32 (m, 
1H), 7.04 (d, J = 8.5 Hz, 1H), 6.51 (dd, J = 8.4, 2.6 Hz, 1H), 6.44 (d, J = 2.6 Hz, 1H), 4.37 (t, J = 
7.0 Hz, 1H), 3.39–3.35 (m, 2H), 3.29–3.21 (m, 2H), 2.71 (m, 2H), 2.25 (m, 1H), 2.16–2.06 (m, 
5H), 1.98 (m, 2H), 1.59–1.17 (complex, 6H), 1.02 (s, 3H); 13C NMR (126 MHz, DMSO-d6) δ 
175.4, 155.0, 146.3, 137.0, 130.4, 130.2, 128.9 (2C), 127.8, 126.0, 125.1 (2C), 121.4, 114.7, 
112.8, 47.7, 46.3, 43.8, 43.7, 42.2, 40.5, 38.1, 34.3, 29.4, 27.2, 25.8, 25.6, 20.4, 18.0. HRMS 




 3β-Hydroxy-5α-androstane-derived D-Ring Lactam, 1.88.  To a solution of 1.117 
(85.0 mg, 0.200 mmol) in anhydrous THF (4.0 mL) was condensed liquid NH3 (~15 mL) at –78 
˚C. To the cooled solution was added pieces of sodium metal until the solution turned blue. The 
blue solution was stirred at –78˚C for 2 h, and was quenched by adding solid NH4Cl slowly (until 
the disappearance of blue). The resulting mixture was diluted with H2O (20 mL) and EtOAc (30 
mL). The organic layer was washed with brine, dried over anhydrous Na2SO4, filtered, and 
concentrated. Purification was carried out by an automated MPLC system using a 12 g normal 
phase silica column with gradient elution from 0–5% MeOH/CH2Cl2 to afford 1.88 as a white 
amorphous solid (56.8 mg, 0.186 mmol, 93% yield, UPLC/HRMS purity: ≥99.5%). 
Characterization data were consistent to 1.88 synthesized via the Beckmann rearrangement. 
HRMS (FT-ICR, HESI) m/z: [M + H]+ calcd for C19H32NO2 306.2428, found 306.2423.   
 
 3β-Hydroxy-5α-androstane-derived D-Ring Lactam, 1.149.  To a solution of 1.118 
(57.2 mg, 0.134 mmol) in anhydrous THF (4.0 mL) was condensed liquid NH3 (~15 mL) at –78 
˚C. To the cooled solution was added pieces of sodium metal until the solution turned blue. The 
blue solution was stirred at –78 ˚C for 2 h, and was quenched by adding solid NH4Cl slowly 
(until the disappearance of blue). The resulting mixture was diluted with H2O (20 mL) and 
EtOAc (30 mL). The organic layer was washed with brine, dried over anhydrous Na2SO4, 
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filtered, and concentrated. Purification was carried out by an automated MPLC system using a 12 
g normal phase silica column with gradient elution from 0–5% MeOH/CH2Cl2 to afford 1.149 as 
a white amorphous solid (37.1 mg, 0.121 mmol, 90% yield, UPLC/HRMS purity: ≥99.5%). Rf = 
0.26 (4% MeOH/CH2Cl2); IR (neat) 3378, 1646 cm-1; mp 253–256 ˚C; 1H NMR (400 MHz, 
CDCl3) δ 5.52 (s, 1H), 3.59 (tt, J = 10.7, 4.8 Hz, 1H), 3.34 (m, 1H), 3.24 (m, 1H), 2.14 (m, 1H), 
1.91–1.72 (m, 3H), 1.67–1.21 (complex, 12H), 1.14 (s, 3H), 1.12–1.05 (m, 1H), 1.00–0.83 (m, 
2H), 0.80 (s, 3H), 0.69 (m, 1H); 13C NMR (101 MHz, CDCl3) δ 179.2, 71.3, 53.5, 46.0, 44.4, 
41.6, 41.1, 38.1, 36.8, 35.8, 34.6, 34.0, 31.6, 31.2, 28.6, 20.5, 20.1, 18.4, 12.4. HRMS (FT-ICR, 
HESI) m/z: [M + H]+ calcd for C19H32NO2 306.2428, found 306.2423.   
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New Variations of the Schmidt Reaction 
2.1 Introduction 
2.1.1 The Schmidt Reaction 
 The “Schmidt reaction” is a family of related transformations that involves the reaction of 
hydrazoic acid (HN3; generally formed in situ from sodium azide (NaN3)) or alkyl azides with an 
electrophile to prepare various types of nitrogen-inserted products.1-2 In 1923, Karl F. Schmidt 
first reported the Schmidt reaction as a method for preparing amides from sulfuric acid (H2SO4)-
promoted treatment of HN3 with carbonyl reactants. Thus, the phrase “classical Schmidt reaction” 
is loosely defined as reactions that specifically combine HN3 with ketones or aldehydes (Scheme 
2.1). The mechanism of the classical Schmidt reaction is shown in Figure 2.1.1-2 The initial 
nucleophilic attack of HN3 onto the acid-activated ketone leads to the formation of an azidohydrin 
intermediate. At this point, the reaction may proceed via one of two routes to afford the 
corresponding amide. In path a, analogous to that of the Baeyer-Villiger reaction, direct 
rearrangement proceeds through concomitant migration of the antiperiplanar carbon and 
elimination of the nitrogen leaving group. Alternatively, as shown as path b, initial dehydration 
affords a diazoiminium species which subsequently rearranges to form an iminium ion (drawn in 
two resonance forms: iminocarbonium or nitrilium ion); the iminium ion becomes hydrated to give 
the final lactam product. Path b mechanism was originally proposed by Peter A. S. Smith in the 
1940s and is related to that of the Beckmann rearrangement.3 Mechanism b is commonly preferred 
for a several reasons: (1) the correlation of the migrating group size with antiperiplanar migration 
is resultant from the formation of the least sterically hindered diazoiminium ion (i.e., migratory 
aptitude), and (2) the synthesis of tetrazole byproducts indicates involvement of the iminium ion 
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intermediates. The reaction of such intermediates with a second nucleophilic azide produces a 
tetrazole (tetrazoles are more commonly seen when excess amounts of azide and ketone substrates 
are used).  
 
Scheme 2.1. The classical Schmidt reaction.  
 
 
Figure 2.1. Mechanism of the Schmidt reaction between cyclohexanone and HN3.  
 
 The Schmidt reaction is a useful transformation for the synthesis of nitrogenous 
compounds. Despite this broad utility, the reaction remains underutilized in the synthetic 
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community for a number of reasons. One practical limitation affecting nearly every version of the 
Schmidt reaction has been the requirement of using super-stoichiometric amounts of acid catalysts 
for high product conversions, which unfortunately renders the reaction unsuitable for acid-
sensitive substrates, as well as restricting scalability. This issue is mainly attributed to the product 
being a strong Lewis basic amide, which sequesters catalyst deterring reaction progress and 
requiring use of excess acid. In 2013, a former research group member, Dr. Hashim F. Motiwala, 
discovered that a strong hydrogen-bond-donating solvent, hexafluoro-2-isopropanol (HFIP), 
promotes catalysis in the intramolecular Schmidt reaction and reduces the amount of acid 
equivalents necessary for mediating this reaction (Figure 2.2a).4 Originally, this transformation 
was invented by Milligan and Aubé in 1991, and they used super-stoichiometric amounts (>3.0 
equiv) of titanium (IV) chloride (TiCl4) to facilitate high reaction conversions.5 The recent report 
by Motiwala el al. is a significant advancement because the authors demonstrated that (1) HFIP 
aided in overcoming the complexation formed between the catalyst and product that typically 
inhibited catalyst turnover (Figure 2.2b), and (2) HFIP was key to high conversions using low 
loadings of HCl generated in situ from dissolving procatalysts, acetyl chloride (AcCl) or TiCl4, in 
the solvent.  
 Another critical drawback of the classical Schmidt reaction is associated with the use of 
toxic and explosive HN3, which in recent years have been replaced with azidotrimethylsilane 
(TMSN3) as a more convenient azide source. Although, like any other azide source TMSN3 
requires safe handling, it is more stable and commercially available than HN3, and avoids the need 
for in situ generation of the latter.6 Altogether, we envisioned that the shortcomings of the Schmidt 
reaction could be circumvented by developing modern variants of these reaction types. Herein, we 
envisage starting this program with replacements of traditional solvents and azide sources with 
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HFIP and TMSN3 that could aid in the development of milder and new variations of these reaction 
types. These alterations could entail (1) reducing the amounts of catalyst equivalents, (2) reducing 
reaction times, and (3) enhancing substrate scope.  
 
 
Figure 2.2. The intramolecular Schmidt reaction of azidoalkyl ketones mediated by HFIP. (a) The 
catalytic intramolecular Schmidt reaction of azidoalkyl ketones. (b) Proposed catalytic cycle using 
HFIP as solvent to overcome product inhibition of catalyst regeneration (adapted from Motiwala 
et al.4).  
 
 In this chapter, I focus on development of a new variation of the Schmidt reaction, 
specifically the “interrupted Schmidt” reaction. This work arose from initial collaborative efforts 
with Dr. Motiwala to determine whether other types of Schmidt reactions (other than the 
intramolecular Schmidt reaction) could benefit in yield and scope, or lead to changes in reactivity 
and reaction profile from being carried out in HFIP media (Scheme 2.2a).7 One main conclusion 
from this collaborative study was that HFIP is indeed an attractive medium for carrying out 
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synthetic variants of the Schmidt reaction. Particularly, we learned that the reaction of ketone with 
TMSN3 in HFIP led to a change in product profile where selectivity was observed for tetrazole 
over lactam as compared to those reactions carried out traditional solvents (discussion of this work 
in Section 2.2). Moreover, we believe that HFIP either stabilizes or renders more reactive the 
iminium ions (iminocarbonium or nitrilium ion) formed in the proposed step-wise rearrangement 
proceeding via path b mechanism. This work led to a hypothesis: HFIP may enable 
iminocarbonium or nitrilium ion reactivity with various nucleophiles and allow extension of the 
Schmidt reaction pathway towards the synthesis of new heterocycles (Scheme 2.2b). To test this 
hypothesis, I showed that it was possible to interrupt the classical Schmidt reaction between 
ketones and TMSN3 in HFIP media using 1,3,5-trimethoxybenzene (1,3,5-TMB) as the 
nucleophile. This concept of diverting the classical Schmidt reaction from its normal pathway with 
an added reagent has been phrased the “interrupted Schmidt reaction”. Traditionally, the iminium 
ions prepared through the Schmidt reaction have only been reacted with water leading to a lactam 
product and azide leading to a tetrazole product. We envisioned that intercepting the iminium ion 




Scheme 2.2. Remodeling the Schmidt reaction pathways in HFIP. (a) Collaborative study about 
the effect of HFIP on the reaction of ketones with TMSN3 and hydroxyalkyl azide. (b) 
Development of the “interrupted Schmidt reaction” concept.  
 
2.1.2 Examples of “Interrupted Reactions” 
Interrupted Beckmann and Schmidt reactions  
 Evidence for iminium intermediates generated via either the Beckmann or Schmidt 
reactions have been reported in the literature.8 For example, nitrilium ions observed via the 
Beckmann rearrangement of oximes have been isolated and characterized as tosylate-imines or 
pyridine-imine cations by a number of researchers (Scheme 2.3).9-12 Although examples other than 
the traditional hydrolysis to amide or lactam outcome exists, these representative examples from 
the early literature are typically products generated from nucleophiles that arise from the acid 
counterion (e.g., tosylate) or solvent (e.g., pyridine, methanol). In 1982, Yamamoto and coworkers 
238 
 
described a route to iminoethers, imino selenoethers, and imino nitriles from oxime sulfonates 
using organoaluminum reagents.13 To my knowledge, this was the first example of methodology 
development that aimed to extend the nucleophile scope of the Beckmann rearrangement. In this 
work, organoaluminum reagents were applied to “attach” or capture the intermediate cation with 
various nucleophiles, particularly these reagents dually acted to promote the Beckmann 
rearrangement and trap the iminocarbocation (Scheme 2.4a).   
In 1991, Schinzer and coworkers demonstrated the synthesis of heterocycles by carrying 
out tandem reactions of the Beckmann rearrangement and an intramolecular Sakurai reaction.14-16 
In this sequence, diisobutylaluminum hydride (DIBAH) first induces the rearrangement, giving a 
ring-expanded intermediate, which is then intramolecularly trapped by allylsilane as shown in 
Scheme 2.4b. Besides Schinzer’s endeavor, there are relatively few examples of the interrupted 
Beckmann reaction with olefins and allylsilanes, and most of which are examples that were 
intramolecularly designed.17-18   
Only a few interrupted Schmidt ring-expansion reactions are known. An early example was 
demonstrated in a report where the iminocarbocation was intercepted with trifluoroacetate or 
trichloroacetate counterions of the reagents used to promote the Schmidt reaction of flavonoids 
(Scheme 2.5a).19 More recently Ghorai described the trapping of an azidocarbenium ion derived 
from an aldehyde precursor20 (Scheme 2.5b) and Chiba reported accidental intramolecular trapping 







Scheme 2.3. Iminium intermediates observed in early Beckmann rearrangement literature. The 
scheme was adapted from Gawley.8 (a) 2-Arylcyclohexanone oxime tosylate solvolyzed in 
pyridine. (b) Treatment of oxime with p-toluene sulfonyl chloride (TsCl) in pyridine. (c) Treatment 
of oxime tosylate in mild Lewis acid (e.g., silica, alumina) affords tosyl-caprolactam. (d) 
Cycloheptanone oxime tosylate solvolyzed in methanol affords the ring-expanded ether.  
 
 
Scheme 2.4. Examples of the interrupted Beckmann reaction. (a) Yamamoto’s organoaluminum-





Scheme 2.5. Examples of the interrupted Schmidt reaction. (a) Synthesis of iminoesters. (b) 
Trapping of azidocarbenium ion with triethylsilane. (c) Trapping of nitrilium ion with tosyl amine.  
 
 
Interrupted Nazarov reaction  
 The Nazarov reaction is an intramolecular 4π-electrocyclic ring closure of a conjugated 
dienone (divinyl ketone) substrate into a cyclopentanone and is catalyzed by strong Lewis or 
Brønsted acids.22-23 Conventionally, upon ring closure, the five-membered oxyallyl cation 
undergoes elimination through loss of E-hydrogen and enol tautomerization to form the 
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cyclopentanone product (Scheme 2.6a). Since its discovery, new methods have been developed to 
intercept the oxyallyl cation with various carbon- or heteroatom-based nucleophiles leading to a 
wide array of functionalized cyclopentanones.22-23 For example, West and coworkers described 
examples using the thermal Nazarov cyclization to perform cationic cyclizations. In Scheme 2.6b, 
upon electrocyclic conrotatory closure, cation-olefin cyclization resulted in a stereoselective 
polycyclic product.24 This seminal work and other reports by West inspired broad development of 
scope using various nucleophilic trapping groups with the oxyallyl cation intermediate, which 
included amongst other olefins, arenes, and heteroarenes nucleophiles (Scheme 2.6c).22-23  
 
Scheme 2.6. Classical and modern variants of the Nazarov reaction. (a) The classical Nazarov 
reaction. (b) The first interrupted thermal Nazarov reaction developed by Fredrick G. West. (c) 








 Sporadic examples of the interrupted Fischer indolization reactions have been reported in 
the literature over the past 50 years.25-27 Recently, Garg and coworkers developed a general 
approach to access the indoline scaffold shown in Scheme 2.7.27-29 Here, the implementation of 
the interrupted Fischer indolization process led to the formation of two heterocyclic rings, three 
new bonds, and two new stereogenic centers. The authors used this methodology to prepare 
indoline scaffolds representative in general complex natural products.27-29  




2.2 Enhancing and Remodeling the Schmidt Reaction Pathways in HFIP 
2.2.1 The Reaction of Ketone with Azidotrimethylsilane in HFIP  
 In 2013, Dr. Motiwala reported that HFIP as a solvent improved the outcome of the 
intramolecular Schmidt reaction, particularly by aiding in overcoming catalyst sequestration by 
Lewis basic amide products.4 The use of HFIP allowed catalyst turnover, and accordingly, 
permitted the use of low catalyst loadings, which led to better yields as compared to those in the 
original report (TiCl4 in CH2Cl2).5 With this new condition in hand, Dr. Motiwala and I 
investigated the effect of HFIP solvent on two other variants of the Schmidt reaction: the reaction 
of ketones with (1) TMSN3 and (2) hydroxyalkyl azide (Scheme 2.2a above). Specifically, Dr. 
Motiwala examined the reactions of ketones with TMSN3, while I studied those with hydroxyalkyl 
azide. The studies carried out in the following section were published in the Journal of Organic 
Chemistry in 2016.7 We instituted this study with the straightforward goal of simply determining 
whether HFIP-modified conditions could lead to improvements in catalyst loading, yield, and 
scope. Unexpectedly, this study also led to alterations in the reaction profile and product outcome 
of the reaction of ketone with TMSN3. In this section, I provided a brief overview to Dr. 
Motiwala’s study because these experiments were critical towards to the design and development 
of the interrupted Schmidt reaction. Mainly, the change in reaction pathway along with the 
observation of certain side-products prompted a plausible hypothesis towards various diversions 
in reaction pathway from the classical Schmidt reaction pathway.  
 Generally, the classical Schmidt reaction of ketones with an azide (HN3, NaN3 or TMSN3) 
yields amides or lactams as the major products, while tetrazoles are usually observed as the minor 
byproducts.1-2 The formation of tetrazoles has received less attention employing the Schmidt 
methodology because excess amounts of azide are required for its synthesis, and the prevalence of 
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such heterocycles are highly dependent on the reaction conditions and ketone structures. To our 
surprise, Dr. Motiwala determined that the formation of tetrazoles was the preferred outcome in 
HFIP media during the reactions of ketones with TMSN3 regardless of stoichiometry. Following 
optimization studies, triflic acid (TfOH) was identified as the optimal acid catalyst for the 
transformation of ketones to tetrazoles at room temperature. For example (Scheme 2.8), 4-
phenylcyclohexanone 2.1 was reacted with 2.5 equiv of TMSN3 to afford tetrazole 2.2 in high 
yield, while aminotetrazole 2.3 and lactam 2.4 were observed as minor byproducts (2.3 resulting 
from two ring expansions). This protocol represents a significant advance over Nishiyama’s report, 
which described the synthesis of tetrazoles using 10 mol% tin (II) chloride dihydrate (SnCl2yH2O) 
and 3.0 equiv of TMSN3 under solvent-free conditions at an elevated temperature of 55 ˚C for 16 
h.30 A report by Yadav and coworker described the synthesis of only lactam products from ketones 
with 1.5 equiv of TMSN3 using 1.0 equiv of iron (III) chloride (FeCl3) in 1,2-dichloroethane (DCE) 
in moderate yields.31 For comparison, Motiwala et al. carried out a similar reaction to Yadav and 
coworkers using FeCl3 in HFIP, which gave a 60% isolated yield of tetrazole 2.2.  
 
Scheme 2.8. HFIP-modified reaction between 4-phenylcyclohexanone 2.1 and TMSN3.  
 
 
Overall, Dr. Motiwala obtained a range of tetrazoles in modest yields in this study.7 This 
diversion of the reaction pathway to favor tetrazoles over lactams as the primary reaction product 
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suggests that the intermediate iminocarbonium or nitrilium ions are better stabilized or rendered 
more reactive in HFIP that in traditional reaction solvents. This possibility is consistent with the 
fact that HFIP is a highly polar and ionizing solvent.32 Seemingly, the properties of HFIP allow 
persistent reactivity of carbocation with a second nucleophile azide, which also explains the 
increased amounts of the “double Schmidt” aminotetrazole byproducts. Interestingly, the 
formation of aminotetrazoles was consistently observed as minor byproducts throughout this 
investigation (Figure 2.3). Although substituted aminotetrazoles are known in the literature33-36 
and represent a unique heterocyclic scaffold, they are rarely observed and prepared from the 
Schmidt reaction.2  
 
 
Figure 2.3. Proposed mechanism for aminotetrazole 2.3 formation. The figure was adapted from 
Motiwala et al.7 
  
 The product profile of the reaction of flavanone was mechanistically intriguing in so far as 
it afforded tetrazole in moderate yields along with three unusual minor products. These byproducts 
246 
 
(shown in Scheme 2.9) an iminoether, guanyl azide (a doubly ring expanded product), and 
aminobenzoxazole were obtained presumably through an intra- and intermolecular trapping of the 
nitrilium ion with either HFIP or azide. Iminoether arising from HFIP trapping of the nitrilium ion 
is related to the formation of iminoesters, which was previously documented as the major product 
upon treatment of flavanone with NaN3 in trifluoroacetic acid (see Scheme 2.5a above).19 The 
intramolecular trapping of the aminonitrilium or amino-iminocarbonium ion with azide 
nucleophile led to the formation of guanyl azide. In principle, this product should cyclize to afford 
the aminotetrazole, however this was not the case (transient stability of certain iminium 
intermediates has been noted for specific cases in old literature).37 The formation of 
aminobenzoxazole is mechanistically fascinating, because it is formed after two sequential 
Schmidt reactions. Specifically following the second ring expansion, the oxygen atom interacts 
intramolecularly with the iminium intermediate, which subsequently becomes hydrated leading to 
the final aminobenzoxazole (Figure 2.4). The formation of aminobenzoxazole has been reported 
to arise from the Schmidt reaction of substituted flavanones with NaN3.38  
 
Scheme 2.9. Byproducts obtained from the reaction of flavanone with TMSN3 in HFIP. The 





Figure 2.4. Proposed mechanism for guanyl azide and aminobenzoxazole formation. The figure 
was adapted from Motiwala et al.7  
 
2.2.2 The Reaction of Ketone with 3-Azidopropanol in HFIP.  
 In this section, I describe work toward improving the Schmidt reaction of ketones with 
hydroxyalkyl azide 1.1 to prepare N-hydroxyalkyl lactams.39-40 This variant was originally 
developed to overcome the poor reactivity and scoped associated with the TiCl4-promoted 
intermolecular Schmidt reaction of alkyl azides (e.g., n-hexyl, benzyl azides) with ketones.41-42 
Since then, this reaction has been applied towards asymmetric ring expansion reactions and 
developments of screening collections as discussed in Chapter 1.  
 Originally, this version of the Schmidt reaction required 2.0–5.0 equiv of boron trifluoride 
diethyl etherate (BF3yOEt2) in dichloromethane (CH2Cl2) to achieve successful iminium ether 
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formation over extended reaction times.39-40 However, in principle, only 1.0 equiv of the acid 
promoter should be sufficient to promote the reaction to completion as only 1.0 equiv of counterion 
should be necessary to stabilize the iminium ether intermediate. Thus, carrying out this 
transformation with minimally 1.0 equiv of acid promoter over a short time period would constitute 
as a significant and practical improvement to prepare the iminium ether intermediate.  
 We began optimization by comparing the standard BF3yOEt2-promoted reaction of 4-
phenylcyclohexanone 2.1 with 3-azidopropanol 1.1 in the presence of CH2Cl2 or HFIP at room 
temperature (entries 1–3, Table 2.1). In this optimization study, the iminium ether intermediate 
was hydrolyzed with a saturated solution of sodium bicarbonate (NaHCO3). Compared to CH2Cl2, 
the use of HFIP efficiently promoted the reaction in 6 h requiring just 1.1 equiv of BF3yOEt2 for 
good conversions (cf. entries 1 and 2 with entry 3). In previous reports,39-40 other Lewis and protic 
acids could be used in place of BF3yOEt2; accordingly, expanding our screen to other acid sources 
(entries 4–7) revealed that 1.0 equiv of TfOH in HFIP was sufficient to afford a complete 
conversion from 2.1 to the corresponding iminium ether within a 1 h reaction time. Following 











Table 2.1. Optimization of conditions for the reaction of 4-phenylcyclohexanone 2.1 with 3-








1H NMR ratio 
2.5:2.1c 
yield (%)d 
1 2.0 BF3yOEt2 2.0 CH2Cl2 24 88:12 82e 
2 1.5 BF3yOEt2 1.1 CH2Cl2 6 73:27 62 
3 1.5 BF3yOEt2 1.1 HFIP 6 >98:2 92 
4 1.5 H2SO4 0.55f HFIP 6 71:29 62 
5 1.5 TiCl4 0.28f HFIP 6 >97:3 89 
6 1.5 CH3COCl 1.1f HFIP 6 >95:5 85 
7 1.5 CF3SO3H 1.0 HFIP 1 >98:2g 95 
aTo a solution of 4-phenylcyclohexanone 2.1 (1.0 equiv) and 3-azidopropanol 1.1 in solvent (0.75 mL) 
at room temperature was added a catalyst and reaction mixture was allowed to stir for a specified time. 
Further hydrolysis with aqueous NaHCO3 for 12–14 h followed by purification on a silica gel afforded 
product 2.5. bConcentration of reaction mixture ca. 0.40 M. c1H NMR ratio of crude reaction mixture. 
dIsolated yield. eThe yield of 88% has been reported when the reaction was allowed to stirred for 48 h.40 
fAcetyl chloride is known to generate an equimolar amount of HCl upon dissolution in HFIP.4 gComplete 
conversion of 2.1 to 2.5 was observed as determined by 1H NMR of a crude reaction mixture.  
 
 Encouraged by these initial results, we subjected a selection of ketones to the optimized 
conditions (Table 2.2). Reaction of simple cyclohexanones afforded very high yields of N-
hydroxyalkyl lactams in 1–6 h (entries 1–4). In entry 1, unsubstituted cyclohexanone 2.6 was 
converted to lactam 2.7 in an excellent yield in just 1 h; similarly in entry 2, a mixture of isomeric 
dimethylcyclohexanones 2.8 afforded the corresponding lactams 2.9 in 94% yield. Functionalized 
six-membered cyclic ketones such as tetrahydropyran-4-one 2.10 and 1-benzoyl-4-piperidone 
2.12, each having a functional group capable of catalyst deactivation, still underwent facile 
conversion to their corresponding lactams within 6 h in good yields (entries 3 and 4, respectively). 
Previously, seven- and eight-membered cyclic ketones had required relatively harsh conditions 
(5.0 equiv of BF3yOEt2 in refluxing CH2Cl2 for 72 h) to get either lactam or amino-lactone 
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depending on the base (NaHCO3 or NaOH) used in the hydrolysis step.43 Application of the HFIP-
methodology to cycloheptanone 2.14 provided a moderate yield of the corresponding lactam 2.15 
upon hydrolysis with NaOH (entry 5). The reaction of cyclooctanone 2.16 afforded the 
corresponding macrocyclic amino-lactone 2.17 exclusively, and in a higher yield than previously 
reported (entry 6).43 The reaction of benzylic ketones provided lactams in excellent yield (entry 7 
and 8); however, unsymmetrical E-tetralone 2.18 gave an isomeric mixture of lactams as ca. 2:1 
ratio (entry 7). In the presence of HFIP, the reaction of isatin 2.23 proceeded for 6 h affording 
products with two different ring systems quinoxaline dione 2.24 and quinazoline dione 2.25 as a 
mixture in ca. 2:1 ratio in an overall 76% isolated yield.  
 
Table 2.2. Synthesis of N-hydroxyalkyl lactams. 
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 2.34  2.35 (15%)j  2.36 (69%)  
aTo a solution of a ketone (1.0 equiv) and 1.1 (1.5 equiv) in HFIP (1.0 mL) at room temperature was 
added TfOH (1.0 equiv) and the reaction was allowed to stir at room temperature for the specified time 
(time indicated in the table refers to the time required for the formation of iminium ether). Further 
hydrolysis with aqueous NaHCO3 or 15% NaOH for 12–24 h followed by purification on a silica gel 
afforded products (see the Experimental Section for details). bConcentration of ketone ca. 0.40 M. 
cIsolated yield. dMixture of isomers (ca. 95% major isomer). eCorrected yield of major isomer from a 
mixture of isomers (see the Experimental Section for details). fSimilar reaction of cycloheptanone with 
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1.5 equiv of TfOH provided 2.15 in 69% yield (see the Experimental Section for details). gRatio of two 
inseparable isomers from a purified mixture as determined by 1H NMR. hThe reaction was carried out 
with 1.5 equiv of TfOH. iCombined yield of 2.35 and 2.36. jMixture of rotamers (ratio = 79:21).  
 
  
The reaction with bicyclic ketones proceeded efficiently in 1–2 h to afford the 
corresponding lactams in excellent yields as a mixture of two regiochemical isomers (entries 10 
and 11). 2-Adamantanone 2.32 also only required just 1 h to afford the tricyclic lactam 2.33 in 
96% yield (entry 12). In the case of acyclic ketone 2.34, 1.5 equiv of TfOH was required for 
successful iminium ether conversion, which upon hydrolysis with NaHCO3 provided aminoester 
2.36 as the major product in 69% yield and hydroxypropylamide 2.35 in 15% yield (entry 13).43 
Overall, good to excellent yields were obtained with only 1.0 equiv of TfOH in a relatively short 
time period, which is a practical advancement to original protocol published in 1995.  
In this study, we demonstrated that HFIP aided dramatically towards reducing the amount 
of acid required to promote the initial iminium ether formation reaction between ketone and 3-
azidopropanol. The key highlights of this improved protocol include the reduced use of acid 
equivalents and short reaction times. However, the methodology remains more robust and practical 
with cyclic ketones than acyclic ketones. Several other acyclic ketones (e.g., dicyclohexyl ketone, 
dibenzyl ketone) were also investigated during this time, however, pure products were difficult to 
isolate.  
 
2.3 Method Development of the Interrupted Schmidt Reaction in HFIP  
 In this section, I described the development of a general protocol to effect an interruption 
of the classic Schmidt reaction in HFIP media, particularly to capture the cationic ring-expanded 
intermediate (nitrilium or iminocarbonium ion) with various nucleophiles in order extend the 
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synthetic utility of Schmidt transformations. In doing so, the methodology devised would provide 
access to new and diverse types of ring-expanded heterocycles, which may be of medicinal value.  
 
2.3.1. Optimization of Reaction Conditions 
 The investigation of an interrupted Schmidt reaction began with identifying an acid catalyst 
in HFIP that would allow trapping of the cationic ring-expanded intermediate with an added 
electron-rich arene nucleophile, 1,3,5-trimethoxybenzene (1,3,5-TMB). While there is no 
precedence for carbon-based nucleophiles participating in the interrupted Schmidt reaction, 
minimal precedence is available on heteroatom-based nucleophiles as trapping reagents. For 
example, Chiba and coworkers have previously published an example on intramolecular trapping 
of nitrilium ion with tosylamine to observe dihydroimidazole in a moderate yield (see Scheme 2.5c 
above).21 Comparablely, we have reported azide and HFIP as incidental trapping groups for this 
cationic intermediate in a flavanone substrate (see Scheme 2.9 above).7 We sought to develop a 
more valuable protocol on a six-membered cyclic ketone substrate, which is a prime substrate for 
Schmidt ring-expansion chemistry. 4-Phenylcyclohexanone 2.1 was selected for this study as it 
also includes an inherent chromophore to aid in visualization. Furthermore, since the iminium ion 
intermediate is an electrophile, we figured that a carbon-based π-electron-rich nucleophile may 
prove suitable in preliminary development work. Accordingly, a recent disclosure on HFIP-
promoted Friedel-Crafts reaction44-45 using electron-rich arenes prompted the selection of 1,3,5-
TMB as the trapping reagent. Thus, we carried out an acid screen on the conversion of 4-
phenylcyclohexanone 2.1 to 1,3,5-TMB-trapped imine product 2.37 using TMSN3 to facilitate 
nitrogen ring-expansion in HFIP media (Tables 2.3 and 2.4). In Tables 2.3 and 2.4, the reactions 
were carried out using a syringe pump, which permitted slow addition (over 6 h) a solution of 
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TMSN3 (2.0 equiv) in HFIP (2.0 mL) into a solution of ketone 2.1, acid catalyst (1.0 equiv), and 
1,3,5-TMB (5.0 equiv) in HFIP (1.0 mL).  
 In Table 2.3, we examined 15 Lewis acids using 1.0 equiv of catalyst with HFIP as the 
solvent at room temperature. Of these, aluminum bromide (AlBr3) gave a complete conversion 
from ketone 2.1 to desired imine product 2.37 by 1H NMR quantification of reaction mixture using 
benzyl benzoate as the internal standard, whereas, aluminum chloride (AlCl3), bismuth (III) triflate 
(Bi(OTf)3), silicon tetrachloride (SiCl4), and titanium tetrachloride (TiCl4) gave moderate 
conversions. However, some of these reagents were not selected for further screening because they 
also promoted the conversion to either lactam 2.2 or tetrazole 2.4 byproducts. Additionally, the 
basic workup of reactions using TiCl4 and SiCl4 were tedious due to the presence of emulsions. 
Therefore, AlCl3 and AlBr3 were selected for further evaluation. Attempts to lower the catalyst 
loading of either aluminum reagents led to reduced yields and observations of minor amounts of 













Table 2.3. Lewis acid catalyst screen in HFIP.a-d  
 
entry catalyst catalyst (equiv) conversion (%) 
2.37b,c 2.1:2.37b,d 2.4b 
1 AlCl3 1.00 74 (54) ND ND 
2 AlCl3 0.30e 29 52:29 5 
3 AlBr3 0.30e 20 77:20 2 
4 AlBr3 1.00 95 (83) 5:≥95f ND 
5 Al(OTf)3 1.00 38 46:38 10 
6 MgCl2 1.00 NR 100:0g NR 
7 InCl3 1.00 NR 100:0g NR 
8 ZnBr2 1.00 NR 100:0g NR 
9 In(OTf)3 1.00 75 19:75 9 
10 Bi(OTf)3 1.00 77 15:77 12 
11 BF3•OEt2 1.00 46 47:46 4 
12 SiCl4h 1.00 75 ND ND 
13 Sc(OTf)3 1.00 38 59:38 1 
14 FeCl3 1.00 ND (14) ND ND 
15 TiCl4h 1.00 68i ND ND 
16 TiCl4h 0.25j 37 40:37 ND 
17 AgOTf 1.00 13 78:13 2 
18 Cu(OAc)2 0.20 NR 100:0g NR 
19 CuCl 0.20 NR 100:0g NR 
20 AuCl3 0.20 ND 77:0 5 
aSee experimental section general procedure B for reaction protocol. bProduct conversion was determined 
by 1H NMR of the crude reaction mixture using benzyl benzoate as an internal standard. cYield in 
parentheses represents isolated yield. dConversion was determined using 1H NMR of the crude reaction 
mixture. eSpeculation on generation of an equimolar amount of HX (X = Cl, Br) upon dissolution in 
HFIP.4 fComplete conversion of 2.1 to 2.37 was observed by 1H NMR of the crude reaction mixture. 
gCatalyst was insoluble in HFIP. h1.0 M solution in CH2Cl2 was used. i15% conversion to 2.2 was 
observed by 1H NMR of the crude reaction mixture using benzyl benzoate as an internal standard. jTiCl4 
is known to generate an equimolar amount of HCl upon dissolution in HFIP.4 ND = Not determined; NR 
= No reaction.  
 
We then examined the efficiency of protic acids in the presence of HFIP at room 
temperature to mediate the interrupted Schmidt reaction (Table 2.4). Particularly, upon treatment 
of 4-phenylcyclohexanone 2.1, 1,3,5-TMB, and TMSN3 in HFIP with 1.0 equiv of either TfOH or 
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TsOH acid gave ca. 60% of the desired product 2.37 along with minor amounts (>10%) of 
tetrazoles (entries 1 and 2). A similar reaction carried out using 2.0 equiv of TsOH did not prove 
more effective (entry 3). In contrast, attempts to carry out the reaction with other acids, particularly 
with reagents acetyl chloride (AcCl) or acetyl bromide (AcBr), which are known in the presence 
of HFIP4 to in situ generate HCl or HBr, failed (entries 4–7). Perfluoro-tert-butyl alcohol (PFTB, 
pKa 5.4) is a highly acidic media similar to HFIP (pKa 9.3). As seen in entries 8 and 9, we 
examined the reaction only in fluorinated solvents, however without added acids neither resulted 
in any reaction.  
 
Table 2.4. Bronsted acid catalyst screen in HFIP.a-d 
 
entry catalyst catalyst (equiv) conversion (%) 
2.37b,c 2.1:2.37b,d 2.4b 
1 TfOH 1.00 60 17:60 7 
2 TsOH 1.00 64g 17:64 6 
3 TsOH 2.00 59h 0:59 4 
4 TFA 1.00 9i 87:9 ND 
5 TMSOTf 1.00 10 54:10 6 
6 CH3COCle 1.00 ND (15) 72:0j ND 
7 CH3COBrf 1.00 18 NDk:18 4 
8 PFTB 1.00 NR 100:0 NR 
9 HFIP 1.00 NR 100:0 NR 
aSee experimental section general procedure B for reaction protocol. bProduct conversion was determined 
by 1H NMR of the crude reaction mixture using benzyl benzoate as an internal standard. cYield in 
parentheses represents isolated yield. dConversion was determined using 1H NMR of the crude reaction 
mixture. eKnown to generate an equimolar amount of HCl upon dissolution in HFIP.4 fSpeculation on 
generation an equimolar amount of HBr upon dissolution in HFIP.4 g15% conversion to 2.2 was observed 
by 1H NMR of the crude reaction mixture using benzyl benzoate as an internal standard. h37% conversion 
to 2.2 was observed by 1H NMR of the crude reaction mixture using benzyl benzoate as an internal 
standard. i9% 2.2 to lactam was observed by 1H NMR of the crude reaction mixture using benzyl benzoate 
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as an internal standard. j2.37 minimally observed by 1H NMR of the crude reaction. k2.1 observed by 1H 
NMR of the crude reaction. ND, Not determined; NR, No reaction. 
  
 The preliminary acid screen of 22 reagents revealed that AlBr3 and AlCl3 catalysts were 
effective for the promotion of the interrupted Schmidt reaction of 1,3,5-TMB. In particular, the 
identification of AlBr3 mediated a complete conversion over 6 h. We then explored the effects of 
time and stoichiometry in the interrupted Schmidt using AlCl3 in presence of HFIP (Table 2.5). 
The reaction is critically dependent on the order of addition (cf entries 1 and 2). Without the slow 
addition of TMSN3 solution, the conversion to desired 2.37 stalls and 38% of product was isolated 
after an extended reaction time of 24 h. In contrast, 6 h slow addition of TMSN3 solution revealed 
43% conversion to 2.37 by 1H NMR quantification of reaction mixture using benzyl benzoate as 
the internal standard. Changing the time of slow addition from 2–7 h did not have an effect on the 
reaction outcome (entries 2–5). However, increasing the concentration of the reaction mixture 
aided in conversion to product (cf. entries 7 and 8). More significantly, increasing AlCl3 catalyst 
loading to 2.0 equiv improved the conversion (cf. entries 2 and 10), although the reaction was still 
incomplete. Comparing entries 11 and 12, it is apparent that 2.0 equiv of TMSN3 was necessary 
for high and complete conversions; following basic workup, 88% was observed by internal 
standard and 75% was isolated after normal phase column chromatography. These results were 
comforting because previous acid screens were carried out with 2.0 equiv of TMSN3 (reaffirming 




















1 1.00 1.25 4.0 6e,f (33) ND 
2 1.00 1.25 4.0 6 (43) ND 
3 1.00 1.25 4.0 2 (37) ND 
4 1.00 1.25 4.0 5 (44) ND 
5 1.00 1.25 4.0 7 (47) ND 
6g 1.20 1.25 4.0 6 68 (57) ND 
7 1.20 1.25 4.0 6 66 (52) ND 
8 1.20 1.25 3.0 6 71 (62) 21:71 
9 1.50 1.25 3.0 6 71 (52) 19:71 
10 2.00 1.25 3.0 6 76 (64) 13:87 
11 2.00 1.50 3.0 6 79 (71) 11:89 
12 2.00 2.00 3.0 6 88 (75) 5:≥95h 
13 2.00 2.00 3.0 6i 87 (79) 5:≥95h 
14 2.00 2.00 3.0 6i,j 83 (77) 5:≥95h 
15k 2.00 2.00 3.0 6 85 (74) 5:≥95h 
16l 2.00 2.00 3.0 6 64 (53) 9:≥91h 
17 2.00 2.00 3.0 10 87 (75) 5:≥95h 
18 2.00 2.00 3.0 2 80m 14:80 
19 1.50 2.00 3.0 6 80 (66) 5:≥95h 
20 1.20 2.00 3.0 6 74 (61) 15:85 
21 1.00 2.00 3.0 6 74 (54) ND 
22 1.00 2.00 3.0 6e 31n ND 
23 2.00 2.00 3.0 6e 54o 20:54 
24 2.00 -p 3.0 6e - 66:3 
25 2.00 -p,q 3.0 6e - 52:5 
aSee experimental section general procedure C for reaction protocol. bProduct conversion was determined 
by 1H NMR of the crude reaction mixture using benzyl benzoate as an internal standard. cYield in 
parentheses represents isolated yield. dRatio was determined using 1H NMR of the crude reaction 
mixture. eDump and stir: slow addition was not carried out. fThe reaction was allowed to stir further at 
room temperature for 24 h, which still only gave 38% of isolated product 2.37. gThe reaction was carried 
out without a nitrogen balloon. hComplete conversion of 2.1 to 2.37 was observed by 1H NMR of the 
crude reaction mixture. iFollowing slow addition the reaction mixture was allowed to stir for an additional 
15 h. jBasic work up with a saturated solution of NaHCO3 was not carried; product isolated as iminium 
HCl salt 2.38. kThe reaction was carried out with 7.0 equiv of 1,3,5-trimethoxybenzene. lThe reaction 
was carried out with 2.0 equiv of 1,3,5-trimethoxybenzene. m3% conversion to 2.4 was observed by 1H 
NMR of the crude reaction mixture using benzyl benzoate as an internal standard. n9% conversion to 2.4 
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was observed by 1H NMR of the crude reaction mixture using benzyl benzoate as an internal standard. 
o23% conversion to 2.4 was observed by 1H NMR of the crude reaction mixture using benzyl benzoate 
as an internal standard. pNaN3 (2.0 equiv) was used instead of TMSN3 solution. qTMSCl (1.0 equiv) was 
used as an additive. ND, Not determined.  
 
Moreover, we determined that increasing the reaction time to overnight at room 
temperature following slow addition did not impact the isolation of 2.37 (cf. entries 12 and 13). 
Likewise, isolating the product in its HCl salt form 2.38 still afforded product in less than 80% 
yield (cf. entries 13 and 14). Conversely, the reaction with 7.0 equiv of 1,3,5-TMB, instead of 5.0 
equiv, yielded similar conversions (cf. entries 12 and 15). In contrast, the reaction with 2.0 equiv 
of 1,3,5-TMB diminished conversions significantly (entry 16). Lastly, we demonstrated that 
replacing TMSN3 with NaN3, or attempting to generate in situ TMSN3 via mixing NaN3 with 
TMSCl were both detrimental reactions (entries 24 and 25).  
Due to the requirement of excess AlCl3 for complete reaction conversions, we examined 
AlBr3 for the transformation. We speculated that if the TMB-trapped imine were isolated as the 
HCl salt form 2.38, under these conditions AlBr3 might generate HBr in situ, along with versions 
of Al[OCH(CF3)2]3 or Al[OCH(CF3)2]Br2. Evaluation of AlBr3 revealed it indeed led to better 
reaction conversions and isolated yields, specifically Table 2.6 depicts these improvements in the 
isolation of desired product 2.39 as its HBr salt. We again reaffirmed that slow addition was 
necessary for complete conversion; entry 1 of Table 2.6 revealed 50% conversion to 2.39 when 
the reaction was set up as a standard “dump and stir”. However, upon 6 h of slow addition of the 
azide-HFIP solution followed by additional stirring at room temperature overnight, normal phase 
chromatographic purification afforded TMB-imine HBr salt 2.39 in 92% yield. The product 
outcome was confirmed by X-ray crystal analysis and is shown in Figure 2.5. Lastly, as expected, 
changing or diluting HFIP solvent with a related fluorinated solvent trifluoroethanol (TFE, pKa 
12.4), or a non-fluorinated solvent toluene was detrimental towards 2.39 formation.   
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1 1.00 2.00 3.0 6e 50f ND 
2 1.00 2.00 3.0 6 95 (78)g 5:≥95h 
3 1.00 2.00 3.0 6i 95 (87)g 5:≥95h 
4 1.00 2.00 3.0 6i ≥100 (92) 5:≥95h 
5 0.50 2.00 3.0  6i 63 ND 
6 1.00 1.50 3.0 6i 93 5:≥95g 
7 1.00 2.00 3.0 2 33g NDj:33 
8k 1.00 2.00 3.0 6i 47l NDj:47 
9 1.00 2.00 TFE (1):2.0 6 42g 21:42 
10 1.00 2.00 Toluene (1):2.0 6 10g 90:10 
aSee experimental section general procedure D for reaction protocol. bProduct conversion was 
determined by 1H NMR of the crude reaction mixture using benzyl benzoate as an internal standard. 
cYield in parentheses represents isolated yield. dRatio was determined using 1H NMR of the crude 
reaction mixture. e”Dump and stir”; slow addition was not carried out. f3% conversion to 2.4 was observed 
by 1H NMR of the crude reaction mixture using benzyl benzoate as an internal standard. gBasic work up 
with a saturated solution of NaHCO3 and brine was carried out; free imine 2.37 was isolated. hComplete 
conversion of 2.1 to 2.39 was observed by 1H NMR of the crude reaction mixture. iAfter slow addition, 
the reaction mixture was allowed to stir for an additional 15 hours at rt. j2.1 was observed by 1H NMR 
of the crude reaction. kThe reaction was carried out with 2.0 equiv of 1,3,5-trimethoxybenzene. l2% 
conversion to 2.4 was observed by 1H NMR of the crude reaction mixture using benzyl benzoate as an 





Figure 2.5. X-ray crystal structure of 2.39 (CCDC 1832152).  
 
2.3.2 Ketone Scope and Functionalization 
Having identified suitable reaction conditions that achieved a high conversion to imine 
2.39, we sought to establish the ketone scope of this interrupted Schmidt reaction. The above noted 
conditions proved acceptable for most cyclic and acyclic ketone substrates (Table 2.7). We began 
with cyclohexanone derivatives (entries 1–10) because these are generally the most facile 
substrates for nitrogen ring-expansion. Indeed, excellent results were obtained with unhindered 4-
substituted cyclohexanone derivatives using the 6 h slow addition protocol at room temperature 
(entries 1–4). However, the transformation proved more robust with either extended room 
temperature stir or slight heating of the reaction mixture. For example, the reaction of 4-
methylketone 2.40 to imine 2.41 proceeded in 80% isolated yield, however the yield improved to 
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87% when the reaction mixture was heated at 35 ˚C. The reaction of 2-substituted cyclohexanone 
proceeded but met some challenges; the reaction of 2-methylcyclohexanone 2.48 afforded desired 
imine 2.49 in 83% isolated yield when the reaction was performed at 35 ˚C, whereas the reaction 
of 2-tert-butylcyclohexanone 2.50 afforded only 11% isolated yield of product 2.51 under similar 
conditions. The difference in yields obtained from the reactions with 2-methyl or 2-tert-
butylcyclohexanone exemplify the sensitivity of the reaction toward additional steric bulk near the 
reacting carbonyl. Moreover, the reaction of functionalized and sterically hindered 
cyclohexanones required extended time and slight heat to afford imines in moderate yields (entries 
7–8). The reaction of enantiopure L-methanone 2.52 delivered at best 54% of imine 2.53, however, 
minor amounts of previously reported tetrazole were also isolated during this reaction (entry 7). 
Functionalized six-membered cyclic ketones such as tetrahydropyran-4-one 2.10 proceeded to 
afford imine 2.54 in moderate yields (entry 8), whereas the reaction of 1-methylpiperidin-4-one 
2.55 in the presence of TMSN3 and trapping reagent 1,3,5-TMB did not yield any desired imine 
(entry 9 and Scheme 2.10). Instead, likely due to the presence of a functional group capable of 
catalyst deactivation, the ketone underwent an addition-elimination reaction with 1,3,5-TMB to 
afford 2.56.  
 
Table 2.7. Synthesis of 1,3,5-TMB imines.a-c  
 















































































































  2.69 2.70  
 2.68 2.69:2.70 = 80:20 i  
aSee experimental section general procedure E and F for reaction protocol. bIsolated yield after 6 h slow 
addition, unless otherwise noted. cIsolated yield following an additional 15 h stir of the reaction mixture 
at room temperature after the 6 h slow addition of azide solution. dIsolated yield following an additional 
15 h stir of reaction mixture at 35 ˚C after the 6 h slow addition of azide solution at 35 ˚C. eYield 
determined by 1H NMR of the crude reaction mixture using benzyl benzoate as an internal standard. 
fMinor amounts (2–19%) of previously reported tetrazole were isolated.  gReaction was carried out over 
18 h slow addition of azide solution. h2.45 confirmed as HBr salt by elemental analysis. iRegiochemical 






Scheme 2.10. Reaction of 1-methylpiperidin-4-one 2.55 with 1,3,5-TMB.  
 
 
Reactions of smaller and medium-sized ketone rings faced expected challenges and 
afforded imines in poor to moderate yields (cf. entry 10 with entries 11–13). A poor yield was 
obtained with cyclopentanone 2.58, in which 14% of imine 2.59 was isolated following normal 
phase column chromatography. We have been unable so far to obtain reasonable yields of the ring-
expansion products from cyclopentanone derivatives; at most 20% was observed by 1H NMR of 
the crude reaction mixture of the simple cyclopentanone substrate using an internal standard (along 
with unidentifiable peaks). Likewise, the reactions of cyclobutanone substrates were sluggish and 
failed to provide any quantifiable imine. Application of the present methodology to 
cycloheptanone 2.14 provided a reasonable yield of the corresponding imine 2.60. In fact, we 
found that heating the reaction mixture at 35 ˚C improved the yield by 16% (50→66%). However, 
the reaction of cyclooctanone 2.16 afforded both the desired imine 2.61 and previously observed 
tetrazole7 in poor yields (entry 13). We attributed the poor yields especially that of the 
cyclopentanone and cyclooctanone examples to the lack of ketone reactivity with the azide 
nucleophile and to ring strain associated with the formation of tetrahedral intermediates during the 
course of nitrogen insertion. In fact, cyclopentanones are not good reacting partners in the TiCl4-
promoted ring expansion with simple alkyl azides either.41 Likewise, the reaction of 2-
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adamantanone 2.32 proceeded sluggishly to the corresponding tricyclic imine 2.62 and resulted in 
20% isolated yield (entry 14).  
The interrupted Schmidt reaction of acyclic aliphatic ketones with the model 1,3,5-TMB 
trapping reagent proceeded smoothly to afford the corresponding imines in good yields (Table 2.7, 
entries 15–18). In some cases, these reactions were more facile when carried out 35 ˚C as opposed 
to room temperature and resulted in relatively high yields (68–89%). The reaction of 
unsymmetrical ketone 2.68 afforded 80:20 isomeric mixture of imine 2.69, and reliably, with 
migratory preference for the electron-rich alkyl group. We investigated relatively few 
unsymmetrical ketones because regiochemical control is difficult to achieve with this variant of 
the Schmidt reaction. A range of benzylic and aromatic ketones were also investigated, i.e., 
specifically substrates D-tetralone, E-tetralone, flavanone, and indanone. However, these reactions 
were unsuccessful and failed to provide any quantifiable imine products. With respect to D-
tetralone and flavanone, both substrates were non-reactive with AlBr3 and led to recovery of 
starting material. The non-reactivity of flavanone was especially surprising because previous 
report with TfOH in HFIP furnished tetrazoles, as well as HFIP- and azide-trapped imine 
products.7  
Upon successful synthesis of a range of 1,3,5-TMB-trapped imines, we sought to extend 
the scope of this methodology towards the preparation of related functionalities. We next examined 
the synthesis of enamide with a range of ketones and electrophiles (e.g., acetic anhydride as 
electrophile in Scheme 2.11). Enamides are versatile organic substrates that display balance in 
stability and reactivity, as well as are commonly present in medicinal compounds.46-47 
Interestingly, a direct conversion of ketones to substituted ring-expanded enamides is an 
unprecedented transformation in the literature. We realized this represented a straightforward 
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opportunity to incorporate functional diversity to our methodology, and accordingly devised a one-
pot protocol to report a direct conversion of ketone to ring-expanded enamides. To do this, we 
utilized, either separately or in combination, 4-dimethylaminopyridine (DMAP) or triethylamine 
(TEA) bases to mediate the transformation with electrophiles. Figure 2.6 depicts the synthesis of 
seven acetyl-enamide derivatives 2.71–2.77 in good yields. We carried out this two-step 
transformation in one pot; fortuitously, the enamide proved easier to purify by normal phase 
chromatography (i.e., they appeared as a clean single spot as opposed to a streak on TLC). The 
synthesis of enamide derivatives 2.75 and 2.76 were obtained in higher yields as compared to their 
imine precursors 2.60 and 2.61, respectively.  
 







Figure 2.6. Synthesis of enamide derivatives using acetic anhydride. Yield in parentheses refer to 
the overall yield for the two sequential steps.   
 
 Given the success with acetic anhydride as the electrophile, we sought to apply the 
methodology towards application of other readily available electrophiles. As shown in Figure 2.7, 
we applied the developed route to synthesize a range of functionalized enamides. Here again, the 
reaction was mediated by DMAP and/or TEA base. Instead of acetic anhydride, the 2.1-ketone 
derived imine substrates were reacted with additional electrophiles, including di-tert-butyl 
dicarbonate, 4-substituted acyl chlorides, tosyl chlorides, and 4-substituted phenyl isocyanates. 
The corresponding enamide derivatives 2.78–2.86 were synthesized in 29–77% yields. Even 
though the process of enamide formation is unoptimized, this current application demonstrated 




Figure 2.7. Synthesis of enamide derivatives using various electrophiles. Yield in parentheses 
refer to the overall yield for the two sequential steps.   
 
Given the ease of preparing enamides, we sought to determine if the imine could also be 
reductively converted to amines, which would further advance the utility of this methodology. In 
order to devise a one-pot route towards amine preparation, we carried out a brief screen of reducing 
agents, which included sodium borohydride, triethysilane, and sodium triacetoxyborohydride. Of 
the reagents screened, only sodium borohydride (NaBH4) gave clean and relatively high 
conversions to the amine 2.87 (Scheme 2.12). In fact, by using an achiral substrate, we achieved 
stereoselective conversion to amine 2.87 in high diastereoselectivity (dr 20:1). Using 1H NMR, we 
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observed only one isomer and the stereochemistry of 2.87 was assigned as shown in Scheme 2.12. 
Stereochemical assignments were proposed based on large J-coupling values of the protons 
adjacent to the aromatic substitution. Additionally, in a one-pot fashion, the amine 2.87 was readily 
derivatized using acetic anhydride and di-tert-butyl dicarbonate to afford 2.88 and 2.89 in 76% 
yields, respectively.  
 
Scheme 2.12. Synthesis of amine derivatives. Yield in parentheses refer to the overall yield for the 
two or three sequential steps.   
 
 
2.3.3 Nucleophile Scope and Mechanism Discussion 
 The most challenging endeavor associated with the development of the interrupted Schmidt 
reaction that we have encountered has been the extension of the current methodology towards 
various arene nucleophiles. For example, adapting the current methodology to closely related 
arenes like 1,2,3-trimethoxybenzene, 1,3-dimethoxybenzene, and anisole failed. These reactions 
do not produce quantifiable product outcomes, though in some cases product masses were 
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observed by UPLC. To address this, we examined a modification of the current methodology in 
which nucleophiles were added after the slow addition of azide solution. This methodology (Table 
2.8) discloses preliminary investigations of protocols that include the addition of nucleophile in 
portions during or after slow addition (entries 1–5) or, alternatively, dual slow addition of 
nucleophile and azide using the syringe pumps (entry 6). Unfortunately, only moderate 
conversions (>80%) to desired imine 2.39 were observed. Despite this setback, the proposed 
method would be most impactful if it could accommodate other nucleophiles. Thus, we chose to 
carry out a preliminary screen of a limited set of reaction partners.  
 














1 1.00 2.00 3.0 6 5.0 equiv 64:4 
2 1.50 2.00 3.0 6 5.0 equiv 55:11 
3 1.00 2.00 3.0 6 5.0 equiv e 56:ND 
4 1.00 2.00 3.5 6 1.0 equiv added after 3 h, 
then 4.0 equiv after 6 hf 
71:ND 
5 1.00 2.00 3.5 6 2.5 equiv added after 3 h, 
then 2.5 equiv after 6 hf 
67:ND 
6 1.00 2.00 4.0 6 5.0 equiv (+ HFIP 2.0 mL) 
added using syringe pumpg  
79:ND 
aAzide added as a solution in HFIP (1.0 mL) using syringe pump (0.40 mL/h, 20 gauge needle). bTotal 
volume of reaction mixture after slow addition. c1,3,5-TMB was added after 6 h slow addition and the 
reaction mixture was allowed to stir overnight (+15 h), unless otherwise noted. dConversion to desired 
2.39 and side-product 2.4 were observed by 1H NMR of the crude reaction mixture using benzyl benzoate 
as an internal standard. eThe reaction was heated at 40 ˚C after addition of 1,3,5-trimethoxybenzene. 
fNucleophile added in portions during and after slow addition. gNucleophile added at the same rate as the 
azide solution using a syringe pump (0.40 mL/h, 20 gauge needle). ND, Not determined.  
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 The results of the nucleophile investigation are shown in Figure 2.8. So far, we successfully 
examined and reported examples for 1,3-dimethoxybenzene, indole derivatives, and pyrrole as 
nucleophile trapping agents added after the slow addition of TMSN3 in HFIP (Figure 2.8a). A 
moderate amount of optimization was performed for these individual examples. For example, 
when 5.0 equiv of 1,3-dimethoxybenzene was added to the reactive species derived from 4-
phenylcyclohexanone 2.1 and TMSN3 43% of the isomer 2.90 was isolated (the reaction was also 
carried using 10.0 equiv of 1,3-dimethoxybenzene, however similar conversions were obtained by 
crude 1H NMR to that of the reaction with 5.0 equiv). Alternatively, we found that the reaction 
was slightly sensitive to the order of nucleophile addition for indoles 2.91–2.95. As can be seen 
by comparing yields of 2.92, 2.94 and 2.95, higher amounts were isolated when the nucleophile 
was added in two portions (once at the 3 h time point of slow addition, and then again after 6 h 
slow addition). Although the synthesis of indole-derivatives proceeded in moderate yields, it 
appears that electron-rich or electron-poor indoles may function as effective nucleophiles for the 
interrupted Schmidt reaction. Pyrrole was also effective in trapping the Schmidt ring-expanded 
cation and resulted in the product 2.96. Our preliminary examination into other nucleophiles 
including 1,2,3-TMB, anisole, triethylsilane, allylsilane, furan, benzofuran, and benzothiophene 
were unsuccessful (Figure 2.8b). In spite of this, the preliminary success with indole nucleophiles 
suggests that adaptation to other carbon-based nucleophiles and broad utility in synthesis may be 




Figure 2.8. Preliminary screen of nucleophiles for the interrupted Schmidt reaction. (a) Successful 
examples. (b) Unsuccessful nucleophiles as trapping reagents. aAfter slow addition of azide-HFIP 
solution, ca. 5.0 equiv of nucleophile was added and the reaction mixture allowed to stir for an 
additional 15 h at room temperature. bAfter slow addition of azide-HFIP solution, ca. 10.0 equiv 
of nucleophile was added and conversion was determined by 1H NMR of the crude reaction 
mixture using benzyl benzoate as an internal standard. cAfter slow addition of azide-HFIP solution, 
ca. 10.0 equiv of nucleophile was added and the reaction mixture allowed to stir for an additional 
15 h at room temperature. dNucleophile was added in portions during and after the slow addition 
of azide-HFIP solution. eNucleophile and azide were added as HFIP solutions using syringe 
pumps.  
 
 A proposed mechanism for the interrupted Schmidt reaction is summarized in Figure 2.9. 
The mechanism begins with activation of the carbonyl by AlBr3 and formation of an azidohydrin 
intermediate, which dehydrates to afford a diazonium ion species (Figure 2.9a). At this point, 
rearrangement gives an iminium ion intermediate, which may directly react with 1,3,5-TMB, 
forming the C–C bond and resulting in the final imine 2.39 (Figure 2.9b). Alternatively, the 
nitrilium ion could react with AlBr3, in situ generated HBr, or solvent HFIP. This would lead to a 
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substituted intermediate (halo-iminium ion or HFIP-iminium ion) that might behave as the active 
species in the reaction with 1,3,5-TMB. In this scenario, stepwise addition of 1,3,5-TMB and 
elimination of X (Br, OCH(CF3)2) takes place to afford the product 2.39. At the present time, we 
have not established which pathway is occurring, however subsequent work towards answering 
this question is proposed in the laboratory.  
 The thought-provoking question is why does the iminium ion persist long enough in 
solution to react with 1,3,5-TMB. In either mechanism, AlBr3 or silyl byproducts contribute to 
sequestering the hydroxide ion, which may circumvent its addition to the nitrilium ion to generate 
lactam, and as described above, facilitate the formation of the proposed active species (X-iminium 
ion in Figure 2.9b). Lastly, the course of the aluminium reagent is unclear (Figure 2.9c). It is likely 
that AlBr3 reacts with HFIP to generate in situ HBr (indicative through the isolation of products 
as HBr salts). The ionization process could be envisioned in many variations, although the role of 





Figure 2.9. Proposed mechanism for the interrupted Schmidt reaction. (a) Formation of 
diazoiminum ion. (b) Formation of possible iminium ion intermediates. (c) Representative fates of 
aluminum reagent.  
 
2.4 Conclusion and Future Directions 
In summary, we have for the first time disclosed a general methodology to promote the 
interrupted Schmidt reaction concomitant with C–C bond formation. A promising synthetic 
strategy was established for intercepting the Schmidt reaction cationic intermediate using slow 
addition of TMSN3 solution and AlBr3 in the presence of HFIP. The ketone scope of the current 
methodology was extensively explored with 1,3,5-TMB and the preliminary nucleophile scope has 
been examined which identified indoles effective as trapping reagents as well. Additionally, 
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functional diversity was incorporated in this work by enabling the protocol towards the preparation 
of imine, enamide, and amine derivatives.  
There is opportunity for further optimization towards substantial extension of carbon-based 
and heteroatom-based nucleophiles for the interrupted Schmidt reaction. Although further work to 
elucidate the mechanism of this reaction is important, the utility of the method for heterocycle 
synthesis has been demonstrated and should lead to other applications in organic and medicinal 
chemistry.  
 
2.5 Experimental Section 
2.5.1 Experimental Section for 2.2.2 
General Information. Caution: Although we have not experienced any untoward events 
with the compounds mentioned in this thesis, azides and their precursors are known explosive 
hazards and should be used with appropriate safety precautions. Minimally, careful control of 
temperature and scale should be exercised. We do not recommend distillation of reaction 
mixtures that may contain residues of azide sources.  
Reactions were performed under inert atmosphere (argon or nitrogen) in glass sample vials 
with TFE-lined cap. All chemicals were purchased from commercial sources and used without 
further purification. New containers of BF3xOEt2, TfOH, and HFIP were used. Anhydrous was 
dried by passage through neutral alumina columns using a commercial solvent purification system 
prior to use. Thin-layer chromatography (TLC) was performed using commercial glass-backed 
silica plates (250 µM) with an organic binder. Preparative TLC was carried out using silica gel GF 
TLC plates (UV 254 nm, 1000 µM). Visualization was accomplished with UV light, Seebach’s 
stain, or aqueous KMnO4 stain, and heating. Purification was carried out by an automated flash 
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chromatography/medium-pressure liquid chromatography (MPLC) system using normal phase 
silica gel flash columns (4 or 12 g). The infrared (IR) spectra were acquired as thin films or solids 
using a universal ATR sampling accessory on a PerkinElmer Spectrum One FT-IR spectrometer; 
the absorption frequencies are reported in cm-1. All nuclear magnetic resonance spectra were 
recorded on a Bruker 400 MHz, or 500 MHz with a dual carbon/proton cryoprobe. NMR samples 
were recorded in deuterated chloroform (CDCl3) or deuterated dimethylsulfoxide (DMSO-d6). 
Chemical shifts are reported in parts per million (ppm) and referenced to the center line of solvent 
(CDCl3: δ 7.26 ppm for 1H NMR and 77.16 ppm for 13C NMR; DMSO-d6 δ 2.50 ppm for 1H NMR 
and 39.52 ppm for 13C NMR). Coupling constants are given in Hertz (Hz). HRMS data were 
collected using a Time-of-flight mass spectrometer (TOF) with an electrospray ion source (ESI). 
Melting points were determined in open capillary tubes using OptiMelt, an automated melting 
point apparatus, and were uncorrected. Data for the known compounds prepared according to the 
methodology described in the section match with those reported in the literature.  
 
 General procedure A for the synthesis of N-hydroxyalkyl lactams. To a solution of 
ketone (0.400 mmol, 1.0 equiv) and 3-azidopropanol 1.1 (0.600 mmol, 1.5 equiv) in HFIP (1.0 
mL) in a nitrogen-flushed two-dram vial was added TfOH (0.400–0.600 mmol, 1.0–1.5 equiv); 
immediate gas evolution was noted upon addition of acid for most substrates. The vial was capped 
and the reaction mixture was stirred at room temperature for 1–6 h. The solution was concentrated 
under nitrogen using a sample concentrator and dried under vacuum. The residual oil was diluted 
with CH2Cl2 and treated with either saturated NaHCO3 solution (1.5 mL) or 1M NaOH solution 
(1.5 mL) at room temperature for 12–24 h. The reaction mixture was further diluted with CH2Cl2 
(50 mL), dried over Na2SO4, filtered, and concentrated to afford a crude oil. Purification was 
281 
 
carried out either by elution with 10% MeOH/CH2Cl2 through a short bed of silica gel packed in a 
phase separator tabless, or by using a 4 g normal phase silica flash column on an automated MPLC 
system with a gradient elution from 0–25% MeOH/CH2Cl2. Concentration of appropriate fractions 
afforded products.  
 
 1-(3c-Hydroxypropyl)-5-phenylazepan-2-one, 2.5.40 Prepared as described in the general 
procedure A. Colorless oil (70.5 mg, 0.285 mmol, 95% yield).  
 
 1-(3c-Hydroxypropyl)azepan-2-one, 2.7.40 Following the general procedure A, to a 
solution of cyclohexanone 2.6 (39.3 mg, 0.400 mmol, 1.0 equiv) and 3-azidopropanol 1.1 (60.7 
mg, 0.600 mmol, 1.5 equiv) in HFIP (1.0 mL) was added TfOH (35.0 PL, 0.395 mmol, 1.0 equiv). 
The reaction mixture was stirred at room temperature for 1 h. Subsequently, hydrolysis was carried 
out with saturated NaHCO3 solution for 12 h. The crude oil obtained was eluted through a short 
bed of silica gel using 10% MeOH/CH2Cl2. Concentration of solvents afforded 2.7 as a colorless 




 1-(3c-Hydroxypropyl)-4,6-dimethylazepan-2-one, 2.9. Following the general procedure 
A, to a solution of 3,5-dimethylcyclohexanone 2.8 (ca. 95% major isomer, 50.6 mg, 0.401 mmol, 
1.0 equiv) and 3-azidopropanol 1.1 (60.4 mg, 0.597 mmol, 1.5 equiv) in HFIP (1.0 mL) was added 
TfOH (35.0 PL, 0.397 mmol, 1.0 equiv). The reaction mixture was stirred at room temperature for 
1 h. Subsequently, hydrolysis was carried out by treatment with 1 M NaOH solution for 14 h. 
Purification was carried out on an automated MPLC system with gradient elution from 0–10% 
MeOH/CH2Cl2 to afford 2.9 as a colorless oil (76.8 mg, 0.385 mmol, 94% yield). Rf = 0.40 (5% 
MeOH/CH2Cl2); IR (neat) 3390, 1619 cm-1; 1H NMR (400 MHz, CDCl3) G 0.84 (m, 4H), 0.92 (m, 
3H), 1.58 (m, 3H), 1.70 (m, 1H), 1.79 (m, 1H), 2.25 (m, 1H), 2.35–2.42 (dd, J = 13.6, 11.2 Hz, 
1H), 2.84 (m, 1H), 3.20–3.26 (dd, J = 14.9, 10.1 Hz, 1H), 3.42 (m, 4H), 4.11 (s, 1H); 13C NMR 
(100 MHz, CDCl3) G 21.0, 24.5, 30.1, 30.2, 34.0, 44.6, 44.9, 48.0, 56.3, 58.0, 175.9. HRMS (ESI) 
m/z calcd for C11H22NO2 [M + H]+ 200.1651, found 200.1656.  
 
 4-(3c-Hydroxypropyl)-1,4-oxazepan-5-one, 2.11. Following the general procedure A, to 
a solution of tetrahydro-4H-pyran-4-one 2.10 (37.0 PL, 0.401 mmol, 1.0 equiv) and 3-
azidopropanol 1.1 (60.6 mg, 0.599 mmol, 1.5 equiv) in HFIP (1.0 mL) was added TfOH (35.0 PL, 
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0.397 mmol, 1.0 equiv). The reaction mixture was stirred at room temperature for 6 h. 
Subsequently, hydrolysis was carried out with saturated NaHCO3 solution for 13 h. Purification 
was carried out on an automated MPLC system with gradient elution from 0–5% MeOH/CH2Cl2 
to afford 2.11 as a colorless oil (58.5 mg, 0.338 mmol, 84% yield). Rf = 0.51 (5% MeOH/CH2Cl2); 
IR (neat) 3394, 1620 cm-1; 1H NMR (400 MHz, CDCl3) G 1.66 (m, 2H), 2.75 (m, 2H), 3.45 (m, 
2H), 3.52 (m, 4H), 3.72 (m, 2H), 3.76 (m, 2H); 13C NMR (100 MHz, CDCl3) G 30.3, 41.1, 45.3, 
52.1, 58.2, 65.6, 70.4, 175.9. HRMS (ESI) m/z calcd for C8H16NO3 [M + H]+ 174.1130, found 
174.1134. 
 
 1-Benzoyl-4-(3c-hydroxypropyl)-1,4-diazepan-5-one, 2.13. Following the general 
procedure A, to a solution of 1-benzoyl-4-piperidone 2.12 (81.3 mg, 0.400 mmol, 1.0 equiv) and 
3-azidopropanol 1.1 (60.4 mg, 0.597 mmol, 1.5 equiv) in HFIP (1.0 mL) was added TfOH (35.0 
PL, 0.397 mmol, 1.0 equiv). The reaction mixture was stirred at room temperature for 6 h. 
Subsequently, hydrolysis was carried out with saturated NaHCO3 solution for 12 h. Purification 
was carried out on an automated MPLC system with gradient elution from 0–10% MeOH/CH2Cl2 
to afford 2.13 as a colorless oil (88.9 mg, 0.322 mmol, 80% yield). Rf = 0.20 (5% MeOH/CH2Cl2); 
IR (neat) 3408, 1618 cm-1; 1H NMR (400 MHz, CDCl3) G 1.67 (br s, 2H), 2.71 (br s, 2H), 3.51–
3.84 (complex, 10H), 7.32–7.42 (complex, 5H); 13C NMR (100 MHz, CDCl3) G 30.4, 39.0, 45.2, 
45.4, 50.1, 50.7, 58.3, 127.0, 128.9, 130.2, 135.4, 171.3, 174.5. HRMS (ESI) m/z calcd for 




 1-(3c-Hydroxypropyl)-1-azacyclooctan-2-one, 2.15.48 Following the general procedure 
A, to a solution of cycloheptanone 2.14 (44.7 mg, 0.399 mmol, 1.0 equiv) and 3-azidopropanol 1.1 
(60.8 mg, 0.601 mmol, 1.5 equiv) in HFIP (1.0 mL) was added TfOH (35.0 PL, 0.397, 1.0 equiv). 
The reaction mixture was stirred at room temperature for 6 h. Subsequently, hydrolysis was carried 
out with 1 M NaOH solution for 24 h. The crude oil obtained was eluted through a short bed of 
silica gel using 10% MeOH/DCM. Concentration of solvents afforded 2.15 as a yellow oil (45.2 
mg, 0.244 mmol, 61% yield).  
Similarly, the solution of cycloheptanone 2.14 (44.9 mg, 0.400 mmol, 1.0 equiv) and 3-
azidopropanol 1.1 (60.7 mg, 0.600 mmol, 1.5 equiv) in HFIP (1.0 mL) was treated with TfOH 
(53.0 μL, 0.600 mmol, 1.5 equiv) for 6h. Subsequent hydrolysis and purification as described 
above afforded 2.15 as a yellow oil (51.0 mg, 0.275 mmol, 69% yield).  
 
 1-Oxa-5-azacyclotridecan-13-one, 2.17.48 Following the general procedure A, to a 
solution of cyclooctanone 2.16 (50.8 mg, 0.403 mmol, 1.0 equiv) and 3-azidopropanol 1.1 (60.9 
mg, 0.602 mmol, 1.5 equiv) in HFIP (1.0 mL) was added TfOH (35.0 PL, 0.397 mmol, 1.0 equiv). 
The reaction mixture was stirred at room temperature for 6 h. Subsequently, hydrolysis was carried 
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out with saturated NaHCO3 solution for 12 h. Purification was carried out on an automated MPLC 
system with gradient elution from 0–25% MeOH/CH2Cl2 to afford 2.17 as an orange low melting 
solid (45.3 mg, 0.227 mmol, 56% yield).  
 
 3-(3c-Hydroxypropyl)-4,5-dihydro-1H-benzo[d]azepin-2(3H)-one, 2.19 and 2-(3c-
hydroxypropyl)-4,5-dihydro-1H-benzo[c]azepin-3(2H)-one, 2.20. Following the general 
procedure A, to a solution of E-tetralone (58.5 mg, 0.400 mmol, 1.0 equiv) 2.18 and 3-
azidopropanol 1.1 (60.7 mg, 0.600 mmol, 1.5 equiv) in HFIP (1.0 mL) was added TfOH (35.0 PL, 
0.397 mmol, 1.0 equiv). The reaction mixture was stirred at room temperature for 3 h. 
Subsequently, hydrolysis was carried out with saturated NaHCO3 solution for 13 h. Purification 
was carried out on an automated MPLC system with gradient elution from 0–10% MeOH/CH2Cl2 
to afford a mixture of lactams 2.19 and 2.20 as an orange oil (combined yield of 2.19 and 2.20: 
82.3 mg, 0.375 mmol, 94%; ratio of 2.19:2.20 = 63:37). 2.19 and 2.20: Rf = 0.39 (5% 
MeOH/CH2Cl2); IR (neat) 3382, 1625 cm-1; 1H NMR (400 MHz, CDCl3) G 1.65 (m, 2H), 1.72 (m, 
2H), 2.94 (m, 2H), 3.13 (m, 2H), 3.18 (t, J = 6.68 Hz, 2H), 3.35 (t, J = 5.52 Hz, 2H), 3.48 (t, J = 
5.52 Hz, 2H), 3.57 (m, 2H), 3.61 (m, 2H), 3.72 (m, 2H), 3.92 (s, 2H), 4.49 (s, 2H), 7.04–7.25 
(complex, 8H); 13C NMR (100 MHz, CDCl3) G 28.8, 30.4, 30.5, 32.4, 33.5, 42.9, 43.6, 44.5, 46.9, 
53.1, 58.0, 58.2, 126.2, 126.7, 127.3, 128.3 128.7, 130.4, 130.6, 131.0, 131.3, 134.3, 135.6, 137.4, 
173.4, 175.0. Diagnostic peaks of 2.19: 1H NMR (400 MHz, CDCl3) G 1.72 (m, 2H), 3.13 (m, 2H), 
3.48 (t, J = 5.52 Hz, 2H), 3.57 (m, 2H), 3.72 (m, 2H), 3.92 (s, 2H); 13C NMR (100 MHz, CDCl3) 
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G 30.5, 32.4, 42.9, 43.6, 46.9, 58.2, 131.3, 135.6, 173.4. Diagnostic peaks of 2.20: 1H NMR (400 
MHz, CDCl3) G 1.65 (m, 2H), 2.94 (m, 2H), 3.18 (m, J = 6.68 Hz, 2H), 3.35 (t, J = 5.52 Hz, 2H), 
3.61 (m, 2H), 4.49 (s, 2H); 13C NMR (100 MHz, CDCl3) G 28.8, 30.4, 33.5, 44.5, 53.1, 58.0, 175.0. 
HRMS (ESI) m/z calcd for C13H18NO2 [M + H]+ 220.1338, found 220.1346. 
 
 2-(3c-Hydroxypropyl)-1,2-dihydroisoquinolin-3(4H)-one, 2.22.40 Following the 
procedure A, to a solution of 2-indanone 2.21 (39.7 mg, 0.300 mmol, 1.0 equiv) and 3-
azidopropanol 1.1 (45.5 mg, 0.450 mmol, 1.5 equiv) in HFIP (0.75 mL) was added TfOH (27.0 
PL, 0.306, 1.0 equiv). The reaction mixture was stirred at room temperature for 1 h. Subsequently, 
hydrolysis was carried out with saturated NaHCO3 solution for 24 h. Purification was carried out 
on an automated MPLC system with gradient elution from 0–10% MeOH/CH2Cl2 to afford 2.22 
as a brown oil (55.4 mg, 0.270 mmol, 90% yield). 
 
 1-(3c-Hydroxypropyl)quinoxaline-2,3(1H,4H)-dione, 2.24 and 3-(3c-
hydroxypropyl)quinazoline-2,4(1H, 3H)-dione, 2.25. Following the general procedure A, to a 
solution of isatin 2.23 (58.9 mg, 0.400 mmol, 1.0 equiv) and 3-azidopropanol 1.1 (60.7 mg, 0.600 
mmol, 1.5 equiv) in HFIP (1.0 mL) was added TfOH (35.0 PL, 0.397 mmol, 1.0 equiv). The 
reaction mixture was stirred at room temperature for 6 h. Subsequently, hydrolysis was carried out 
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with saturated NaHCO3 solution for 12 h. The precipitate was filtered, washed with water, and 
dried under vacuum to obtain a mixture of lactams 2.24 and 2.25 as a cream amorphous solid 
(combined yield of 2.24 and 2.25: 67.2 mg, 0.305 mmol, 76% yield; ratio of 2.24:2.25 = 63:37. 
2.24 and 2.25: Rf = 0.21 and 0.48 (5% MeOH/CH2Cl2); IR (neat): 3410, 1673, 1601; 1H NMR (400 
Hz, DMSO-d) G 1.72–1.77 (m, 4H), 3.47 (t, J = 6.40 Hz, 2H), 3.52 (t, J = 6.1 Hz, 2H), 3.94 (m, 
2H), 4.14 (m, 2H), 7.19 (m, 5H), 7.39 (m, 1H), 7.63 (ddd, J = 8.4, 7.3, 1.5 Hz, 1H), 7.91 (dd, J 
=8.0, 1.5 Hz, 1H); 13C NMR (100 MHz, DMSO-d) G 30.8, 31.8, 38.8, 40.9, 59.2, 59.8, 114.7, 
115.8, 116.0, 116.7, 123.4, 124.2, 124.4, 126.8, 127.2, 128.3, 135.8, 140.3, 151.1, 154.5, 156.0, 
162.9. Diagnostic peaks of 2.24: 1H NMR (400 Hz, DMSO-d6) G 3.52 (t, J = 6.08 Hz, 2H), 4.14 
(m, 2H), 7.39 (m, 1H); 13C NMR (100 MHz, DMSO-d6) G 31.8, 40.9, 59.2, 126.8, 127.3, 154.5, 
156.0. HRMS (ESI) m/z calcd for C11H13N2O3 [M + H]+ 221.0926, found 221.0937. Diagnostic 
peaks of 2.25: 1H NMR (400 Hz, DMSO-d6) 3.47 (t, J = 6.40 Hz, 2H), 3.94 (m, 2H), 7.63 (ddd, J 
= 8.4, 7.3, 1.5 Hz, 1H), 7.91 (dd, J = 8.0, 1.5 Hz, 1H); 13C NMR (100 MHz, DMSO-d6) G 30.8, 
38.8, 59.8, 114.7, 128.3, 135.8, 140.3, 151.1, 162.9. HRMS (ESI) m/z calcd for C11H13N2O3 [M + 
H]+ 221.0926, found 221.0928.  
 
 (3aR*,6aS*)-2-(3c-Hydroxypropyl)-2,3,3a,4-tetrahydrocyclopenta[c]pyrrol-1(6aH)-
one 2.27 and (3aR*,6aS*)-1-(3c-hydroxypropyl)-3,3a,6,6a-tetrahydrocyclopenta[b]pyrrol-
2(1H)-one 2.28. Following the general procedure A, to a solution of (r)-cis-bicyclo[3.2.0]hept-2-
en-6-one 2.26 (42.0 PL, 0.398 mmol, 1.0 equiv) and 3-azidopropanol 1.1 (60.7 mg, 0.600 mmol, 
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1.5 equiv) in HFIP (1.0 mL) was added TfOH (35.0 PL, 0.397 mmol, 1.0 equiv). The reaction 
mixture was stirred at room temperature for 1 h. Subsequently, hydrolysis was carried out with 
saturated NaHCO3 solution for 12 h. The crude oil obtained was eluted through a short bed of 
silica gel using 10% MeOH/CH2Cl2. Concentration of solvents afforded a mixture of lactams 2.27 
and 2.28 as a brown oil (combined yield of 2.27 and 2.28: 69.0 mg, 0.381 mmol, 95% yield; ratio 
of 2.27:2.28 = 74:26). 2.27 and 2.28: Rf = 0.25 (5% MeOH/CH2Cl2); IR (neat) 1652, 3382 cm-1; 
1H NMR (400 MHz, CDCl3) G 1.56–1.71 (complex, 4H), 2.28 (dd, J = 17.5, 2.9, 1H), 2.48 (m, 
1H), 2.53 (m, 1H), 2.67–2.56 (complex, 2H), 2.69 (m, 1H), 2.74 (m, 1H), 3.09–3.17 (complex, 
2H), 3.20 (m, 1H), 3.29 (m, 1H), 3.40–3.34 (complex, 3H), 3.52–3.42 (complex, 3H), 3.60 (m, 
2H), 4.24 (td, J = 6.9, 1.8 Hz, 1H), 5.58 (m, 1H), 5.65 (m, 1H), 5.67 (m, 1H), 5.78 (m, 1H); 13C 
NMR (100 MHz, CDCl3) 29.4, 30.2, 35.8, 36.2, 37.3, 37.4, 38.8, 42.3, 42.5, 44.6, 51.9, 58.1, 58.5, 
61.6, 128.7, 131.8, 132.0, 133.1, 175.5, 178.3. Diagnostic peaks of 2.27: 1H NMR (400 MHz, 
CDCl3) G 5.58 (m, 1H), 5.78 (m, 1H); 13C NMR (100 MHz, CDCl3) G 29.4, 36.2, 38.8, 42.5, 44.6, 
51.9, 58.1, 131.8, 132.0, 178.3. HRMS (ESI) m/z calcd for C10H16NO2 [M + H]+ 182.1181, found 
182.1184. Diagnostic peaks of 2.28: 1H NMR (400 MHz, CDCl3) G 2.28 (dd, J = 17.5, 2.9, 1H), 
2.48 (m, 1H), 2.53 (m, 1H), 2.74 (m, 1H), 3.20 (m, 1H), 4.24 (td, J = 6.9, 1.8 Hz, 1H), 5.65 (m, 
1H), 5.67 (m, 1H); 13C NMR (100 MHz, CDCl3) G 30.2, 35.8, 37.3, 37.4, 42.3, 58.5, 61.6, 128.7, 




 (1R*,5S*)-3-(3c-Hydroxypropyl)-3-azabicyclo[3.2.1]octan-2-one, 2.30 and (1R*,5S*)-
2-(3c-hydroxypropyl)-2-azabicyclo[3.2.1]octan-3-one, 2.31. Following the general procedure A, 
to a solution of norcamphor 2.29 (44.9 mg, 0.408 mmol, 1.0 equiv) and 3-azidopropanol 1.1 (61.0, 
0.603 mmol, 1.5 equiv) in HFIP (1.0 mL) was added TfOH (35.0 PL, 0.397 mmol, 1.0 equiv). The 
reaction mixture was stirred at room temperature for 2 h. Subsequently, hydrolysis was carried out 
with 1 M NaOH solution for 12 h. Purification was carried out on an automated MPLC system 
with gradient elution from 0–10% MeOH/CH2Cl2 to afford a mixture of lactams 2.30 and 2.31 as 
orange oil (combined yield of 2.30 and 2.31: 67.1 mg, 0.366 mmol, 90% yield; ratio of 2.30:2.31 
= 58:42). 2.30 and 2.31: Rf = 0.32 (5% MeOH/CH2Cl2); IR (neat) 3380, 1616 cm-1. 1H NMR (400 
MHz, CDCl3) G 1.49–1.81 (complex, 10 H), 1.82–1.97 (complex, 6H), 2.24 (m, 1H), 2.51 (m, 2H), 
2.59 (m, 1H), 2.75 (br, s, 1H), 2.92 (m, 1H), 3.07 (m, 1H), 3.20 (m, 1H), 3.31 (dd, J = 11.4, 4.04 
Hz, 1H), 3.36–3.43 (m, 1H), 3.45 (m, 1H), 3.50–3.64 (m, 2H), 3.81 (m, 1H); 13C NMR (100 MHz, 
CDCl3) G 29.1, 29.21 (2C), 29.3, 30.2, 31.4, 32.6, 32.9, 33.5, 33.6, 36.6, 41.6, 42.1, 42.8, 43.5, 
55.7, 58.1, 58.7, 170.8, 176.2. Diagnostic peaks of 2.30: 1H NMR (400 MHz, CDCl3) G 2.75 (br, 
s, 1H), 2.92 (m, 1H), 3.20 (m, 1H), 3.31 (dd, J = 11.4, 4.04 Hz, 1H); 13C NMR (100 MHz, CDCl3) 
G 41.6, 43.5, 55.7, 176.2. Diagnostic peaks of 2:31: 1H NMR (400 MHz, CDCl3) G 2.24 (m, 1H), 
2.59 (m, 1H), 3.07 (m, 1H), 3.81 (m, 1H); 13C NMR (100 MHz, CDCl3) G 36.6, 42.1, 42.8, 58.7, 




 (1R*,3R*,8S*)-4-(3c-Hydroxypropyl)-4-azatricyclo[4.3.1.13,8]undecan-5-one, 2.33. 
Following the general procedure A, to a solution of 2-adamantanone 2.32 (60.0 mg, 0.399 mmol, 
1.0 equiv) and 3-azidopropanol 1.1 (60.7 mg, 0.600 mmol, 1.5 equiv) in HFIP (1.0 mL) was added 
TfOH (35.0 PL, 0.397 mmol, 1.0 equiv). The reaction mixture was stirred at room temperature for 
1 h. Subsequently, hydrolysis was carried out with 1 M NaOH solution for 12 h. The crude oil 
obtained was eluted through a short bed of silica gel using 10% MeOH/CH2Cl2. Concentration of 
solvents afforded 2.33 as a yellow oil (85.6 mg, 0.383 mmol, 96% yield). Rf = 0.21 (5% 
MeOH/CH2Cl2); IR (neat) 3387, 1604 cm-1; 1H NMR (400 MHz, CDCl3) G 1.64 (m, 2H), 1.70–
1.95 (complex, 10H), 2.05 (m, 2H), 2.86 (m, 1H), 3.33 (m, 1H), 3.51 (m, 4H), 4.26 (t, J = 7.16 Hz, 
1H); 13C NMR (100 MHz, CDCl3) G 26.4 (2C), 30.2, 31.3 (2C), 34.5, 35.7 (2C), 42.4, 45.4, 53.7, 
58.1, 180.6. HRMS (ESI) m/z calcd for C13H22NO2 [M + H]+ 224.1651, found 224.1645.  
 
 N-(3c-Hydroxypropyl)-N-butylpentanamide (mixture of rotamers) 2.35, and 3-
Butylaminopropylpentanoate, 2.36.48 Following the general procedure A, to a solution of 5-
nonanone 2.34 (57.5 mg, 0.404 mmol, 1.0 equiv) and 3-azidopropanol 1.1 (60.7 mg, 0.600 mmol, 
1.5 equiv) in HFIP (1.0 mL) was added TfOH (35.0 PL, 0.397 mmol, 1.0 equiv). The reaction 
mixture was stirred at room temperature for 6 h, and was followed by hydrolysis with saturated 
NaHCO3 solution for 24 h. Purification was carried out on an automated MPLC system with 
gradient elution from 0–25% MeOH/CH2Cl2 to afford 2.35 (mixture of rotamers) as a colorless oil 
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(13.1 mg, 0.0610 mmol, 15% yield; ratio of rotamers = 79:21) and 2.36 as a yellow oil (59.9 mg, 
0.278 mmol, 69% yield).  
 
2.5.2 Experimental Section for 2.3 
Caution: Although we have not experienced any untoward events with the compounds 
mentioned in this paper, azides and their precursors are known explosive hazards and should 
be used with appropriate safety precautions. Minimally, careful control of temperature and scale 
should be exercised. We do not recommend distillation of reaction mixtures that may contain 
residues of azide sources. We recommend the use of blast shields for heated reactions.  
Reactions were performed under inert atmosphere (argon or nitrogen). Reactions were 
carried out in flame-dried round bottom flasks. Slow addition reactions were carried out a Harvard 
Apparatus Pump 33, which features a dual infuse/withdraw pump system. All chemicals were 
purchased from commercial sources and used without further purification. New containers of acid 
catalysts and HFIP were used. HFIP was purchased from Oakwood Chemical. Anhydrous CH2Cl2, 
MeOH, and DMF were purchased from Sigma-Aldrich and used as received. Thin-layer 
chromatography (TLC) was performed using commercial glass-backed silica plates (250 µM) with 
an organic binder. Visualization was accomplished with UV light and an iodine chamber. Reaction 
was monitored on analytical Waters Acquity UPLC using C18 column, BEH 2.1 × 50 mm, 1.7 
µm, at 30 ˚C with mobile phases A (H2O + 0.1% formic acid) and B (MeCN + 0.1% formic acid). 
Purification was carried out by an automated flash chromatography/medium-pressure liquid 
chromatography (MPLC) system using normal phase silica gel flash columns (4 or 12 g) and 
reverse phase C18 columns (13 g, Gold 15.5 g, or Gold 50.0 g).  
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The infrared (IR) spectra were acquired as thin films or solids using a universal ATR 
sampling accessory on a Thermo Scientific Nicolet iS5 FT-IR spectrometer; the absorption 
frequencies are reported in cm-1. All nuclear magnetic resonance spectra were recorded on a Varian 
400 MHz, Varian 500 MHz with a dual carbon/proton cyroprobe, or Bruker 600 MHz with a dual 
carbon/proton cryoprobe instrument. NMR samples were recorded in deuterated chloroform 
(CDCl3) or deuterated dimethylsulfoxide (DMSO-d6). Chemical shifts are reported in parts per 
million (ppm) and referenced to the center line of solvent (CDCl3: δ 7.26 ppm for 1H NMR and 
77.16 ppm for 13C NMR; DMSO-d6 δ 2.50 ppm for 1H NMR and 39.52 ppm for 13C NMR); 
coupling constants are given in Hertz (Hz). HRMS data were collected using Thermo LTQ Fourier 
transform ion cyclotron resonance (FT-ICR, 7T) with a heated electrospray ion source (HESI) or 
electrospray ion source (ESI). Purity data were collected using Waters Acquity H-class UPLC-
PDA detector coupled to the Thermo LTQ Fourier transform ion cyclotron resonance mass 
spectrometer (FT-ICR, 7T) with a heated electrospray ion source (HESI). Samples were run on 
analytical Acquity UPLC BEH 2.1 × 50 mm, 1.7 µm, C18 column, and analytical Acquity UPLC 
HSS T3, 2.1 × 50 mm, 3.18 µm, C18 column, at 40 ˚C with mobile phases A (H2O + 0.1% formic 
acid) and B (MeCN + 0.1% formic acid). Melting points were determined in open capillary tubes 
using OptiMelt, an automated melting point apparatus and are uncorrected. Elemental analysis was 
serviced by Atlantic Microlab, Inc. Data for the known tetrazoles prepared according to the 
methodology described in the section match with those reported in the literature.  
 
 General procedure B for catalyst screening. To a solution of 4-phenylcyclohexanone 2.1 
(0.300 mmol, 1.0 equiv), 1,3,5-trimethoxybenzene (1.50 mmol, 5.0 equiv), and catalyst (0.060–
0.300 mmol, 20–100 mol%) in HFIP (1.0 mL) in a flame-dried nitrogen-flushed 25 mL round 
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bottom flask was added a solution of TMSN3 (80 μL, 0.600 mmol, 2.0 equiv) in HFIP (2.0 mL) 
using a syringe pump (0.40 mL/h, 14.00 mm diameter, and 20 gauge needle) over 6 h at room 
temperature. Following slow addition, the reaction mixture was stirred for an additional 20–30 min 
and concentrated under a stream of nitrogen. The residual crude was redissolved in CH2Cl2 (ca. 40 
mL). The organic layer was washed with a saturated solution of NaHCO3 (3 × 5 mL), brine (5 
mL), dried over anhydrous Na2SO4, filtered, and concentrated. Conversion to product was 
determined by 1H NMR of the crude reaction mixture using benzyl benzoate as an internal 
standard; alternatively, purification was carried out by an automated MPLC system using a 12 g 
normal phase silica column with gradient elution from 0–6% MeOH/CH2Cl2.  
 
 General procedure C for the Optimization of Reaction Conditions Using AlCl3. To a 
solution of 4-phenylcyclohexanone 2.1 (0.300 mmol, 1.0 equiv), 1,3,5-trimethoxybenzene (0.600–
2.10 mmol, 2.0–7.0 equiv), and AlCl3 (0.300–0.600 mmol, 1.0–2.0 equiv) in HFIP (1.0–2.0 mL) 
in a flame-dried nitrogen-flushed 25 mL round bottom flask was added a solution of TMSN3 
(0.375–0.600 mmol, 1.25–2.0 equiv) in HFIP (2.0 mL) using a syringe pump (0.20–1.00 mL/h, 
14.00 mm diameter, and 20 gauge needle) over 2–10 h at room temperature. Following slow 
addition, the reaction mixture was stirred for an additional 20–30 min or 15 h and concentrated 
under a stream of nitrogen. The residual crude was redissolved in CH2Cl2 (ca. 40 mL). The organic 
layer was washed with a saturated solution of NaHCO3 (3 × 5 mL), brine (5 mL), dried over 
anhydrous Na2SO4, filtered, and concentrated, unless otherwise noted. Conversion to product was 
determined by 1H NMR of the crude reaction mixture using benzyl benzoate as an internal 
standard; alternatively, purification was carried out by an automated MPLC system using a 12 g 




 General procedure D for the optimization of reaction conditions using AlBr3. To a 
solution of 4-phenylcyclohexanone 2.1 (0.300 mmol, 1.0 equiv), 1,3,5-trimethoxybenzene (0.600–
1.50 mmol, 2.0–5.0 equiv), and AlBr3 (0.150–0.300 mmol, 0.5–1.0 equiv) in HFIP (1.0 mL) in a 
flame-dried nitrogen-flushed 25 mL round bottom flask was added a solution of TMSN3 (0.400–
0.600 mmol, 1.5–2.0 equiv) in HFIP (2.0 mL) using a syringe pump (0.20–0.40 mL/h, 14.00 mm 
diameter, and 20 gauge needle) over 2–6 h at room temperature. Following slow addition, the 
reaction mixture was stirred for an additional 20–30 min or 15 h and concentrated under a stream 
of nitrogen. The residual crude was redissolved in CH2Cl2 (ca. 40 mL), filtered to remove residual 
solids, and concentrated, unless otherwise noted. Conversion to product was determined by 1H 
NMR of the crude reaction mixture using benzyl benzoate as an internal standard; alternatively, 
purification was carried out by an automated MPLC system using a 12 g normal phase silica 
column with MeOH/CH2Cl2 gradient elution or  using a 15.5 g C18 reverse phase column with 
H2O/MeCN gradient elution.  
 
 General procedure E for reactions carried out at room temperature using AlBr3. To 
a solution of 4-phenylcyclohexanone 2.1 (0.300 mmol, 1.0 equiv), 1,3,5-trimethoxybenzene (1.50 
mmol, 5.0 equiv), and AlBr3 (0.300–0.480 mmol, 1.0–1.6 equiv) in HFIP (1.0–2.0 mL) in a flame-
dried nitrogen-flushed 25 mL round bottom flask was added a solution of TMSN3 (80.0 μL, 0.600 
mmol, 2.0 equiv) in HFIP (2.0 mL) using a syringe pump (0.40 mL/h, 14.00 mm diameter, and 20 
gauge needle) over 6 h at room temperature. Following slow addition, the reaction mixture was 
stirred for an additional 20–30 min or 15 h, and concentrated under a stream of nitrogen. The crude 
residue was redissolved in CH2Cl2 (ca. 40 mL), filtered to remove residual solids, and 
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concentrated. Conversion to product was determined by 1H NMR of the crude reaction mixture 
using benzyl benzoate as an internal standard; alternatively, purification was carried out by an 
automated MPLC system using a 12 g normal phase silica column with MeOH/CH2Cl2 gradient 
elution or  using a 15.5 g C18 reverse phase column with H2O/MeCN gradient elution.  
 
 General procedure F for reactions carried out under heating at 35 °C using AlBr3. To 
a solution of 4-phenylcyclohexanone 2.1 (0.300 mmol, 1.0 equiv), 1,3,5-trimethoxybenzene (1.50 
mmol, 5.0 equiv) and AlBr3 (0.300–0.337 mmol, 1.0–1.1 equiv) in HFIP (1.0 mL) in a flame-dried 
nitrogen-flushed 25 mL round bottom was added a solution of TMSN3 (80.0 μL, 0.600 mmol, 2.0 
equiv) in HFIP (2.0 mL) using a syringe pump (0.40 mL/h, 14.00 mm diameter, and 20 gauge 
needle) over 6 h at 35 °C. Following slow addition, the reaction mixture was stirred at 35 °C for 
an additional 15 h, allowed to room temperature, and concentrated under nitrogen. The crude 
residue was redissolved in CH2Cl2 (~40 mL), filtered to remove residual solids, and concentrated. 
Conversion to product was determined by 1H NMR of the crude reaction mixture using benzyl 
benzoate as an internal standard; alternatively, purification was carried out by an automated MPLC 
system using a 12 g normal phase silica column with MeOH/CH2Cl2 gradient elution.  
 
 General procedure G for enamide formation. Following slow addition via general 
procedure E, the crude residue was redissolved in CH2Cl2 (~40 mL), filtered to remove residual 
solids, and concentrated under high vacuum. To the crude residue in anhydrous CH2Cl2 (3.0–4.0 
mL) was added an electrophile (0.641–3.71 mmol, 2.2–13.0 equiv), DMAP (0.196–0.451 mmol, 
0.65–1.5 equiv), and/or triethylamine (0.360–0.897 mmol, 1.2–3.0 equiv). The reaction mixture 
was stirred at room temperature for 24 h under argon atmosphere. Purification was carried out by 
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an automated MPLC system using a 12 g normal phase silica column with MeOH/CH2Cl2 gradient 
elution or a C18 reverse phase column with H2O/MeCN gradient elution.  
 
 General procedure H for amine formation. Following slow addition via general 
procedure E, the crude residue was redissolved in CH2Cl2 (~40 mL), filtered to remove residual 
solid, and concentrated under high vacuum. To the crude residue in anhydrous MeOH (3.0 mL) at 
0 °C was added sodium borohydride (15.0–23.0 mg, 0.397–0.608 mmol, 1.9–2.0 equiv). The 
reaction mixture was stirred at room temperature for 4 h under argon atmosphere. MeOH was 
removed under a stream of nitrogen. The residual crude was diluted with CH2Cl2 (35 mL), washed 
with H2O (5 mL), saturated solution of NaHCO3 (2 × 5 mL), brine (5 mL), dried over anhydrous 
Na2SO4, filtered, and concentrated. Purification was carried out by an automated MPLC system 
using a 12 g normal phase silica column with MeOH (0.5% NH4OH)/CH2Cl2 gradient elution; 
alternatively, the crude residue was further functionalized using acetic anhydride or di-tert-butyl 
dicarbonate.  
 
 4-Phenyl-7-(2,4,6-trimethoxyphenyl)-3,4,5,6-tetrahydro-2H-azepine, 2.37. Following 
the general procedure B, TMSN3 (80.0 µL, 0.603 mmol, 2.0 equiv) in HFIP (2.0 mL) was added 
using a syringe pump over 6 h to a solution of 4-phenylcyclohexanone 2.1 (52.2 mg, 0.300 mmol, 
1.0 equiv), AlCl3 (80.2 mg, 0.601 mmol, 2.0 equiv), and 1,3,5-trimethoxybenzene (252 mg, 1.50 
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mmol, 5.0 equiv) in HFIP (1.0 mL). Purification by an automated MPLC system on a 12 g normal 
phase silica column with gradient elution from 0–5.5% MeOH/CH2Cl2 afforded the 2.37 as a 
yellow oil (80.6 mg, 0.237 mmol, 79% yield). Rf = 0.25 (4% MeOH/CH2Cl2); IR (neat) 2931, 
2840, 1650, 1605, 1586 cm-1. 1H NMR (400 MHz, CDCl3) 1H NMR (400 MHz, CDCl3) δ 7.33–
7.29 (m, 2H), 7.22–7.18 (m, 3H), 6.13 (s, 2H), 4.23 (ddd, J = 12.8, 6.5, 1.5 Hz, 1H), 3.81 (d, J = 
5.3 Hz, 9H), 3.64 (m, 1H), 2.94–2.86 (m, 1H), 2.84–2.77 (m, 1H), 2.65–2.60 (m, 1H), 2.03–1.97 
(m, 1H), 1.84–1.72 (m, 3H); 13C NMR (101 MHz, CDCl3) δ 172.7, 160.9, 158.0, 147.8, 128.5, 
126.8, 126.2, 115.6, 90.7, 55.9, 55.4, 51.7, 49.7, 35.3, 33.7, 30.7. HRMS (FT-ICR, ESI) m/z: [M 
+ H]+ calcd for C21H26NO3 340.1907, found 340.1904.  
 
 4-Phenyl-7-(2,4,6-trimethoxyphenyl)-3,4,5,6-tetrahydro-2H-azepinium Chloride, 
2.38. Following the general procedure C, TMSN3 (80.0 µL, 0.603 mmol, 2.0 equiv) in HFIP (2.0 
mL) was added using a syringe pump over 6 h to a solution of 4-phenylcyclohexanone 2.1 (52.3 
mg, 0.300 mmol, 1.0 equiv), AlCl3 (80.2 mg, 0.601 mmol, 2.0 equiv), and 1,3,5-
trimethoxybenzene (252 mg, 1.50 mmol, 5.0 equiv) in HFIP (1.0 mL). Following slow addition, 
the reaction mixture was stirred for an additional 15 h and concentrated under a stream of nitrogen. 
Purification by an automated MPLC system on a 12 g normal phase silica column with gradient 
elution from 0–5.5% MeOH/CH2Cl2 afforded the 2.38 as a yellow oil (87.3 mg, 0.232 mmol, 77% 
yield). Rf = 0.25 (4% MeOH/CH2Cl2); IR (neat) 3386, 2940, 2842, 1650, 1602 cm-1. 1H NMR (400 
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MHz, CDCl3) δ 7.31 (m, 2H), 7.23 (m, 1H), 7.16 (m, 2H), 6.12 (s, 2H), 4.44 (m, 1H), 3.84 (d, J = 
9.8 Hz, 9H), 3.72–3.65 (m, 1H), 3.07 (m, 1H), 2.97–2.82 (m, 2H), 2.12–2.06 (m, 1H), 2.02–1.97 
(m, 1H), 1.91–1.76 (m, 2H); 13C NMR (151 MHz, CDCl3) δ 180.8, 165.2, 159.9, 145.7, 128.8, 
126.8, 126.6, 106.3, 91.0, 56.2, 55.7, 48.8, 47.3, 35.5, 32.4, 29.7. HRMS (FT-ICR, ESI) m/z: [M 
– Cl]+ calcd for C21H26NO3 340.1907, found 340.1903. 
 
 4-Phenyl-7-(2,4,6-trimethoxyphenyl)-3,4,5,6-tetrahydro-2H-azepinium Bromide, 
2.39. Following the general procedure F, TMSN3 in HFIP was added to a solution of 4- 
phenylcyclohexanone 2.1 (52.3 mg, 0.300 mmol, 1.0 equiv), AlBr3 (80.0 mg, 0.300 mmol, 1.0 
equiv), and 1,3,5-trimethoxybenzene (252 mg, 1.50 mmol, 5.0 equiv) in HFIP. Following slow 
addition, the reaction mixture was stirred for an additional 15 h and concentrated under a stream 
of nitrogen. Purification by an automated MPLC system on a 12 g normal phase silica column with 
gradient elution from 0–5% MeOH/CH2Cl2 afforded the 2.39 as a colorless amorphous solid (116 
mg, 0.276 mmol, 92% yield). Rf = 0.25 (5% MeOH/CH2Cl2); mp decomposed; IR (neat) 3405, 
2942, 2841, 1649, 1599, 1576 cm-1. 1H NMR (400 MHz, CDCl3) 1H NMR (400 MHz, CDCl3) δ 
13.5 (br s, 1H), 7.32 (m, 2H), 7.23 (m, 1H), 7.17 (m, 2H), 6.13 (s, 2H), 4.60 (dt, J = 13.2, 6.3 Hz, 
1H), 3.88 (d, J = 14.7 Hz, 9H), 3.72 (m, 1H), 3.29 (dd, J = 14.5, 7.4 Hz, 1H), 3.00–2.86 (m, 2H), 
2.18–2.06 (m, 2H), 1.97–1.79 (m, 2H); 13C NMR (101 MHz, CDCl3) δ 182.4, 166.4, 160.5, 145.4, 
128.9, 127.1, 126.7, 104.5, 91.2, 56.6, 55.9, 48.5, 46.7, 35.7, 32.3, 29.7. Note: X-ray crystal 
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structure of this analog is provided in the CCDC (CCDC 1832152). HRMS (FT-ICR, ESI) m/z: 
[M – Br]+ calcd for C21H26NO3 340.1907, found 340.1897.  
 
Table 2.9. Selected crystallographic and refinement parameters for 2.39.  
compound 2.39 
CCDC 1832152 
empirical formula  C22H27BrCl3NO3 
formula weight 539.70 
temperature 200(2) K 
wavelength  1.54178 Å 
crystal system monoclinic 
space group Pc 
unit cell dimensions a = 11.9047(5) Å, D= 90° 
b = 14.5768(5) Å, E= 101.780(2)° 
c = 29.1414(10) Å, J = 90° 
Z 8 
volume   4950.5(3) Å3 
density 1.448 Mg/m3 
absorption coefficient 5.430 µ mm-1 
F(000) 2208 
crystal size 0.105 × 0.045 × 0.025 mm3 
Theta range for data collection  1.548 to 69.844°   
index ranges -14<=h<=11, -17<=k<=16, -32<=l<=34 
reflections collected 64216 
independent reflections 12880 [R(int) = 0.0633] 
completeness to theta = 66.000° 98.6% 
absorption correction multi-scan 
max. and min. transmission 1.000 and 0.632 
refinement method full-matrix least-squares on F2 
data/restraints/parameters 12880/14/1084 
Goodness-of-fit F2 1.068 
final R indices [I>2sigma(I)] R1 = 0.0591, wR2 = 0.1525 
R indices (all data) R1 = 0.0670, wR2 = 0.1588 





 4-Methyl-7-(2,4,6-trimethoxyphenyl)-3,4,5,6-tetrahydro-2H-azepinium Bromide, 
2.41. Following the general procedure F, TMSN3 in HFIP was added to a solution of-
methylcyclohexanone 2.40 (37.0 µL, 0.301 mmol, 1.0 equiv), AlBr3 (82.1 mg, 0.308 mmol, 1.0 
equiv), 1,3,5-trimethoxybenzene (252 mg, 1.50 mmol, 5.0 equiv) in HFIP. Following slow 
addition, the reaction mixture was stirred for an additional 15 h and concentrated under a stream 
of nitrogen. Purification by an automated MPLC system on a 12 g normal phase silica column with 
gradient elution from 0–5% MeOH/CH2Cl2 afforded 2.41 as an off-white amorphous solid (86.7 
mg, 0.242 mmol, 80% yield). Rf = 0.17 (4% MeOH/CH2Cl2); mp 182–183 ˚C; IR (neat) 2952, 
2870, 1637, 1601, 1576 cm-1. 1H NMR (400 MHz, CDCl3) δ 13.3 (br s, 1H), 6.11 (s, 2H), 4.42 (m, 
1H), 3.88 (s, 6H), 3.85 (s, 3H), 3.62 (m, 1H), 3.14 (m, 1H), 2.77 (m, 1H), 1.89 (m, 3H), 1.38 (m, 
2H), 1.02 (d, J = 6.3 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 182.8, 166.2, 160.3 (2C), 104.6, 
91.1 (2C), 56.5 (2C), 55.8, 46.4, 36.8, 35.01, 33.1, 29.7, 23.0. HRMS (FT-ICR, ESI) m/z: [M – 
Br]+ calcd for C16H24NO3 278.1751, found 278.1746.  
Alternatively following the general procedure F, TMSN3 in HFIP was added to a solution 
of 2.40 (37.0 µL, 0.301 mmol, 1.0 equiv), AlBr3 (87.4 mg, 0.328 mmol, 1.1 equiv), 1,3,5-
trimethoxybenzene (252 mg, 1.50 mmol, 5.0 equiv) in HFIP. Purification by an automated MPLC 
system on a 12 g normal phase silica column with gradient elution from 0–5% MeOH/CH2Cl2 
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afforded 2.41 as an off-white crystalline solid (94.4 mg, 0.263 mmol, 87% yield). Characterization 
data was consistent with the above entry.  
 
 4-(tert-Butyl)-7-(2,4,6-trimethoxyphenyl)-3,4,5,6-tetrahydro-2H-azepinium Bromide, 
2.43. Following the general procedure F, TMSN3 in HFIP was added to a solution of 4-tert-
butylcyclohexanone 2.42 (46.4 mg, 0.301 mmol, 1.0 equiv), AlBr3 (82.7 mg, 0.310 mmol, 1.0 
equiv), and 1,3,5-trimethoxybenzene (252 mg, 1.50 mmol, 5.0 equiv) in HFIP. Following slow 
addition, the reaction mixture was stirred for an additional 15 h and concentrated under a stream 
of nitrogen. Purification by an automated MPLC system on a 12 g normal phase silica column with 
gradient elution from 0–5% MeOH/CH2Cl2 afforded 2.43 as a colorless amorphous solid (109 mg, 
0.272 mmol, 91% yield). Rf = 0.40 (5% MeOH/CH2Cl2); mp 168–172 ˚C; IR (neat) 2949, 2868, 
1655, 1600, 1577 cm-1. 1H NMR (400 MHz, CDCl3) δ 13.37 (br s, 1H), 6.12 (s, 2H), 4.51 (m, 1H), 
3.89 (s, 6H), 3.86 (s, 3H), 3.55 (m, 1H), 3.21 (dd, J = 14.4, 7.6 Hz, 1H), 2.69 (m, 1H), 2.13–2.03 
(m, 2H), 1.48–1.32 (m, 3H), 0.90 (s, 9H); 13C NMR (101 MHz, CDCl3) δ 182.7, 166.2, 160.4 (2C), 
104.5, 91.1 (2C), 56.6 (2C), 55.9, 52.1, 46.9, 35.5, 33.6, 27.5 (3C), 26.6, 23.0. HRMS (FT-ICR, 




 4,4-Dimethyl-7-(2,4,6-trimethoxyphenyl)-3,4,5,6-tetrahydro-2H-azepinium Bromide, 
2.45. Following the general procedure E, TMSN3 in HFIP was added to a solution of 4,4-
dimethylcyclohexanone 2.44 (38.3 mg, 0.303 mmol, 1.0 equiv), AlBr3 (80.3 mg, 0.301 mmol, 1.0 
equiv), and 1,3,5-trimethoxybenzene (252 mg, 1.50 mmol, 4.9 equiv) in HFIP. Purification by an 
automated MPLC system on a 12 g normal phase silica column with gradient elution from 0–2% 
MeOH/CH2Cl2 afforded 2.45 as a white amorphous solid (88.8 mg, 0.239 mmol, 79% yield). Rf = 
0.29 (5% MeOH/CH2Cl2); mp 181–184 ˚C; IR (neat) 2940, 2862, 2836, 1648, 1602, 1579 cm-1. 
1H NMR (400 MHz, CDCl3) δ 13.3 (br s, 1H), 6.12 (s, 2H), 4.00 (m, 2H), 3.90 (s, 6H), 3.86 (s, 
3H), 2.92 (m, 2H), 1.60 (m, 4H), 1.07 (s, 6H); 13C NMR (101 MHz, CDCl3) δ 182.7, 166.2, 160.4 
(2C), 104.6, 91.2 (2H), 56.8, 56.0 (2C), 43.3, 37.8, 34.4, 33.4, 31.7, 28.9 (2C). HRMS (FT-ICR, 
ESI) m/z: [M – Br]+ calcd for C17H26NO3 292.1907, found 292.1902; Anal. calcd. for 
C17H26BrNO3: C 54.84, H 7.04, N 3.76, Br 21.46, found C 54.72, H 7.09, N 3.77, Br 21.32.  
Alternatively following the general procedure F, TMSN3 in HFIP was added to a solution 
of 2.44 (37.4 mg, 0.296 mmol, 1.0 equiv), AlBr3 (82.9 mg, 0.311 mmol, 1.1 equiv), and 1,3,5-
trimethoxybenzene (252 mg, 1.50 mmol, 5.1 equiv) in HFIP. Purification by an automated MPLC 
system on a 12 g normal phase silica column with gradient elution from 0–2% MeOH/CH2Cl2 
afforded 2.45 as a white amorphous solid (91.4 mg, 0.245 mmol, 83% yield). Characterization data 




 8-(2,4,6-Trimethoxyphenyl)-7-azaspiro[3.6]dec-7-en-7-ium Bromide, 2.47. Following 
the general procedure E, TMSN3 in HFIP was added to a solution of spiro[3.5]nonan-7-one 2.46 
(42.4 mg, 0.307 mmol, 1.0 equiv), AlBr3 (88.0 mg, 0.330 mmol, 1.1 equiv), 1,3,5-
trimethoxybenzene (251 mg, 1.49 mmol, 4.9 equiv) in HFIP. Following slow addition, the reaction 
mixture was stirred for an additional 15 h and concentrated under a stream of nitrogen. Purification 
by an automated MPLC system on a 12 g normal phase silica column with gradient elution from 
0–5% MeOH/CH2Cl2 afforded 2.47 as a pale pink crystalline solid (91.9 mg, 0.239 mmol, 78% 
yield). Rf = 0.28 (4% MeOH/CH2Cl2); mp 183–185 ˚C; IR (neat) 2919, 2839, 1637, 1601, 1574 
cm-1. 1H NMR (400 MHz, CDCl3) δ 6.11 (s, 2H), 3.93 (m, 2H), 3.88 (s, 6H), 3.85 (s, 3H), 2.85 
(m, 2H), 2.02–1.80 (complex, 10H); 13C NMR (151 MHz, CDCl3) δ 182.9, 166.1, 160.3 (2C), 
104.6, 91.1 (2C), 56.5 (2C), 55.8, 43.2, 42.2, 36.8, 33.6, 32.4, 31.6, 14.3. Note: Missing one carbon 
signal due to signal overlap. HRMS (FT-ICR, ESI) m/z: [M – Br]+ calcd for C18H26NO3 304.1907, 




 2-Methyl-7-(2,4,6-trimethoxyphenyl)-3,4,5,6-tetrahydro-2H-azepinium Bromide, 
2.49. Following the general procedure E, TMSN3 in HFIP was added to a solution of 2-
methylcyclohexanone 2.48 (36.0 µL, 0.297 mmol, 1.0 equiv), AlBr3 (83.1 mg, 0.312 mmol, 1.1 
equiv), and 1,3,5-trimethoxybenzene (251 mg, 1.49 mmol, 5.0 equiv) in HFIP. Purification by an 
automated MPLC system on a 12 g normal phase silica column with gradient elution from 0–6% 
MeOH/CH2Cl2 afforded 2.49 as a pale yellow amorphous solid (78.9 mg, 0.220 mmol, 74% yield). 
Characterization data was consistent with the entry below. 
Alternatively following the general procedure F, TMSN3 in HFIP was added to a solution 
of 2.48 (36.0 µL, 0.297 mmol, 1.0 equiv), AlBr3 (83.4 mg, 0.331 mmol, 1.1 equiv), and 1,3,5-
trimethoxybenzene (251 mg, 1.49 mmol, 5.0 equiv) in HFIP. Purification by an automated MPLC 
system on a 12 g normal phase silica column with gradient elution from 0–6% MeOH/CH2Cl2 
afforded 2.49 as a pale yellow amorphous solid (88.5 mg, 0.247 mmol, 83% yield, UPLC-HRMS 
purity: ≥99.5%). Rf = 0.19 (3% MeOH/CH2Cl2); mp 156–160 ˚C (decomposed); IR (neat) 2933, 
2858, 1601, 1578 cm-1. 1H NMR (400 MHz, CDCl3) δ 13.1 (br s, 1H), 6.10 (s, 2H), 4.32 (m, 1H), 
3.87 (s, 6H), 3.84 (s, 3H), 3.04 (m, 1H), 2.90 (m, 1H), 2.03 (m, 1H), 1.88–1.76 (complex, 5H), 
1.73 (d, J = 7.0 Hz, 3H); 13C NMR (151 MHz, CDCl3) δ 182.9, 166.0, 160.1 (2C), 104.8, 91.1 
(2C), 56.7, 56.4 (2C), 55.7, 36.3, 32.7, 27.9, 21.8, 20.1. HRMS (FT-ICR, HESI) m/z: [M – Br]+ 




 2-(tert-Butyl)-7-(2,4,6-trimethoxyphenyl)-3,4,5,6-tetrahydro-2H-azepinium Bromide, 
2.51. Following the general procedure F, TMSN3 in HFIP was added to a solution of 2-(tert-
butyl)cyclohexanone 2.50 (45.9 mg, 0.298 mmol, 1.0 equiv), AlBr3 (117 mg, 0.438 mmol, 1.5 
equiv), and 1,3,5-trimethoxybenzene (252 mg, 1.50 mmol, 5.0 equiv) in HFIP. Purification by an 
automated MPLC system on a 12 g normal phase silica column with gradient elution from 0–9% 
MeOH/CH2Cl2 afforded 2.51 as a yellow oil (12.8 mg, 0.032 mmol, 11% yield). Rf = 0.15 (4% 
MeOH/CH2Cl2); IR (neat) 2938, 2861, 1601, 1579 cm-1. 1H NMR (400 MHz, CDCl3) δ 6.11 (s, 
2H), 3.84 (s, 9H), 3.66 (m, 1H), 2.98–2.90 (m, 2H), 2.07–1.88 (m, 3H), 1.82–1.67 (m, 2H), 1.47 
(m, 1H), 1.18 (s, 9H); 13C NMR (151 MHz, CDCl3) δ 165.1, 160.1 (2C), 91.3 (2C), 70.9, 56.3 
(2C), 55.8, 36.0, 34.6, 29.8, 28.9, 26.8 (2C), 26.7, 22.3. Note: Missing two imine peaks in 13C 




azepin-ium Bromide, 2.53. Following the general procedure E, TMSN3 in HFIP was added to a 
solution of L-methanone 2.52 (52.0 µL, 0.301 mmol, 1.0 equiv), AlBr3 (86.0 mg, 0.322 mmol, 1.1 
equiv), and 1,3,5-trimethoxybenzene (252 mg, 1.50 mmol, 5.0 equiv) in HFIP. Purification by an 
automated MPLC system on a 12 g normal phase silica column with gradient elution from 0–3% 
MeOH/CH2Cl2 afforded 2.53 as an off-white amorphous solid (36.0 mg, 0.089 mmol, 30% yield) 
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and known tetrazole ((5S,8R)-5-isopropyl-8-methyl-6,7,8,9-tetrahydro-5Htetrazolo[1,5-
a]azepine,7 1.40 mg, 0.007 mmol, 2% yield). Rf = 0.14 (4% MeOH/CH2Cl2); mp 146–150 ˚C; IR 
(neat) 2958, 2915, 2870, 1597, 1569 cm-1; [α]𝐷22 = + 28.0 (c = 0.50, CHCl3). 1H NMR (400 MHz, 
CDCl3) δ 12.7 (br s, 1H), 6.09 (s, 2H), 3.85 (s, 6H), 3.82 (s, 3H), 3.58 (m, 1H), 2.88 (d, J = 14.1 
Hz, 1H), 2.75–2.64 (m, 2H), 2.04–1.91 (m, 3H), 1.64–1.41 (m, 2H), 1.15 (d, J = 6.6 Hz, 3H), 1.05 
(dd, J = 6.7, 3.0 Hz, 6H); 13C NMR (101 MHz, CDCl3) δ 181.2, 166.2, 160.5 (2C), 104.7, 91.1 
(2C), 67.4, 56.2, 55.8 (2C), 43.2, 37.8, 30.1, 28.3, 27.7, 23.6, 20.5, 19.4. HRMS (FT-ICR, ESI) 
m/z: [M – Br]+ calcd for C19H30NO3 320.2220, found 320.2218.  
Alternatively following the general procedure F, TMSN3 in HFIP was added to a solution 
of 2.52 (52.0 µL, 0.301 mmol, 1.0 equiv), AlBr3 (84.0 mg, 0.315 mmol, 1.1 equiv), and 1,3,5-
trimethoxybenzene (252 mg, 1.50 mmol, 5.0 equiv) in HFIP. Purification by an automated MPLC 
system on a 12 g normal phase silica column with gradient elution from 0–5% MeOH/CH2Cl2 
afforded 2.53 as an off-white amorphous solid (64.5 mg, 0.161 mmol, 54% yield) and known 
tetrazole7 ((5S,8R)-5-isopropyl-8-methyl-6,7,8,9-tetrahydro-5Htetrazolo[1,5-a]azepine, 6.90 mg, 
0.036 mmol, 12% yield). Characterization data was consistent with the above entry.  
 
 5-(2,4,6-Trimethoxyphenyl)-2,3,6,7-tetrahydro-1,4-oxazepin-4-ium Bromide, 2.54. 
Alternatively following the general procedure F, TMSN3 in HFIP was added to a solution of 
tetrahydro-4H-pyran-4-one 2.10 (28.0 µL, 0.303 mmol, 1.0 equiv), AlBr3 (124 mg, 0.464 mmol, 
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1.5 equiv), and 1,3,5-trimethoxybenzene (255 mg, 1.52 mmol, 5.0 equiv) in HFIP (2.0 mL). 
Following slow addition, the reaction mixture was stirred for an additional 15 h and concentrated 
under a stream of nitrogen. Purification by an automated MPLC system on a 12 g normal phase 
silica column with gradient elution from 0–4% MeOH/CH2Cl2 afforded 2.54 as a yellow 
amorphous solid (66.5 mg, 0.192 mmol, 63% yield). Rf = 0.36 (5% MeOH/CH2Cl2); mp 165–169 
˚C (decomposed); IR (neat) 2942, 2848, 1601, 1572 cm-1. 1H NMR (400 MHz, CDCl3) δ 6.13 (s, 
2H), 4.28 (m, 2H), 3.92–3.90 (m, 8H), 3.88–3.86 (m, 5H), 3.26 (m, 2H); 13C NMR (101 MHz, 
CDCl3) δ 182.5, 166.8, 160.5 (2C), 104.3, 91.2 (2C), 67.9, 64.8, 56.7 (2C), 55.9, 50.8, 40.9. HRMS 
(FT-ICR, ESI) m/z: [M – Br]+ calcd for C14H20NO4 266.1387, found 266.1383.  
 
 1-Methyl-4-(2,4,6-trimethoxyphenyl)-1,2,3,6-tetrahydropyridine Hydrobromide, 
2.56. A solution of 1-methylpiperidin-4-one 2.55 (37.0 µL, 0.300 mmol, 1.0 equiv), 1,3,5-
trimethoxybenzene (254 mg, 1.51 mmol, 5.0 equiv), and AlBr3 (85.1 mg, 0.319 mmol, 1.1 equiv) 
in HFIP (1.5 mL) was stirred at room temperature for 6 h. HFIP was removed under a stream of 
nitrogen. The crude residue was redissolved in CH2Cl2 (ca. 40 mL), filtered to remove residual 
solids, and purified. Purification by an automated MPLC system on a 12 g normal phase silica 
column with gradient elution from 0–6% MeOH/CH2Cl2 afforded 2.56 as an off-white amorphous 
solid (90.1 mg, 0.262 mmol, 87% yield). Rf = 0.31 (4% MeOH/CH2Cl2); mp 221–223 ̊ C; IR (neat) 
2939, 2673, 1607, 1582 cm-1. 1H NMR (400 MHz, CDCl3) δ 6.12 (s, 2H), 5.48 (m, 1H), 3.82–3.74 
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(complex, 10H, contains s, 3.82, 3H; s, 3.76, 6H), 3.36 (m, 2H), 2.92 (s, 3H), 2.63 (m, 2H); 13C 
NMR (151 MHz, CDCl3) δ 161.2, 158.2 (2C), 131.0, 117.5, 110.4, 90.7 (2C), 56.0 (2C), 55.5, 
51.4, 49.9, 40.5, 24.1. Note: Missing one proton signal. HRMS (FT-ICR, ESI) m/z: [M – Br]+ calcd 
for C15H22NO3 264.1594, found 264.1575. Anal. calcd. for C15H22BrNO3: C 52.34, H 6.44, N 4.07, 
Br 23.21, found C 52.45, H 6.47, N 4.01, Br 23.07.  
 
 7-(2,4,6-Trimethoxyphenyl)-3,4,5,6-tetrahydro-2H-azepinium Bromide, 2.57. 
Following the general procedure E, TMSN3 in HFIP was added to a solution of cyclohexanone 2.6 
(31.0 µL, 0.299 mmol, 1.0 equiv), AlBr3 (82.5 mg, 0.309 mmol, 1.0 equiv), and 1,3,5-
trimethoxybenzene (252 mg, 1.50 mmol, 5.0 equiv) in HFIP. Purification by an automated MPLC 
system on a 15.5 g C18 reverse phase column with gradient elution from 0–100% MeCN/H2O 
afforded 2.57 as a colorless amorphous solid (93.0 mg, 0.270 mmol, 90% yield).  Rf = 0.25 (5% 
MeOH/CH2Cl2); mp 185–188 ˚C (decomposed); IR (neat) 2944, 2866, 1642, 1603, 1575 cm-1. 1H 
NMR (400 MHz, CDCl3) δ 13.4 (br s, 1H), 6.11 (s, 2H), 4.05 (m, 2H), 3.89 (s, 6H), 3.85 (s, 3H), 
2.98 (m, 2H), 1.94 (m, 2H), 1.82 (m, 4H); 13C NMR (101 MHz, CDCl3) δ 183.5, 166.1, 160.2 
(2C), 104.8, 91.1 (2C), 56.5 (2C), 55.8, 47.9, 36.6, 30.4, 25.5, 22.1. HRMS (FT-ICR, ESI) m/z: 




 6-(2,4,6-Trimethoxyphenyl)-2,3,4,5-tetrahydropyridinium Bromide, 2.59. Following 
the general procedure E, TMSN3 in HFIP was added to a solution of cyclopentanone 2.58 (27.0 
µL, 0.305 mmol, 1.0 equiv), AlBr3 (83.1 mg, 0.312 mmol, 1.0 equiv), 1,3,5-trimethoxybenzene 
(250 mg, 1.49 mmol, 4.9 equiv) in HFIP. Purification by an automated MPLC system on a 12 g 
normal phase silica column with gradient elution from 0–4% MeOH/CH2Cl2 afforded 2.59 as an 
orange oil (13.6 mg, 0.041 mmol, 14% yield). Rf = 0.22 (5% MeOH/CH2Cl2); IR (neat) 2936, 
1603, 1581 cm-1. 1H NMR (400 MHz, CDCl3) δ 6.10 (s, 2H), 3.91 (m, 2H), 3.85 (s, 6H), 3.83 (s, 
3H), 2.93 (m, 2H), 1.91 (m, 4H); 13C NMR (151 MHz, CDCl3) δ 178.3, 165.5, 159.7 (2C), 103.6, 
91.1 (2C), 56.5 (2C), 55.7, 45.0, 31.5, 19.9, 17.8. HRMS (FT-ICR, ESI) m/z: [M – Br]+ calcd for 
C14H20NO3 250.1438, found 250.1433.  
Alternatively following the general procedure E, TMSN3 in HFIP was added to a solution 
of 2.58 (27.0 µL, 0.305 mmol, 1.0 equiv), AlBr3 (80.5 mg, 0.302 mmol, 1.0 equiv), 1,3,5-
trimethoxybenzene (252 mg, 1.50 mmol, 4.9 equiv) in HFIP. Following slow addition, the reaction 
mixture was stirred for an additional 15 h and concentrated under a stream of nitrogen. Conversion 
of 20% (19.6 mg, 0.059 mmol) to the 2.59 was determined by 1H NMR of the crude reaction 




 (E)-8-(2,4,6-Trimethoxyphenyl)-2,3,4,5,6,7-hexahydroazocinium Bromide, 2.60. 
Following the general procedure F, TMSN3 in HFIP was added to a solution of cycloheptanone 
2.14 (35.0 µL, 0.297 mmol, 1.0 equiv), AlBr3 (83.5 mg, 0.313 mmol, 1.1 equiv), 1,3,5-
trimethoxybenzene (252 mg, 1.50 mmol, 5.0 equiv) in HFIP. Following slow addition, the reaction 
mixture was stirred for an additional 15 h and concentrated under a stream of nitrogen. Purification 
by an automated MPLC system on a 12 g normal phase silica column with gradient elution from 
0–5% MeOH/CH2Cl2 afforded 2.60 as a white amorphous solid (53.0 mg, 0.148 mmol, 50% yield) 
and known tetrazole (5,6,7,8,9,10-hexahydrotetrazolo[1,5-a]azocine,7 8.40 mg, 0.055 mmol, 19% 
yield). Rf = 0.21 (4% MeOH/CH2Cl2); mp 169–171 ˚C; IR (neat) 2924, 2630, 1671, 1606, 1584 
cm-1. 1H NMR (400 MHz, CDCl3) δ 6.13 (s, 2H), 3.98 (m, 2H), 3.89 (s, 6H), 3.85 (3H), 3.06 (m, 
2H), 2.06 (m, 2H), 1.83 (m, 3H), 1.73–1.61 (m, 3H); 13C NMR (151 MHz, CDCl3) δ 182.4, 165.6, 
159.8 (2C), 103.6, 91.3 (2C), 56.4 (2C), 55.8, 46.0, 32.7, 30.4, 29.5, 25.8, 24.2. HRMS (FT-ICR, 
ESI) m/z: [M – Br]+ calcd for C16H24NO3 278.1751, found 278.1743.  
Alternatively following the general procedure F, TMSN3 in HFIP was added to a solution 
of 2.14 (35.0 µL, 0.297 mmol, 1.0 equiv), AlBr3 (82.0 mg, 0.307 mmol, 1.1 equiv), and 1,3,5-
trimethoxybenzene (252 mg, 1.50 mmol, 5.1 equiv) in HFIP. Purification by an automated MPLC 
system on a 12 g normal phase silica column with gradient elution from 0–5% MeOH/CH2Cl2 
afforded 2.60 as a white amorphous solid (69.8 mg, 0.195 mmol, 66% yield) and known tetrazole 
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((5,6,7,8,9,10-hexahydrotetrazolo[1,5-a]azocine,7 8.30 mg, 0.055 mmol, 18% yield). 
Characterization data was consistent with the above entry.  
 
 (E)-9-(2,4,6-Trimethoxyphenyl)-3,4,5,6,7,8-hexahydro-2H-azoninium Bromide, 2.61. 
Following the general procedure E, TMSN3 in HFIP was added to a solution of cyclooctanone 2.16 
(39.0 mg, 0.309 mmol, 1.0 equiv), AlBr3 (93.0 mg, 0.349 mmol, 1.1 equiv), 1,3,5-
trimethoxybenzene (251 mg, 1.49 mmol, 4.8 equiv) in HFIP. Following slow addition, the reaction 
mixture was stirred for an additional 15 h and concentrated under a stream of nitrogen. Purification 
by an automated MPLC system on a 12 g normal phase silica column with gradient elution from 
0–6% MeOH/CH2Cl2 afforded 2.61 as yellow amorphous solid (34.6 mg, 0.094 mmol, 30% yield) 
and known tetrazole (6,7,8,9,10,11-hexahydro-5H-tetrazolo[1,5-a]azonine,7 5.30 mg, 0.032 mmol, 
10% yield). Rf = 0.22 (4% MeOH/CH2Cl2); mp 151–154 ˚C; IR (neat) 2925, 2892, 2844, 1643, 
1599, 1576 cm-1. 1H NMR (400 MHz, CDCl3) δ 6.13 (s, 2H), 4.02 (m, 2H), 3.86 (s, 6H), 3.84 (s, 
3H), 3.07 (m, 2H), 2.03 (m, 2H), 1.78–1.54 (m, 8H); 13C NMR (151 MHz, CDCl3) δ 181.3, 165.2, 
159.6 (2C), 104.1, 91.3 (2C), 56.4 (2C), 55.7, 47.8, 33.1, 26.4, 26.0, 25.6, 23.7, 21.4. HRMS (FT-
ICR, ESI) m/z: [M – Br]+ calcd for C17H26NO3 292.1907, found 292.1902.  
Alternatively following the general procedure F, TMSN3 in HFIP was added to a solution 
of 2.16 (39.7 mg, 0.315 mmol, 1.0 equiv), AlBr3 (83.3 mg, 0.312 mmol, 1.0 equiv), and 1,3,5-
trimethoxybenzene (252 mg, 1.50 mmol, 4.7 equiv) in HFIP. Purification by an automated MPLC 
system on a 12 g normal phase silica column with gradient elution from 0–6% MeOH/CH2Cl2 
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afforded the 2.61 as a cream amorphous solid (44.2 mg, 0.119 mmol, 38% yield) and known 
tetrazole (6,7,8,9,10,11-hexahydro-5H-tetrazolo[1,5-a]azonine,7 5.30 mg, 0.032 mmol, 10% 
yield). Characterization data was consistent with the above entry.  
 
 (1R,3r,6s,8S)-5-(2,4,6-Trimethoxyphenyl)-4-azatricyclo[4.3.1.13,8]undec-4-en-4-ium 
Bromide, 2.62. Following the general procedure E, TMSN3 in HFIP was added to a solution of 2-
adamantanone 2.32 (45.8 mg, 0.305 mmol, 1.0 equiv), AlBr3 (82.3 mg, 0.309 mmol, 1.0 equiv), 
1,3,5-trimethoxybenzene (254 mg, 1.51 mmol, 5.0 equiv) in HFIP. Purification by an automated 
MPLC system on a 12 g normal phase silica column with gradient elution from 0–5% 
MeOH/CH2Cl2 afforded 2.62 as a white amorphous solid (24.5 mg, 0.062 mmol, 20% yield). Rf = 
0.36 (5% MeOH/CH2Cl2); IR (neat) 2930, 2653, 1662, 1606, 1576 cm-1. 1H NMR (600 MHz, 
CDCl3) δ 13.6 (br s, 1H), 6.11 (s, 2H), 4.63 (m, 1H), 3.88 (s, 6H), 3.84 (s, 3H), 3.20 (m, 1H), 2.26 
(m, 2H), 2.08–2.04 (m, 4H), 1.97 (m, 2H), 1.89–1.85 (m, 4H); 13C NMR (151 MHz, CDCl3) δ 
186.9, 165.7, 159.7 (2C), 105.1, 91.1 (2C), 56.5 (2C), 55.8, 52.7, 40.4, 34.4, 32.3 (2C), 29.4 (2C), 
27.1 (2C). HRMS (FT-ICR, ESI) m/z: [M – Br]+ calcd for C19H26NO3 316.1907, found 316.1906.  
Alternatively, to a solution of 2.32 (45.0 mg, 0.300 mmol, 1.0 equiv), AlBr3 (91.8 mg, 
0.344 mmol, 1.2 equiv), and 1,3,5-trimethoxybenzene (250 mg, 1.50 mmol, 5.0 equiv) in HFIP 
(1.0 mL) in a flame-dried nitrogen-flushed 25 mL round bottom was added a solution of TMSN3 
(0.600 mmol, 2.0 equiv) in HFIP (2.0 mL) using a syringe pump (0.15 mL/h, 14.00 mm diameter, 
and 20 gauge needle) over 18 h at room temperature. Following slow addition, the reaction mixture 
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was stirred for an additional 1 h and concentrated under nitrogen. The residual crude was 
redissolved in CH2Cl2 (ca. 40 mL), filtered, and concentrated. Purification by an automated MPLC 
system on a 12 g normal phase silica column with gradient elution from 0–7% MeOH/CH2Cl2 
afforded 2.62 as a white amorphous solid (30.6 mg, 0.077 mmol, 26% yield). Characterization data 
was consistent with the above entry.  
 
 (E)-N-(1-(2,4,6-Trimethoxyphenyl)propylidene)ethanaminium Bromide, 2.64. 
Following the general procedure E, TMSN3 in HFIP was added to a solution of pentan-3-one 2.63 
(32.0 µL, 0.302 mmol, 1.0 equiv), AlBr3 (100.6 mg, 0.377 mmol, 1.3 equiv), 1,3,5-
trimethoxybenzene (252 mg, 1.50 mmol, 5.0 equiv) in HFIP. Following slow addition, the reaction 
mixture was stirred for an additional 15 h and concentrated under a stream of nitrogen. Purification 
by an automated MPLC system on a 12 g normal phase silica column with gradient elution from 
0–5% MeOH/CH2Cl2 afforded 2.64 as a yellow sticky oil (74.5 mg, 0.224 mmol, 74% yield).  Rf 
= 0.30 (3% MeOH/CH2Cl2); IR (neat) 3409, 2976, 2841, 2706, 1666, 1603, 1581 cm-1. 1H NMR 
(400 MHz, CDCl3) δ 6.16 (s, 2H), 3.86 (s, 3H), 3.80 (s, 6H), 3.46 (q, J = 7.3 Hz, 2H), 3.19 (q, J = 
7.6 Hz, 2H), 1.38 (t, J = 7.3 Hz, 3H), 1.09 (t, J = 7.6 Hz, 3H); 13C NMR (151 MHz, CDCl3) δ 
186.2, 164.8, 157.6 (2C), 100.4, 90.9 (2C), 56.1 (2C), 55.9, 44.8, 31.8, 13.4, 10.7. HRMS (FT-
ICR, HESI) m/z: [M – Br]+ calcd for C14H22NO3 252.1594, found 252.1594.  
Alternatively following the general procedure F, TMSN3 in HFIP was added to a solution 
of pentan-3-one 2.63 (32.0 µL, 0.302 mmol, 1.0 equiv), AlBr3 (82.0 mg, 0.307 mmol, 1.0 equiv), 
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1,3,5-trimethoxybenzene (251 mg, 1.49 mmol, 4.9 equiv) in HFIP. Purification by an automated 
MPLC system on a 12 g normal phase silica column with gradient elution from 0–5% 
MeOH/CH2Cl2 afforded 2.64 as a yellow sticky oil (87.9 mg, 0.265 mmol, 88% yield). 
Characterization data was consistent with the above entry.  
 
 (E)-N-(1-(2,4,6-Trimethoxyphenyl)butylidene)propanaminium Bromide, 2.66. 
Following the general procedure E, TMSN3 in HFIP was added to a solution of heptan-4-one 2.65 
(42.0 µL, 0.300 mmol, 1.0 equiv), AlBr3 (86.6 mg, 0.325 mmol, 1.1 equiv), 1,3,5-
trimethoxybenzene (252 mg, 1.50 mmol, 5.0 equiv) in HFIP. Purification by an automated MPLC 
system on a 12 g normal phase silica column with gradient elution from 0–5% MeOH/CH2Cl2 
afforded 2.66 as a yellow sticky oil (66.2 mg, 0.214 mmol, 71% yield, UPLC-HRMS purity: 
≥95.5%). Rf = 0.25 (3% MeOH/CH2Cl2); IR (neat) 3424, 2966, 2700, 1665, 1606, 1582 cm-1. 1H 
NMR (400 MHz, CDCl3) δ 6.16 (s, 2H), 3.87 (s, 3H), 3.81 (s, 6H), 3.37 (t, J = 7.4 Hz, 2H), 3.18 
(t, J = 7.8 Hz, 2H), 1.89 (h, J = 7.4 Hz, 2H), 1.53 (h, J = 7.4 Hz, 2H), 0.96 (t, J = 7.4 Hz, 3H), 0.85 
(t, J = 7.4 Hz, 3H); 13C NMR (151 MHz, CDCl3) δ 185.0, 164.8, 157.7 (2C), 101.0, 90.9 (2C), 
56.1 (2C), 55.8, 51.5, 40.0, 21.4, 20.3, 13.8, 11.3. HRMS (FT-ICR, HESI) m/z: [M – Br]+ calcd 
for C16H26NO3 280.1907, found 280.1907.  
Alternatively following the general procedure F, TMSN3 in HFIP was added to a solution 
of 2.65 (42.0 µL, 0.300 mmol, 1.0 equiv), AlBr3 (82.9 mg, 0.311 mmol, 1.0 equiv), 1,3,5-
trimethoxybenzene (252 mg, 1.50 mmol, 5.0 equiv) in HFIP. Purification by an automated MPLC 
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system on a 12 g normal phase silica column with gradient elution from 0–5% MeOH/CH2Cl2 
afforded 2.66 as a yellow sticky oil (96.7 mg, 0.268 mmol, 89% yield). Characterization data was 
consistent with the above entry.  
 
 (E)-N-(1-(2,4,6-Trimethoxyphenyl)pentylidene)butan-1-aminium Bromide, 2.67. 
Following the general procedure E, TMSN3 in HFIP was added to a solution of 2.34 (52.0 µL, 
0.302 mmol, 1.0 equiv), AlBr3 (87.4 mg, 0.328 mmol, 1.1 equiv), 1,3,5-trimethoxybenzene (252 
mg, 1.50 mmol, 5.0 equiv) in HFIP. Following slow addition, the reaction mixture was stirred for 
an additional 15 h and concentrated under a stream of nitrogen. Purification by an automated 
MPLC system on a 12 g normal phase silica column with gradient elution from 0–5% 
MeOH/CH2Cl2 afforded 2.67 as a yellow sticky oil (79.5 mg, 0.205 mmol, 68% yield, UPLC-
HRMS purity: ≥95.5%). Rf = 0.30 (4% MeOH/CH2Cl2); IR (neat) 2956, 2932, 2870, 2605, 1662, 
1604, 1582 cm-1. 1H NMR (400 MHz, CDCl3) δ 6.15 (s, 2H), 3.86 (s, 3H), 3.79 (s, 6H), 3.30 (t, J 
= 7.5 Hz, 2H), 3.00 (br s, 2H), 1.75 (p, J = 7.7 Hz, 2H), 1.48–1.21 (complex, 6H), 0.83 (dtd, J = 
14.6, 7.3, 1.1 Hz, 6H); 13C NMR (151 MHz, CDCl3) δ 163.9, 157.5 (2C), 103.2, 90.7 (2C), 55.9 
(2C), 55.7, 50.4, 38.8, 30.5, 28.6, 22.5, 20.1, 13.9, 13.6. Note: Missing imine carbonyl signal. 
HRMS (FT-ICR, ESI) m/z: [M – Br]+ calcd for C18H30NO3 308.2220, found 308.2214.  
Following the general procedure F, TMSN3 in HFIP was added to a solution of 2.34 (52.0 
µL, 0.302 mmol, 1.0 equiv), AlBr3 (90.0 mg, 0.337 mmol, 1.1 equiv), 1,3,5-trimethoxybenzene 
(251 mg, 1.49 mmol, 4.9 equiv) in HFIP. Purification by an automated MPLC system on a 12 g 
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normal phase silica column with gradient elution from 0–5% MeOH/CH2Cl2 afforded 2.67 as a 
yellow sticky oil (95.4 mg, 0.246 mmol, 81% yield). Characterization data was consistent with the 
above entry.  
 
 (E)-N-(1-(2,4,6-Trimethoxyphenyl)ethylidene)butanaminium Bromide, 2.69 and (Z)-
N-(1-(2,4,6-Trimethoxyphenyl)pentylidene)methanaminium Bromide 2.70. Following the 
general procedure E, TMSN3 in HFIP was added to a solution of 2.68 (37.0 µL, 0.300 mmol, 1.0 
equiv), AlBr3 (88.5 mg, 0.332 mmol, 1.1 equiv), 1,3,5-trimethoxybenzene (252 mg, 1.50 mmol, 
5.0 equiv) in HFIP. Purification by an automated MPLC system on a 12 g normal phase silica 
column with gradient elution from 0–5% MeOH/CH2Cl2 afforded the 2.69 and 2.70 as a yellow 
sticky oil (73.5 mg, 0.212 mmol, 71% yield) as a mixture of isomers (ratio 80:20). 2.69 and 2.70: 
Rf = 0.29 (3% MeOH/CH2Cl2); IR (neat) 2933, 2841, 1667, 1603, 1580, 1455, 1413 cm-1. 
Diagnostic peaks of 2.69: 1H NMR (400 MHz, CDCl3) δ 6.15 (s, 2H), 3.86 (s, 3H), 3.80 (s, 6H), 
3.36 (m, 2H), 2.75 (s, 3H), 1.80 (m, 2H), 1.29 (m, 2H), 0.82 (m, 3H); 13C NMR (151 MHz, CDCl3) 
δ 180.6, 164.6, 157.3 (2C), 102.6, 90.8 (2C), 56.1 (2C), 55.8, 49.9, 29.8, 25.7, 20.0, 13.5. 
Diagnostic peaks of 2.70: 1H NMR (400 MHz, CDCl3) δ 6.16 (s, 2H), 3.86 (s, 3H), 3.81 (s, 6H), 
3.12 (s, 3H), 3.08 (m, 2H), 1.46 (m, 2H), 1.34 (m, 2H), 0.93 (m, 3H); 13C NMR (151 MHz, CDCl3) 
δ 164.8, 157.9, 101.3, 90.9, 38.4, 35.7, 28.7, 22.4, 13.8. HRMS (FT-ICR, HESI) m/z: [M – Br]+ 
calcd for C15H24NO3 266.1751, found 266.1746.  
317 
 
Alternatively following the general procedure F, TMSN3 in HFIP was added to a solution 
of 2.68 (37.0 µL, 0.300 mmol, 1.0 equiv), AlBr3 (89.9 mg, 0.337 mmol, 1.1 equiv), 1,3,5-
trimethoxybenzene (253 mg, 1.50 mmol, 5.0 equiv) in HFIP. Purification by an automated MPLC 
system on a 12 g normal phase silica column with gradient elution from 0–5% MeOH/CH2Cl2 
afforded 2.69 as a yellow sticky oil (80.9 mg, 0.234 mmol, 78% yield) as a mixture of isomers 
(ratio 80:20). Characterization data was consistent with the above entry. 
 
 1-(4-Phenyl-7-(2,4,6-trimethoxyphenyl)-2,3,4,5-tetrahydro-1H-azepinyl)ethanone, 
2.71. Following the general procedure E, TMSN3 in HFIP was added to a solution of 2.1 (52.8 mg, 
0.303 mmol, 1.0 equiv), AlBr3 (83.8 mg, 0.314 mmol, 1.0 equiv), 1,3,5-trimethoxybenzene (253 
mg, 1.50 mmol, 5.0 equiv) in HFIP. Then, following general procedure G to the crude residue in 
anhydrous CH2Cl2 (3.0 mL) was added acetic anhydride (0.20 mL, 2.12 mmol, 7.0 equiv) and 
DMAP (25.0 mg, 0.205 mmol, 0.66 equiv). Purification by an automated MPLC system on a 12 g 
normal phase silica column with gradient elution from 0–3% MeOH/CH2Cl2 afforded 2.71 as a 
white amorphous solid (108 mg, 0.283 mmol, 93% yield, UPLC-HRMS purity: 99.0%). Rf = 0.41 
(3% MeOH/CH2Cl2); mp 106–109 ˚C; IR (neat) 2940, 1599, 1580 cm-1. 1H NMR (400 MHz, 
CDCl3) δ 7.29 (m, 2H), 7.21 (m, 3H), 6.12 (s, 2H), 5.79 (dd, J = 8.7, 4.7 Hz, 1H), 4.48 (br s, 1H), 
3.83 (s, 3H), 3.78 (s, 6H), 3.33 (br s, 1H), 2.71–2.57 (m, 2H), 2.38 (m, 1H), 2.05 (m, 2H), 1.79 (s, 
3H); 13C NMR (151 MHz, CDCl3) δ 170.3, 161.0, 159.0 (2C), 147.6, 136.9, 128.9, 128.4 (2C), 
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126.7 (2C), 126.1, 109.5, 90.6 (2C), 55.7 (2C), 55.3, 46.3, 42.3, 37.7, 35.0, 21.6. HRMS (FT-ICR, 
HESI) m/z: [M + H]+ calcd for C23H28NO4 382.2013, found 382.2011.  
 
 1-(4-(tert-Butyl)-7-(2,4,6-trimethoxyphenyl)-2,3,4,5-tetrahydro-1H-
azepinyl)ethanone, 2.72. Following the general procedure E, TMSN3 in HFIP was added to a 
solution of 2.42 (46.2 mg, 0.300 mmol, 1.0 equiv), AlBr3 (86.8 mg, 0.324 mmol, 1.1 equiv), 1,3,5-
trimethoxybenzene (251 mg, 1.50 mmol, 5.0 equiv) in HFIP. Then, following general procedure 
G to the crude residue in anhydrous CH2Cl2 (3.0 mL) was added acetic anhydride (0.35 mL, 3.71 
mmol, 12.0 equiv) and DMAP (38.0 mg, 0.311 mmol, 1.0 equiv). Purification by an automated 
MPLC system on a 12 g normal phase silica column with gradient elution from 0–3% 
MeOH/CH2Cl2 afforded 2.72 as a white amorphous solid (88.1 mg, 0.244 mmol, 82% yield, 
UPLC-HRMS purity: ≥95.5%). Rf = 0.48 (3% MeOH/CH2Cl2); mp 137–139 ˚C; IR (neat) 2944, 
1636, 1602, 1579 cm-1. 1H NMR (400 MHz, CDCl3) δ 6.10 (s, 2H), 5.71 (dd, J = 8.7, 5.3 Hz, 1H), 
4.38 (br s, 1H), 3.82 (s, 3H), 3.76 (s, 6H), 3.23 (br s, 1H), 2.31 (m, 1H), 2.05–1.93 (m, 2H), 1.73 
(s, 3H), 1.64–1.54 (m, 1H), 1.22 (m, 1H), 0.88 (s, 9H); 13C NMR (151 MHz, CDCl3) δ 170.2, 
160.9, 159.2 (2C), 136.3, 130.0, 110.0, 90.7 (2C), 55.9 (2C), 55.4, 46.9, 45.6, 33.3, 30.6, 29.3, 






2.73. Following the general procedure E, TMSN3 in HFIP was added to a solution of 2.40 (37.0 
µL, 0.301 mmol, 1.0 equiv), AlBr3 (88.0 mg, 0.330 mmol, 1.1 equiv), 1,3,5-trimethoxybenzene 
(251 mg, 1.49 mmol, 5.0 equiv) in HFIP. Then, following general procedure G to the crude residue 
in anhydrous CH2Cl2 (3.0 mL) was added acetic anhydride (0.35 mL, 3.71 mmol, 12.3 equiv) and 
DMAP (44.0 mg, 0.360 mmol, 1.2 equiv). Purification by an automated MPLC system on a 12 g 
normal phase silica column with gradient elution from 0–3% MeOH/CH2Cl2 afforded 2.73 as a 
white amorphous solid (82.9 mg, 0.260 mmol, 86% yield, UPLC-HRMS purity: ≥95.0%). Rf = 
0.32 (4% MeOH/CH2Cl2); IR (neat) 2943, 1626, 1602, 1578 cm-1; mp 132–134 ˚C. 1H NMR (400 
MHz, CDCl3) δ 6.10 (s, 2H), 5.67 (m, 1H), 4.19 (br s, 1H), 3.81 (s, 3H), 3.75 (s, 6H), 3.36 (br s, 
1H), 2.16–2.04 (m, 2H), 1.87 (m, 1H), 1.73 (s, 3H), 1.67 (br s, 1H), 1.52 (m, 1H), 0.96 (d, J = 6.6 
Hz, 3H); 13C NMR (151 MHz, CDCl3) δ 170.1, 160.9, 159.2 (2C), 136.6, 129.1, 110.2, 90.8 (2C), 
55.9 (2C), 55.4, 45.9, 37.6, 35.7, 30.3, 22.7, 21.8. HRMS (FT-ICR, HESI) m/z: [M + H]+ calcd for 




 1-(5-(2,4,6-Trimethoxyphenyl)-2,3-dihydro-1,4-oxazepin-4(7H)-yl)ethan-1-one, 2.74. 
Following the general procedure E, TMSN3 in HFIP was added to a solution of 2.10 (28.0 µL, 
0.303 mmol, 1.0 equiv), AlBr3 (128.0 mg, 0.480 mmol, 1.6 equiv), 1,3,5-trimethoxybenzene (253 
mg, 1.50 mmol, 5.0 equiv) in HFIP. Then, following general procedure G to the crude residue in 
anhydrous CH2Cl2 (3.0 mL) was added acetic anhydride (0.35 mL, 3.70 mmol, 12.2 equiv) and 
DMAP (44.0 mg, 0.360 mmol, 1.2 equiv). Purification by an automated MPLC system on a 12 g 
normal phase silica column with gradient elution from 0–3% MeOH/CH2Cl2 afforded 2.74 as an 
off-white amorphous solid (63.8 mg, 0.184 mmol, 61% yield). Rf = 0.48 (3% MeOH/CH2Cl2); IR 
(neat) 2949, 2840, 1658, 1636, 1602, 1581 cm-1; mp 158–160 ˚C. 1H NMR (400 MHz, CDCl3) δ 
6.10 (d, J = 0.9 Hz, 2H), 5.76 (td, J = 6.2, 0.9 Hz, 1H), 4.18 (d, J = 6.2 Hz, 1H), 3.94 (br s, 2H), 
3.84–3.82 (complex, 5H, contains d, J = 0.9 Hz, 3H), 3.76 (d, J = 0.9 Hz, 6H), 1.76 (d, J = 0.9 Hz, 
3H); 13C NMR (151 MHz, CDCl3) δ 170.2, 161.5, 159.3 (2C), 139.7, 126.4, 109.1, 90.6 (2C), 71.5, 
66.8, 55.9 (2C), 55.5, 48.0, 21.9. HRMS (FT-ICR, HESI) m/z: [M + H]+ calcd for C16H22NO4 




 (Z)-1-(8-(2,4,6-Trimethoxyphenyl)-3,4,5,6-tetrahydroazocin-1(2H)-yl)ethanone, 2.75. 
Following the general procedure F, TMSN3 in HFIP was added to a solution of 2.14 (35.0 µL, 
0.296 mmol, 1.0 equiv), AlBr3 (81.9 mg, 0.307 mmol, 1.0 equiv), 1,3,5-trimethoxybenzene (250 
mg, 1.49 mmol, 5.0 equiv) in HFIP. Then, following general procedure G to the crude residue in 
anhydrous CH2Cl2 (3.0 mL) was added acetic anhydride (0.35 mL, 3.71 mmol, 12.0 equiv) and 
DMAP (44.0 mg, 0.360 mmol, 1.2 equiv). Purification by an automated MPLC system on a 12 g 
normal phase silica column with gradient elution from 0–3% MeOH/CH2Cl2 afforded 2.75 as a 
white sticky (low boiling) solid (76.9 mg, 0.241 mmol, 81% yield, UPLC-HRMS purity: ≥95.5%). 
Rf = 0.43 (3% MeOH/CH2Cl2); IR (neat) 2929, 2846, 1633, 1602, 1580 cm-1. 1H NMR (400 MHz, 
CDCl3) δ 6.11 (s, 2H), 5.85 (m, 1H), 3.81 (s, 3H), 3.74 (s, 6H), 3.55 (m, 2H), 2.17 (m, 2H), 2.11 
(s, 3H), 1.74–1.60 (complex, 6H); 13C NMR (151 MHz, CDCl3) δ 171.7, 161.0, 159.7 (2C), 135.0, 
132.1, 108.7, 90.7 (2C), 55.6 (2C), 55.4, 47.5, 28.3, 27.5, 26.9, 26.3, 21.9. HRMS (FT-ICR, HESI) 






2.76. Following the general procedure F, TMSN3 in HFIP was added to a solution of 2.16 (38.3 
mg, 0.303 mmol, 1.0 equiv), AlBr3 (88.2 mg, 0.331 mmol, 1.1 equiv), 1,3,5-trimethoxybenzene 
(252 mg, 1.50 mmol, 4.9 equiv) in HFIP. Then, following general procedure G to the crude residue 
in anhydrous CH2Cl2 (3.0 mL) was added acetic anhydride (0.35 mL, 3.70 mmol, 12.0 equiv) and 
DMAP (44.0 mg, 0.360 mmol, 1.2 equiv). Purification by an automated MPLC system on a 12 g 
normal phase silica column with gradient elution from 0–3% MeOH/CH2Cl2 afforded 2.76 as an 
off-white crystalline solid (59.8 mg, 0.179 mmol, 59% yield, UPLC-HRMS purity: ≥95.5%). Rf = 
0.47 (3% MeOH/CH2Cl2); mp 133–135 ̊ C; IR (neat) 2935, 2853, 1629, 1602, 1579 cm-1. 1H NMR 
(500 MHz, CDCl3, 0 ˚C) δ 6.10 (s, 2H), 5.51 (t, J = 8.2 Hz, 1H), 3.82 (s, 3H), 3.74 (s, 6H), 3.68 
(br m, 1H), 2.72 (br m, 1H), 2.52 (br m, 1H), 2.22 (s, 3H), 2.08 (br m, 2H), 1.61–1.32 (complex, 
7H); 13C NMR (151 MHz, CDCl3) δ 172.1, 161.1, 159.9 (2C), 134.0, 132.4, 108.8, 90.7 (2C), 55.7 
(2C), 55.5, 44.4, 26.4, 25.06, 25.02, 22.6, 21.6, 21.2. HRMS (FT-ICR, HESI) m/z: [M + H]+ calcd 




 (E)-N-Butyl-N-(1-(2,4,6-Trimethoxyphenyl)pentenyl)acetamide, 2.77. Following the 
general procedure F, TMSN3 in HFIP was added to a solution of 2.34 (50.0 µL, 0.290 mmol, 1.0 
equiv), AlBr3 (81.8 mg, 0.307 mmol, 1.1 equiv), 1,3,5-trimethoxybenzene (252 mg, 1.50 mmol, 
5.2 equiv) in HFIP. Then, following general procedure G to the crude residue in anhydrous CH2Cl2 
(3.0 mL) was added acetic anhydride (0.35 mL, 3.70 mmol, 13.0 equiv) and triethylamine (50.0 
µL, 0.360 mmol, 1.2 equiv). Purification by an automated MPLC system on a 12 g normal phase 
silica column with gradient elution from 0–3% MeOH/CH2Cl2 afforded 2.77 as a colorless oil 
(82.2 mg, 0.235 mmol, 81% yield, UPLC-HRMS purity: ≥95.5%). Rf = 0.46 (3% MeOH/CH2Cl2); 
IR (neat) 2931, 2867, 1630, 1604, 1581 cm-1. 1H NMR (400 MHz, CDCl3) δ 6.11 (s, 2H), 5.50 (t, 
J = 7.4 Hz, 1H), 3.83 (s, 3H), 3.74 (s, 6H), 3.13 (m, 2H), 2.29 (s, 3H), 1.84 (q, J = 7.4 Hz, 2H), 
1.39 (m, 4H), 1.19 (m, 2H), 0.83 (dt, J = 9.6, 7.4 Hz, 6H); 13C NMR (151 MHz, CDCl3) δ 171.4, 
161.7, 159.7 (2C), 132.9, 131.9, 105.6, 90.3 (2C), 55.48 (2C), 55.45, 44.5, 30.8, 29.6, 22.3, 22.1, 
20.3, 14.05, 14.01. HRMS (FT-ICR, HESI) m/z: [M + H]+ calcd for C20H32NO4 350.2326, found 
350.2311.   
 
 tert-Butyl-4-phenyl-7-(2,4,6-trimethoxyphenyl)-2,3,4,5-tetrahydro-1H-azepine-1-
carboxylate, 2.78. Following the general procedure E, TMSN3 in HFIP was added to a solution 
of 2.1 (52.4 mg, 0.301 mmol, 1.0 equiv), AlBr3 (85.5 mg, 0.321 mmol, 1.1 equiv), 1,3,5-
trimethoxybenzene (253 mg, 1.50 mmol, 5.0 equiv) in HFIP. Then, following general procedure 
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G to the crude residue in anhydrous CH2Cl2 (3.0 mL) was added di-tert-butyl carbonate (0.21 mL, 
0.910 mmol, 3.0 equiv) and DMAP (44.0 mg, 0.360 mmol, 1.2 equiv). Purification by an 
automated MPLC system on a 12 g normal phase silica column with gradient elution from 0–20% 
EtOAc/hexanes afforded 2.78 as a colorless oil (102 mg, 0.232 mmol, 77% yield, UPLC-HRMS 
purity: ≥95.5%). Rf = 0.49 (20% EtOAc/hexanes); IR (neat) 2936, 1682, 1651, 1602, 1584 cm-1. 
1H NMR (400 MHz, CDCl3) δ 7.34–7.20 (m, 5H), 6.15 (s, 2H), 5.62 (m, 1H), 4.34 (m, 1H), 3.86 
(s, 3H), 3.80 (s, 6H), 3.36 (m, 1H), 2.74 (m, 2H), 2.43 (m, 1H), 2.05 (m, 2H), 1.17 (s, 9H); 13C 
NMR (151 MHz, CDCl3) δ 160.4, 159.1 (2C), 154.5, 148.1, 136.4, 128.5 (2C), 127.0 (2C), 126.1, 
124.8, 111.4, 90.5, 79.6, 55.8 (2C), 55.5, 47.6, 42.1, 38.3, 35.1, 28.1 (3C). HRMS (FT-ICR, HESI) 
m/z: [M + H]+ calcd for C26H34NO5 440.2431, found 440.2421.   
 
 (4-Nitrophenyl)(4-phenyl-7-(2,4,6-trimethoxyphenyl)-2,3,4,5-tetrahydro-1H-azepin-
1-yl)methanone, 2.79.  Following the general procedure E, TMSN3 in HFIP was added to a 
solution of 2.1 (52.5 mg, 0.301 mmol, 1.0 equiv), AlBr3 (80.5 mg, 0.302 mmol, 1.0 equiv), 1,3,5-
trimethoxybenzene (253 mg, 1.51 mmol, 5.0 equiv) in HFIP. Then, following general procedure 
G to the crude residue in anhydrous CH2Cl2 (4.0 mL) was added 4-nitrobenzoyl chloride (164 mg, 
0.882 mmol, 2.9 equiv), DMAP (55.1 mg, 0.451 mmol, 1.5 equiv), and triethylamine (125 µL, 
0.897 mmol, 3.0 equiv). Purification was carried out by an automated MPLC system on a 12 g 
normal phase silica column with gradient elution from 0–45% EtOAc/hexanes afforded 2.79 as a 
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yellow amorphous solid (103 mg, 0.210 mmol, 70% yield). Rf = 0.38 (30% EtOAc/hexanes); IR 
(neat) 2936, 2838, 1630, 1599, 1580 cm-1; mp 200–202 ˚C. 1H NMR (400 MHz, CDCl3) δ 7.95 
(m, 2H), 7.35 (m, 2H), 7.30–7.22 (m, 5H), 5.75–5.71 (complex, 3H, contains s, 5.75, 2H), 4.75 (br 
s, 1H), 3.71 (s, 3H), 3.55 (s, 6H), 2.85–2.75 (m, 3H), 2.60 (m, 1H), 2.25–2.09 (m, 2H); 13C NMR 
(151 MHz, CDCl3) δ 168.4, 161.3, 158.5 (2C), 147.6, 147.3, 143.3, 136.7, 128.7 (2C), 127.6 (2C), 
127.2, 126.9 (2C), 126.4, 122.4 (2C), 109.8, 89.8 (2C), 55.5 (2C), 55.4, 46.8, 42.0, 38.1, 35.5. 
HRMS (FT-ICR, ESI) m/z: [M + Na]+ calcd for C28H28N2O6 511.1840, found 511.1839.  
 
 (4-Bromophenyl)(4-phenyl-7-(2,4,6-trimethoxyphenyl)-2,3,4,5-tetrahydro-1H-
azepin-yl)methanone, 2.80. Following the general procedure E, TMSN3 in HFIP was added to a 
solution of 2.1 (52.2 mg, 0.300 mmol, 1.0 equiv), AlBr3 (90.8 mg, 0.340 mmol, 1.1 equiv), 1,3,5-
trimethoxybenzene (251 mg, 1.49 mmol, 5.0 equiv) in HFIP. Then, following general procedure 
G to the crude residue in anhydrous CH2Cl2 (4.0 mL) was added 4-bromobenzoyl chloride (200 
mg, 0.911 mmol, 3.0 equiv), DMAP (55.0 mg, 0.450 mmol, 1.5 equiv), and triethylamine (84.0 
µL, 0.603 mmol, 2.0 equiv). Purification was carried out twice by an automated MPLC system on 
a 12 g normal phase silica column with gradient elution from 0–35% EtOAc/hexanes afforded 2.80 
as a white foam (117 mg, 0.223 mmol, 75% yield). Rf = 0.23 (30% EtOAc/hexanes); IR (neat) 
2936, 1630, 1602, 1586 cm-1; mp (decomposed). 1H NMR (400 MHz, CDCl3) δ 7.31 (m, 4H), 7.22 
(m, 3H), 7.00 (m, 2H), 5.80 (s, 2H), 5.67 (m, 1H), 4.74 (br s, 1H), 3.74 (s, 3H), 3.57 (s, 6H), 3.37 
326 
 
(br s, 1H), 2.79–2.72 (m, 2H), 2.55 (t, J = 10.9 Hz, 1H), 2.21–2.05 (m, 2H); 13C NMR (151 MHz, 
CDCl3) δ 169.8, 161.0, 158.6 (2C), 147.6, 137.5, 136.4, 130.3 (2C), 128.7 (2C), 128.4 (2C), 126.9 
(2C), 126.3, 122.7, 110.1, 89.9, 55.6 (2C), 55.5, 46.7, 42.1, 38.6, 35.6. Note: Missing two carbon 
signal due to signals overlap. HRMS (FT-ICR, ESI) m/z: [M + H]+ calcd for C28H29NO4 522.1274, 
found 522.1268.   
 
 (4-Methoxyphenyl)(4-phenyl-7-(2,4,6-trimethoxyphenyl)-2,3,4,5-tetrahydro-1H-
azepin-1-yl)methanone, 2.81. Following the general procedure E, TMSN3 in HFIP was added to 
a solution of 2.1 (52.3 mg, 0.300 mmol, 1.0 equiv), AlBr3 (81.6 mg, 0.306 mmol, 1.0 equiv), 1,3,5-
trimethoxybenzene (253 mg, 1.50 mmol, 5.0 equiv) in HFIP. Then, following general procedure 
G to the crude residue in anhydrous CH2Cl2 (4.0 mL) was added 4-methoxybenzoyl chloride (41.0 
µL, 0.303 mmol, 1.0 equiv) and DMAP (55.0 mg, 0.450 mmol, 1.5 equiv). Purification was carried 
out by an automated MPLC system on a 12 g normal phase silica column with gradient elution 
from 0–40% EtOAc/hexanes afforded 2.81 as a white amorphous solid (52.8 mg, 0.111 mmol, 
37% yield). Rf = 0.20 (30% EtOAc/hexanes); IR (neat) 2935, 1603, 1582 cm-1; mp 153–155 ˚C. 
1H NMR (400 MHz, CDCl3) δ 7.32–7.24 (m, 4H), 7.20 (m, 1H), 7.13 (m, 2H), 6.60 (m, 2H), 5.78 
(s, 2H), 5.66 (m, 1H), 4.78 (br s, 1H), 3.73 (s, 3H), 3.70 (s, 3H), 3.55 (s, 6H), 3.35 (br s, 1H), 2.78 
(m, 2H), 2.54 (m, 1H), 2.09 (m, 2H); 13C NMR (151 MHz, CDCl3) δ 170.4, 160.6, 160.1, 158.6 
(2C), 147.9, 138.2, 130.3, 128.7 (2C), 128.6 (2C), 127.0 (2C), 126.2, 125.7, 112.5 (2C), 110.4, 
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90.0 (2C), 55.6 (2C), 55.4 (2C), 46.7, 42.1, 38.7, 35.6. HRMS (FT-ICR, ESI) m/z: [M + H]+ calcd 
for C29H32NO5 474.2275, found 474.2262.   
 
 1-(Methylsulfonyl)-4-phenyl-7-(2,4,6-trimethoxyphenyl)-2,3,4,5-tetrahydro-1H-
azepine, 2.82. Following the general procedure E, TMSN3 in HFIP was added to a solution of 2.1 
(52.4 mg, 0.301 mmol, 1.0 equiv), AlBr3 (83.5 mg, 0.313 mmol, 1.0 equiv), 1,3,5-
trimethoxybenzene (251 mg, 1.49 mmol, 5.0 equiv) in HFIP. Then, following general procedure 
G to the crude residue in anhydrous CH2Cl2 (4.0 mL) was added methanesulfonyl chloride (50.0 
µL, 0.646 mmol, 2.2 equiv), DMAP (40.0 mg, 0.327 mmol, 1.1 equiv), and triethylamine (100 µL, 
0.717 mmol, 2.4 equiv). Purification was carried out by an automated MPLC system on a 12 g 
normal phase silica column with gradient elution from 0–50% EtOAc/hexanes afforded 2.82 as a 
pale yellow amorphous solid (117 mg, 0.223 mmol, 75% yield, UPLC-HRMS purity: ≥95.5%). Rf 
= 0.55 (50% EtOAc/hexanes); IR (neat) 2938, 2839, 1601, 1582 cm-1; mp 153–155 ˚C. 1H NMR 
(400 MHz, CDCl3) δ 7.32–7.28 (m, 2H), 7.25–7.18 (m, 3H), 6.13 (br s, 2H), 5.69 (dd, J = 8.8, 4.9 
Hz, 1H), 3.95 (dt, J = 14.3, 3.9 Hz, 1H), 3.83 (br s, 9H), 3.45 (ddd, J = 14.0, 11.1, 2.5 Hz, 1H), 
2.87 (m, 1H), 2.66 (m, 1H), 2.50 (s, 3H), 2.39 (m, 1H), 2.21–2.05 (m, 2H); 13C NMR (151 MHz, 
CDCl3) δ 161.4, 159.7 (2C), 147.7, 135.0, 128.7, 128.6 (2C), 126.9 (2C), 126.3, 108.3, 91.1, 90.6, 
56.3, 55.8, 55.5, 49.9, 42.3, 40.1, 38.9, 35.0. HRMS (FT-ICR, ESI) m/z: [M + H]+ calcd for 




 4-Phenyl-1-tosyl-7-(2,4,6-trimethoxyphenyl)-2,3,4,5-tetrahydro-1H-azepine, 2.83. 
Following the general procedure E, TMSN3 in HFIP was added to a solution of 2.1 (52.6 mg, 0.302 
mmol, 1.0 equiv), AlBr3 (87.4 mg, 0.328 mmol, 1.1 equiv), 1,3,5-trimethoxybenzene (252 mg, 
1.50 mmol, 5.0 equiv) in HFIP. Then, following general procedure G to the crude residue in 
anhydrous CH2Cl2 (4.0 mL) was added 4-toluenesulfonyl chloride (138 mg, 0.725 mmol, 2.4 
equiv), DMAP (46.4 mg, 0.380 mmol, 1.3 equiv), and triethylamine (91.0 µL, 0.660 mmol, 2.2 
equiv). Purification was carried out by an automated MPLC system on a 12 g normal phase silica 
column with gradient elution from 0–25% EtOAc/hexanes afforded 2.83 as a pale yellow solid 
(87.0 mg, 0.176 mmol, 58% yield). Rf = 0.30 (30% EtOAc/hexanes); IR (neat) 2938, 1602, 1584 
cm-1; mp 182–184 ˚C. 1H NMR (400 MHz, CDCl3) δ 7.33–7.26 (m, 4H), 7.23–7.19 (m, 3H), 7.08 
(d, J = 7.9 Hz, 2H), 6.12 (br s, 1H), 5.77 (br s, 1H), 5.70 (dd, J = 8.8, 4.8 Hz, 1H), 4.11 (dt, J = 
14.4, 3.9 Hz, 1H), 3.83 (s, 6H), 3.45 (m, 1H), 3.34 (br s, 3H), 2.76 (m, 1H), 2.64 (m, 1H), 2.38 (s, 
3H), 2.33 (m, 1H), 2.27–2.17 (m, 1H), 2.07 (m, 1H); 13C NMR (151 MHz, CDCl3) δ 161.2, 159.6, 
159.3, 147.8, 141.9, 138.7, 135.1, 128.9, 128.7 (2C), 128.6 (2C), 127.2 (2C), 126.9 (2C), 126.2, 
108.7, 90.8, 90.1, 56.3, 55.5, 54.9, 50.3, 42.1, 39.8, 34.8, 21.5. HRMS (FT-ICR, ESI) m/z: [M + 





1H-azepine, 2.84. Following the general procedure E, TMSN3 in HFIP was added to a solution of 
2.1 (51.5 mg, 0.296 mmol, 1.0 equiv), AlBr3 (80.1 mg, 0.300 mmol, 1.0 equiv), 1,3,5-
trimethoxybenzene (253 mg, 1.50 mmol, 5.1 equiv) in HFIP. Then, following general procedure 
G to the crude residue in anhydrous CH2Cl2 (4.0 mL) was added 4-nitrobenzenesulfonyl chloride 
(150 mg, 0.725 mmol, 2.3 equiv), DMAP (44.9 mg, 0.368 mmol, 1.2 equiv), and triethylamine 
(91.0 µL, 0.653 mmol, 2.2 equiv). Purification was carried out by an automated MPLC system on 
a 12 g normal phase silica column with gradient elution from 0–25% EtOAc/hexanes afforded 2.84 
as a yellow amorphous solid (44.5 mg, 0.085 mmol, 29% yield). Rf = 0.60 (30% EtOAc/hexanes); 
IR (neat) 2928, 1603, 1583, 1524 cm-1; mp 184–220 ˚C. 1H NMR (400 MHz, CDCl3) δ 8.06 (m, 
2H), 7.47 (m, 2H), 7.31 (m, 2H), 7.34–7.19 (m, 3H), 6.12 (br s, 1H), 5.74 (dd, J = 8.8, 4.8 Hz, 
1H), 5.62 (br s, 1H), 4.14 (dt, J = 14.3, 3.8 Hz, 1H), 3.80 (br s, 3H), 3.77 (s, 3H), 3.51 (m, 1H), 
3.33 (br s, 3H), 2.82 (m, 1H), 2.67 (m, 1H), 2.40 (m, 1H), 2.28–2.18 (m, 1H), 2.12 (m, 1H); 13C 
NMR (151 MHz, CDCl3) δ 161.7, 159.8, 159.2, 149.2, 147.4, 147.1, 134.1, 130.0, 128.7 (2C), 
128.1 (2C), 126.9 (2C), 126.4, 123.2, 107.9, 91.0, 89.4, 56.3, 55.5, 55.1, 50.9, 42.0, 40.2, 34.8. 





azepine-1-carboxamide, 2.85. Following the general procedure E, TMSN3 in HFIP was added to 
a solution of 2.1 (52.0 mg, 0.298 mmol, 1.0 equiv), AlBr3 (85.4 mg, 0.320 mmol, 1.1 equiv), 1,3,5-
trimethoxybenzene (253 mg, 1.50 mmol, 5.1 equiv) in HFIP. Then, following general procedure 
G to the crude residue in anhydrous THF (4.0 mL) was added 4-chlorophenyl isocyanate (98.5 mg, 
0.641 mmol, 2.2 equiv), DMAP (24.5 mg, 0.672 mmol, 0.67 equiv), and triethylamine (63.0 µL, 
0.452 mmol, 1.5 equiv). Purification was carried out twice by an automated MPLC system; first 
using a 12 g normal phase silica column with gradient elution from 0–15% EtOAc/hexanes, and 
second using a 13 g C18 reverse phase column with 0–100% MeCN/H2O gradient elution afford 
2.85 a white amorphous solid (75.2 mg, 0.153 mmol, 51% yield). Rf = 0.31 (25% EtOAc/hexanes); 
IR (neat) 3360, 2940, 1667, 1603, 1591, 1521, 1491 cm-1; mp decomposed. 1H NMR (400 MHz, 
CDCl3) δ 7.48 (s, 1H), 7.32–7.15 (m, 9H), 6.14 (br s, 2H), 5.84 (m, 1H), 4.49 (br s, 1H), 3.87 (s, 
6H), 3.81 (s, 3H), 3.43 (br s, 1H), 2.69–2.63 (m, 2H), 2.42–2.37 (m, 1H), 2.13–2.06 (m, 2H); 13C 
NMR (151 MHz, CDCl3) δ 161.5, 158.9 (2C), 153.3, 147.8, 138.7, 131.9, 128.8 (2C), 128.6 (2C), 
127.0, 126.9 (2C), 120.1 (2C), 109.5, 91.1 (2C), 56.1 (2C), 55.5, 46.0, 42.1, 38.6, 35.3. HRMS 





carboxamido)benzoate, 2.86. Following the general procedure E, TMSN3 in HFIP was added to 
a solution of 2.1 (52.7 mg, 0.302 mmol, 1.0 equiv), AlBr3 (87.2 mg, 0.327 mmol, 1.1 equiv), 1,3,5-
trimethoxybenzene (252 mg, 1.50 mmol, 5.0 equiv) in HFIP. Then, following general procedure 
G to the crude residue in anhydrous THF (4.0 mL) was added methyl 4- isocyanatobenzoate (126 
mg, 0.709 mmol, 2.3 equiv), DMAP (24.0 mg, 0.196 mmol, 0.65 equiv), and triethylamine (63.0 
µL, 0.454 mmol, 1.5 equiv). Purification was carried out twice by an automated MPLC system; 
first using a 12 g normal phase silica column with gradient elution from 0–40% EtOAc/hexanes, 
and then using a 13 g C18 reverse phase column with 0–100% MeCN/H2O gradient elution 
afforded 2.86 a white amorphous solid (77.2 mg, 0.149 mmol, 49% yield). Rf = 0.20 (20% 
EtOAc/hexanes); IR (neat) 3355, 2945, 1715, 1674, 1605, 1589, 1522 cm-1; mp 105 ˚C 
decomposed. 1H NMR (400 MHz, CDCl3) δ 7.91 (m, 2H), 7.67 (s, 1H), 7.39 (m, 2H), 7.29 (m, 
2H), 7.22 (m, 3H), 6.14 (s, 2H), 5.87 (m, 1H), 4.50 (br s, 1H), 3.89 (s, 6H), 3.86 (s, 3H), 3.80 (s, 
3H), 3.45 (br s, 1H), 2.67 (m, 2H), 2.41 (m, 1H), 2.08 (m, 2H); 13C NMR (151 MHz, CDCl3) δ 
167.1, 161.5, 158.8 (2C), 153.0, 147.7, 144.4, 134.9, 132.2, 130.8 (2C), 128.7 (2C), 126.9 (2C), 
126.3, 123.4, 117.7 (2C), 109.3, 91.1 (2C), 56.1 (2C), 55.5, 51.9, 46.1, 42.1, 38.6, 35.3. HRMS 




 (2R,5S)-5-Phenyl-2-(2,4,6-trimethoxyphenyl)azepane, 2.87.  Following the general 
procedure E, TMSN3 in HFIP was added to a solution of 2.1 (52.3 mg, 0.300 mmol, 1.0 equiv), 
AlBr3 (87.7 mg, 0.329 mmol, 1.1 equiv), 1,3,5-trimethoxybenzene (252 mg, 1.50 mmol, 5.0 equiv) 
in HFIP. Then, following the general procedure H to the crude residue in anhydrous MeOH (3.0 
mL) was added sodium borohydride (23.0 mg, 0.608 mmol, 2.0 equiv). Purification by an 
automated MPLC system on a 12 g normal phase silica column with gradient elution from 0–12% 
MeOH (0.5% NH4OH)/CH2Cl2) afforded 2.87 as a cream amorphous solid (78.2 mg, 0.229 mmol, 
76% yield, dr 20:1). Rf = 0.49 (20% EtOAc/hexanes); IR (neat) 3372, 3027, 2996, 2921, 2837, 
1598, 1585, 1117, 670 cm-1; mp 123–126 ˚C. 1H NMR (500 MHz, CDCl3) δ 7.30 (m, 2H), 7.24 
(m, 2H), 7.18 (m, 1H), 6.13 (s, 2H), 4.56 (dd, J = 9.1, 6.0 Hz, 1H), 3.83 (s, 6H), 3.79 (s, 3H), 3.38 
(dt, J = 14.4, 3.6 Hz, 1H), 2.94 (ddd, J = 12.0, 9.2, 3.0 Hz, 1H), 2.80 (ddd, J = 14.6, 12.1, 2.7 Hz, 
1H), 2.23–2.08 (m, 2H), 2.02–1.96 (m, 2H), 1.94–1.81 (m, 2H); 13C NMR (151 MHz, CDCl3) δ 
159.9 (2C), 158.1, 149.6, 128.6 (2C), 126.7 (2C), 125.8, 115.1, 91.3 (2C), 55.9 (2C), 55.5, 54.0, 
50.6, 45.0, 42.4, 34.4, 33.9. HRMS (FT-ICR, ESI) m/z: [M + H]+ calcd for C21H28NO3 342.2064, 
found 342.2060.  
Alternatively, following the general procedure H, to a solution of 2.39 (85.0 mg, 0.202 
mmol, 1.0 equiv) in anhydrous MeOH (3.0 mL) was added sodium borohydride (15.0 mg, 0.397 
mmol, 2.0 equiv). Purification by an automated MPLC system on a 12 g normal phase silica 
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column with gradient elution from 0–12% MeOH(0.5%NH4OH)/CH2Cl2 afforded 2.87 as a cream 
amorphous solid (63.3 mg, 0.185 mmol, 92% yield). Characterization data was consistent with the 
above entry.  
 
 1-((2R,5S)-5-Phenyl-2-(2,4,6-trimethoxyphenyl)azepanyl)ethanone, 2.88. Following 
the general procedure E, TMSN3 in HFIP was added to a solution of 2.1 (52.5 mg, 0.301 mmol, 
1.0 equiv), AlBr3 (81.1 mg, 0.304 mmol, 1.0 equiv), 1,3,5-trimethoxybenzene (251 mg, 1.49 
mmol, 5.0 equiv) in HFIP. Then, following the general procedure H to the crude residue in 
anhydrous MeOH (3.0 mL) was added sodium borohydride (23.0 mg, 0.608 mmol, 2.0 equiv). 
Following reaction work-up, to a solution of crude residue in anhydrous CH2Cl2 (3.0 mL) was 
added di-tert-butyl carbonate (0.21 mL, 0.910 mmol, 3.0 equiv) and DMAP (7.40 mg, 0.061 mmol, 
0.2 equiv). The reaction mixture was stirred at room temperature for 24 h under argon atmosphere. 
Purification by an automated MPLC system on a 12 g normal phase silica column with gradient 
elution from 0–3% MeOH/CH2Cl2 afforded 2.88 as a white sticky (low boiling) solid (87.7 mg, 
0.229 mmol, 76% yield) as a mixture of rotamers (ratio = 76:24). Rf = 0.33 (2% MeOH/CH2Cl2); 
IR (neat) 2921, 2846, 1643, 1602, 1584 cm-1. Diagnostic peaks of major rotamer: 1H NMR (400 
MHz, CDCl3) δ 7.33–7.28 (m, 4H), 7.22–7.26 (m, 1H), 6.09 (s, 2H), 5.25 (dd, J = 12.2, 4.0 Hz, 
1H), 4.42 (ddd, J = 14.6, 4.9, 3.7 Hz, 1H), 3.78 (s, 3H), 3.76 (s, 6H), 3.73–3.67 (m, 1H), 3.05 (m, 
1H), 2.38–1.88 (complex, 8H, contains s, 1.93, 3H), 1.66 (m, 1H); 13C NMR (101 MHz, CDCl3) δ 
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171.8, 160.3 (2C), 158.3, 145.7, 128.5 (2C), 127.6 (2C), 125.9, 112.1, 91.0 (2C), 55.8 (2C), 55.4, 
54.6, 39.1, 39.0, 33.3, 33.2, 28.8, 21.7. Diagnostic peaks of minor rotamer: 1H NMR (400 MHz, 
CDCl3) δ 6.09 (s, 2H), 5.74 (dd, J = 13.1, 3.8 Hz, 1H), 4.20 (ddd, J = 16.1, 11.3, 5.0 Hz, 1H), 3.80 
(s, 3H), 2.75 (s, 6H), 2.08 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 170.2, 159.7, 158.7, 145.8, 
128.5, 127.5, 126.2, 113.6, 91.6, 56.1, 55.4, 51.9, 42.4, 34.4, 33.2, 28.3, 27.3, 22.3. HRMS (FT-
ICR, ESI) m/z: [M + H]+ calcd for C23H30NO4 384.2169, found 384.2177.  
 
 tert-Butyl (2R,5S)-5-Phenyl-2-(2,4,6-trimethoxyphenyl)azepane-1-carboxylate, 2.89.   
Following the general procedure E, TMSN3 in HFIP was added to a solution of 2.1 (52.6 mg, 0.302 
mmol, 1.0 equiv), AlBr3 (80.4 mg, 0.301 mmol, 1.0 equiv), 1,3,5-trimethoxybenzene (252 mg, 
1.50 mmol, 5.0 equiv) in HFIP. Then, following the general procedure H to the crude residue in 
anhydrous MeOH (3.0 mL) was added sodium borohydride (22.0 mg, 0.582 mmol, 1.9 equiv). 
Following reaction work-up, to a solution of crude residue in anhydrous CH2Cl2 (3.0 mL) was 
added di-tert-butyl carbonate (0.17 mL, 0.730 mmol, 2.4 equiv) and DMAP (14.0 mg, 0.115 mmol, 
0.4 equiv). The reaction mixture was stirred at room temperature for 24 h under argon atmosphere. 
Purification by an automated MPLC system on a 12 g normal phase silica column with gradient 
elution from 0–20% EtOAc/hexanes afforded 2.89 as a colorless sticky (low boiling) solid (101 
mg, 0.302 mmol, 76% yield) as a mixture of rotamers (ratio = 79:21). Rf = 0.25 (15% 
EtOAc/hexanes); IR (neat) 2929, 1682, 1590, 1401 cm-1. Diagnostic peaks of major rotamer: 1H 
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NMR (400 MHz, CDCl3) δ 7.32–7.27 (m, 4H), 7.18 (m, 1H), 6.07 (s, 2H), 5.34 (dd, J = 12.3, 3.6 
Hz, 1H), 4.09 (m, 1H), 3.82–3.74 (complex, 10H, contains s, 3.79, 3H; s, 3.74, 6H), 3.06 (m, 1H), 
2.27–1.90 (complex, 5H), 1.64 (m, 1H), 1.41 (s, 3H), 1.24 (s, 6H); 13C NMR (151 MHz, CDCl3) 
δ 159.5 (2C), 158.4, 156.4, 146.2, 128.4 (2C), 127.6 (2C), 125.8, 114.4, 90.7 (2C), 78.8, 55.7 (2C), 
55.4, 52.9, 39.9, 39.5, 34.2, 33.2, 28.5 (3C), 28.1. Diagnostic peaks of minor rotamer: 1H NMR 
(400 MHz, CDCl3) δ 5.53 (m, 1H); 13C NMR (101 MHz, CDCl3) δ 158.7, 156.0, 146.5, 125.8, 
114.0, 91.7, 78.6, 565.2, 52.6, 40.9, 39.4, 28.8, 28.2. HRMS (FT-ICR, ESI) m/z: [M + Na]+ calcd 
for C26H35NO5 464.2407 found, 464.2389.  
 
 7-(2,4-Dimethoxyphenyl)-4-phenyl-3,4,5,6-tetrahydro-2H-azepinium Bromide, 2.90. 
To a solution of 2.1 (53.0 mg, 0.304 mmol, 1.0 equiv) and AlBr3 (85.0 mg, 0.319 mmol, 1.1 equiv) 
in HFIP (1.0 mL) in a flame-dried nitrogen-flushed 25 mL round bottom was added a solution of 
TMSN3 (80.0 μL, 0.603 mmol, 2.0 equiv) in HFIP (2.0 mL) using a syringe pump (0.40 mL/h, 
14.00 mm diameter, and 20 gauge needle) over 6 h at room temperature. Following slow addition, 
1,3-dimethoxybenzene (200 μL, 1.53 mmol, 5.2 equiv) was added and the reaction mixture was 
stirred for an additional 15 h. The reaction mixture was concentrated under nitrogen, the crude 
residue was redissolved in CH2Cl2 (~40 mL), filtered to remove residual solids, and concentrated. 
Conversion of 65% (76.8 mg, 0.197 mmol) to 2.89 was determined by 1H NMR of the crude 
reaction mixture using benzyl benzoate as an internal standard. Purification by an automated 
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MPLC system using on a 12 g normal phase silica column with gradient elution from 0–7% 
MeOH/CH2Cl2 afforded 2.90 as a colorless sticky (low boiling) solid (50.9 mg, 0.130 mmol, 43% 
yield). Rf = 0.29 (4% MeOH/CH2Cl2); IR (neat) 2922, 1598 cm-1. 1H NMR (600 MHz, CDCl3) δ 
7.72 (d, J = 8.7 Hz, 1H), 7.31 (t, J = 7.6 Hz, 2H), 7.23 (t, J = 7.4 Hz, 1H), 7.17 (m, 2H), 6.61 (dd, 
J = 8.8, 2.3 Hz, 1H), 6.50 (d, J = 2.3 Hz, 1H), 4.54 (dd, J = 13.7, 5.9 Hz, 1H), 3.93 (s, 3H), 3.87 
(s, 3H), 3.72 (m, 1H), 3.35 (dd, J = 14.4, 7.3 Hz, 1H), 2.97 (m, 1H), 2.87 (m, 1H), 2.17–2.07 (m, 
2H), 1.85 (m, 1H), 1.74 (q, J = 12.5 Hz, 1H); 13C NMR (151 MHz, CDCl3) δ 181.8, 165.6, 160.7, 
145.9, 132.9, 128.9 (2C), 126.9, 126.8 (2C), 117.5, 105.9, 99.1, 56.3, 56.0, 48.8, 48.4, 33.4, 32.9, 
30.2. HRMS (FT-ICR, ESI) m/z: [M – Br]+ calcd for C20H24NO2 310.1802, found 310.1800.  
 
 7-(1H-indol-3-yl)-4-phenyl-3,4,5,6-tetrahydro-2H-azepinium Bromide, 2.91. To a 
solution of 2.1 (52.5 mg, 0.301 mmol, 1.0 equiv) and AlBr3 (82.8 mg, 0.310 mmol, 1.0 equiv) in 
HFIP (1.0 mL) in a flame-dried nitrogen-flushed 25 mL round bottom flask was added a solution 
of TMSN3 (80.0 μL, 0.603 mmol, 2.0 equiv) in HFIP (2.0 mL) using a syringe pump (0.40 mL/h, 
14.00 mm diameter, and 20 gauge needle) over 6 h at room temperature. Following 3 h slow 
addition, 1H-indole (90.0 mg, 0.768 mmol, 2.6 equiv) was added, and then after 6 h additional 1H-
indole (90.0 mg, 0.768 mmol, 2.6 equiv) was added and the reaction mixture was stirred for an 
additional 15 h. The reaction mixture was concentrated under nitrogen, the crude residue was 
redissolved in CH2Cl2 (ca. 40 mL), filtered to remove residual solids, and concentrated. 
Purification carried out twice by an automated MPLC system using a 15.5 g C18 reverse phase 
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column with gradient elution from 0–100% MeCN/H2O afforded 2.91 as a cream amorphous solid 
(58.6 mg, 0.159 mmol, 53% yield). RT = 1.80 (UPLC, MeOH(0.05% CH2O2)/H2O); mp 
decomposed; IR (neat) 3024, 2912, 1603, 1580, 1433 cm-1. 1H NMR (600 MHz, CDCl3) δ 8.34 
(br s, 1H), 8.05 (s, 1H), 7.74 (d, J = 8.0 Hz, 1H), 7.33–7.23 (m, 6H), 7.16 (d, J = 7.6Hz, 1H), 4.48 
(m, 1H), 3.71 (m, 1H), 2.97 (m, 1H), 2.84 (t, J = 13.3 Hz, 1H), 2.21 (m, 2H), 1.86 (q, J = 12.7 Hz, 
1H), 1.65 (q, J = 12.9 Hz, 1H); 13C NMR (151 MHz, CDCl3) δ 177.4, 145.0, 137.8, 137.6, 129.0 
(2C), 127.2, 126.7 (2C), 124.6, 124.0, 123.8, 120.8, 114.3, 109.4, 48.3, 45.8, 33.8, 32.1, 30.6. 
HRMS (FT-ICR, ESI) m/z: [M – Br]+ calcd for C20H21BrN2 289.1699, found 289.1688.  
 
 7-(1-Methyl-1H-indol-3-yl)-4-phenyl-3,4,5,6-tetrahydro-2H-azepin-1-ium bromide, 
2.92. To a solution of 2.1 (52.6 mg, 0.302 mmol, 1.0 equiv) and AlBr3 (83.3 mg, 0.312 mmol, 1.0 
equiv) in HFIP (1.0 mL) in a flame-dried nitrogen-flushed 25 mL round bottom flask was added a 
solution of TMSN3 (80.0 μL, 0.603 mmol, 2.0 equiv) in HFIP (2.0 mL) using a syringe pump (0.40 
mL/h, 14.00 mm diameter, and 20 gauge needle) over 6 h at room temperature. Following 3 h slow 
addition, 1-methyl-1H-indole (100 μL, 0.801 mmol, 2.7 equiv) was added, and then after 6 h 
additional 1-methyl-1H-indole (100 μL, 0.801 mmol, 2.7 equiv) was added and the reaction 
mixture was stirred for an additional 15 h. The reaction mixture was concentrated under nitrogen, 
the crude residue was redissolved in CH2Cl2 (ca. 40 mL), filtered to remove residual solids, and 
concentrated. Purification carried out twice by an automated MPLC system using a 15.5 g C18 
reverse phase column with gradient elution from 0–100% MeCN/H2O afforded 2.92 as an orange 
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amorphous solid (51.7 mg, 0.135 mmol, 45% yield). RT = 1.87 (UPLC, MeOH(0.05% 
CH2O2)/H2O); mp decomposed; IR (neat) 3022, 2932, 1605, 1579, 1531 cm-1. 1H NMR (400 MHz, 
CDCl3) δ 12.6 (br s, 1H), 9.42 (s, 1H), 7.88 (d, J = 7.4 Hz, 1H), 7.47–7.44 (m, 1H), 7.42–7.37 (m, 
2H), 7.34–7.30 (m, 2H), 7.24 (m, 1H), 7.18–7.15 (m, 2H), 4.42 (dt, J = 13.4, 6.3 Hz, 1H), 3.96 (s, 
3H), 3.87 (dd, J = 14.6, 7.8 Hz, 1H), 3.75 (m, 1H), 3.03 (m, 2H), 2.36 (m, 1H), 2.18 (m, 1H), 1.97–
1.78 (m, 2H); 13C NMR (151 MHz, CDCl3) δ 177.5, 145.0, 140.7, 138.5, 129.0 (2C), 127.3, 126.7 
(2C), 125.9, 124.5, 124.4, 120.2, 111.7, 108.5, 48.6, 45.1, 34.7, 33.7, 31.6, 30.2. HRMS (FT-ICR, 
ESI) m/z: [M – Br]+ calcd for C21H23BrN2 303.1856, found 303.1844. Anal. calcd. for 
C21H23BrNO2: C 65.80, H 6.05, N 7.31, found C 66.12, H 6.07, N 7.15.  
 
 7-(5-Methyl-1H-indol-3-yl)-4-phenyl-3,4,5,6-tetrahydro-2H-azepinium Bromide, 
2.93. To a solution of 2.1 (52.5 mg, 0.301 mmol, 1.0 equiv) and AlBr3 (83.9 mg, 0.315 mmol, 1.1 
equiv) in HFIP (1.0 mL) in a flame-dried nitrogen-flushed 25 mL round bottom flask was added a 
solution of TMSN3 (80.0 μL, 0.600 mmol, 2.0 equiv) in HFIP (2.0 mL) using a syringe pump (0.40 
mL/h, 14.00 mm diameter, and 20 gauge needle) over 6 h at room temperature. Following 3 h slow 
addition, 5-methyl-1H-indole (100 mg, 0.762 mmol, 2.5 equiv) was added, and then after 6 h 
additional 5-methyl-1H-indole (100 mg, 0.762 mmol, 2.5 equiv) was added and the reaction 
mixture was stirred for an additional 15 h. The reaction mixture was concentrated under nitrogen, 
the crude residue was redissolved in CH2Cl2 (~40 mL), filtered to remove residual aluminum, and 
concentrated. Purification was carried out twice by an automated MPLC system; first, using a 15.5 
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g C18 reverse phase column with gradient elution from 0–50% MeCN/H2O, and then using a 12 g 
normal phase silica column with gradient elution from 0–8% MeOH/CH2Cl2 afforded 2.93 as a 
pale cream amorphous solid (40.2 mg, 0.105 mmol, 35% yield). RT = 1.88 (UPLC, MeOH(0.05% 
CH2O2)/H2O); mp decomposed; IR (neat) 2918, 1603, 1586, 1516, 1434 cm-1. 1H NMR (400 MHz, 
CDCl3) δ 8.37 (br s, 1H), 7.85 (s, 1H), 7.63 (d, J = 8.3 Hz, 1H), 7.33–7.29 (m, 2H), 7.26–7.21 (m, 
2H), 7.16–7.10 (m, 3H), 4.44 (dd, J = 14.4, 5.6 Hz, 1H), 3.69 (m, 1H), 3.41 (m, 1H), 2.96 (m, 1H), 
2.80 (m, 1H), 2.51 (m, 3H), 2.23–2.15 (m, 2H), 1.83 (q, J = 12.7 Hz, 1H), 1.61 (q, J = 12.8 Hz, 
1H); 13C NMR (151 MHz, CDCl3) δ 177.2, 145.1, 137.5, 136.2, 133.9, 129.0 (2C), 127.2, 126.7 
(2C), 126.1, 124.2, 120.6, 114.0, 109.0, 48.4, 45.6, 34.0, 31.9, 30.6, 21.9. HRMS (FT-ICR, ESI) 
m/z: [M – Br]+ calcd for C21H23BrN2 303.1856, found 303.1850. Anal. calcd. for C21H22.95Br0.95N2: 
C 66.50, H 6.10, N 7.39, found C 66.51, H 6.49, N 7.03.   
 
 7-(5-Methoxy-1H-indol-3-yl)-4-phenyl-3,4,5,6-tetrahydro-2H-azepinium Bromide, 
2.94. To a solution of 2.1 (52.5 mg, 0.301 mmol, 1.0 equiv) and AlBr3 (83.7 mg, 0.314 mmol, 1.0 
equiv) in HFIP (1.0 mL) in a flame-dried nitrogen-flushed 25 mL round bottom flask was added a 
solution of TMSN3 (80.0 μL, 0.603 mmol, 2.0 equiv) in HFIP (2.0 mL) using a syringe pump (0.40 
mL/h, 14.00 mm diameter, and 20 gauge needle) over 6 h at room temperature. Following 3 h slow 
addition, 5-methoxy-1H-indole (110 mg, 0.747 mmol, 2.5 equiv) was added, and then after 6 h 
additional 5-methyl-1H-indole (110 mg, 0.747 mmol, 2.5 equiv) was added and the reaction 
mixture was stirred for an additional 15 h. The reaction mixture was concentrated under nitrogen, 
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the crude residue was redissolved in CH2Cl2 (ca. 40 mL), filtered to remove residual aluminum, 
and concentrated. Purification was carried out twice by an automated MPLC system; first, using a 
50.0 g C18 reverse phase column with gradient elution from 0–100% MeCN/H2O, and then using 
a 12 g normal phase silica column with gradient elution from 0–8% MeOH/CH2Cl2 afforded 2.94 
as a cream amorphous solid (57.0 mg, 0.143 mmol, 47% yield). RT = 1.73 (UPLC, MeOH(0.05% 
CH2O2)/H2O); mp decomposed; IR (neat) 2918, 1604, 1516, 1486, 1440 cm-1. 1H NMR (400 MHz, 
CDCl3) δ 7.82 (br s, 1H), 7.59 (s, 1H), 7.52 (d, J = 8.9 Hz, 1H), 7.34–7.31 (m, 2H), 7.28–7.22 (m, 
4H), 6.90 (m, 1H), 4.59 (dd, J = 14.5, 5.5 Hz, 1H), 4.07 (s, 3H), 3.65 (m, 1H), 3.17 (m, 1H), 2.93 
(m 1H), 2.78 (m, 1H), 2.19 (m, 2H), 1.87 (m, 1H), 1.63 (m, 1H); 13C NMR (151 MHz, CDCl3) δ 
176.1, 157.2, 145.2, 137.7, 132.3, 129.0 (2C), 127.2, 126.8 (2C), 124.1, 115.2, 114.9, 109.3, 103.0, 
56.7, 48.5, 45.9, 33.9, 32.6, 31.1. HRMS (FT-ICR, ESI) m/z: [M – Br]+ calcd for C21H23BrN2O 
319.1805, found 319.1797.  
 
 7-(5-Bromo-1H-indol-3-yl)-4-phenyl-3,4,5,6-tetrahydro-2H-azepinium Bromide, 
2.95. To a solution of 2.1 (52.6 mg, 0.302 mmol, 1.0 equiv) and AlBr3 (88.1 mg, 0.330 mmol, 1.1 
equiv) in HFIP (1.0 mL) in a flame-dried nitrogen-flushed 25 mL round bottom flask was added a 
solution of TMSN3 (80.0 μL, 0.600 mmol, 2.0 equiv) in HFIP (2.0 mL) using a syringe pump (0.40 
mL/h, 14.00 mm diameter, and 20 gauge needle) over 6 h at room temperature. Following 3 h slow 
addition, 5-bromo-1H-indole (150 mg, 0.765 mmol, 2.5 equiv) was added, and then after 6 h 
additional 5-bromo-1H-indole (150 mg, 0.765 mmol, 2.5 equiv) was added and the reaction 
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mixture was stirred for an additional 15 h. The reaction mixture was concentrated under nitrogen, 
the crude residue was redissolved in CH2Cl2 (ca. 40 mL), filtered to remove residual aluminum, 
and concentrated. Purification by an automated MPLC system using a 15.5 g C18 reverse phase 
column with gradient elution from 0–100% MeCN/H2O afforded 2.95 as a pale brown amorphous 
solid (69.5 mg, 0.155 mmol, 51% yield). RT = 1.92 (UPLC, MeOH (0.05% CH2O2)/H2O); mp 
decomposed; IR (neat) 3082, 1611, 1518, 1451 cm-1. 1H NMR (400 MHz, CDCl3) δ 12.6 (br s, 
1H), 11.6 (br s, 1H), 8.56 (s, 1H), 8.09 (s, 1H), 7.57 (dd, J = 8.7 Hz, 1H), 7.30–7.25 (m, 3H), 7.23–
7.18 (m, 1H), 7.12 (m, 2H), 4.45 (m, 1H), 3.82 (m, 1H), 3.49 (dd, J = 14.6, 7.5 Hz, 1H), 2.98 (m, 
2H), 2.25 (m, 1H), 2.15 (m, 1H), 1.86 (q, J = 12.3, 1H), 1.67 (q, J = 12.6 Hz, 1H); 13C NMR (151 
MHz, CDCl3) δ 177.7, 144.9, 137.8, 136.4, 129.0 (2C), 127.5, 127.2, 126.7 (2C), 125.6, 123.0, 
117.5, 115.8, 108.8, 48.4, 46.0, 33.6, 32.3, 30.4. HRMS (FT-ICR, ESI) m/z: [M – Br]+ calcd for 
C20H20Br2N2 367.0804, found 367.0804.  
 
 4-Phenyl-7-(1H-pyrrol-3-yl)-3,4,5,6-tetrahydro-2H-azepinium Bromide, 2.96. To a 
solution of 2.1 (52.3 mg, 0.300 mmol, 1.0 equiv) and AlBr3 (82.4 mg, 0.309 mmol, 1.0 equiv) in 
HFIP (1.0 mL) in a flame-dried nitrogen-flushed 25 mL round bottom flask was added a solution 
of TMSN3 (80.0 μL, 0.600 mmol, 2.0 equiv) in HFIP (2.0 mL) using a syringe pump (0.40 mL/h, 
14.00 mm diameter, and 20 gauge needle) over 6 h at room temperature. Following slow addition, 
1H-pyrrole (104 µL, 1.50 mmol, 5.0 equiv) was added and the reaction mixture was stirred for an 
additional 15 h. The reaction mixture was concentrated under nitrogen, the crude residue was 
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redissolved in CH2Cl2 (ca. 40 mL), filtered to remove residual solids, and concentrated. 
Purification by an automated MPLC system using a 15.5 g C18 reverse phase column with gradient 
elution from 0–100% MeCN/H2O afforded 2.96 as a pale brown amorphous solid (39.1 mg, 0.122 
mmol, 41% yield). RT = 1.55 (UPLC, MeOH (0.05% CH2O2)/H2O); mp decomposed; IR (neat) 
3142, 3080, 3007, 2926, 2869, 1626 cm-1. 1H NMR (400 MHz, CDCl3) δ 13.0 (br s, 1H), 12.6 (br 
s, 1H), 7.53 (m, 1H), 7.34–7.31 (m, 2H), 7.27–7.20 (m, 2H), 7.15 (m, 2H), 6.45 (dt, J = 4.3, 2.2 
Hz, 1H), 4.20–4.12 (m, 1H), 3.70 (ddd, J = 15.1, 11.4, 4.5 Hz, 1H), 3.40 (dd, J = 14.8 , 7.6 Hz, 
1H), 2.95 (tt, J = 12.3, 3.6 Hz, 1H), 2.86 (dd, J = 14.6, 12.1 Hz, 1H), 2.27 (m, 1H), 2.17 (m, 1H), 
1.87 (m, 1H), 1.70 (m, 1H); 13C NMR (151 MHz, CDCl3) δ 169.0, 144.9, 134.4, 129.1 (2C), 127.3, 
126.7 (2C), 125.6, 124.5, 113.5, 48.5, 45.1, 33.9, 31.2, 30.3. HRMS (FT-ICR, ESI) m/z: [M – Br]+ 
calcd for C16H19BrN2 239.1543, found 239.1542.  
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Chapter 3 
Enabling Chemistry Technologies: 
High Temperature and High Pressure Continuous Flow Chemistry 
 
3.1 Introduction 
3.1.1 Advantages and Challenges in Flow Technology  
Ongoing innovations in flow chemistry and continuous processing have emerged as tools 
that can significantly impact organic synthesis. Flow chemistry is an enabling technology that 
surpasses benchtop chemistry in many ways (Table 3.1).1-8 Some advantages are attributed to the 
high surface-to-volume ratio within micro- and meso-structured flow systems. The small 
dimensions of a flow reactor permit the precise control of reaction variables and access to 
unprecedented process windows (e.g., high temperatures, pressures, concentrations)2, which are 
challenging regimes to accomplish concomitantly in traditional chemistry. Continuous processing 
enables organic chemistry by providing additional opportunities that include the ability to perform 
multiple functions on a single integrated device (e.g., synthesis, purification, analysis, biological 
screening), accelerate the pace of discovery to production (e.g., automated reaction optimization, 
high-throughput library development, production-scale synthesis), and sustain green protocols of 
chemical synthesis (e.g., use of green solvents, reduction of material consumption and waste 
generation).1-7 These innovative technologies have enhanced efficiency and improved safety 
profiles of chemical synthesis, essentially providing new approaches for performing organic 






   
Table 3.1. Advantages of continuous-flow processing.1-7 
 
x Efficient mixing (micromixing) 
x Efficient heat transfer and precise control of temperature (due to high surface-to-volume ratio) 
x Process intensification: high-temperature and high-pressure capabilities  
x Novel process window: access to a wider range of temperatures, pressures, and concentrations 
x Control over multiple reaction variables (e.g., residence time, flow rate, reactor volume)  
x Immobilization of catalysts and reagents 
x Safer use of hazardous reagents, gases, and reactive intermediates  
x Use of green solvents, low-boiling solvents, and access to supercritical fluid states  
x Increased photon flux in photochemical reactions 
x Reproducibility 
x Integration of in-line purification, analytical techniques, and automation  
x Multistep reactions in a continuous sequence  
x Telescoping of reaction and purification processes 
x Ease of scale-ups (e.g., increase the number of reactors or the reactor dimensions) 
 
However, there are many challenges hampering the application of continuous-flow 
technologies toward routine organic synthesis.1, 4, 6, 8-11 For example, many researchers are 
unfamiliar with flow techniques, and effective application of such techniques demands the 
understanding of both synthetic chemistry and engineering principles. Secondly, there are 
fundamental differences between batch and flow processes. The use of flow reactors is not 
straightforward, and has many challenges associated with technology maintenance including 
dissolution (managing solids), integration of reactor components (e.g., pumps, reactors, back-
pressure regulators), and integration of multi-step processes (e.g., in-line analysis, purification, 
automation). The relative value of flow application should be evaluated by case and depends on 
various factors including reaction kinetics (e.g., Curtin-Hammett principle), safety (e.g., use of 
hazardous reagents, heat exchange, pressurized reactions), scalability, and others.1, 8, 11 Principally, 
selecting the appropriate flow system requires a critical evaluation of factors governing the 
reaction of interest that would ultimately make the applications of flow processing impactful and 
advantageous over batch chemistry.  
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3.1.2 High-Temperature Chemistry  
 There is long-standing evidence that high-temperature chemistry using oil baths, hot plates, 
or reflux-apparatus speeds up synthetic transformations when compared to room temperature 
chemistry. In principle of the Arrhenius equation (k = Ae-Ea/RT), the reaction rate increases 
exponentially as the absolute temperature is increased. However, under traditional heating 
conditions, reactions can still take up to days or weeks to complete and experiments are often 
limited by the solvent’s boiling point. The introduction of microwave irradiation to organic 
synthesis has provided alternative means to rapidly heat reaction mixtures.12-14 As a result of the 
microwave technology, there have been a plethora of protocols demonstrating reduced reaction 
times in comparison to traditional heating sources. Particularly, protocols that rapidly heat in 
sealed vessels to permit low boiling point solvents for high-temperature reactions, and synthetic 
transformations that require several hours to reach completion within minutes. As shown in Table 
3.2, microwave technology offers several advantages over traditional chemistry, which includes 
rapid heating and experimentation above the boiling point of some solvents (limited by pressure 
<30 bar).12-14 It has also become an essential tool in solvent-free and water-mediated reactions, 
whereby microwave-irradiation facilitates high-temperature homogeneity. Despite the wide 
adoption of microwave technology, there are some drawbacks compared to flow technology.12-14 
Similar to benchtop chemistry, syntheses developed in the laboratory often cannot become 
translated to large-scale production without substantial optimization. Specifically, heating and 
cooling profiles on small-scale microwave reactors cannot easily become duplicated on larger 
scale; microwave preparative quantities are generally limited to 30 mL reaction volumes.8 
Additionally, microwave-assisted reactions depend on the ability of the reaction mixture, 
particularly the solvent, to efficiently absorb microwave energy. Consequently, microwave 
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processing can become inefficient in cases of low absorptivity. Lastly, the low-pressure threshold 
(i.e., headspace limitations) of this technology impedes genuine high-temperature–high-pressure 
processing, which in turn, restricts the options of low-boiling solvents. Pressurized flow reactors 
eliminate headspace, thereby maintaining uniform reagent concentrations and efficiency with low-
boiling reagents. As a consequence of the drawbacks in both traditional and microwave processing, 
efforts have been made toward high-temperature and high-pressure continuous-flow processing.  
 
Table 3.2. Comparison of traditional heating, microwave reactor, and flow reactor.8, 12-14  
 
Traditional heating Microwave reactor Flow reactor 
+ High temperature  
(<200 ˚C; limited by the bp of 
solvent) 
– Atmospheric pressure 
– Not as efficient for either rapid 
heating or cooling 
+ High temperature (<250 ˚C) 
+ High pressure (<30 bar)  
+ Rapid heating 
– Limited headspace (explosion 
possibility & reduced efficiency 
with low-boiling solvents)  
+ High temperature (<450 ˚C) 
+ High pressure (<200 bar)  
+ Rapid heating 
+ Back-pressure regulator 
+ No headspace limitations 
+ Heterogeneous reaction 
mixtures 
+ Heterogeneous reaction 
mixtures 
– Difficulties w/ heterogeneous 
reaction mixtures 
+ Scalable w/ optimization – Not scalable (limited to 30 mL) + Directly scalable  
  
Thus, flow technology is a major advance towards high-temperature–high-pressure 
processing.2, 7, 13 Applying a continuous-flow regime not only facilitates the replication of 
temperatures and pressures in traditional and microwave experimentations, but also provides many 
other advantages (as highlighted in Tables 3.1 and 3.2).2, 7 Flow chemistry has an edge over 
conventional batch chemistry due to the smaller temperature gradients derived from the reactors’ 
large surface-to-volume, which may play a role in heat transfer efficiency. In turn, reactors 
promoting efficient heat exchange are conducive to high-pressure conditions. This new mode of 
operation has significant appeal because it is an approach towards chemical space that has yet to 
be extensively explored and demonstrated. For example, high-pressure capabilities of flow devices 
has enabled possibilities to work with low-boiling solvents well beyond their boiling points, 
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replace solvents with liabilities, exploit reaction telescoping (e.g., simplifications in reaction work-
up by evaporation of low-boiling solvents, eliminate isolation/purification sequences), and explore 
solvent reactivity near or in its supercritical state (i.e., changes in the physical properties of solvent 
under extreme conditions). A particularly important advantage of flow compared to conventional 
devices is the direct scalability with minimal optimization through the operation of multiple 
systems in parallel or related strategies. In fact, preparative scale high-temperature–high-pressure 
reactions are much safer in flow. Finally, additional to the intensifications of reaction conditions, 
flow technologies are amendable to integration with multiple devices facilitating the incorporation 
of various chemistry techniques and high-throughput chemical synthesis.  
 
3.1.3 Examples of High-Temperature and High-Pressure Flow Chemistry  
Common continuous-flow technologies for organic synthesis are commercially available 
(Figure 3.1). The majority of commercial reactors use either direct electric heating of a metallic 
coil (ThalesNano X-Cube Flash), or an Al heating block (Uniqsis Flow Syn). Alternatively, gas-
heated or cooled chambers that accommodate a tube reactor have been incorporated in flow 
systems as well (Vapourtec R Series). Additionally, the standard use of back-pressure regulators 
in combination with HPLC or syringe pumps allows reaction mixtures to be processed safely at 
high pressures (typically 70–180 bar).7, 13 In our investigations, we utilized the Phoenix Flow 
ReactorTM commercially available from ThalesNano.  
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(a)  (b)  (c)  
Figure 3.1. Commercially available continuous flow reactors for high-temperature organic 
synthesis. (a) ThalesNano X-Cube FlashTM (350 ˚C, 180 bar). (b) Uniqsis FlowSyn (260 ˚C, 70 
bar). (c) Vapourtec R4 Reactor (250 ˚C, 50 bar). Images adapted from commercial websites.15-17  
 
 
There are many aspects of synthesis and stages in medicinal chemistry that can be 
accomplished in flow devices in the pharmaceutical industry: (1) synthesis of a few milligrams or 
multigram scale of compound for drug discovery, (2) synthesis of building blocks for parallel 
synthesis in drug discovery, (3) multi-step reaction sequences in flow, (4) preparation of kilogram 
quantities of drug candidate for clinical research, and (5) production of drug molecules for 
marketing.2-3, 5-6 Ultimately, process improvements in either of the above noted points have the 
potential to reduce manufacturing cost and cycle time, as well as, streamline the journey from early 
discovery to production.  
 
3.1.4 Instrumentation: The Phoenix Flow ReactorTM Platform  
In our investigations, we modified a commercially available high-temperature and high-
pressure Phoenix Flow ReactorTM from ThalesNano. This commercial flow reactor is a coil 
consisting of a stainless steel tubing (Hastelloy, 1.0 mm in diameter) of variable length (variable 
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volume) that is wrapped around a metallic housing tube placed inside an insulated chamber (Figure 
3.2a). In our set-up, a stainless steel tubing of 8-mL volume was used. The coil directly heats 
across the full length and can achieve temperatures as high as 450 ˚C. Within the reactor body, we 
added a temperature probe outside the coil in order to better monitor the reaction temperature. 
Further, we realized equilibration to the desired temperature of the reactor (approximately 30 
minutes) was necessary prior to experimentations and only for the first run each day. The platform 
operated through 4 main components: (1) the Phoenix Flow ReactorTM, (2) a manual injection 
valve, (3) a JASCO PU-2085 Plus HPLC pump, and (4) a JASCO BP-2080 Plus back-pressure 
regulator (Figure 3.2b). The HPLC pump allowed for a continuous-flow of reaction mixtures into 
the coil with variable flow rates from 0.01 to 4.00 mL/min. The back-pressure regulator allowed 
the flow system to achieve a pressure maximum of 140 bar. This modified flow platform readily 
accessed a wide range of temperatures, pressures, and residence times. Additionally, the platform 
could be modified to incorporate an automated sample processor, as well as, alternative back-
pressure regulators, valve injector volume, and stainless steel tubing of variable volumes (2–16 
mL volumes). Thereby, through the configuration of individual components into a flow platform, 
we designed a system that was flexible and amendable to integration with other devices.  
 In general, the Phoenix system was flushed with a solvent of choice, and then pressurized 
and set to the desired temperature. Substrates were dissolved in solvent and loaded into the 1 mL-
injection loop, which would then inject into the Phoenix system at a specific flow rate. Samples 
were collected at the outlet of the reactor in scintillation vials, which were concentrated under a 
nitrogen sample concentrator and analyzed either by analytical HPLC/MS or UPLC/MS. Samples 
were either characterized following purification using either automated chromatography or 
preparative HPLC, or characterized without further purification.  
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Figure 3.2. The Phoenix Flow ReactorTM platform. (a) Picture of the high-temperature Phoenix 
flow reactor. (b) Schematic diagram of the Phoenix flow platform configuration. The figure was 
adapted from Charaschanya et al.18 and Bogdan et al.19. 
 
With a modified Phoenix Flow ReactorTM platform in hand, my externship at AbbVie 
comprised: (a) evaluation of this Phoenix platform for synthesis, (b) development of organic 
methodologies in unconventional reaction space (>250 ˚C and >20 bar), and (c) demonstration of 
the flow platform towards medicinal chemistry efforts. During this endeavor, organic chemistry 
investigated focused on the improvements of heterocycle synthesis and C–N bond formations, 
which are both important facets in pharmaceutical development of small-molecules. In this work, 
I collaborated with Dr. Andrew Bogdan, Dr. Jennifer Tsoung, and Dr. Amanda W. Dombrowski 
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from the high-throughput chemistry group of AbbVie, who contributed to the study design, 
research, interpretation, and review of data.  
 
3.2 Synthesis of Nitrogen Heterocycles  
The U.S. FDA approved drug database reveals that 59% of small-molecule drugs contain 
a nitrogen heterocycle.20 Nitrogen heterocycles are among the most important structural 
components of pharmaceutical agents, and for this reason, heterocyclic formations are commonly 
utilized chemical transformations in the medicinal and pharmaceutical communities.21-22 New 
methodologies and technologies that augment the rapid generation of diverse nitrogen heterocycles 
are desirable as they hold significant impact in this area. In this section, I discuss a flow chemistry 
investigation on the Gould-Jacobs reaction (Scheme 3.1). The Gould-Jacobs reaction is a well-
known synthetic transformation for the construction of 4-quinolones from anilines (or 
heteroaromatic amines) and alkylidene diesters (or malonic ester derivatives).23 Traditionally, the 
reaction proceeds via a two-step mechanism; condensation of the amine with an alkylidene diester 
to form the enamine intermediate is followed by a high-temperature ring closure. Typically, the 
intramolecular cyclization step requires prolonged heating at temperatures >200 ˚C in high-boiling 
solvents (e.g., diphenyl ether (DPE), DowthermTM, tetraglyme).24-26 Accordingly, preparations of 
such heterocyclic cores via the Gould-Jacobs reaction are uncommon mainly because reaction 
work-up is tedious due to difficulties in the removal or uncontrolled precipitation of high-boiling 
solvents. In rare circumstances, flash vacuum pyrolysis has been applied to synthesize 
quinolones.27-28 However, current flash vacuum pyrolysis devices are not suitable for continuous-
flow or scale-up operations. In general, this thermal cyclization reaction is underutilized in 
medicinal chemistry research. These restrictive high-temperature and high-boiling solvent 
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requirements marked this chemical transformation as an ideal opportunity to explore in a high-
temperature–high-pressure flow system. Flow technologies could enable milder reaction 
conditions and unprecedented solvent states for this transformation. Thus, we relied on flow 
chemistry to provide a practical solution with better synthetic tractability and prospects of high-
throughput library development of such heterocyclic scaffolds. In this context, Lengyel and 
coworkers have developed a flow protocol for the intramolecular thermal cyclization of the Gould-
Jacobs reaction29, which we selected as the model to study, compare and contrast with our flow 
platform and potentially extend the scope of this chemistry. The substrates used in the following 
studies have been published.30  
 
Scheme 3.1. The Gould-Jacobs reaction. 
 
 
Quinolone, quinoline and related heterocycles (e.g., pyrimidinones) are important synthetic 
intermediates and scaffolds prominent in lead chemical series and marketed drugs.31-32 For 
example, this heterocyclic core is observed in quinolone antibiotics, such as fluoroquinolones (e.g., 
norfloxacin), nalidixic acid and oxolinic acid, as well as in non-steroidal anti-inflammatory drugs 
such as floctafenine and glafenine (Figure 3.3). The biological activities associated with such 
heterocycles represents one of the most important classes of anti-infective agents32, and thus 




   
 
Figure 3.3. Quinolone and quinoline pharmacophores in marketed drugs.  
 
3.2.1 Exploration of Reaction Conditions for the Gould-Jacobs Reaction  
In this investigation, the intramolecular thermal cyclization of the Gould-Jacobs reaction 
was used as a model to evaluate the configuration of the Phoenix flow platform. Our initial 
attempts to reproduce the cyclization results of compound 3.1 reported by Lengyel and coworkers 
were unsuccessful (Scheme 3.2a).29 They carried out the thermal cyclization in a flow system at 
temperature and pressure in the ranges of 300–360 ˚C and 100–160 bar, with short residence times 
(0.45–4.5 minutes) in tetrahydrofuran (THF). In our hands, when the transformation was carried 
out in the Phoenix reactor two product types were consistently observed from the two substrates 
tested (Scheme 3.2b), which was distinctive from Lengyel et al.’s work. While Lengyel and 
coworkers carried out the cyclization reaction in the X-Cube Flash flow system, the system still 
operated by direct electric heating of a metallic coil similar to that of the Phoenix system. This 
suggested that other variables were responsible for the product outcomes. For the specific 
transformation highlighted in Scheme 3.2a, Lengyel and coworkers reported a 70% isolated yield 
of only the ester-product 3.2. To synthesize 3.2, the authors used a flow reactor with steel tubing 
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of 4.5 mL volume at a flow rate of 4.0 mL/min (residence time 1.13 minute), pressure of 130 bar, 
and temperature of 360 ˚C. In contrast, we utilized a flow reactor with steel tubing of 8.0 mL 
volume at a flow rate of 4.0 mL/min (2 minutes residence time), pressure of 100 bar, and 
temperature of 360 ˚C. Under our process window, a separable mixture of ester-product 3.2 and 
decarboxylated-product 3.3 were synthesized. To further substantiate this mixture, the reaction 
was carried out with a second substrate 3.4, which indeed gave two separable product types, ester-
product 3.5 and decarboxylated-product 3.6. Additionally, we sought out an alternative scaffold 
3.7, which was readily prepared by refluxing aniline and diethyl ethoxymethylenemalonate in 
ethanol (EtOH); analogous to the preparation of the other substrates 3.1 and 3.4. With the flow 
conditions at hand, the outcome observed was a conversion only to the decarboxylated-product 
3.8, while the ester-containing heterocycle in either tautomeric forms 3.9a or 3.9b was not 
observed by analytical HPLC/MS (Scheme 3.3). It was evident from the differences between the 
two flow systems that product outcomes were significantly dependent on the pressure and 
residence time (i.e., time that the reaction mixture spends in the reactor, which is determined by 
the tubing volume and flow rate).  
Although the product selectivities were not as anticipated, these results were informative 
about our flow configuration. First, the ability to form two products from one common precursor 
is potentially attractive if the yields of each scaffold could be optimized. Secondly, variation of 
reaction parameters such as residence time, flow rate, pressure, and temperature may have 
significant influence on product selectivities. Thirdly, the formation of the decarboxylated-
products (3.3, 3.6 or 3.8) under these preliminary conditions is interesting and possibly useful. The 
traditional synthesis of 3.3 requires multiple sequential steps of cyclization, hydrolysis, and 
decarboxylation from the ester-containing heterocycle or synthesis from an alternative starting 
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material.33-34 Interestingly, the heterocycle 3.8 is reported in the literature, however only reported 
as the ester-containing heterocycle synthesized by heating substrate 3.7 in DPE at 240–250 ˚C for 
an extended period.34-35  
 
Scheme 3.2. Model reaction: intramolecular thermal cyclization reaction of the Gould-Jacobs 
reaction. (a) Work by Lengyel and coworkers.29 (b) This work.  
 
 
Scheme 3.3. Intramolecular thermal cyclization using the Phoenix flow platform.  
 
 
Following the investigations of the thermal intramolecular cyclization, we sought to 
determine if the entire sequence of the Gould-Jacobs reaction, amidation followed by cyclization, 
could be carried out in the Phoenix reactor (Table 3.3). Here, we examined a reaction between 
diethyl phenylmalonate and 4-methyl aniline to form 4-hydroxy-6-methyl quinolinone 3.10 in 
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flow. We first utilized the Conjure flow system to systematically screen solvents for the reaction 
sequence. The Accendo Conjure flow system relies on a segmented flow approach as opposed to 
continuous flow, which uses an immiscible florous spacer to create segments in flow. Specifically, 
using this approach multiple reactions can flow through the reactor at any one time, which 
maximizes the reaction optimization process.36 Table 3.3 describes the reaction in solvents that 
afforded identifiable products by analytical HPLC/MS. Unfortunately, the desired product 3.10 
was minimally formed under all conditions tested. In the best scenario, reaction in 
dimethylacetamide (DMA) gave 33% of 3.10 by HPLC/MS (entry 4), whereas, in most cases, a 
range of amidated-products 3.11–3.13 were observed by HPLC/MS. Although conversion to 3.10 
in DMA was not optimal in the Conjure flow system, we attempted the reaction sequence in the 
Phoenix system anyway. Unfortunately, the desired product 3.10 was not observed, and instead 
amidated-product 3.11 and DMA-fragmentation product 3.14 were observed by HPLC/MS (not 
reported in the table because it was not quantified). In the Phoenix as well, the reaction sequence 
was carried out in 1,4-dioxane and similarly amidated-product 3.11 was observed (entry 6). It was 
clear from this investigation that execution of this tandem reaction sequence in flow is difficult. 
Moreover, the results obtained from the Conjure system do not necessarily translate well with the 
Phoenix system. Despite this lack of success, this investigation provided meaningful insights about 
re-designing experiments and the flow configuration. In this light, we learned that the Phoenix 
could execute amide-bond formations using activated esters without added reagents (e.g., 
formation of HPLC/MS observed compounds 3.11–3.13). Secondly, the system readily favored 
the decarboxylation of esters in a tandem sequence of ester hydrolysis and decarboxylation. This 
inferred to the possibility of conducting certain types of tandem reaction sequences in flow, but 
would warrant optimization of product selectivities. Thirdly, reaction with solvent itself is highly 
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possible when subjected to unconventional conditions and could obstruct reaction development. 
However, there is discussion in the literature that certain solvents in it supercritical state (i.e., as 
solvent approaches temperature and pressure above its critical point, the properties of its gas and 
liquid phases converge) may enhance chemical transformations.2, 7 Finally, different flow reactor 
configurations can result in variable chemical transformations and product outcomes. Thus, the 
synthetic abilities of each flow system may require a thorough experimentation in order to execute 
challenging chemical transformations. In fact, during our preliminary investigations we learned 
that the Phoenix reactor required an equilibration time period in order to achieve the set 
temperature of study. Specifically, we determined that approximately 30 minutes was necessary 
to equilibrate the reactor at the set temperature. Unfortunately, because at the time we lacked 
knowledge about this reactor design, the reactions carried out in this section did not achieve 













   
Table 3.3. Preliminary investigation of the Gould-Jacobs reaction in flow.a-d  
 
entry flow system solvent 3.10 3.11 3.12 3.13 3.14 
1 Conjure toluene >1 72 16 10 - 
2 Conjure DPE >1 3 8 39 - 
3 Conjure THF 4 41 22 15 - 
4 Conjure DMA 33 35 11 9 - 
5 Conjure dioxane - 72 2 1 - 
6 Phoenix dioxane - 19 - - - 
aThe Accendo Conjure flow reactor relies on segmented flow, and uses an immiscible florous spacer to 
create discrete reaction segments in flow.36 bThe Phoenix was flushed with solvent and the system 
pressurized to 100 bar. The temperature was set to 275 ˚C. Substrates were dissolved in THF (0.1 M) and 
loaded into the 1 mL-injection loop. The flow rate was set 4.0 mL/min, and the sample injected into the 
Phoenix system. Samples were collected at the outlet of the reactor, concentrated under a nitrogen sample 
concentrator, and analyzed by analytical HPLC/MS without any further purification. cThe Phoenix 
system was not allowed to equilibrate to the set temperature, because at the time we were unaware that 
the reactor required equilibration. dConversion by UV trace of the HPLC/MS after solvent removal.  
 
 
3.2.2 Conclusions and Future Directions  
Our preliminary investigation of the Gould-Jacobs reaction in flow was informative. We 
realized the challenges associated with executing chemical transformations in flow, and the 
necessity of understanding reactor concept to effectively apply the flow regime towards organic 
synthesis. Though we were unable to reproduce the original results of the intramolecular thermal 
cyclization by Lengyel and coworkers, we identified the possibility of optimizing two scaffolds in 
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flow. Interestingly, decarboxylation of esters is highly favorable under these unconventional 
conditions, which gave rise to a new scaffold that traditionally required alternative sequences to 
access. Although we were unable to carry out the two-step sequence of the Gould-Jacobs reaction, 
we were able to carry out the intramolecular cyclization from fixed starting materials (i.e., pre-
coupled amide). It appeared that a tandem amidation-thermal cyclization sequence is less 
straightforward, and thus requires a thorough investigation of several reaction parameters in flow.  
The preliminary investigations carried out during my externship provided a foundation for 
a detailed study carried out at AbbVie following the completion of my internship. Dr. Jennifer 
Tsoung and Dr. Andrew Bogdan successfully optimized conditions that selectively and exclusively 
accessed in high yields both the ester- and decarboxylated-scaffolds (Scheme 3.4).30 Correlations 
between increasing pressure and residence time were key determinants to increase the conversion 
of decarboxylated products. Another important factor that was unaccounted for in our preliminary 
investigation was the effect of concentration on the reaction outcome. They found that high 
concentration favored the decarboxylation process, and is most likely attributed to catalysis by the 
presence of minimal water in the solvent. Confirming this, Tsoung and coworkers were able to 
utilize a mixture of THF and water to optimize and accelerate the decarboxylation process. In this 
paper, published in early 2017 in the Journal of Organic Chemistry30, they employed Design-of-
Experiments (DoE) software (Stat-Ease Design Expert 7) to rapidly facilitate the synthesis of a 
heterocyclic library (this optimization approach is further described in section 3.3). In this work, 
the Phoenix was modified to allow for robotic liquid handling and rapid injections featuring 
automation onto the Phoenix platform. Moreover, using the automated platform, they 
demonstrated the application of the cyclization reaction on a preparative scale of approximately 
18.2 g/h. Advantageous to this protocol as well was the combination of a low-boiling solvent (e.g., 
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THF) with high conversions that streamlined work-up and isolation of products unlike traditional 
methods.  
 
Scheme 3.4. Synthesis of two scaffolds using the automated Phoenix system. The scheme was 
adapted from Tsoung et al.30 
 
In future directions, this general approach could be adapted to various heterocyclic amines, 
especially the application of customized monomers could give rise to new chemical series for 
pharmaceutical developments. The combination of DoE and automated flow provides an approach 
for the rapid synthesis of therapeutic agents.  
 
3.3 C–N Bond Formation thru Nucleophilic Aromatic Substitution  
The nucleophilic aromatic substitution (SNAr) of aryl compounds and heterocycles is a 
synthetically valuable and versatile chemical transformation that is widely used in both 
pharmaceutical and industrial communities. The reaction is guided by three basic principles: an 
electron deficient aromatic system, the nature of the leaving group to be displaced, and the 
reactivity of the nucleophile.37-38 Generally, electron-deficient arenes will proceed through SNAr 
in an addition-elimination sequence; aryl halides (particularly fluorides) and diazonium arenes 
have shown to be the most successful in the literature.37-38 In this section, I focus on the 
displacement of aza-substituted aryl halides with nitrogen nucleophiles. A number of synthetic 
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methods have been developed to install nitrogen functionalities on aryl rings, including transition-
metal catalyzed reactions39-40 such as the Buchwald-Hartwig coupling reaction, Ullmann reaction, 
Chan-Lam coupling, as well as, metal-free reactions41 such as the SNAr reaction. In comparison to 
transition-metal catalyzed reactions, the classic SNAr reactions are limited by poor scope and high 
temperature requirements.39 However, the classic SNAr reaction remains fundamental because it 
is cost-effective, atom economical, and avoids the requirement of designer ligands and the removal 
of trace metal impurities.40-41 Recently published, perspectives in the Journal of Medicinal 
Chemistry cited the SNAr reaction as the most frequently used chemical transformation in current 
medicinal chemistry.20-22 Thus, despite its shortcomings, the SNAr remains a fundamental reaction 
in the synthetic community.  
Traditionally, standard heating is used to conduct SNAr reactions on electron-deficient aryl 
halides. In contrast, unactivated substrates require more forcing conditions, such as highly elevated 
temperatures or microwave-assisted heating. For example, aminations of 2-chloroquinazoline can 
occur in refluxing 1-pentanol or isopropyl alcohol, heating in EtOH in sealed tubes at 150 ˚C until 
reaction completion, and heating in high-boiling solvents (e.g., in N-methyl-2-pyrrolidone (NMP) 
heated at 110 ˚C) for an extended period. Alternatively, microwave-assisted heating in acetonitrile 
(MeCN) has been employed to lower reaction times.42 A few examples of using flow chemistry to 
promote SNAr transformations have been reported in the literature; for example, (1) 2-
chloropyridine and piperidine were heated in NMP at 260 ˚C to afford desired product in 20 
minutes43, and (2) a step-wise SNAr of activated difluorobenzene to monoamidated products was 
achieved in the X-Cube flash reactor44.  
The classic SNAr reaction is an attractive candidate for high-temperature–high-pressure 
continuous-flow processing because of its need for high-temperature. Accordingly, we sought to 
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develop a protocol for SNAr reactions in flow (Scheme 3.5). As noted above, high-temperature–
high-pressure flow reactors can execute synthesis in solvents above their boiling points without 
pressure and solvent limitations. The Phoenix flow platform provided a new spectrum of reaction 
conditions, as well as, the opportunity to incorporate green solvents, minimize reaction time, 
broaden substrate scope, and maximize yield of the classic SNAr reaction. The studies carried out 
in the following sections have been published.18  
 
Scheme 3.5. Metal-free strategies for the SNAr reaction of nitrogen nucleophiles. (a) Classical 
approach. (b) Example of a SNAr reaction in flow.7 (c) This work.  
 
In this study, we evaluated the SNAr reaction of 2-chloroquinazoline with nitrogen 
nucleophiles to afford 2-aminopyrimidine-like structures. Aminopyrimidines are found in many 
drug-like compounds, such as Rosuvastatin and Imatinib (Figure 3.4).20  
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Figure 3.4. Aminoquinazolines with biological activities. 
 
3.3.1 Optimization of Reaction Conditions  
We utilized a DoE software, Stat-Ease Design Expert 7, to develop a general approach for 
the direct amination of heterocycles in continuous-flow. Statistical DoE is a powerful optimization 
approach because the software provides the ability to quickly determine how multiple parameters 
and interactions between them can affect product yield.45 Essentially, this multi-parameter 
optimization procedure uses mathematical modeling to determine optimal conditions, which must 
be verified experimentally to validate the results. In this work, the SNAr reaction between 2-
chloroquinazoline and benzylamine was optimized using a DoE approach. A comprehensive 
evaluation of three reaction parameters was carried out, which included temperature, pressure, and 
flow rate (Table 3.4). In this study, EtOH was selected as the solvent of choice because of its green 
facet46 and its wide application in SNAr chemistry. With the aid of DoE, a series of reactions were 
designed involving all three selected variables; these test points used are shown in Table 3.4. 
Subsequently, 17 reaction conditions were carried out on the Phoenix, and the crude reaction 
mixtures were analyzed by analytical HPLC/MS to obtain theoretical values of the product yield 
(Table 3.5). The resulting data were worked into the DoE software for plot analysis, which 
illustrated the relationship between temperature, pressure, and flow rate on the reaction outcome 
in the form of three-dimensional response surfaces.  
 
369 
   
Table 3.4. DoE-designed reaction test points for the optimization of the SNAr reaction in flow.  
parameters reaction test points 
temperature (˚C) 250, 325, 400 
pressure (MPa) 8, 10, 12 
flow rate (mL/min) 1.0, 2.5, 4.0  
 
Table 3.5. DoE optimization of the SNAr reaction conditions of 2-chloroquinazoline and 
benzylamine in a flow reactor.a  
 
entry temperature (˚C) pressure  (bar) flow rate (mL/min) 3.15 (%)b 
1 250 80 2.5 46 
2 250 100 4.0 29 
3 250 100 1.0 75 
4 250 120 2.5 42 
5 325 80 1.0 37 
6 325 80 4.0 20 
7 325 100 2.5 34c 
8 325 120 1.0 62 
9 325 120 4.0 47 
10 400 80 2.5 25 
11 400 100 1.0 37 
12 400 100 4.0 27 
13 400 120 2.5 37 
aThe Phoenix system was flushed with EtOH at 0.5 mL/min and the system pressurized to the desired 
test point. The temperature was set and allowed to equilibrate for 30 minutes. Substrates were dissolved 
in EtOH (0.1 M) and loaded into the 1mL-injection loop. The flow rate was set, and the sample injected 
into the Phoenix system. Samples were collected at the outlet of the reactor, concentrated under a nitrogen 
sample concentrator, and analyzed by analytical HPLC/MS without any further purification. bPercent 
product determined by UV trace of the HPLC/MS. cCenter point, average of 4 runs. (1 MPa = 10 bar)   
 
Upon plot analysis of DoE results (Table 3.5), data revealed that the reaction has 
considerable dependence on all three variables. In Figure 3.5a, the plot indicated that lower 
temperatures and higher pressures gave higher percentages of desired product 3.15. While 
conversions were reasonable in all cases, significant decomposition and side-reactions were 
observed at temperatures of 325 ˚C and above. In comparison, reactions performed at 250 ˚C 
afforded cleaner conversions and recovery of 3.15. For this reason, reaction temperatures less than 
250 ˚C were deemed optimal for the SNAr reaction.  
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In Figure 3.5b, data revealed higher percentages of 3.15 when a slower flow rate was used. 
This suggested that increasing the residence time of the reaction mixture in the flow reactor favored 
more product formation. Figure 3.5b also confirmed that higher pressures in this flow system gave 
higher percentages of desired product 3.15. Based on the 17 reactions carried out, optimal 
conditions were predicted by Design Expert: flow reactor temperature of 225 ˚C or lower, pressure 
of 120 bar, and flow rate of 0.5 mL/min (equivalent to a 16 minute residence time). The predicted 
conditions were carried out, and indeed a complete conversion to 3.15 was observed by analytical 
HPLC/MS leading to an isolated yield of 97% (Scheme 3.6). It is worth noting that no EtOH 







   
(a)  
(b)  
Figure 3.5. DoE contour plots. (a) The relationship between temperature and pressure at 1.0 
mL/min. (b) The relationship between flow rate and pressure at 250 ˚C. Product conversion is 
indicated in the white box; contour color changes from blue to red resembles that of low to high 
product conversion, respectively. The figure was adapted from Charaschanya et al.18 (1 MPA = 10 
bar)   
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Scheme 3.6. DoE-suggested optimal reaction condition and isolated yield of 3.15. 
 
3.3.2 Substrate Scope  
Utilizing the optimal conditions, a range of nucleophiles was screened to demonstrate the 
scope of the SNAr methodology in flow. The SNAr of 2-chloroquinazoline with primary amines 
gave desired products in excellent yields (Figure 3.6, 3.16–3.21). A practical use of a low 
molecular weight amine in flow was demonstrated; for example, the reaction of 2-
chloroquinazoline with methylamine to afford 3.16 in a high yield. Presumably, due to the use of 
the diamine as a hydrochloride salt, compound 3.19 was isolated in a low yield in comparison to 
other compounds. Moreover, examples with secondary amines afforded desired products in modest 
to high yields (compounds 3.22–3.27).  
 Nucleophilic amines such as imidazole and substituted benzylamines were examined, and 
the resultant products were isolated in modest yields (compounds 3.15 and 3.28–3.29). Both 
electron-rich and electron-poor anilines were examined as well (compounds 3.30–3.32). Electron-
poor anilines afforded desired products in low yields compared to other nucleophiles. Although, 
the electron-rich aniline, 4-methoxyaniline, gave 3.31 in a modest yield comparable to other 
isolated compounds. It should be noted that anilines are weaker nucleophiles than primary amines, 
and as such may demand more forcing conditions to efficiently participate in SNAr chemistry. 
Perhaps, the scope of anilines requires separate optimization studies in order to realize its SNAr 
potential in flow. 
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Figure 3.6. Substrate scope for the SNAr of 2-chloroquinazoline with nitrogen nucleophiles. 
 
From the substrate scope evaluated so far, it can be seen that this methodology is a general 
approach to the direct amination of heterocycles in flow. The methodology works well with 
primary and secondary amines, though modestly with anilines. Of note is that all reactions were 
completed in 16 minutes and only required the removal of solvent under a stream of nitrogen prior 
to preparative HPLC purification. We sought to extend the scope to related heterocycles such as 
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quinoxaline and benzimidazole. In Figure 3.7, the SNAr reactions of both 2-chloroquinoxaline and 
2-chlorobenzimidazole with primary and secondary amines afforded the desired products in 
modest yields (compounds 3.33–3.38). The ability to apply this protocol with ease to other 
heterocycles further reinforced this methodology as practical approach for direct aminations and 
heterocyclic synthesis in flow.  
 
 
Figure 3.7. Additional evaluation of substrate cope using 2-chloroquinoxaline and 2-
chlorobenzimidazole with nitrogen nucleophiles.  
 
3.3.3 Conclusions and Future Directions  
In conclusion, we have developed a general approach in flow to carry out the SNAr reaction 
of heterocycles with nitrogen nucleophiles. The methodology demonstrated good scope with 
primary and secondary amines. However, the method can be improved for weaker nucleophiles 
and the scope could be extended by further investigation. Perhaps, optimization of reaction 
conditions with aniline substrates would be a good starting point prior to development with 
oxygen- and sulfur-based nucleophiles. Regardless, this platform has been validated an alternative 
method to microwave-assisted and traditional heating SNAr protocols. In comparison to 
conventional means, this set-up is advantageous because it permitted the efficient use of EtOH, a 
green and low-boiling solvent, well beyond it is boiling point. Further, the protocol allowed for 
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shorter reaction times, as well as, lacked the need for added base or catalysts which is distinctive 
from traditional C–N formation methods. More significantly, the application of the flow platform 
in conjunction with the Design Expert software demonstrated unusual efficiency in optimization 
and synthesis of amino-substituted heterocycles. This straightforward and easily assembled flow 
platform may have significant impact on streamlining the preparation of heterocycle libraries for 
pharmaceutical interests.  
  
3.4 Thermal Boc Deprotection  
The Boc group (tert-butoxycarbonyl) is one of the most commonly used protection groups 
for amines and is extensively used in peptide and heterocyclic synthesis.21-22, 47 A recent 
perspective in the Journal of Medicinal Chemistry noted that Boc protection-deprotection is one 
of the five most frequently occurring reactions in medicinal chemistry literature in 2014.21 This is 
due to the importance of carbon-heteroatom bonds in the field of medicinal chemistry, especially 
reductive aminations and amide-bond formations.21-22 Other advantages for this protecting group 
include the broad availability of Boc-protected reagents, simple protection–deprotection protocols, 
and the easily removable by-products (t-BuOH, isobutylene, and CO2) The Boc group is inert to 
many nucleophilic reagents and considered non-hydrolysable under basic conditions.47 However, 
it is usually cleaved with strong acids, typically via concentrated hydrochloric acid (HCl) or 
trifluoroacetic acid (TFA).47 We chose to investigate a thermal deprotection of the Boc group in 
flow because this could serve as an alternative methodology to the widely used acidic methods, as 
well as, appeal to substrates that are deleterious (i.e., functional group incompatibility, work-up 
complications, or instability) under acidic Boc removal conditions.  
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Traditional heating and microwave-assisted conditions for the Boc group are reported in 
the literature. The most standard reagent-free, thermolytic removal conditions involve heating the 
substrate neat or in high-boiling solvent, for example, in DPE at 180–185 ˚C for 20–30 minutes.47-
48 Under microwave-assisted heating, substrates are dissolved in mildly acidic solvents, such as 
2,2,2-trifluoroethanol, hexafluoro-2-isopropanol, water, or silica gel/dichloromethane in sealed 
microwave vials, and then heated at 100–170 ˚C or at a specified wattage between a time period 
of 1 minute to 5 hours, depending on substrate.47, 49-51 Though these traditional and microwave-
assisted methods are facile, quantitative, and in some cases green (i.e., neat or in water), these 
conditions are only optimal when performed on a small-scale due to the high temperature 
requirements and the vigorous off-gassing of reaction mixtures.  
 To augment the current protocols in Boc removal, a high-temperature–high-pressure 
continuous flow methodology would remove the need for reagents and reaction work-up 
altogether, as well as, appeal for functional group compatibilities and substrates deleterious under 
acidic conditions. Under a reagent-free flow condition, the amines are isolated in free base form, 
which would enable immediate use in multi-step reaction sequences without adding features such 
as in-line extractions or purifications. Additionally, flow methodology could permit the transition 
to large-scale processing more readily and safely. The studies carried out in the following sections 
have been published.19 
 
3.4.1 Optimization of Reaction Conditions  
We began the optimization by screening a range of temperatures for the deprotection of 
Boc-L-phenylalanine ester in MeCN (Table 3.6). No conversion to the desired product 3.39 was 
observed at 200 ˚C (entry 1). However, when the temperature was increased to 300 ˚C a complete 
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conversion to the deprotected amine 3.39 was observed, and HPLC/MS of this reaction gave a 
reasonable yield of 3.39 (entry 3). However, the mass trace showed more than one peak indicating 
possible decomposition occurring when the reaction was exposed to a high temperature for an 
extended period of time. For this reason, the residence time of the reaction mixture in the flow 
reactor was explored, and particularly shortened by increasing the flow rate via the HPLC pump 
(entries 4–6). In entry 6, we found that a complete conversion was still retained using the system’s 
maximum flow rate of 4.0 mL/min. Moreover, the mass trace of this HPLC run showed a much 
higher percentage of 3.39 formation. A direct comparison to microwave-assisted heating at 200 ˚C 
(recommended maximum temperature for MeCN applications under microwave heating) was 
carried out, which gave no conversion to 3.39 (entry 7).   
 
Table 3.6. Optimization of reaction conditions for the thermal removal of Boc-protected L-
phenylalanine ester in a flow reactor.a  
 










1 200 1.0 8.0 0 - 
2 250 1.0 8.0 49 - 
3 300 1.0 8.0 >99 52 
4 300 2.0 4.0 >99 68 
5 300 3.0 2.7 >99 77 
6 300 4.0 2.0 >99 80 
7d 200 - 8.0 0 - 
aThe Phoenix system was flushed with MeCN at 0.5 mL/min and pressurized to 100 bar. The temperature 
was set and allowed to equilibrate for 30 minutes. Substrates were dissolved in MeCN (0.1 M) and loaded 
into the 1mL-injection loop. The flow rate was set, and the sample was injected into the Phoenix system. 
Samples were collected at the outlet of the reactor, concentrated under a nitrogen sample concentrator, 
and analyzed by analytical HPLC/MS without any further purification. bConversion was determined by 
UV trace of the HPLC/MS. cProduct yield was determined by the MS ion count of the HPLC/MS. 
dSample was carried out in a Biotage microwave at 200 ˚C for 8 minutes.  
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For the reaction of entry 6, MeCN was removed under nitrogen, and crude proton and 
carbon NMR of 3.39 were taken. The resulting spectra indicated that the product was >95% pure 
with very minor baseline peaks; this suggested that subjecting the material to the high-
temperature–high-pressure flow reactor did not cause any appreciable material decomposition. 
Additionally, work-up was not necessary to utilize the crude material. Furthermore, confirmation 
by analytical chiral chromatography indicated that the stereochemistry of the amine is retained 
during this process. To finalize the optimization of reaction conditions, we screened additional 
low-boiling solvents such as EtOH, methanol, THF, and 2-methyltetrahydrofuran. However, 
reactions carried out in these solvent conditions were not promising, because HPLC/MS traces and 
crude NMR spectra showed considerable amounts of impurities. In the case of EtOH, 
transesterification was observed, and so characterization of byproducts during solvent screenings 
was not further carried out.  
 
3.4.2 Substrate Scope 
With optimal conditions in hand, a series of Boc-protected amines were subjected to 
thermal deprotection using the Phoenix (Figure 3.8). The data showed that high temperature-high-
pressure flow processing is a suitable and general methodology for the deprotection of a variety of 
amines. Illustrating this, a series of primary and secondary amines were quantitatively deprotected 
(3.40–3.46). Aniline 3.47, indolines 3.48–3.49, related heterocycles, indole 3.50 and imidazole 
3.51, as well as, lactam 3.52 were also readily deprotected. In this series, we showed that a number 
of functional groups were tolerated which included alcohols, amides, esters, aryl halides, ketones, 
and amines. It is noteworthy that all the substrates in this Figure were completed within a 2-minute 
residence time in the flow reactor. However, in the cases of amines 3.48 and 3.49, products were 
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observed as a mixture of desired product and the oxidized-product (i.e., indole). It was determined 
by LC/MS that crude samples prior to solvent removal showed no traces of the starting material 
or indole, and thus elimination was not due to the flow condition but probably the instability of the 





Figure 3.8. Substrate scope for the thermal Boc deprotection of amines in a flow reactor. The red 
nitrogen indicates the amine that has been deprotected; isolated yields were recorded after solvent 
removal, and compounds were characterized without further purification. All reactions were run 
at 0.1 M substrate, unless otherwise noted. aReactions were run at 0.2 M of substrate. 
bApproximately 10% indole was observed after solvent removal. cApproximately 15% indole was 
observed after solvent removal.  
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In collaborative efforts with Dr. Andrew Bogdan and Dr. Amanda Dombrowski, another 
set of substrates specifically designed to encompass additional protecting groups were synthesized. 
We aimed to demonstrate selective removal of Boc over other protecting groups and determine 
tolerance of functionalities when subjected to the flow reactor. In Figure 3.9, we illustrated that 
protecting groups such as tert-butyldimethylsilyl ethers, tosyl, and carboxybenzyl-group were not 
affected during the thermal deprotection of Boc, and afforded nearly quantitative yields of the 
desired amine. Acetal (first example in the Figure) was observed to be the most sensitive protecting 
group towards flow conditions employed, but still afforded a good yield of the corresponding 
amine. Noteworthy, the Boc groups were selectively cleaved over other protecting groups, and 
acid-labile functional groups were well tolerated under flow conditions. To take this a step further, 
substrates in Figure 3.9 were treated with TFA in order to directly compare our protocol with a 
standard acidic deprotection method. Crude NMR showed desired removal of Boc amines in 
combination with considerable impurities as well as mixtures of products. In contrast, the optimal 




   
 
Figure 3.9. Substrate scope for the thermal Boc deprotection of bis-protected substrates in a flow 
reactor. The red nitrogen indicates the amine that has been deprotected. Isolated yields were 
recorded after solvent removal, unless otherwise noted. aIsolated yield after treatment with TFA. 
bA mixture of products were observed by 1H NMR. c10% of piperdin-4-one was observed by 1H 
NMR. dIsolated yield after normal phase chromatography purification.  
 
3.4.3 Conclusions and Future Directions  
In conclusion, a methodology utilizing a high-temperature–high-pressure flow reactor to 
deprotect Boc-amines has been developed. In this work, temperature, solvent, and flow rates were 
screened to determine the optimal condition (i.e., heating at 300 ˚C and pressurized at 100 bar in 
MeCN at a flow rate of 4.0 mL/min (2-minute residence time)). The protocol demonstrated broad 
scope, functional group tolerance, and selective cleavage over multiple protecting groups. In most 
cases, final products were afforded in excellent yields and high purity. In fact, the protocol only 
required the removal of solvent without further purification of the free-amines.  
Having validated this methodology, Dr. Andrew Bogdan and Dr. Amanda Dombrowski 
sought to use this thermal deprotection in a multi-step reaction sequence towards medicinal 
chemistry efforts. The advantages of this thermolytic protocol include avoiding the use of in-line 
extractors to work-up reaction steps and excessive reagents such as TFA or HCl. As shown in 
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Schemes 3.7 and 3.8, our collaborators demonstrated the application of this protocol in two 
different multi-step reaction sequences highly prevalent in medicinal chemistry, and essentially, 
streamlined 3 batch chemistry processes into one continuous process. Both examples demonstrated 
high-throughput preparation of small-molecules, where analogs were generated within minutes 
and in large quantities.  
In medicinal chemistry, the ability to functionalize scaffolds efficiently and orthogonally 
during SAR campaigns is highly desirable. Additionally, a high-throughput approach to chemical 
synthesis is impactful because compound libraries can be generated within days/weeks for 
screening. The preliminary examples developed here are particularly attractive not only because 
amination and Boc-deprotection reactions are common in medicinal chemistry efforts, but also 
because this methodology is suitable for both small-scale and large-scale synthesis. Essentially, 
this type of continuous-flow processing can provide advantages at many stages in medicinal 
chemistry ranging from hit-to-lead development to large-scale production.  
 
 
Scheme 3.7. Acylation–deprotection–carbamate formation multi-step reaction sequence in flow 
via an in-line high-temperature–high-pressure Boc deprotection. The scheme was adapted from 
Bogdan et al.19.  
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Scheme 3.8. Sulfonylation–deprotection–SNAr multi-step reaction sequence in flow via an in-line 
high-temperature–high-pressure Boc deprotection. The scheme was adapted from Bogdan et al.19.  
 
3.5 Experimental Section 
3.5.1 General Information 
 Reactions were performed in the Phoenix Flow ReactorTM from ThalesNano. The flow 
platform was set up to operate through four main components: (1) the Phoenix Flow ReactorTM, 
(2) a manual injection valve, (3) a JASCO PU-2085 Plus HPLC pump, and (4) a JASCO BP-2080 
Plus back-pressure regulator. All starting materials were commercially available reagents, and 
were used without further purification unless otherwise noted. Purification was carried out by an 
automated flash chromatography/medium-pressure liquid chromatography system (Teledyne 
ISCO Combiflash® Rf system) using normal phase silica flash columns (RediSep® Rf Gold silica 
columns). Preparative HPLC was performed on either an automated preparative-scale purification 
system equipped with a Waters Sunfire C8 5m column (150 × 30 mm) or on a Phenomenex Luna 
C8 5m 100 Å AXIA column (50 × 21.2 mm). A gradient of acetonitrile and 0.1% TFA in water 
was used at a flow rate of 30 mL/min. Proton nuclear magnetic resonance spectra (1H NMR, 400 
or 500 MHz) and proton decoupled carbon nuclear magnetic resonance spectra (13C NMR, 100 or 
125 MHz) were obtained in deuterated chloroform (CDCl3) or deuterated dimethylsulfoxide 
(DMSO-d6), unless otherwise noted. Chemical shifts are in parts per million (ppm), and are 
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reported in the order of multiplicity, coupling constants (J, Hz) and integration. Chemical shifts 
are referenced to the center line of solvent (for CDCl3, δ 7.26 ppm for 1H NMR and 77.16 ppm for 
13C NMR; and for DMSO-d6, δ 2.50 ppm for 1H NMR and 39.52 ppm for 13C NMR). MS data 
were obtained by ionizing samples via electron spray ionization (ESI) or desorption chemical 
ionization (DCI) with a time-of-flight (TOF) as the mass analyzer. Infrared spectra (IR) were 
obtained with attenuated total reflectance Fourier transform midinfrared spectroscopy (ATR/FT-
MIR) using a diamond internal reflection element (IRE). Spectroscopic data for the known 
compounds prepared according to methodologies described in this chapter match with those 
reported in the literature. Lastly, the compounds were characterized according the experimental 
standards at AbbVie pharmaceuticals, which primarily included yield, 1H NMR, and MS.  
 
 General procedure A for the Gould-Jacobs thermal cyclization reaction. The Phoenix 
system was flushed with THF. The system flow rate was set to 4.0 mL/min, back-pressure regulator 
to 100 bar, and temperature to 360 ˚C. The Phoenix reactor did not equilibrate at the set 
temperature (because at the time of this study we were unaware that it was necessary for the 
system). Substrates were dissolved in THF (0.1 M), loaded into the 1.0 mL-injection loop, and 
injected into the Phoenix system. The crude reaction mixtures were collected at the outlet of the 
reactor in 20 mL scintillation vials, which were concentrated under a nitrogen sample concentrator. 
All compounds were analyzed by analytical HPLC/MS and characterized without any further 
purification.  
 
 General procedure B for the SNAR reaction of nitrogen nucleophiles. The Phoenix 
system was flushed with EtOH. The system flow rate was set to 0.5 mL/min, back-pressure 
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regulator to 120 bar, and temperature to 225 ˚C. The Phoenix reactor was allowed to equilibrate 
for 30 minutes; equilibration of the reactor temperature was only required for the first run each 
day. Substrates (2-chloroquinazoline, 2-chloroquinoxaoline, or 2-chlorobenzaimidazole, 0.075 
mmol) and amines (0.150 mmol, used as 0.3 M solutions in EtOH) were premixed, and loaded into 
the 1.0 mL-injection loop. Samples were injected into the Phoenix system. The crude reaction 
mixtures were collected at the outlet of the reactor in 20 mL scintillation vials, which were 
concentrated under a nitrogen sample concentrator. All compounds were purified by mass-
triggered reverse phase HPLC.  
 
 General procedure C for the thermal removal of Boc-protected amino group. The 
Phoenix system was flushed with MeCN. The system flow rate was set to 4.0 mL/min, back-
pressure regulator to 100 bar, and temperature to 300 °C. The Phoenix reactor was allowed to 
equilibrate for 30 minutes; equilibration of the reactor temperature was only required for the first 
run each day. Substrates were dissolved in MeCN (0.1 or 0.2 M), loaded into the 1.0 mL-injection 
loop, and injected into the Phoenix system. The crude reaction mixtures were collected at the outlet 
of the reactor in 20-mL scintillation vials, which were concentrated under a nitrogen sample 
concentrator. Samples were characterized without further purification, unless otherwise noted. 
 
3.5.2 Experimental Section for 3.2 
 Preparation of Starting Materials 3.1, 3.4, and 3.7. The aminomethylene adducts were 
prepared using literature procedures with commercially available starting materials. 
Characterization data was consistent with that reported in the literature.24-25, 29, 34   
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 Ethyl 4-Oxo-4H-pyrido[1,2-a]pyrimidine-3-carboxylate, 3.2. Compound 3.2 was 
prepared from diethyl 2-((pyridin-2-ylamino)methylene)malonate 3.1 according to general 
procedure A. Characterization data were consistent with reported data.25, 28-29   
 
 4H-Pyrido[1,2-a]pyrimidin-4-one, 3.3. Compound 3.3 was prepared from diethyl 2-
((pyridin-2-ylamino)methylene)malonate 3.1 according to general procedure A. Characterization 
data were consistent with reported data.29  
 
 Ethyl 7-Methyl-4-oxo-4H-pyrido[1,2-a]pyrimidine-3-carboxylate, 3.5. Compound 3.5 
was prepared from diethyl 2-(((5-methylpyridin-2-yl)amino)methylene)malonate 3.4 according to 
general procedure A. The product was isolated as an off-white powder in 23% yield. 1H NMR (500 
MHz, CDCl3) δ 9.10 (app dt, J = 2.1, 1.0 Hz, 1H), 9.03 (s, 1H), 7.81 (dd, J = 8.9, 2.1 Hz, 1H), 7.72 
(d, J = 8.9 Hz, 1H), 4.43 (q, J = 7.1 Hz, 2H), 2.51 (s, 3H), 1.42 (t, J = 7.1 Hz, 3H). 13C NMR (100 
MHz, CDCl3) δ 164.9, 158.8, 154.8, 152.3, 141.9, 128.0, 126.6, 126.4, 105.2, 61.1, 18.6, 14.5. 
HRMS (ESI) m/z: [M + Na]+ calcd for C12H12N2O3Na 255.0740, found 255.0741.  
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 7-Methyl-4H-pyrido[1,2-a]pyrimidin-4-one, 3.6. Compound 3.6 was prepared from 
diethyl 2-(((5-methylpyridin-2-yl)amino)methylene)malonate 3.4 according to general procedure 
A. The product was isolated as a cream-colored powder in 32% yield. 1H NMR (400 MHz, DMSO-
d6) δ 8.87 (d, J = 2.1 Hz), 8.30 (d, J = 6.6 Hz, 1H), 7.97 (dd, J = 9.0, 2.1 Hz, 1H), 7.70 (d, J = 9.0 
Hz, 1H), 6.41 (d, J = 6.6 Hz, 1H), 2.42 (s, 3H); 13C NMR (100 MHz, DMSO-d6) δ 156.3, 151.7, 
149.3, 141.6, 127.4, 124.8, 123.7, 103.3, 17.7. HRMS (ESI/TOF-Q) m/z: [M+H]+ calcd for 
C9H9N2O 161.0709, found 161.0714.  
 
 3-Methyl-1-phenyl-1H-pyrazolo[3,4-b]pyridin-4-ol, 3.8. Compound 3.8 was prepared 
from diethyl 2-(((3-methyl-1-phenyl-1H-pyrazol-5-yl)amino)methylene)malonate 3.7 according 
to general procedure A. The product was isolated as a beige powder in 88–91% yield. 1H NMR 
(400 MHz, DMSO-d6) δ 8.28–8.19 (m, 3H), 7.61–7.45 (m, 2H), 7.31–7.22 (m, 1H), 6.60 (d, J = 
5.5 Hz, 1H), 2.63 (s, 3H); 13C NMR (100 MHz, DMSO -d6) δ 161.4, 152.6, 150.2, 142.2, 139.4, 
128.9, 125.1, 120.0, 107.6, 103.6, 14.3. HRMS (ESI/TOF-Q) m/z: [M+H]+ calcd for C13H12N3O 




   
3.5.3 Experimental Section for 3.3 
 
 N-Benzylquinazolin-2-amine, 3.15.42, 52 The title compound 3.15 was prepared according 
to general procedure B as the TFA salt in 97% yield. 1H NMR (400 MHz, DMSO-d6) δ 9.27 (br s, 
1H), 7.92 (br s, 1H), 7.80 (br s, 1H), 7.56 (d, J = 8.5 Hz, 1H), 7.37–7.27 (m, 5H), 7.22 (m, 1H), 
4.67 (br s, 2H). MS (ESI+) m/z: 236.0 (M + H)+.   
 
 N-Methylquinazolin-2-amine, 3.16. The title compound 3.16 was prepared according to 
general procedure B as the TFA salt in 73% yield. 1H NMR (500 MHz, DMSO-d6) δ 9.34 (s, 1H), 
7.99 (dd, J = 7.9 Hz, 1H), 7.89 (t, J = 7.8 Hz, 1H), 7.70 (m, 1H), 7.44 (t, J = 7.5 Hz, 1H), 3.03 (s, 
3H). MS (ESI+) m/z: 160.0 (M + H)+.   
 
 N-Isobutylquinazolin-2-amine, 3.17. The title compound 3.17 was prepared according to 
general procedure B as the TFA salt in 92% yield. 1H NMR (400 MHz, DMSO-d6) δ 9.33 (br s, 
1H), 7.93 (m, 2H), 7.67 (m, 1H), 7.43 (m, 1H), 3.29 (m, 2H), 1.97 (m, 1H), 0.95 (d, J = 6.7 Hz, 
6H). MS (ESI+) m/z: 202.0 (M + H)+.   
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 N-(2-Methoxyethyl)quinazolin-2-amine, 3.18. The title compound 3.18 was prepared 
according to general procedure B as the TFA salt in 92% yield. 1H NMR (400 MHz, DMSO-d6) δ 
9.32 (br s, 1H), 7.92 (m, 2H), 7.64 (m, 1H), 7.43 (m, 1H), 3.65 (m, 2H), 3.57 (m, 2H), 3.29 (s, 
3H). MS (ESI+) m/z: 204.0 (M + H)+.   
 
 N1,N1-Dimethyl-N2-(quinazolin-2-yl)ethane-1,2-diamine, 3.19. The title compound 3.19 
was prepared according to general procedure B as the TFA salt in 38% yield. 1H NMR (400 MHz, 
DMSO-d6) δ 9.70 (br s, 1H), 7.83 (m, 2H), 7.55 (d, J = 8.4 Hz, 1H), 7.33 (m, 1H), 3.76 (m, 2H), 
3.36 (t, J = 5.9 Hz, 2H), 2.88 (s, 6H). MS (ESI+) m/z: 217.0 (M + H)+.   
 
 N-(Cyclohexylmethyl)quinazolin-2-amine, 3.20.52 The title compound 3.20 was 
prepared according to general procedure B as the TFA salt in 90% yield. 1H NMR (500 MHz, 
DMSO-d6) δ 9.39 (br s, 1H), 7.96–7.86 (m. 2H), 7.67 (m, 1H), 7.42 (m, 1H), 3.35 (m, 2H), 1.79–
1.60 (complex, 6H), 1.24–1.10 (complex, 3H), 0.98 (m, 2H). MS (ESI+) m/z: 242.0 (M + H)+.   
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 N-Cyclohexylquinazolin-2-amine, 3.21.52 The title compound 3.21 was prepared 
according to general procedure B as the TFA salt in 82% yield. 1H NMR (500 MHz, DMSO-d6) δ 
9.36 (br s, 1H), 8.00 (d, J = 7.9 Hz, 1H), 7.91 (m, 1H), 7.68 (m, 1H), 7.47 (t, J = 7.5 Hz, 1H), 3.84 
(m, 1H), 1.94 (m, 2H), 1.74 (m, 2H), 1.62 (m, 1H), 1.40–1.20 (complex, 4H), 1.16 (m, 1H). MS 
(ESI+) m/z: 228.0 (M + H)+.   
 
 2-(4-Methylpiperazin-1-yl)quinazoline, 3.22.53 The title compound 3.22 was prepared 
according to general procedure B as the TFA salt in 71% yield. 1H NMR (400 MHz, DMSO-d6) δ 
9.31 (s, 1H), 7.92 (dd, J = 8.1, 1.4 Hz, 1H), 7.80 (ddd, J = 8.5, 6.9, 1.5 Hz, 1H), 7.58 (d, J = 8.5 
Hz, 1H), 7.36 (m, 1H), 4.89 (m, 2H), 3.55 (m, 2H), 3.35 (m, 2H), 3.10 (m, 2H), 2.85 (s, 3H). MS 
(ESI+) m/z: 229.0 (M + H)+.   
 
 4-(Quinazolin-2-yl)morpholine, 3.23.53 The title compound 3.23 was prepared according 
to general procedure B as the TFA salt in 79% yield. 1H NMR (500 MHz, DMSO-d6) δ 9.00 (s, 
1H), 7.88 (m, 1H), 7.77 (m, 1H), 7.55 (m, 1H), 7.32 (m, 1H), 3.83 (m, 4H), 3.69 (m, 4H). MS 
(ESI+) m/z: 216.0 (M + H)+. 
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 2-(Piperidin-1-yl)quinazoline, 3.24.42 The title compound 3.24 was prepared according 
to general procedure B as the TFA salt in 64% yield. 1H NMR (400 MHz, DMSO-d6) δ 9.33 (br s, 
1H), 7.96 (dd, J = 8.0, 1.4 Hz, 1H), 7.86 (ddd, J = 8.5, 7.1, 1.5 Hz, 1H), 7.65 (dd, J = 8.5, 0.9 Hz, 
1H), 7.42 (ddd, J = 8.0, 7.0, 1.0 Hz, 1H), 3.89 (m, 4H), 1.64 (complex, 6H). MS (ESI+) m/z: 214.0 
(M + H)+.  
 
 2-(Pyrrolidin-1-yl)quinazoline, 3.25.53 The title compound 3.25 was prepared according 
to general procedure B as the TFA salt in 73% yield. 1H NMR (400 MHz, DMSO-d6) δ 9.45 (s, 
1H), 8.06 (dd, J = 8.0, 1.3 Hz, 1H), 7.95 (m, 1H), 7.77 (d, J = 8.4 Hz, 1H), 7.51 (t, J = 7.5 Hz, 1H), 
3.57 (m, 2H), 2.00 (m, 6H). MS (ESI+) m/z: 200.0 (M + H)+.  
 
 N-Benzyl-N-methylquinazolin-2-amine, 3.26. The title compound 3.26 was prepared 
according to general procedure B as the TFA salt in 68% yield. 1H NMR (500 MHz, DMSO-d6) δ 
9.37 (s, 1H), 7.98 (d, J = 8.0 Hz, 1H), 7.87 (t, J = 7.9 Hz, 1H), 7.70 (m, 1H), 7.42 (m, 1H), 7.34–
7.25 (m, 5H), 5.05 (s, 2H), 3.23 (s, 3H). MS (ESI+) m/z: 250.0 (M + H)+.  
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 2-(1H-Imidazol-1-yl)quinazoline, 3.27. The title compound 3.27 was prepared according 
to general procedure B as the TFA salt in 50% yield. 1H NMR (400 MHz, DMSO-d6) δ 9.83 (s, 
1H), 9.83 (s, 1H), 8.39 (m, 1H), 8.31 (dd, J = 8.3, 1.3 Hz, 1H), 8.15 (ddd, J = 8.4, 6.8, 1.5 Hz, 1H), 
8.07 (m, 1H), 7.84 (ddd, J = 8.0, 6.0, 1.1 Hz, 1H), 7.65 (s, 1H). MS (ESI+) m/z: 197.0 (M + H)+.  
 
 N-(4-Methoxybenzyl)quinazolin-2-amine, 3.28. The title compound 3.28 was prepared 
according to general procedure B as the TFA salt in 60% yield. 1H NMR (400 MHz, DMSO-d6) δ 
9.24 (br s, 1H), 7.83 (m, 2H), 7.56 (d, J = 8.4 Hz, 1H), 7.33 (m, 3H), 6.89 (m, 2H), 4.61 (m, 2H), 
3.72 (s, 3H). MS (ESI+) m/z: 266.0 (M + H)+.  
 
 N-(4-(Trifluoromethyl)benzyl)quinazolin-2-amine, 3.29.52 The title compound 3.29 
according was prepared to general procedure B as the TFA salt in 63% yield. 1H NMR (400 MHz, 
DMSO-d6) δ 9.24 (br s, 1H), 7.88 (m, 1H), 7 .76 (m, 1H), 7.68 (d, J = 8.1 Hz, 1H), 7.60 (d, J = 8.1 
Hz, 1H), 7.51 (m, 1H), 7.33 (m, 1H), 4.75 (br s, 2H). MS (ESI+) m/z: 304.0 (M + H)+.  
393 
   
 
 N-Phenylquinazolin-2-amine, 3.30.42 The title compound 3.30 was prepared according to 
general procedure B as the TFA salt in 39% yield. 1H NMR (400 MHz, DMSO-d6) δ 9.87 (s, 1H), 
9.31 (s, 1H), 7.98 (m, 2H), 7.92 (dd, J = 8.1, 1.3 Hz, 1H), 7.81 (m, 1H), 7.66 (d, J = 8.5 Hz, 1H), 
7.39 (t, J = 7.5 Hz, 1H), 7.33 (m, 2H), 6.99 (t, J = 7.5, 1H). MS (ESI+) m/z: 222.1 (M + H)+.  
 
 N-(4-Methoxyphenyl)quinazolin-2-amine, 3.31. The title compound 3.31 was prepared 
according to general procedure B as the TFA salt in 63% yield. 1H NMR (400 MHz, DMSO-d6) δ 
9.88 (br s, 1H), 9.29 (s, 1H), 7.91 (dd, J = 8.0, 1.4 Hz, 1H), 7.80 (m, 3H), 7.62 (m, 1H), 7.37 (ddd, 
J = 8.0, 6.9, 1.1 Hz, 1H), 6.94 (m, 2H), 3.75 (s, 3H). MS (ESI+) m/z: 252.0 (M + H)+.  
 
 N-(1H-Pyrazol-5-yl)quinazolin-2-amine, 3.32. The title compound 3.32 was prepared 
according to general procedure B as the TFA salt in 27% yield. 1H NMR (500 MHz, DMSO-d6) δ 
9.54 (s, 1H), 8.49 (d, J = 2.7 Hz, 1H), 8.11 (dd, J = 8.1, 1.4 Hz, 1H), 7.97 (ddd, J = 8.5, 6.9, 1.5 
Hz, 1H), 7.87 (d, J = 8.4 Hz, 1H), 7.61 (ddd, J = 8.1, 6.8, 1.1 Hz, 1H), 5.96 (d, J = 2.8 Hz, 1H). 
MS (ESI+) m/z: 212.0 (M + H)+.  
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 N-Methylquinoxalin-2-amine, 3.33. The title compound 3.33 was prepared according to 
general procedure B as the TFA salt in 59% yield. 1H NMR (400 MHz, DMSO-d6) δ 8.45 (s, 1H), 
7.82 (m, 1H), 7.62 (m, 2H), 7.41 (m, 3H), 7.36 (m, 2H), 7.29 (m, 1H), 4.65 (s, 2H). MS (ESI+) 
m/z: 159.9 (M + H)+.   
 
 N-Benzylquinoxalin-2-amine, 3.34. The title compound 3.34 was prepared according to 
general procedure B as the TFA salt in 42% yield. 1H NMR (500 MHz, DMSO-d6) δ 8.39 (s, 3H), 
7.81 (dd, J = 8.2, 1.3 Hz, 1H), 7.63 (m, 2H), 7.39 (ddd, J = 8.3, 6.9, 1.6 Hz, 1H), 2.98 (s, 3H). MS 
(ESI+) m/z: 236.0 (M + H)+.   
 
 2-(4-Methylpiperazin-1-yl)quinoxaline, 3.35. The title compound 3.35 was prepared 
according to general procedure B as the TFA salt in 60% yield. 1H NMR (400 MHz, DMSO-d6) δ 
8.83 (s, 1H), 7.87 (m, 1H), 7.65 (m, 2H), 7.48 (m, 1H), 4.66 (m, 2H), 3.54 (m, 2H), 3.33 (m, 2H), 
3.15 (m, 2H), 2.84 (s, 3H). MS (ESI+) m/z: 229.0 (M + H)+.   
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 N-Methyl-1H-benzo[d]imidazol-2-amine, 3.36. The title compound 3.36 was prepared 
according to general procedure B as the TFA salt in 73% yield. 1H NMR (500 MHz, DMSO-d6) δ 
7.35 (m, 2H), 7.23 (m, 2H), 2.97 (s, 3H). MS (ESI+) m/z: 148.0 (M + H)+.   
 
 N-Benzyl-1H-benzo[d]imidazol-2-amine, 3.37. The title compound 3.37 was prepared 
according to general procedure B as the TFA salt in 78% yield. 1H NMR (400 MHz, DMSO-d6) δ 
7.38 (m, 6H), 7.23 (m, 3H), 4.59 (s, 1H). MS (ESI+) m/z: 224.0 (M + H)+.   
 
 2-(4-Methylpiperazin-1-yl)-1H-benzo[d]imidazole, 3.38. The title compound 3.38 was 
prepared according to general procedure B as the TFA salt in 65% yield. 1H NMR (400 MHz, 
DMSO-d6) δ 7.44 (m, 2H), 7.26 (m, 2H), 3.87–3.44 (complex, 8H), 2.85 (m, 3H). MS (ESI+) m/z: 






   
3.5.4 Experimental Section for 3.4 
 
 Methyl L-Phenylalaninate, 3.39.54-55 Prepared according to general procedure C using 
methyl (tert-butylcarbonyl)-L-phenylalaninate, (55.8 mg, 0.201 mmol) to afford 3.39 as an oil 
(34.8 mg, >95% yield). 1H NMR (500 MHz, 9:1 v/v DMSO-d6:D2O) δ 7.33–7.25 (m, 2H), 7.25–
7.20 (m, 1H), 7.20–7.13 (m, 2H), 3.62–3.55 (m, 4H), 2.85 (qd, J = 13.4, 6.7 Hz, 2H); 13C NMR 
(101 MHz, DMSO-d6:D2O) δ 175.7, 138.0, 129.6, 128.7, 126.9, 55.9, 51.9, 41.0. MS (ESI+) m/z: 
180.2 (M + H)+.  
 
 (S)-2-Amino-3-(1H-indol-3-yl)propanol, 3.40. Prepared according to the general 
procedure C using tert-butyl (S)-(1-hydroxy-3-(1H-indol-3-yl)propan-2-yl)carbamate (0.2 M, 800 
μL, 0.16 mmol) to afford 3.40 (30.6 mg, >95% yield). 1H NMR (400 MHz, 9:1 v/v DMSO-d6:D2O) 
δ 7.56 (d, J = 7.8 Hz, 1H), 7.37 (d, J = 8.1 Hz, 1H), 7.15 (s, 1H), 7.09 (t, J = 7.5 Hz, 1H), 6.99 (t, 
J = 7.4 Hz, 1H), 3.38 (dd, J = 10.6, 4.7 Hz, 1H), 3.26 (dd, J = 10.6, 6.7 Hz, 1H), 2.98 (td, J = 6.7, 
4.7 Hz, 1H), 2.81 (dd, J = 14.1, 6.3 Hz, 1H), 2.63 (dd, J = 14.2, 7.0 Hz, 1H); 13C NMR (101 MHz, 
9:1 v/v DMSOd6:D2O) δ 136.5, 127.9, 123.7, 121.4, 118.9, 118.8, 111.74, 111.73, 65.7, 53.6, 29.4. 
MS (ESI+) m/z: 191.2 (M + H)+.   
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 (S)-2-Amino-2-phenylethanol, 3.41.56 Prepared according to the general procedure C 
using tert-butyl (S)-(2-hydroxy-1-phenylethyl)carbamate (0.2 M, 800 μL, 0.16 mmol) to afford 
3.41 (20.5 mg, 93% yield). 1H NMR (400 MHz, 9:1 v/v DMSO-d6:D2O) δ 7.39–7.19 (m, 5H), 3.86 
(dd, J = 7.9, 4.7 Hz, 1H), 3.47 (dd, J = 10.5, 4.8 Hz, 1H), 3.33 (dd, J = 10.4, 8.0 Hz, 1H); 13C NMR 
(101 MHz, 9:1 v/v DMSO-d6:D2O) δ 143.9, 128.5, 127.3, 127.2, 67.9, 57.4. MS (ESI+) m/z: 138.2 
(M + H)+.   
 
 1,2,3,4-Tetrahydroquinolin-7-amine, 3.42. Prepared according to the general procedure 
C using tert-butyl (1,2,3,4-tetrahydroquinolin-7-yl)carbamate to afford 3.42 (29.2 mg, >95% 
yield). 1H NMR (400 MHz, 9:1 v/v DMSO-d6:D2O) δ 6.47 (d, J = 7.8 Hz, 1H), 5.74 (dd, J = 7.9, 
2.3 Hz, 1H), 5.69 (d, J = 2.2 Hz, 1H), 3.10–3.01 (m, 2H), 2.46 (t, J = 6.3 Hz, 2H), 1.69 (dd, J = 
6.6, 4.8 Hz, 2H). 13C NMR (101 MHz, 9:1 v/v DMSO-d6:D2O) δ 147.0, 146.0, 129.7, 109.7, 103.9, 
99.9, 41.4, 26.5, 22.8. MS (ESI+) m/z: 149.2 (M + H)+. 
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 2,3-Dihydroquinolin-4(1H)-one, 3.43. Prepared according to the general procedure C 
using tert-butyl 4-oxo-3,4-dihydroquinoline-1(2H)-carboxylate to afford 3.43 (27.9 mg, >95% 
yield). 1H NMR (400 MHz, 9:1 v/v DMSO-d6:D2O) δ 7.59 (dd, J = 8.0, 1.7 Hz, 1H), 7.29 (ddd, J 
= 8.5, 7.0, 1.7 Hz, 1H), 6.77 (dd, J = 8.4, 1.0 Hz, 1H), 6.62 (ddd, J = 8.0, 7.0, 1.1 Hz, 1H), 3.42 
(dd, J = 7.8, 6.6 Hz, 2H), 2.59–2.48 (m, 2H); 13C NMR (101 MHz, 9:1 v/v DMSO-d6:D2O) δ 194.1, 
153.4, 135.5, 127.1, 118.2, 116.7, 116.5, 41.2, 37.8. MS (ESI+) m/z: 148.1 (M + H)+.  
 
 3-Bromo-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine, 3.44.  Prepared according to the 
general procedure C using tert-butyl 3-bromo-6,7-dihydropyrazolo[1,5-a]pyrazine-5(4H)-
carboxylate to afford 3.44 (38.1 mg, 94% yield). 1H NMR (400 MHz, 9:1 v/v DMSO-d6:D2O) δ 
7.50 (s, 1H), 3.97 (t, J = 5.6 Hz, 2H), 3.79 (s, 2H), 3.09 (t, J = 5.5 Hz, 2H); 13C NMR (101 MHz, 
9:1 v/v DMSO-d6:D2O) δ 138.1, 136.7, 88.1, 48.1, 42.8, 41.5. MS (ESI+) m/z: 204.0 (M + H)+.  
 
 1-Benzylpiperazine, 3.35.57-58 Prepared according to the general procedure C using tert-
butyl 4-benzylpiperazine-1-carboxylate to afford 3.35 (33.5 mg, >95% yield). 1H NMR (400 MHz, 
9:1 v/v DMSO-d6:D2O) δ 7.41–7.21 (m, 5H), 3.42 (s, 2H), 2.75–2.65 (m, 4H), 2.47–2.14 (m, 4H); 
13C NMR (101 MHz, 9:1 v/v DMSO-d6:D2O) δ 138.3, 129.5, 128.6, 127.4, 63.2, 53.9, 45.4. MS 
(ESI+) m/z: 177.2 (M + H)+.  
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 2-Benzylpiperazine, 3.46. Prepared according to the general procedure C using tert-butyl 
3-benzylpiperazine-1-carboxylate (0.2 M, 800 μL, 0.16 mmol) to afford 3.46 (28.2 mg, >95% 
yield). 1H NMR (400 MHz, 9:1 v/v DMSO-d6:D2O) δ 7.38–7.25 (m, 2H), 7.25–7.13 (m, 3H), 2.88–
2.59 (m, 4H), 2.59–2.34 (m, 4H), 2.30–2.19 (m, 1H); 13C NMR (101 MHz, 9:1 v/v DMSO-d6:D2O) 
δ 139.2, 129.6, 128.8, 126.5, 56.9, 51.0, 46.2, 45.6, 40.5. MS (ESI+) m/z: 177.2 (M + H)+.  
 
 4,6-Dichloropyridin-2-amine, 3.47. Prepared according to the general procedure C using 
tert-butyl (4,6-dichloropyridin-2-yl)carbamate to afford 3.47 (30.8 mg, >95% yield). 1H NMR 
(400 MHz, 9:1 v/v DMSO-d6:D2O) δ 6.66 (d, J = 1.5 Hz, 1H), 6.49 (d, J = 1.5 Hz, 1H); 13C NMR 
(101 MHz, 9:1 v/v DMSO-d6:D2O) δ 160.7, 149.8, 145.1, 110.6, 106.0. MS (ESI+) m/z: 163.0 (M 
+ H)+.  
 
 4-Fluoro-N-(indolin-6-yl)benzamide, 3.48. Prepared according to the general procedure 
C using tert-butyl 6-(4-fluorobenzamido)indoline-1-carboxylate to afford 3.48 (48.6 mg, >95% 
yield). 1H NMR (400 MHz, DMSO-d6) δ 8.02-7.95 (m, 2H), 7.37–7.30 (m, 2H), 7.05–6.97 (m, 
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2H), 6.87 (dd, J = 7.9, 1.9 Hz, 1H), 3.41 (t, J = 8.4 Hz, 2H), 2.88 (t, J = 8.4 Hz, 2H); 13C NMR 
(101 MHz, DMSO-d6) δ 164.8, 164.3 (d, J = 251.5 Hz), 153.2, 138.3, 130.7 (d, J = 9.1 Hz), 125.2, 
124.4, 115.8 (d, J = 21.8 Hz), 110.1, 102.1, 47.2, 29.2. MS (ESI+) m/z: 257.1 (M + H)+.  
 
 Indolin-6-amine, 3.49. Prepared according to the general procedure C using tert-butyl 6-
aminoindoline-1-carboxylate to afford 3.49 (24.8 mg, 93% yield). After the dry-down, a ~15% 
impurity that is presumed to be the corresponding indole, 1H-indol-6-amine, was observed by 1H 
NMR. 1H NMR (400 MHz, DMSO-d6) δ 6.69 (d, J = 7.8 Hz, 1H), 5.90–5.81 (m, 2H), 3.31 (t, J = 
8.2 Hz, 2H), 2.73 (d, J = 8.3 Hz, 2H); 13C NMR (101 MHz, DMSO-d6) δ 153.6, 148.0, 124.7, 
117.4, 104.2, 96.7, 47.2, 29.0. MS (ESI+) m/z: 135.2 (M + H)+.  
 
 5-Methoxy-1H-indole, 3.50.59-60 Prepared according to the general procedure C using tert-
butyl 5-methoxy-1H-indole-1-carboxylate to afford 3.50 (29.4 mg, >95% yield). 1H NMR (400 
MHz, 9:1 v/v DMSO-d6:D2O) δ 7.35–7.25 (m, 2H), 7.05 (d, J = 2.4 Hz, 1H), 6.74 (dd, J = 8.8, 2.5 
Hz, 1H), 6.36 (dd, J = 3.1, 1.0 Hz, 1H), 3.75 (s, 3H); 13C NMR (101 MHz, 9:1 v/v DMSO-d6:D2O) 
δ 153.7, 131.3, 128.4, 126.0, 112.4, 111.6, 102.2, 101.4, 55.8. MS (ESI+) m/z: 148.1 (M + H)+.  
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 Imidazole, 3.51.61 Prepared according to the general procedure C using tert-butyl 1H-
imidazole-1-carboxylate to afford 3.51 (13.4 mg, >95% yield). 1H NMR (400 MHz, 9:1 v/v 
DMSO-d6:D2O) δ 7.67 (s, 1H), 7.04 (s, 2H); 13C NMR (101 MHz, 9:1 v/v DMSO-d6:D2O) δ 135.5, 
121.7.  
 
 Piperidin-2-one, 3.52.62-63 Prepared according to the general procedure C using tert-butyl 
2-oxopiperidine-1-carboxylate (0.2 M, 800 μL, 0.16 mmol) to afford 3.52 (15.1 mg, >95% yield). 
1H NMR (400 MHz, 9:1v/v DMSO-d6:D2O) δ 3.13 (t, J = 5.6 Hz, 2H), 2.14 (t, J = 6.3 Hz, 2H), 
1.73–1.58 (m, 4H); 13C NMR (101 MHz, 9:1 v/v DMSO-d6:D2O) δ 171.6, 41.6, 31.6, 22.2, 20.9. 
MS (ESI+) m/z: 100.2 (M + H)+. 
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